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Abstract
Background
A common approach to sample size calculation for cluster randomised trials (CRTs) is to calculate
the sample size assuming individual randomisation and multiply it by an inflation factor, the design
effect. This approach is well established for binary and continuous outcomes, but less so for ordinal.
As the variety in trial design increases alternative or more complex methods are required. There is
currently no single resource that provides a comprehensive summary of methods. This thesis aims
to provide a unique contribution towards the review and development of sample size methods for
CRTs, with a focus on ordinal outcomes.
Methods
I provide a comprehensive review of sample size methods for CRTs and summarise the method-
ological gaps that remain. Through simulation I evaluate the power performance, under realistic
trial scenarios, of the design effect for ordinal outcomes calculated using a kappa-type intracluster
correlation coefficient (ICC), the ICC on an assumed underlying variable and an ANOVA ICC. I
provide practical guidance for sample size calculation for ordinal outcomes in CRTs.
Results
Simulation results showed when the number of clusters was large the ANOVA and kappa-type es-
timates were equivalent, and smaller than the latent variable ICC. Use of the ANOVA ICC in the
design effect produced adequately powered trials and power was marginally reduced under a minor
deviation from the common assumption of proportional odds used in ordered regression.
Conclusions
For outcomes with three to five categories the ANOVA ICC, calculated by assigning numerical
equally spaced scores to the ordinal categories, can be used in the simple design effect to produce
an adequately powered trial. The method assumes an analysis by random effects ordered regression
with proportional odds, a reasonable number of clusters, and clusters of the same size.
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Chapter 1
Introduction
The methodology for conducting sample size calculations for individually randomised trials is well
established. Methods for cluster randomised trials are less developed and can be more complex due
to the clustering inherent to the design. As I show in this chapter the use of cluster randomised
trials has increased in recent years and hence there is now more methodological development around
the design, conduct and analysis of these trials. The focus of this thesis is to provide a unique
contribution towards the review and development of sample size methods for cluster randomised
trials.
Many methods of sample size calculation for cluster randomised trials are extensions of methods
used for individually randomised trials. Hence this chapter starts with a description of sample size
formulae for individually randomised trials with explanation of how these are derived in general.
Cluster randomised trials are the focus of the remainder of the chapter, including the rationale behind
their use and a description of the added complexity they present for sample size calculation. The
most common approach to their sample size calculation is presented and its limitations described.
To place my research in context I provide a brief review of the historical development of sample size
calculations for cluster randomised trials. The chapter concludes with a detailed outline of the aims,
objectives and structure of the thesis.
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1.1. RANDOMISED CONTROLLED TRIALS (RCTS)
1.1 Randomised Controlled Trials (RCTs)
Well designed and conducted Randomised Controlled Trials (RCTs) are seen as the gold standard in
research design for the evaluation of medical interventions to improve participant outcomes. In the
most common design individuals are randomly allocated, with pre-defined probability, to treatment
group and their outcomes compared at a pre-defined time point post-randomisation. The design
usually involves two groups; those that receive the intervention under investigation and those that
receive a control (either the currently accepted standard treatment, no treatment, or a placebo).
This is known as a standard two-arm parallel group design.
1.2 Sample size calculations for RCTs
The aim of an RCT is to provide reliable evidence of whether a treatment is safe and efficacious. In
designing an RCT we must calculate in advance the number of participants required that will provide
sufficient probability of detecting a clinically important treatment difference if such a difference
exists, while also providing reasonable evidence to conclude no treatment difference if none is seen.
An appropriately sized trial allows one to reliably conclude that any difference seen between the
treatment groups can be attributed to a real effect of treatment rather than to chance.
At a minimum calculations require knowledge about 1) the primary outcome measure and a descrip-
tion of its variability, 2) an estimate of the minimally important treatment difference, 3) the analysis
to be performed i.e. the null and alternative hypotheses with associated test statistic, 4) the Type I
error to be tolerated and, 5) the amount of statistical power required.1
The following formulae can be used for sample size calculation for different data types in a two-
arm, parallel group individually randomised trial. The number of individuals required per treatment
group is denoted m.
1.2.1 Continuous outcomes
m =
(z1−α/2 + z1−β)22σ2
δ2
(1.1)
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1.2. SAMPLE SIZE CALCULATIONS FOR RCTS
Where Zx is the x’th percentage point of the standard normal distribution, δ represents the minimally
clinically important difference in treatment means, µ1 − µ2, and σ2 the variance in the outcome.
1.2.2 Binary outcomes
m =
(z1−α/2 + z1−β)2[pi1(1− pi1) + pi2(1− pi2)]
δ2
(1.2)
Where pi1 is the probability of an event in the experimental group and pi2 the probability of an event
in the control group and δ represents the minimally clinically important difference in treatment
proportions, pi1 − pi2.
1.2.3 Ordinal outcomes
For an ordered categorical outcome with k levels, q = 1, 2, . . . k the formula for m is given by
Whitehead2
m =
6(z1−α/2 + z1−β)2/(logOR)2
1−∑kq=1 p¯i3q (1.3)
p¯iq is the mean proportion expected in category q and OR is the odds ratio of a patient being in
a given category or less, in one group compared to the other. Whitehead assumes the lower the
category the better the outcome.
1.2.4 Time-to-event outcomes
For time-to-event outcomes there are two commonly used formulae. The first, as defined by Schoen-
feld is:3
m =
(z1−α/2 + z1−β)2
log2eθ(1− pic)
(1.4)
Where θ denotes the hazard ratio of group 1 over group 2 and pic the probability of being censored.
The second formula, defined by Freedman,4 provides an estimate of the total number of events
required, E
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E = (z1−α/2 + z1−β)2
(1 + θ)2
(1− θ)2 (1.5)
1.2.5 Count outcomes
m =
[zα/2
√
2 + zβ
√
[1 + e−b˜]]2
eβ0 b˜2
(1.6)
Where β0 represents the event rate in the control group and b is the model parameter related to
treatment effect.
1.2.6 Rate outcomes
The number of person years required in each arm is given by
m =
(z1−α/2 + z1−β)2(λ1 + λ2)
(λ1 − λ2)2 (1.7)
Where λ1 and λ2 are the expected rates in each arm.
1.2.7 Derivation of sample size formula
Regardless of the trial design the process of deriving a sample size formula can be described in four
steps. These steps are illustrated here, assuming a normally distributed continuous outcome and a
standard two-arm, parallel group design.
Step 1: Define the treatment difference and variance
For continuous normally distributed outcomes the mean provides a useful summary statistic to
describe the response in each treatment group. µ1 and µ2 represent the population mean of the
treatment and control groups with associated variance σ2 (assumed to be the same in each group).
These population means will be estimated by sample means x¯1 and x¯2 with standard deviation s
at the end of the trial. For the purpose of sample size calculation estimates of x¯2 and s might be
estimated from previous similar studies and the value of x¯1 is usually chosen on the basis of clinical
expertise. The difference between the means d = x¯1 − x¯2 provides an estimate of the minimal
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clinically important treatment effect. The standard error of this difference is
√
2σ2
m and can be
estimated using the square of the sample standard deviation, s2 in place of σ2.
Step 2: Define the analysis method
In the context of clinical trials the Null hypothesis, denoted H0 is usually that there is no difference
between the two treatment groups.
H0: x¯1 − x¯2 = d = 0
The alternative hypothesis (our hypothesis of interest), denoted H1 is that there is a difference
between treatment groups, usually a difference in either direction is considered (a two-sided test).
H1: x¯1 − x¯2 = d 6= 0 (2-sided)
Step 3: Define the test statistic
In hypothesis testing we assume that the null hypothesis is true and we use the data collected from
the trial, to find evidence against it. A probability value (or P-value) is calculated to say how likely
it is that we would have obtained the observed trial data, or something more extreme, if in fact the
null hypothesis were true. A P-value of less than 5% is usually taken as providing enough evidence
to reject the null hypothesis. However, it has been argued by some that the results of trials should
not be categorised into significant or non-significant on the basis of a P-value cut-off. Instead they
should be interpreted in the context of the type of study and other available evidence.5
In order to derive the P-value we must first calculate a test statistic. The test statistic is a function
of our data and reduces the observed data to a single value. For continuous outcomes this is usually
the z-test:
z =
(x¯1 − x¯2)− d
σ
√
2
m
(1.8)
An important property of the test statistic is that the distribution under the null hypothesis is
known. In this case, under the null hypothesis the test statistic follows a standard normal distribution
Z ∼ N(0, 1).
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Figure 1.1: The probability density function (pdf) of a standard Normal distribution
When the value for z is 1.96, we know that for a standard normal distribution 0.975 of the distribution
lies below this and 0.025 above. Therefore if our test statistic gives a value of 1.96 or greater there
is a 2.5% chance or less that we would have observed our data under the Null hypothesis, and hence
we would reject the null hypothesis, see Figure 1.1. Due to the symmetry of the normal distribution
2.5% of the distribution also lies below -1.96. Therefore for a two-sided hypothesis test at the 5%
significance level a z value less than -1.96 or greater than 1.96 would provide significant evidence to
reject the Null hypothesis.
Step 4: Evaluate the test statistic under the null and alternative hypotheses
When deciding whether to reject the null hypothesis we can potentially make two types of errors
(1) Type I error: We reject the null hypothesis when it is in fact true (2) Type II error: We fail to
reject the null hypothesis when it is false. The acceptable levels for these errors are controlled by
the researcher at the design stage. The convention is to set the probability of a Type I error to 5%
or less (see step 3), referred to as α and the probability of a Type II error, referred to as β to 20%
or less.
Under the Null hypothesis, the hypothesised treatment effect is 0 and the test statistic, Equation
1.8, can be written as:
z =
(x¯1 − x¯2)
σ
√
2
m
(1.9)
31
1.2. SAMPLE SIZE CALCULATIONS FOR RCTS
Under the null hypothesis if the value of this test statistic is z1−α or greater we are incorrectly
rejecting the null hypothesis i.e. making a Type I error, see Part A of figure 1.2.
z1−α =
(x¯1 − x¯2)
σ
√
2
m
(x¯1 − x¯2) = z1−α[σ
√
2
m
]
Under the Alternative hypothesis, where the hypothesised treatment effect is δ, if the value of the
test statistic is −z1−β or less we make a Type II error, see Part B of figure 1.2.
−z1−β = (x¯1 − x¯2)− δ
σ
√
2
m
(x¯1 − x¯2) = δ − z1−β [σ
√
2
m
]
Equating these two expressions
z1−α[σ
√
2
m
] = δ − z1−β [σ
√
2
m
]
upon rearranging we are left with m, the required number of individuals per treatment group for a
continuous outcome and standard parallel group design
m =
2(z1−α+z1−β)2
∆2
Where ∆ = δσ . For a two-sided test α should be replaced with α/2.
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Figure 1.2: Graphical illustration of hypothesis testing errors
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1.3 Cluster randomised trials (CRTs)
In some circumstances groups (or clusters) of individuals are randomised together, as a unit, rather
than individually. These clusters are formed by some shared characteristic; they may be members
of the same family or people within a particular geographical location. The cluster may be large,
such as a hospital or General Practice surgery, or smaller like a family. These trials are referred to
as Cluster Randomised Trials (CRTs) and are the focus of this thesis.
1.3.1 Rationale for cluster based randomisation
Broadly speaking the rationale for cluster based randomisation is driven by the nature of the inter-
vention, the minimisation of costs, and/or the logistics of implementing the intervention.6–8
Some interventions are naturally applied at the level of the cluster and hence lend themselves to
cluster-based randomisation. For example a water filtration system to prevent diseases from con-
taminated water must be implemented at the water source either for a community or household and
therefore would affect all those living within that community or household.
It may be more cost efficient to implement an intervention at the cluster level. The IRIS trial
assessed the effectiveness of a training intervention to improve the recognition of domestic violence
by General Practitioners (GPs) working in different areas across the UK.9 Under randomisation of
general practice half of the GP practices were visited and trained in the intervention by trial staff.
This was more efficient than to have visited all practices and trained only half of the GPs within
each practice (as would occur under randomisation of individual GPs).
Avoidance of contamination is one of the advantages often cited for cluster-based randomisation.
Contamination refers to the process by which within at least one of the trial arms there may be an
unwanted presence of another trial arm. Contamination of treatment groups can result in a dilution
of the true treatment effect. In a trial of pain management to reduce behavioural disturbances among
dementia sufferers the care home was the unit of randomisation.10 The authors felt that it would be
difficult to individually randomise dementia suffers. Care staff receiving training in the assessment
and treatment of pain would be required to provide specific support to some participants and to, in
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effect, “unlearn” this training when providing treatment to control participants. Therefore an effect
of the training would likely be present in the control arm. Care staff may also struggle with the
ethical implications of having to do this. Randomisation by cluster in the IRIS trial also reduced the
risk of contamination among health professionals, whereby GPs would likely share aspects of their
training and new knowledge with other GPs in their practice had they been randomised individually.
Randomisation of clusters can also provide advantages in terms of treatment compliance. For example
interventions aimed at smoking cessation are more easily implemented at the level of the general
practice. Participants attending the same practice may know each other or come into contact when
attending the practice. The fact that participants are receiving the same intervention and able
to discuss the intervention and support each other, may actually lead to greater compliance to
the treatment than would be obtained in an individually randomised trial, and hence maximize
the effect of the treatment. Along similar lines, cluster randomised trials are often conducted in
infectious diseases or vaccine trials where the impact of the intervention is maximized when a large
proportion receives the intervention.11
1.3.2 Between-cluster variability
The outcomes among individuals within the same cluster are likely to be more similar than those
from a random sample of individuals. For example individuals attending the same general practice
will live within the practice catchment area and likely share a common environment, education and
economic status as well as being treated by the same health care professionals. These factors will
influence their health outcomes in a similar way, leading to similarity within the cluster.
The intracluster correlation coefficient
The magnitude of this similarity, or clustering, is most commonly quantified by a parameter known
as the intracluster correlation coefficient (ICC), usually denoted by ρ. When ρ = 0 we have, in effect,
statistical independence between members of a cluster. When ρ = 1 the opposite is true and we have
total dependence among members of a cluster.
For continuous outcomes the ICC can be expressed as
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ρ =
σ2b
σ2b + σ
2
w
(1.10)
Where σ2w is the within-cluster variance and σ
2
b the between-cluster variance.
Historically ICCs were not explicitly published in reports of CRT’s. Nowadays, however, there are
many sources of ICC estimates8,12,13 as well as publications which describe the general behaviour
and patterns in ICCs across different therapeutic areas, outcomes and clusters.14–18 For three types
of cluster that vary in size: the spouse pair; general practice and country Donner calculated the
within-cluster correlation for lifestyle outcomes: hypertension; smoking status; alcohol consumption;
and body fat. For all outcomes the within-cluster correlation decreased with the corresponding size
of the cluster.19
The coefficient of variation in outcome
An alternative measure of clustering to the ICC is the coefficient of variation in the outcome. This
is the between-cluster standard deviation divided by the parameter of interest i.e. the proportion,
rate or mean within each cluster.20
k =
σb
µ
(1.11)
This measure is particularly useful when the primary outcome variable is a rate as an ICC cannot
be calculated in that situation.
The relationship between the ICC and coefficient of variation
The clustering of outcomes must be accounted for in the sample size calculation using one of the
two measures of correlation, which will be described in more detail later (Section 1.4). For binary
outcomes a simple relationship exists between the two correlation measures but they make different
assumptions about how the between-cluster variation differs across treatment groups and so will
produce different sample size requirements. The use of the ICC is recommended for sample size
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calculations of binary outcomes unless the proportion is very small, where both methods give similar
results.21
1.3.3 Prevalence of cluster based randomisation
Several reviews of CRTs have been published and are summarised in Table 1.1. Many of these
reviews note that the prevalence of CRTs is increasing over time.22–30 In the review by Eldridge et
al the number of cluster trials identified in primary care in 1997 had almost doubled by 1999.25
This increased use of CRTs is reflected in the increase in the methodological literature. The paper
by Cornfield in 197831 was the first to highlight the fact that randomisation by cluster produces a
less efficient design. Since then five textbooks have been published on cluster trials by: Murray32
in 1998; Donner and Klar6 in 2000; Hayes and Moulton7 in 2009; Eldridge and Kerry21 in 2012;
and Campbell and Walters33 in 2014. The journals Statistics in Medicine, Clinical Trials, Statistical
Methods in Medical Research, and the American Journal of Epidemiology have each had a special
issue dedicated to cluster randomised trials. Most recently, in 2015, the Trials Journal published a
collection of articles on stepped-wedge designs, a type of CRT. Cluster randomised trials is a very
exciting, and rapidly expanding, area of research to work in.
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Table 1.1: Characteristics of 20 published reviews of cluster randomised trials
Author Dates Area Main sources N Review topic
Donner (1990)34 1979-1989 Non therapeutic intervention tri-
als
Lancet, NEJM, AJE, IJE 16 Quality of methods
Simpson (1995)35 1990-1993 Primary prevention trials American Journal of Public Health,
Preventive Medicine
21 Quality of methods
Chuang (2000)36 1974-1998 Computer-based clinical decision
support systems
Medline, Embase, and INSPEC 24 Quality of methods
Hayes (2000)11 1986-1999 infectious diseases Medline database 21 Evaluation of de-
sign features
Isaakidis (2003)23 1973-2001 Trials in Sub-Saharan Africa Medline, Cochrane Controlled Trials
Register, African Published Trials Reg-
ister
51 Quality of methods
and reporting
Puffer (2003)37 1997-2002 General medicine BMJ, Lancet, NEJM 36 Risk of bias
Eldridge (2004)25 1997-2000 Primary care Cochrane Controlled Trials register ,
UK National Research Register and
conference proceedings
152 Quality of methods
Varnell (2004)22 1998-2002 General medicine American Journal of Public Health,
Preventative Medicine
60 Quality of methods
Continued on next page
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Table 1.1 – continued from previous page
Author Dates Area Main sources N Review topic
Bland (2004)26 1983-2003 General medicine BMJ 18 Quality of methods
Murray(2008)38 2002-2006 Oncology Medline, PubMed 75 Quality of methods
Eldridge (2008)39 2004-2005 Primary care BMJ, BJGP, FP, preventive medicine,
Annals of internal medicine, journal of
general internal medicine, Paediatrics
34 Internal and exter-
nal validity
Bowater (2009)40 1998-2007 Tropical parasitic disease Medline database 35 Quality of methods
Handlos (2009)27 1998-2008 Maternal and child health Pubmed, SCOPUS, Cochrane library 35 Quality of methods
Mdege (2010)24 To Jan 2010 Stepped wedge trial Medline, Embase, PsycINFO, HMIC,
CINAHL, Cochrane library, Web of
Knowledge, current controlled trials
register, google scholar
25 Areas of applica-
tion
Ivers (2011)30 2000-2008 General Medicine Medline database 300 Quality of methods
and reporting
Walleser (2011)41 2004-2010 Trials in children Medline, CINAHL, Embase, cochrane
central register
106 Quality of report-
ing
Crespi (2011)42 1995-2010 Cancer screening interventions PubMed, Web of Science 50 quality of analy-
sis/outcome report-
ing
Brierley (2012)43 2008 General Medicine BMJ, Lancet, JAMA, NEJM 24 Bias in recruitment
Continued on next page
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Table 1.1 – continued from previous page
Author Dates Area Main sources N Review topic
Giraudeau (2012)44 2008 General Medicine Medline database 173 Reporting of in-
formed consent
Froud(2012)45 2005-2009 Oral Health PubMed and experts in the field 23 Quality of methods
and reporting
Diaz-Ordaz
(2013)28
up to 2010 Trials in old age residential facil-
ities
Medline database 73 Quality of methods
and reporting
Diaz-Ordaz
(2013)29
up to 2010 Trials in old age residential facil-
ities
Medline database 73 Reporting of in-
formed consent
Sutton (2013)46 2003-2011 Stroke PubMed 15 Quality of report-
ing
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1.3.4 Guidelines for best practice
Many of the fundamental principles of RCTs such as informed consent, randomisation, sample size
and analysis are more complex with randomisation by cluster. Methodology and guidelines for best
practice are not as well developed as those for individually randomised trials. The guidance that is
available is described in the following sections.
Design, analysis and conduct
In addition to the published textbooks on CRTs there are some additional sources of guidance on
the design, analysis and conduct of cluster randomised trials. In 1999 the methodological literature
around cluster randomised trials was reviewed and synthesized into 12 methodological recommenda-
tions designed to aid investigators designing and conducting these trials. The review covers study
design, measures of between-cluster variation, sample size and analysis.8 With regards to sample
size, the focus of my research, the advice given was to avoid designing studies with less than four
clusters per group and to calculate a sample size appropriate for cluster randomisation. In 2002 the
Medical Research Council (MRC) produced a brief guidance booklet on the methodological and eth-
ical aspects of cluster randomised trials which provides a basic introduction to the main issues to be
aware of when randomising clusters. Their advice on sample size was for a minimum of five clusters
per group. (http://www.cebma.org/wp-content/uploads/Cluster-randomised-trials-Methodological-
and-ethical-considerations.pdf). Guidance has also been developed for specific aspects of the cluster
randomised trial such as consent procedures for trials conducted in residential facilities.29
Reporting
The CONSORT statement consists of a 25-item checklist for improving and standardising the re-
porting of clinical trials. The statement was first published in 199647 and has since gone through
two further revisions.48,49 In 2004 the statement was extended for cluster randomised trials50 and
this extension was updated in 2012 following the update to the main statement in 2010.51
The item which relates to describing the sample size calculation for individually randomised trials
formally recommends the following descriptive elements to be reported (i) the estimated outcomes
in each group (which implies the minimum important treatment effect); (ii) the level of significance
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(or the α (type I) error level); (iii) the statistical power (or the β (type II) error level); and (iv) for
continuous outcomes, the assumed standard deviation of the outcome. For cluster randomised trials
the 2004 CONSORT extension additionally recommends the reporting of two further descriptive ele-
ments (v) the number of clusters or the cluster size(s) and (vi) the intracluster correlation coefficient
(ICC) or coefficient of variation (k), along with a measure of its uncertainty. The 2012 revision
additionally recommends specification of whether equal or unequal cluster sizes are assumed.
1.4 Sample size calculations for cluster randomised trials
For cluster randomised trials there may be several combinations of the number of clusters and cluster
size that produce designs with equivalent power. In these situations, to determine the optimal
design, one may additionally consider the efficiency of these designs in terms of the costs involved
in recruiting and measuring clusters and individuals within clusters. These scenarios are briefly
considered in Chapter Six but the focus of this thesis are scenarios where the cluster size or number
of clusters is fixed, or constrained, at the point of sample size calculation and the trial is designed
to produce a specified level of power.
In this section I briefly describe the most common approach to sample size calculation for cluster
randomised trials and describe recent developments prior to the start of my research and unresolved
issues to place my research in context. In Chapter Six I will return to look in more detail at the
developments and unresolved issues that remain at the end of my research.
1.4.1 Early work
Cornfield31 recognised that randomisation by cluster resulted in a less efficient design and so the
sample size assuming individual randomisation must be inflated to achieve adequate power under
cluster randomisation. Cornfield’s work was followed in 1981 by Donner52 who quantified this infla-
tion factor and described it as the Design effect. Despite being over 30 years old these two papers
still remain highly cited and use of the design effect for sample size calculation remains the most
common approach.
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1.4.2 The Design Effect(DE)
For continuous and binary outcomes the sample size calculated assuming individual randomisation
(Equations 1.1 or 1.2) is multiplied by the design effect to account for randomisation by cluster.
This design effect is given by
DE = 1 + (n− 1)ρ (1.12)
Where n is the number of individuals per cluster (assumed constant) and ρ is the intracluster corre-
lation coefficient. When we conduct a CRT we may sample an entire cluster such as all participants
registered at a General Practice, or take a sub-sample for inclusion into the trial. Throughout this
thesis, when I refer to cluster size, I am specifically referring to the sample of the cluster that is to
be included in the analysis, which may or may not be the entire cluster.
1.4.3 Recent developments
The design effect proposed by Donner was derived for continuous or binary data analysed at the
cluster level assuming a fixed cluster size. In some trials such as those conducted in ophthalmology
where a subject is the cluster and measurements are taken on each eye fixed cluster size may be a
reasonable assumption to make. However, to have variable cluster sizes is more common. In trials
where the cluster size is very variable use of the average cluster size in the design effect will likely
underestimate the required sample size. For cluster-level analysis simple methods are available that
provide an appropriate sample size using the harmonic mean of the sample size in each cluster.7
Recent reviews have shown developments in sample size calculations including methods allowing for:
variable cluster sizes, matched designs, re-estimation using internal pilots, attrition, incorporation of
covariates or multiple time points, time-to-event outcomes, and incorporation of imprecision in the
ICC.8,53–55
1.4.4 Unresolved issues
The methodological reviews indicate that although many sample size methods are being developed
to deal with variations and complexities in trial design the majority are still only applicable to binary
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or continuous outcomes. Methodology for alternative outcomes such as ordinal, count or time-to-
event is in the minority, especially for variations to the standard parallel group trial. However, these
reviews present only selected methods and do not provide a comprehensive review of all available
sample size methods. In Chapter Two I conduct a systematic review to provide a comprehensive
description of published sample size methods for cluster randomised trials.
1.4.5 Quality of methodology and reporting
Despite the simplicity of the design effect many trialists are still unaware of the need to adjust sample
size calculations to account for clustering in cluster randomised trials, or perhaps unaware that the
design they are using induces such clustering. Many of the reviews in Table 1.1 examined the quality
of both the trial methodology and reporting. The proportion of trials that reported a sample size
calculation and the proportion that reported an appropriate calculation can be seen in Table 1.2.
Despite the introduction of the CONSORT Statement many of the reviews showed that the reporting
was inadequate. In the largest review by Ivers et al whose sample is perhaps the most representative
of the health research field just over half of the trials reported a sample size calculation.30
Given that the CONSORT extension for cluster randomised trials was first published in 2004 it is
clear from Table 1.2 that sample sizes that appropriately account for clustering are reported with
low frequency. Much improvement to reporting is needed, poor reporting can make it difficult for
those designing trials to obtain the estimates they need for sample size calculations.
In this section I have described the use of the design effect as the most common method for sample
size calculation in cluster randomised trials. However, as the variety in trial designs increase such
as variable cluster sizes, attrition or repeated measurements the simple design effect may not always
be appropriate. The focus of my research is sample size calculations for ordinal outcomes. In the
following section I provide the definition of an ordinal outcome used throughout this research and
describe some simple and intuitive approaches to sample size calculation and why they may not
always be adequate.
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Table 1.2: Description of the quality of sample size reporting identified in published reviews of cluster
randomised trials
Author Reported
sample size
calculation
% Reported
appropriate
sample size
calculation
%
Donner (1990)34 NA 3/16 19%
Simpson (1995)35 5/21 24% 4/21 19%
Chuang (2000)36 1/24 4% 0/24 0%
Isaakidis (2003)23 47/51 92% 10/51 20%
Puffer (2003)37 NA 20/36 56%
Eldridge (2004)25 68/152 45% 21/152 14%
Varnell (2004)22 NA 9/60 15%
Murray(2008)38 40/75 53% 18/75 24%
Eldridge (2008)39 29/34 85% 21/34 62%
Bowater (2009)40 17/35 49% 10/35 29%
Handlos (2009)27 33/35 94% 25/35 71%
Mdege (2010)24 8/15 53% 3/15 20%
Ivers (2011)30 164/300 55% 100/300 33%
Walleser (2011)41 87/106 82% 63/106 59%
Froud(2012)45 21/23 91% 15/23 65%
Diaz-Ordaz (2013)28 43/73 59% 20/73 27%
Sutton (2013)46 NA 12/15 80%
1.5 Ordinal outcomes
1.5.1 Definition
An ordinal variable is one which consists of a set of categories which can be ordered or ranked. Disease
severity (mild, moderate, severe) or measures of agreement (completely agree, agree, do not agree,
disagree, do not agree at all) are examples of ordinal variables. The difference between participants
in adjacent categories may not be the same, and are often unmeasurable. For example the difference
in disease severity between moderate and severe could be much greater than the difference between
mild and moderate.
Where the outcome consist of categories which cannot be ordered, therefore each level does not
differ in magnitude for example marital status (single, married, divorced) the variable is referred to
as categorical, or nominal, within this thesis.
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1.5.2 Example of a trial with an ordinal outcome
Encouraging lifestyle changes such as smoking cessation, decreasing fat intake and increasing regular
physical activity can help prevent cardiovascular disease. Visits to primary healthcare can be an
opportunity for those at high risk of coronary heart disease to receive advice about changing their
lifestyle. In a trial by Steptoe et al 20 general practices were randomised to lifestyle counselling or
usual health promotion.56 Patients with one or more risk factors for coronary heart disease were
included in the study. Each patient completed a questionnaire prior to their physician visit and four
and twelve months after. This questionnaire measured a patient’s stage of motivation concerning
regular exercise and patients were categorised into one of five stages of change: Pre-contemplation
(patients are not eating a low-fat diet or currently exercising or are smokers, and they are not seriously
considering changing behaviour), contemplation (patients are considering a change in behaviour but
are not confident they will carry this out within the next month), preparation (patients are seriously
planning to change behaviour and are confident that they will make changes within the next month),
action (patients have changed behaviour within the last 6 months) and maintenance (patients have
maintained the change for at least 6 months).
1.5.3 Sample size approaches
In the Steptoe study the authors chose to dichotomise the ordinal outcome. Those in the action
and maintenance stages were combined and those in the remaining categories were combined. The
benefits of using a binary outcome are: sample size and analysis methods are well established;
parameter estimates are likely to be available; the dichotomised version may be more clinically
relevant; and it avoids problems in the analysis caused by a small number of observations in one of
the ordinal categories.
Had the authors analysed the outcome in its ordinal form they would have likely increased the power
of their study, as dichotomisation of the outcome results in a loss of information. For individually
randomised trials using a sample size calculation appropriate for the ordinal version of the outcome
can result in trials being on average 28% smaller compared to those powered on the dichotomous
version.57 It is unknown how conservative the dichotomous approach would be for the clustered
case. For a cluster randomised trial there is likely to be a large cost associated with recruiting an
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additional cluster as compared to recruiting an additional subject in an individually randomised
trial. Therefore to calculate a conservative estimate of sample size could be considered wasteful.
In addition to the dichotomisation approach there are two other valid approaches that can be taken
to arrive at a sample size estimate. The first is to choose an alternative primary outcome for which
sample size can be calculated easily. In some situations this may be a reasonable approach if several
outcome measures all of clinical relevance are being considered. The Core Outcome Measures in
Effectiveness Trials (COMET) initiative was set up in 2010 to develop a set of standardised core
outcomes that should be measured and reported in all trials of a certain condition. The consistent
use of these core outcomes in trials will ensure that more trials can be included in meta-analyses
and, most importantly, as each set of proposed core outcomes were chosen to be relevant to patients,
clinicians and policy makers the findings from the trial are likely to influence current practice.58
These are important justifications for the choice of outcome measure, convenience for the sample
size calculation is not.
The second method is to calculate the sample size via simulation methods. It can be computationally
intensive but provides a lot of flexibility, allowing full control of all parameters and so giving a closer
representation of real life. The procedure involves simulating a large number of data sets, each
one to represent a potential data set of results from the trial. For each simulated data set the
planned analysis is conducted and the empirical power calculated as the percentage of tests where
the null hypothesis is rejected. Changes in the input parameters can be made until adequate power
is achieved. This is a valid approach to use for ordinal outcomes and user written commands are
available in the statistical computer package Stata to aid the implementation.59 However, this
approach has disadvantages in both the time taken to compile the simulation and its potential
complexity. The aim of my research is to recommend an approach that is simpler to implement,
even if its use is only to provide an initial benchmark estimate that may be further refined with more
complex procedures.
1.5.4 The importance of this research
The literature around sample size calculations for cluster randomised trials has focused heavily on
continuous and binary outcomes. There is little guidance around sample size methods for ordinal
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outcomes. Simple approaches such as calculating a sample size based on the dichotomisation of the
outcome can be used but may be overly conservative and simulation methods require programming
knowledge to implement. Although less common than binary and continuous outcomes the use of
ordinal outcomes is not rare and hence there is a need for appropriate sample size calculations.
In my opinion the use of ordinal outcomes will become more prevalent in the future, particularly
for trials conducted in the UK setting. This is because the National Health Service in the UK is
becoming more patient centred and many Patient Reported Outcome Measures (PROMs) such as
quality of life tend to be ordinal.
1.6 The research aim
The aim of this research is to comprehensively review the existing state of knowledge of sample size
calculations for cluster randomised trials and to focus on the development of methods for ordinal
outcomes. These aims are covered in the following chapters:
• Chapter Two A comprehensive summary of sample size methods available for cluster randomised
trials. The review has two main aims: To identify the prevalence of sample size methods for ordinal
outcomes which will provide evidence for or against the need for development in this area; and to
identify the methods that have been used to derive sample size calculations for cluster randomised
trials, it may be possible to adapt or emulate one of these approaches to derive a sample size formula
for ordinal outcomes.
• Chapter Three A review of 300 published cluster randomised trials to determine the prevalence
and characteristics of trials with ordinal outcomes, providing additional motivation and context for
the development of sample size methods for ordinal outcomes.
• Chapter Four Analysis methods available for clustered ordinal outcomes: their assumptions,
advantages and disadvantages. Several proposed estimates for measuring between-cluster variability
in ordinal data that may be used in sample size calculation are also presented.
• Chapter Five Monte Carlo simulation studies are conducted to explore the relationship between
ICC estimators for ordinal outcomes and to assess the performance of using each of these ICCs in
sample size calculations.
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• Chapter Six A return to the review of sample size methods for cluster randomised trials with the
aim of identifying where there is scope for further development beyond this thesis.
• Chapter Seven A summary and discussion of the main findings from this research.
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Chapter 2
Sample size methods for CRTs
At the time of this research there is no single, up-to-date, published, resource that provides a
comprehensive summary of sample size methods available for cluster randomised trials. In this
chapter I undertake such a review to meet three main aims:
• The first is to identify the current availability of sample size methods for ordinal outcomes, the
results of which will inform the direction of my research.
• The second aim is to identify the different approaches that have been used to derive sample size
calculations for cluster randomised trials. It may be possible to adapt or emulate one of these
approaches, if necessary, to derive new sample size formulae for ordinal outcomes.
• The final aim is to provide researchers with a comprehensive summary of sample size methods for
cluster randomised trials that allows them to easily identify the formula to use for a given design,
outcome and analysis method.
This chapter describes the methods I used to conduct the review followed by the results relevant
to the first two aims: a description of the methods available for ordinal outcomes and a summary
of the approaches that have been used to derive sample size formulae. This chapter concludes with
a discussion of how the findings impact upon the research plan. The results of the third aim will
be provided in Chapter Six where the focus will be on summarising where the methodological gaps
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remain at the end of my research to inform the direction of future work. My review has been
published and can be found in appendix (ix).60
2.1 Review methods
The methods of the review were specified in advance and documented in a protocol (version 1.0
31/03/2011) to be found in appendix (i). SE and AC reviewed the protocol prior to implementation.
The following sections describe the actual conduct of the review, section 2.1.7 provides the detail
and explanation for any differences from the planned protocol.
2.1.1 Data sources
Cluster randomised trials are found within the educational literature as well as within health research.
However, the health research literature is the focus of my review as this is my area of expertise. In
addition CRTs are commonly used in health research and much of their methodological development
is focused around health research.
I conducted the review using electronic online databases, a personal collection of 41 articles on
sample size in CRT’s provided by SE, key text books on cluster randomised trials,6–8,32 and special
issue journals on cluster randomised trials.61–64 For the electronic search I used the online databases
PubMed and Web of Science.
The PubMed database is a free online database developed and maintained by the National Center for
Biotechnology Information (NCBI), at the U.S. National Library of Medicine (NLM). It contains over
20 million citations from the biomedical literature. The MEDLINE database is the largest component
of the PubMed database. Searches conducted in the MEDLINE database cover biomedicine and
health articles dating from 1946 onwards. Articles in the MEDLINE database are indexed using
Medical Subject Heading (MeSH) terms. MeSH terms are used by indexers to provide a consistent
way to index articles that may have used different terminology to describe the same concepts. In
addition to the MEDLINE database, PubMed also contains additional references such as those which
are yet to be indexed with MeSH and citations that precede the date that a journal was selected for
MEDLINE indexing.
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The Web of Science online database contains seven citation databases. The search was conducted
using only the most relevant, the “Science citation index expanded database”. This database contains
articles across 150 scientific disciplines from the year 1970.
2.1.2 Inclusion and exclusion criteria
I included an article in the review if it provided a method of sample size calculation for cluster
randomised trials, via formula, simulation or other approach. The first paper to report a particular
methodology was included in the review; subsequent papers describing the same approach were
excluded. The two electronic databases searched, PubMed and Web of Science contained articles
from 1946 and 1970 onwards respectively, no further date restrictions were applied. I excluded those
papers written in a language other than English. To have conducted this search in other languages
would not have been feasible due to the cost involved in translation of manuscripts.
The following types of paper were excluded from the review as they were considered to be: too general
for the review; unlikely to contain new methodology or sufficient detail on sample size calculation;
or contain information irrelevant to the review aims
• Those reporting a trial protocol or trial results
• Those that provide a very general discussion on the effects of clustering or correlated data
• Papers focusing on non-randomised observational studies
• Those that only discuss the calculation of the within-cluster correlation component of sample
size estimation
• Those describing correlated data but individually randomised, for example:
– Clustering induced by the treatment itself, for example several participants attending a
group therapy intervention, but individually randomised to treatment group
– Clustering present due to centre effects
– Correlated data due to recurrent events occurring to the same subject
– Correlation due to multivariate outcomes
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Development of the inclusion and exclusion criteria
I developed the inclusion and exclusion criteria from a preliminary basic search I conducted of the
sample size literature for CRTs in the PubMed database. This search revealed articles covering a
broad range of topics:
1. Those which derive some or all methodological aspects of sample size formulae, using either a
Bayesian or frequentist approach.
2. Those which provide suggested adaptations or extensions to previously derived formulae.
3. Papers with a broader focus that discuss design features in general for cluster randomised
trials.
4. Overviews or summaries of the current methodology in a particular area.
5. Papers which focus on the calculation/estimation of the intracluster correlation or coefficient
of variation of outcome.
6. Papers evaluating or comparing alternative methods.
7. Papers with a general discussion on the effects of clustering upon sample size and power.
8. Papers describing application tools for implementation of the methodology.
9. Protocols or design papers for specific cluster randomised trials, describing the sample size
calculation, as applied to a specific trial.
10. Reports of results from cluster randomised trials.
To fulfil the objectives of this review I developed the search criteria to target articles of type 1-4.
Papers of type 5-10 were to be excluded due to reasons described at the beginning of this section.
2.1.3 Search terms
To improve the relevancy of results retrieved I chose to base my search terms on only the article title
and MeSH term used to index the paper.
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The list below contains the search terms for the PubMed database. This list includes all changes
which were made after validation of the search terms (see section 2.1.6)
1. cluster analysis[MeSH] AND sample size[MeSH]
2. “sample size” [Title]
3. “design effect”[Title] OR “design effects”[Title] OR “variance inflation factor”[Title]
4. (design*[Title] OR plan*[Title] OR siz*[Title]) AND cluster*[Title] 1
5. power [title] AND cluster*[Title]
6. “intraclass correlation*”[Title] OR “interclass correlation*”[Title] OR “intracluster correla-
tion*”[Title] OR “coefficient of variation”[Title] OR “between cluster”[Title]
7. coefficient[Title] AND variation[Title]
8. (design[Title] OR matching[Title]) AND community[Title]
9. power[Title] AND correlated[Title]
10. number[Title] AND clusters[Title]
11. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10
The Web of Science database does not index articles with MeSH so I did not perform this component
of the search for this database. I additionally refined the searches within Web of Science by limiting
the search to articles only, thereby excluding conference proceedings and letters etc. which are not
listed in the PubMed database.
All articles retrieved using these search terms were assessed for eligibility following the procedure
described in section 2.1.4.
1The “*” is used as a wildcard to search on all words that are formed from the truncated word entered. For example
siz* will find all words formed from siz such as “size” and “sizing”.
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Development of search terms
I developed the search terms using the personal collection of 41 articles from SE to determine (1)
the most common MeSH terms used to index these papers and (2) the terminology commonly used
in the title description.
Thirty five of the papers were available via PubMed and had 199 associated MeSH terms. The most
frequent being “randomized controlled trials as Topic” (n=28), “cluster analysis” (n=20), “research
design” (n=16), and “sample size” (n=20). However, the definition of the MeSH term “Cluster
analysis” is not strictly applicable to cluster randomised trials. MeSH description of cluster analysis
is
“A set of statistical methods used to group variables or observations into strongly inter-
related subgroups. In epidemiology it may be used to analyse a closely grouped series of
events or cases of disease or other health related phenomenon with well-defined distribu-
tion patterns in relation to time or place or both”
The term cluster analysis is unreliable due to its incorrect and inconsistent use for indexing papers.
Therefore its use was combined with the term sample size to reduce retrieval of irrelevant results.
The term “randomized controlled trials as topic” and “research design” are very broad and their
use would retrieve a vast amount of literature irrelevant to this review, including literature related
to individually randomised trials. With this in mind I did not use the MeSH term for randomised
controlled trials or research design. A review of all MeSH terms available for indexing did not identify
any further terms that might be useful to this review.
Due to the inconsistent use of MeSH terms and the lack of terms specific to the needs of this review
the use of MeSH terms alone would likely retrieve a large number of irrelevant results and may miss
some that are relevant. Therefore I supplemented the search by a search for specific text within
the article title only. In the 41 papers of the personal collection the term “sample size” was the
most frequently used. However, the terms “Design effect” and “power” were also frequently used.
As the term power has a large number of meanings, I restricted its search to those papers which
additionally mentioned clustering in some form within the title in order to reduce the number of
irrelevant articles retrieved.
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Within PubMed the word “of” is a stopword and is ignored when searching for a phrase. There-
fore rather than search on the phrase “coefficient of variation” I chose to search on the separate
components, similarly with the phrase “number of clusters”.
Web of Science treats the word “of” as a placeholder when contained in the search for a phrase.
Therefore a search with the phrase “coefficient of variation” will retrieve all results where the two
terms are separated by one word, such as “coefficient and variation” and “coefficient of variation”.
I used this search rather than the search on the two separate components which was required when
searching PubMed. The word “between” is similarly treated as a placeholder in Web of Science.
This means that a search on ”“between cluster” will retrieve any article with the word cluster in
the title. This retrieves a vast number of articles, with many irrelevant articles relating to disease
clusters and laboratory data. Therefore I excluded the search term “between cluster” from the Web
of Science search.
2.1.4 Search strategy
I applied the search terms first to the online databases, this was followed by a hand search of personal
collections, textbooks and special issue journals.
An article was first assessed for inclusion based upon the title. Where eligibility was unclear I then
reviewed the abstract, and if still unclear I reviewed the full text. Any paper where eligibility was
still unclear after examination of the full text was discussed and eligibility agreed with SE and AC.
The references of all papers identified as eligible were searched. Any new eligible articles were added
to the review and the process continued until it was agreed with SE and AC that sufficient saturation
of new methodology or concepts had been achieved.
I sent the final list of included papers to experts who have made significant contribution in the field
for their thoughts upon its coverage: G.J.P. van Breukelen, Mike Campbell, Allan Donner, Steven
Tereenstra, and Obi Ukoumunne. Additional papers suggested by these experts for inclusion or
review were assessed using the process described in this section.
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2.1.5 Data collection and management
All details of the articles retrieved from the search of the electronic databases were imported into a
Microsoft Access 2010 database for storage. I designed and created this database and screen prints
can be found in the protocol (see appendix i). Each article was stored with a unique identifica-
tion number and the information imported from the electronic databases included authors, year,
title, journal, volume, issue, start page, end page, and the abstract. Within the Access database I
categorised each retrieved result for inclusion or exclusion, with associated reason.
For each paper that was identified as eligible I extracted the following information 1) the authors,
title, journal, date of publication and database id 2) the trial design features 3) the formulae described
for each design 4) the correlation measure used 5) the analysis method assumed 6) the assumptions
underpinning the methodology 7) the simulation procedures used to evaluate the methodology 8)
the strengths and weaknesses as stated by the authors and 9) any extensions of the methodology.
This extracted information was collected on a paper based data extraction form which I designed
and can be found in the protocol (appendix i).
Where I made assumptions with regard to information that was not explicitly stated within a paper
I clearly identified as ”assumed” on the data extraction form. For example it was not always explicit
that fixed cluster sizes were assumed but it could be reasonably assumed if the formula clearly
included only an estimate for the average cluster size or a fixed cluster size. Where reasonable
assumptions could not be made the information was recorded as unclear on the data extraction
form. In papers where much of the paper and its methodology was unclear I collected only basic
information about the trial design and relevant sample size formulae, as agreed with SE and AC.
I performed all data extraction and articles with ambiguity were discussed with SE and AC.
2.1.6 Validation
I implemented validation methods at various stages of the review process in order to provide confi-
dence in the quality of the review and its ability to fulfil its intended objectives.
Inclusion/exclusion criteria
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I piloted the inclusion/exclusion criteria on 20 search results in order to identify any need for revision.
No revision was deemed necessary. However, during the review some of the criteria were more
explicitly defined.
Search terms and strategy
At the design stage the appropriateness of the search terms and general strategy to retrieve the
targeted papers was validated in two ways.
First I assessed the titles of the papers included in the personal collection of 41 papers to determine
if they would be identified from the proposed search terms, and in the majority of cases they were.
Those which were not identified were cited by eligible papers and so would have been identified as
eligible for the review from a search of references, alongside the context of the citation in the included
paper.
Secondly I compared the search terms with the retrieved results from a search that could be con-
sidered to be a “gold standard”. A computer based search of the Statistics in Medicine journal was
used as the “gold standard” search as this journal was considered most likely to contain articles on
methodology of sample size calculations. Using PubMed I retrieved all articles published in Statistics
and Medicine from 1982 to March 2011 and included reference to clustered data or cluster randomised
trials. This search produced fewer than 200 results. Based upon an individual assessment of each
title these results were reduced to those which would warrant further examination and compared to
the proposed search terms. Of these 200 results many of the early articles made reference to com-
munity intervention trials rather than cluster randomised trials, as they are now more commonly
known. The term community was therefore added to the search terms in combination with design
or matching to pick up these articles in the main review. “Number of clusters” was also a common
phrase used to describe sample size and was added to the search terms.
Data extraction
Before its implementation I piloted the data extraction form on five papers from the personal collec-
tion of articles. The test papers were selected to cover different styles of article, from those of a very
practical nature to those with detailed information on the mathematical derivations. The extraction
form was then refined based on this pilot.
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The data extraction process was validated by an independent double data extraction for ten articles.
Five were additionally extracted by SE and five by AC. Discussions took place to agree any differences
in interpretation. In the protocol I stated that these ten articles would be randomly selected.
However, during the process of the review it became clear that the ease of data extraction varied
among the papers and that it would be most useful to perform double data extraction on the more
challenging papers.
In addition during the process of preparing the review for publication many of the papers were dis-
cussed with SE and AC which provided further reassurance of my interpretation and understanding
of the methods described and the assumptions made.
2.1.7 Changes in conduct from the planned protocol
In the protocol I stated that monthly email notifications based on the search terms would be set
up within the electronic databases for the duration of the project in order to keep informed of new
developments. However, the email notifications were not received, possibly due to anti-virus or spam
technology. Therefore to identify any new methodological developments since the main search date
I re-ran the search on the two online databases near the end of my research, 27th August 2015.
The additionally identified methods are described in Chapter Six where I provide a comprehensive
summary of sample size methods.
During the course of the review several special issue journals on cluster randomised trials came to
light. All special issue journals were then additionally included as data sources as they contained a
high concentration of articles with potential for eligibility in the review.
I had planned an electronic search based on first authors of papers identified as eligible. After
completion of the electronic searches and reference searches of eligible papers it was agreed with SE
and AC that a search on first authors would not be conducted. Due to the large number of distinct
contributors in the review a search based on first authors would likely retrieve a very large number
of potential results for assessment and, given the time needed to review the results, was unlikely to
identify a significant number of methods that would not have already been identified through the
other data sources.
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In the protocol I stated that
”articles will be eligible for the review if they discuss any aspect relating to the method-
ology of sample size or power. This includes those papers which may discuss or simulate
only components of the sample size.”
During the process of the review I decided to exclude papers that reported only on the calculation
or estimation of the ICC for two reasons. The first being that the definitions of ICCs relevant
for a sample size calculation would be most likely found in the paper that described the sample
size calculation. ICCs calculations without reference to a sample size formula were not likely to be
useful. Secondly the ICC has other uses in addition to its place in CRTs so irrelevant results would be
retrieved. For example it can be used in quantifying the inter-rater reliability of instruments, often
psychometric scales. Inter-rater reliability assesses the degree to which two raters give consistent
observations, if raters do not agree either the scale is defective or the raters need to be trained in its
use. In this context the ICC is high when there is little variability among the raters.
In the protocol sample size calculations for correlated data due to repeated measurements on the
same individual were to be excluded. However, during the review one paper that reported a sample
size method for longitudinal data was included. The reason for its inclusion was that it was one of
very few papers to consider ordinal outcomes and I considered it important to assess its potential to
be applied to cluster randomised trials.
2.2 Results
2.2.1 Description of included papers
I applied the search terms to the online databases on the 31st of March 2011. From 8393 retrieved
records 77 papers were identified as eligible. A further 4 were identified as eligible from the personal
collection of articles on sample size in CRTs provided by SE and special issue journals and 4 were
identified as eligible ad-hoc during the review and collation of results (identified: via colleagues; from
feedback from experts in the field; or published after the initial search). In total 85 papers describing
sample size methodology were included in the review. A list of the included papers can be found in
appendix (ii). Figure 2.1 shows the flow of articles through the review process.
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Records identified in Web of Science (n=5704)
Records identified in PubMed (n=3027)
Records after duplicates removed (n=8393)
Full text articles assessed for eligibility
(n=72)
Excluded (n=11):
a) Results in an earlier included paper (n=1)
b) Not applicable in CRT context (n=2)
c) One sample (n=2)
d) Other form of clustering (n=4)
e) Methodology already included (n=2)
Papers included (n=61) Identified through reference searches (n=15)
Papers included (n=76) Identified through reference searches (n=1)
Total papers included (N=85)
Books, special issue journals, personal collec-
tion search (n=4)
Identified ad-hoc during the review (n=4)
Figure 2.1: Systematic review sample size methods selection: Flow diagram describing number of papers
screened, assessed for eligibility and included
The two journals where the largest number of the included papers were published were Statistics in
Medicine 29 (34%) and Biometrics 7 (8%). The number of sample size methods has increased over
time, with 58 (68%) of papers published since 2000. In terms of the trial characteristics the majority
of sample size methodology was aimed at binary or continuous outcomes, completely randomised,
parallel group superiority designs, see Table 2.1.
The results of the review are now presented according to the initial objectives:
• To identify and describe sample size methods available for ordinal outcomes.
• To identify the approaches used to derive sample size formulae.
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Table 2.1: Characteristics of the 85 published sample size methods for CRTs included in the systematic
review
N (%)
Journal Statistics in Medicine 29 (34%)
Biometrics 7 (8%)
International Journal of Epidemiology 4 (5%)
American Journal of Epidemiology 2 (2%)
Journal of Clinical Epidemiology 3 (4%)
Controlled Clinical Trials 4 (5%)
Clinical trials 3 (4%)
Journal of Biopharmaceutical Statistics 3 (4%)
Journal of Educational and Behavioral Statistics 3 (4%)
Journal of Educational Statistics 1 (1%)
Journal of the Royal Statistical Society 3 (4%)
Other Journals/books 23 (27%)
Year of publication pre 1990 6 (7%)
1990-2000 21 (25%)
2000-2010 43 (51%)
2010 onwards 15 (18%)
Type of outcome *Binary/Continuous 74 (87%)
Time-to-event 5 (6%)
Rates 2 (2%)
Count 2 (2%)
Ordinal 2 (2%)
Randomisation Simple 78 (92%)
Matched 6 (7%)
Stratified 1 (1%)
Minimisation 0 (0%)
Design Parallel group 80 (94%)
Cross-over 3 (3%)
Stepped wedge 2 (2%)
Objective Superiority 83 (98%)
Non-inferiority 1 (1%)
equivalence 1 (1%)
* Notes. Binary and continuous outcomes were often contained within the same paper. They have
been combined here so the denominator is the 85 papers included in the review.
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2.2.2 Objective 1: Sample size methods for ordinal outcomes
Of the 85 sample size methods included there were two that were applicable to clustered ordinal data.
The first method was proposed by Kim et al in 2005.65 It deals with clustered ordinal data occurring
in repeated measurement designs where the individual can be thought of as a cluster and measure-
ments are taken on each individual at several time points. The second method was proposed by
Campbell and Walters in their textbook on the design, analysis and reporting of cluster randomised
trials published in 2014.33 A standard parallel group design is assumed where measurements are
taken on individuals within a cluster.
In the following sections I present the details of each method with a worked example. I start with
the method proposed by Campbell and Walters which is more readily applied to the CRT context
and the simpler of the two methods.
Campbell and Walters sample size method for ordinal outcomes
Notation
Campbell and Walters33 state that the sample size formula for ordinal outcomes in individually
randomised trials, derived by Whitehead,2 can be inflated by the standard design effect to account
for randomisation by cluster. For an ordered categorical outcome with k levels, q = 1, 2, . . . k where
a higher category implies a worse outcome the sample size per group, m, is calculated as:
m =
6[z1−α/2 + z1−β ]2/θ2
[1−∑kq=1 p¯i3q ] [1 + (n− 1)ρ] (2.1)
Where α and β are the overall Type I and Type II errors respectively, z(1−α/2) and z(1−β) the corre-
sponding percentage points of a standard normal distribution. p¯iq is the mean proportion expected
in ordinal category q calculated as p¯iq = (piq1 +piq2)/2, where piq1 and piq2 are the proportions in cate-
gory q for the intervention and control groups. The number of individuals per cluster, n, is assumed
constant and ρ is the intracluster correlation coefficient. The log-odds-ratio, θq is the probability of
a response q or better (i.e. in a lower category) for a subject in the experimental group relative to
a subject in the control group and is calculated as
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θq = log
(
Pq1(1− Pq2)
Pq2(1− Pq1)
)
(2.2)
Where Pq1 and Pq2 are the cumulative probabilities of an individual in the experimental and control
groups respectively giving a response in category q or better.
The underlying assumption of Whitehead’s method is that of proportional odds, i.e. the log-odds-
ratios for being in each category or better, θq share a common value, θ, which is used in the sample size
calculation. If the observed probabilities do not satisfy the assumption of proportional odds power
may be substantially reduced. Whitehead does not suggest an alternative sample size calculation if
the proportional odds assumption is violated.
The method by Whitehead assumes an eventual analysis by a Mann-Whitney test which is equivalent
to an ordinal regression when only treatment group is fitted in the model.66 Ordinal regression
methods can be extended to deal with clustered data and are more available in statistical packages
than their non-parametric counterparts. It is assumed in this thesis that use of the design effect for
ordinal outcomes assumes a random effects ordinal regression with proportional odds, although this
is not explicitly stated by Campbell and Walters. More detail on the analysis of ordinal outcomes
will be considered in Chapter Four.
Worked example
The use of the formula is illustrated by extending the example provided in the Whitehead paper to
a CRT design.
In a two-arm clinical trial patient response after three months of treatment is measured as a four-level
ordinal outcome (very good, good, moderate, poor). The proportions, piq, and cumulative propor-
tions, Pq, expected in each category are provided in Table 2.2 for the control (2) and experimental
groups (1).
As can be seen in the table the log odds ratio does appear to be reasonably equal across the response
categories, indicating the assumption of proportional odds is reasonable. In this example the reference
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Table 2.2: Sample size calculation for an ordinal outcome example: Expected proportions in each outcome
category for each treatment group of a trial*
Very Good Good Moderate Poor
(q = 1) (q = 2) (q = 3) (q = 4)
piq2 0.2 0.5 0.2 0.1
Pq2 0.2 0.7 0.9 1
piq1 0.378 0.472 0.106 0.044
Pq1 0.378 0.85 0.956 1
p¯iq =
1
2 (pq1 + pq2) 0.289 0.486 0.153 0.072
p¯i3q = 0.024 0.115 0.00358 0.000373
θq 0.888 0.887 0.881
* (Source: Whitehead2)
improvement for the sample size calculation was chosen by Whitehead as 0.887, power was set at
90% and a two-sided alpha of 0.05 chosen. For illustration I assume an ICC of 0.05 (a typical value
for outcomes and clusters in health services research21) and cluster size of 5 in the design effect.
Using equation 2.1 the number of individuals required per group for the clustered design is
m =
6[z1−α/2+z1−β ]
2/θ2
[1−∑kq=1 p¯i3q ] [1 + (n− 1)ρ]
= 6[1.96+1.282]
2/(0.887)2
[0.857] [1 + (5− 1)× 0.05]
= 93.53× 1.2 =115 people per arm
This corresponds to 23 clusters of size 5 in each treatment group.
Areas for further development
The use of the design effect for ordinal outcomes has been suggested only recently and therefore is
not as well established as it is for binary or continuous outcomes. This means that the reporting of
the relevant estimates required may not be standard practice and it may be difficult for researchers to
implement this formula if they have no good estimates to base their calculations upon. Examples of
the parameter estimates calculated from real data may aid researchers in implementing this method.
It would also be useful to use real datasets to consider how realistic the assumption of proportional
odds might be. I present some real-life estimates in Chapter Four.
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As described in Chapter One there are several papers that describe the calculation of the ICC
for binary or continuous outcomes. The calculation for ordinal outcomes has received much less
attention. For ordinal outcomes there are no recommendations about which ICC estimator to use
in the design effect. Therefore evaluating the performance of this method using several different
estimators of the ICC and under deviations from the underlying assumption of proportional odds is
needed in order to provide clear recommendations for its use. I undertake this work in Chapter Five.
Kim et al sample size method for ordinal outcomes
Notation and model
Kim et al65 propose a sample size calculation based upon an analysis by GEE, with inference based
on the Wald test. Their sample size method is an extension of the method proposed by Rochon67 for
binary outcomes and assumes the analysis method of Lipsitz et al.68 The method by Kim assumes
a longitudinal design where measurements are taken at several time points for each individual. In
the following notation I refer to sub-units within a cluster, in this example these subunits are time
points but within the usual CRT context these would be individuals. At the end of this example I
discuss the application of this method in the CRT context.
For each sub-unit we observe the response on a k-level ordinal outcome with categories q = 1, 2, . . . , k.
A higher category here is used to indicate a better outcome. Let Zij denote the ordinal response
of the j’th sub-unit in the i’th cluster, j = 1, 2, . . . , n and i = 1, 2, . . . C. The size of the cluster is
assumed constant and denoted by n.
We form k indicator variables Yijq, where Yijq = 1 if sub-unit j has response q and Yijq = 0 otherwise.
For each sub-unit we form a k-1 response vector Yij = [Yij1, . . . , Yij(k−1)]′ formed from the indicator
variables, and for each cluster Yi = [Y
′
ij, . . . ,Y
′
in]
′
The marginal probability of a response in category q is denoted by Pr[Zij = q] = E[Yijq] = Pr[Yijq =
1] = piijq and the corresponding marginal cumulative probabilities by Pr[Zij ≤ q] = Pijq
Lipsitz et al analyse the data using a marginal model based on cumulative logits
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logit[Pijq] = Xβ (2.3)
Where X denotes a (k − 1) × k design matrix for the j′th sub-unit of the i′th cluster and β =
[α1, . . . , αk−1, β]′ denotes a k×1 parameter vector. Where the αq correspond to the q′th cumulative
logit and β denotes the effect of the intervention.
The GEE method assumed for the analysis is taken from Lipsitz et al,68 an extension of Liang and
Zegar’s method for binary data.69 The estimate of the treatment effect, β, is found by solution of
the generalised estimating equation proposed by Lipsitz.68 Calculation requires specification of the
correlation matrix and the working covariance matrix. The significance of the treatment effect is
then determined using the Wald test statistic. The variance of the treatment effect used in the Wald
test can be calculated in two ways: via the model-based estimate of variance or a robust calculation
which is less sensitive to miss-specification of the working covariance matrix. The details of these
calculations will be seen in the worked example that follows and discussed in Chapter Four. The
sample size method is described as being conservative if a maximum likelihood approach is taken.
Worked example
Here I work through the example described in section four of the original paper by Kim. I include
additional detail providing the explicit step by step calculations to implement the method.
A clinical trial was conducted to assess the efficacy of auranofin compared to placebo for rheumatoid
arthritis. Patients were randomly assigned to one of the two groups with equal allocation and
assessed at 1 month, 3 months and 5 months post randomisation. The outcome measurement was a
three-level ordinal outcome measuring self-assessment of arthritis (1) poor, (2) fair, (3) good. In the
paper the power calculation was performed post-hoc with the correlation parameters and observed
proportions in each ordinal category at each time point taken directly from the analysis, power was
identified to be only 68%. In order to replicate the result given in the paper and for illustration
of using this method to calculate a sample size at the design stage of a trial I set the power in
the following worked example to be 68% and assume the observed proportions are those that were
assumed for the trial design , with a two-sided 5% significance level. In this example the authors
plan a test for an overall difference between the two groups for the three timepoints i.e. they assume
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the treatment effect is the same at every time point. This may not be the case for all longitudinal
studies.
There are twelve steps in calculating the sample size.
Step 1: Specify the error rates
α = 0.05
Type II error=β=0.32
∴ power = 0.68
Step 2: Specify the number of treatment groups and their relative sizes
The number of treatment groups, T=2 [t=1 (intervention), t=2 (control)]. The relative size of each
treatment group=1 i.e. equal allocation
Step 3: Specify the number of categories in the ordinal response
Number of categories in the ordinal response, k=3 (poor, fair, good)
Step 4: Specify the cluster size
In this example 3 measurements are taken on each individual at 1 month, 3 month and 5 month
follow-up time points. Therefore the cluster size n=3.
Step 5: For each sub-unit specify the probabilities of a response for each ordinal cate-
gory, by treatment group
The probabilities are described in Table 2.3.
Table 2.3: Sample size calculation for an ordinal outcome example: Observed proportions in each outcome
category for each time-point and treatment group of a trial*
Treatment Response 1 month 3 months 5 months
Placebo Poor 29.7% (pii11) 27.7% (pii21) 25.2% (pii31)
Fair 33.8% (pii12) 42.6% (pii22) 35.4% (pii32)
Good 36.5% (pii13) 29.7% (pii23) 39.5% (pii33)
Auranofin Poor 11.9% (pii11) 20.3% (pii21) 15.1% (pii31)
Fair 51.0% (pii12) 35.1% (pii22) 34.9% (pii32)
Good 37.1% (pii13) 44.6% (pii23) 50.0% (pii33)
* (Source: Kim65)
Step 6: Specify the link function
The link function assumed is the cumulative logit link (clogit)
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Step 7: Specify the design matrix
Assuming a proportional odds model the [Tn(k − 1)× k] design matrix is given as:
X =

1 0 0
0 1 0
1 0 0
0 1 0
1 0 0
0 1 0
1 0 1
0 1 1
1 0 1
0 1 1
1 0 1
0 1 1

This can be defined separately for each treatment group.
X2 =

1 0 0
0 1 0
1 0 0
0 1 0
1 0 0
0 1 0

,X1 =

1 0 1
0 1 1
1 0 1
0 1 1
1 0 1
0 1 1

Step 8: Determine the correlation structure, R
The correlation matrix R is a matrix of n(k − 1) × n(k − 1) dimension. The n diagonal blocks of
R are defined by the (k − 1) × (k − 1) standard correlation matrix of a multinomial variable, the
diagonal elements of which are
corr(Yijq, Yijq) = 1
and the off-diagonal elements are
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corr(Yijq, Yijq′) =
−piijqpiijq′√
(piijq(1−piijq)piijq′ (1−piijq′ ))
where q and q′ refer to levels of the response variable and q 6= q′
The remaining unknown elements of R are the elements of the (k − 1)× (k − 1) correlation matrix
of two sub-units from the same cluster. The diagonal elements represent the correlation for pairs
of indicators between two sub-units for the same category (either ‘poor’ or ’fair’). The off-diagonal
elements represent the correlation between two sub-units for two adjacent categories. In this example
the matrix used is that provided in Table V directly from the analysis of this dataset by Lipsitz et
al, as the calculation is being performed post-hoc.68 Exchangeability is assumed among members of
a cluster.
Φ = Corr(Yij ,Yij′) =
Corr(Yij1, Yij′1) Corr(Yij1, Yij′2)
Corr(Yij2, Yij′1) Corr(Yij2, Yij′2)
 =
0.392 0.151
0.151 0.208

Therefore, the correlation matrices for the treatment and control group are defined as:
R1 =

1 −0.37 0.392 0.151 0.392 0.151
−0.37 1 0.151 0.208 0.151 0.208
0.392 0.151 1 −0.371 0.392 0.151
0.151 0.208 −0.371 1 0.151 0.208
0.392 0.151 0.392 0.151 1 −0.308
0.151 0.208 0.151 0.208 −0.308 1

R2 =

1 −0.462 0.392 0.151 0.392 0.151
−0.462 1 0.151 0.208 0.151 0.208
0.392 0.151 1 −0.533 0.392 0.151
0.151 0.208 −0.533 1 0.151 0.208
0.392 0.151 0.392 0.151 1 −0.428
0.151 0.208 0.151 0.208 −0.428 1

Step 9: Derive the working covariance matrix V and the matrix D
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The matrix Vi is the working covariance matrix of Yi, the cluster response vector. Since the marginal
distribution of Yij is multinomial the (k − 1) × (k − 1) diagonal blocks of Vi are the multinomial
covariance matrices. That is each diagonal entry is the variance piijq(1 − piijq) with covariance
−piijqpiijq′ on the off diagonal.
The covariance matrix V can be defined for each treatment group as
Vt = A
1/2
t RtA
1/2
t
Where Aij is a diagonal matrix with the binary variances of the indicator variable, var(Yijq), on the
diagonal Aij = Diag[piij1(1− piij1), . . . piij(k−1)(1− piij(k−1))].
∴ A1/2it = Diag[piit1(1− piit1)1/2, . . . piit(k−1)(1− piit(k−1))1/2]
and the matrix At = Diag[Ai1, Ai2, . . . , Ai(k−1)]
Using the matrices R and A the matrix V for the intervention group is calculated as:
V1 =

0.104839 −0.06069 0.0510534 0.0233353 0.0454454 0.0233046
−0.06069 0.2499 0.0303625 0.0496275 0.0270273 0.0495621
0.0510534 0.0303625 0.161791 −0.071253 0.0564554 0.0289506
0.0233353 0.0496275 −0.071253 0.227799 0.0258045 0.0473198
0.0454454 0.0270273 0.0564554 0.0258045 0.128199 −0.052699
0.0233046 0.0495621 0.0289506 0.0473198 −0.052699 0.227199

⇒ V−11 =

25.366113 10.094366 −9.066519 −5.892443 −7.66796 −4.19997
10.094366 8.5726621 −4.535907 −3.380871 −3.730698 −2.488696
−9.066519 −4.535907 16.285962 8.3823852 −6.047153 −3.304235
−5.892443 −3.380871 8.3823852 9.313599 −3.812866 −2.550373
−7.66796 −3.730698 −6.047153 −3.812866 17.726874 7.2767969
−4.19997 −2.488696 −3.304235 −2.550373 7.2767969 8.0152027

and the control group
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V2 =

0.208791 −0.100386 0.0801588 0.0341188 0.0777666 0.0329952
−0.100386 0.223756 0.0319649 0.0486532 0.031011 0.047051
0.0801588 0.0319649 0.200271 −0.118002 0.0761634 0.032315
0.0341188 0.0486532 −0.118002 0.244524 0.0324182 0.0491861
0.0777666 0.031011 0.0761634 0.0324182 0.188496 −0.089208
0.0329952 0.047051 0.032315 0.0491861 −0.089208 0.228684

⇒ V−12 =

33.168681 24.883259 −29.4581 −23.04584 −2.800597 −1.878367
24.883259 23.892531 −24.02663 −19.19547 −2.02613 −1.77263
−29.4581 −24.02663 56.39634 42.262828 −21.67354 −16.32029
−23.04584 −19.19547 42.262828 36.393116 −16.87288 −13.1071
−2.800597 −2.02613 −21.67354 −16.87288 26.991706 18.041944
−1.878367 −1.77263 −16.32029 −13.1071 18.041944 17.171919

D = ∂pi∂β is a matrix of partial derivatives of the mean of the outcome with respect to the regression
parameters. If we assume η represents the linear predictor using the chain rule Rochon derives:67
∂pi
∂β =
∂pi
∂η × ∂η∂β = ∂pi∂ηX
Therefore the matrix D for each treatment group is defined as:
Dt = ∆tXt
For each treatment group the D matrices are calculated as:
D1 =

0.208791 0 0 0 0 0
0 0.0229840 0 0 0
0 0 0.200271 0 0 0
0 0 0 0.00852 0 0
0 0 0 0 0.188496 0
0 0 0 0 0 0.050268


1 0 0
0 1 0
1 0 0
0 1 0
1 0 0
0 1 0

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∴ D1 =

0.208791 0 0
0 0.022984 0
0.200271 0 0
0 0.00852 0
0.188496 0 0
0 0.050268 0

D2 =

0.104839 0 0 0 0 0
0 0.12852 0 0 0 0
0 0 0.161791 0 0 0
0 0 0 0.085293 0 0
0 0 0 0 0.128199 0
0 0 0 0 0 0.121801


1 0 1
0 1 1
1 0 1
0 1 1
1 0 1
0 1 1

∴ D2 =

0.104839 0 0.104839
0 0.12852 0.12852
0.161791 0 0.161791
0 0.085293 0.085293
0.128199 0 0.128199
0 0.121801 0.121801

Step 10: Calculate βˆ
The vector of parameters in the model can now be estimated by solution of the following generalised
estimating equation.
βˆ = [
∑
t D
′
tV
−1
t Dt]
−1[
∑
t X
′
tWth(θt)]
Where Wt = ∆tV
−1
t ∆t and h(θt) is a vector of cumulative logits i.e. ln(cumulative probability/(1-
cumulative probability). For the treatment and placebo groups these vectors are:
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h(θ1) =

−2.001934
0.5279292
−1.367649
0.2168457
−1.726779
0

,h(θ2) =

−0.861625
0.5537276
−0.959392
0.8616248
−1.087974
0.4305291

Using the matrices as previously defined
[
∑
t D
′
tV
−1
t Dt]
−1 =

2.7910582 2.1564694 −2.572864
2.1564694 10.146841 −4.90384
−2.572864 −4.90384 6.2484071

W1 =

1.4459449 0.1194111 −1.231784 −0.040996 −0.110221 −0.019714
0.1194111 0.0126216 −0.110595 −0.003759 −0.008778 −0.002048
−1.231784 −0.110595 2.2619711 0.0721134 −0.818182 −0.1643
−0.040996 −0.003759 0.0721134 0.0026418 −0.027098 −0.005614
−0.110221 −0.008778 −0.818182 −0.027098 0.9590353 0.1709531
−0.019714 −0.002048 −0.1643 −0.005614 0.1709531 0.0433912

and in the other treatment group
W2 =

0.2788044 0.1360106 −0.153786 −0.05269 −0.103059 −0.053631
0.1360106 0.141598 −0.094317 −0.037061 −0.061467 −0.038958
−0.153786 −0.094317 0.4263067 0.1156739 −0.125427 −0.065114
−0.05269 −0.037061 0.1156739 0.0677555 −0.041692 −0.026495
−0.103059 −0.061467 −0.125427 −0.041692 0.2913409 0.1136255
−0.053631 −0.038958 −0.065114 −0.026495 0.1136255 0.1189094

∴ β =

−0.9802
0.4783
−0.5032

Therefore the GEE estimate of the treatment effect is -0.5032.
Step 11: Identify the specific hypothesis of interest
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The Null and Alternative hypotheses are defined as:
H0 : Hβ = ho versus H1 : Hβ 6= h0, In this example h0 = 0
H =
[
0 0 1
]
Step 12: Calculate the sample size per group (m)
The sample size calculations are based on the Wald test statistic which is asymptotically distributed
as a χ2(h),λ random variable with non-centrality parameter λ. In this example, as in most cluster
randomised trials, we conduct a one degree of freedom hypothesis test on the difference between the
two treatments. Therefore h=1.70
The sample size is found by solving the following equation for the minimum number of subjects, m,
required in each treatment group.
1− β =
∫ ∞
χ2
(h),1−α
f(x;h, λ)dx (2.4)
Where β is the type II error rate, χ2(h),1−α is the critical value from the central χ
2
(h) distribution with
h degrees of freedom and f(x;h, λ)dx is the probability density function of the χ2(h),λ distribution.
In this example from tables of the chi-squared distribution on 1 degree of freedom at the 5% 2-sided
level, the critical value from the central chi-squared distribution is 3.84.
The non-centrality parameter is calculated as
λ ≈ m(Hβˆ − h0)′[H[
∑
t D
′
tV
−1
t Dt]
−1H′]−1(Hβˆ − h0)
Using previously defined estimates
λ ≈ m[−0.5032× 0.1600407722×−0.5032] = m[0.04052]
Given h, α and β we can use the CNONCT function in SAS to return the non-negative non-centrality
parameter from a non-central chi-square distribution
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λ=CNONCT(3.84, 1, 0.32)=5.8259921.
Therefore, m per group=5.8259921/0.04052=144. For 90% power m per group increases to 260.
Adaptation to cluster randomised trials
Methods designed for longitudinal data are not always generalizable to CRTs. Often a treatment
interaction with time is the main parameter of interest, the correlation structure is often assumed to
be autoregressive and the cluster sizes tend to be small. In some respects the methodology by Kim
might be transferable to the CRT scenario. The form of the model used in the example presented
here does not include an effect for time and the correlation matrix for two individuals from the same
cluster is assumed to be exchangeable, a common assumption in the CRT context too. However,
there are a number of practical limitations that limit its usefulness in calculating sample size for a
CRT.
In the longitudinal context, for which the method was designed, the number of observations per
person (or cluster size) is usually small. In the cluster randomised trial context the cluster size is
much larger and the definition of matrices and matrix algebra involved in using this method become
increasingly complex with increasing cluster size and the number of ordinal categories. This may
substantially increase the computational time of using this method in the CRT context. Currently
the GEE approach to the analysis of clustered ordinal outcomes assumed in this approach is a less
popular approach and not available in all statistical software packages. The complexity involved in
using this method also means that in practice a statistician would be required to implement it.
Areas for development
Further work could be done on the methodology by Kim to: look at whether this method could
be adapted to be suitable to the CRT design; consider its performance under situations that are
more reflective of a CRT, such as larger cluster sizes; and find appropriate estimates to use in its
calculation. I chose not to look at developing this method further given that it did not seem to offer
any advantages over the design effect approach, the calculations are more complex and the GEE is
not a common approach in the analysis of ordinal outcomes.
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2.2.3 Objective 2: Methods used in the derivation of sample size formulae
The second objective of the review was to identify the different approaches used in the derivation of
sample size formula for cluster randomised trials. In a minority of papers (n=9, 11%) a sample size
method was presented and evaluated but the description of how it was derived was unclear. The
approaches used in the remaining 76 papers could be broadly categorised into one of the following
six methods: calculation of the power function from first principles (n=44, 52%); derivation of the
inflation factor as a ratio of variances of the treatment effect (n=8, 10%); sample size subject to
optimality or cost constraint criteria (n=11, 14%); sample size by simulation (n=5, 6%); Bayesian
methods (n=4, 5%); or adaptation of a pre-existing method (n=3, 4%).
I now describe each of these approaches in more detail.
Calculation of a power function from first principles
The majority of papers, n=44 (52%) took a general approach to sample size derivation, mirroring
the derivation method described in Chapter One for individually randomised trials. The steps in
this approach are as follows:
1. Describe the estimate of the intervention effect
2. Select a test statistic for the intervention effect
3. Express the variance of the intervention effect under the null (and possibly alternative hypothesis)
4. Determine the distribution of the test statistic under the null hypothesis
5. Generate a statement about power or sample size required
In 18 (41%) of these papers the variance of the intervention effect calculated in step 3 simplified to
the variance under individual randomisation multiplied by a factor, termed the design effect. The
sample size formula then simplified to the formula for an individually randomised trial multiplied
by the design effect. The first of these papers was published in 1982 by Donner, Birkett and Buck
for continuous and binary data analysed at the cluster level. Since then design effects have been
established for: time-to-event outcomes;71,72 count outcomes;73 variable cluster sizes;74–76 cross-
over, equivalence, three-level and stepped-wedge designs;77–82analysis by GEE75,83 or analysis of
covariance,84 and adjusting for attrition.85 In the majority of cases the design effect methods were
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derived for cluster-level analysis. For continuous outcomes with fixed cluster sizes this is equivalent
to an individual-level analysis adjusted for clustering.
In the remaining 26 (59%) papers there was no such simplification of the variance into the two
components. These methods were more likely to assume an individual-level analysis where the
estimate of the treatment effect can be more complex.
For derivation based upon a GEE (or marginal model) the estimate of treatment effect became
more complex with the inclusion of covariates,86 more complex correlation structures,87 ordinal
outcomes,65 adaptive designs88 and time-to-event outcomes.89
For a random effects model the treatment effect, β, is usually estimated via maximization of the
likelihood function and the significance of the treatment effect assessed using the likelihood-ratio,
Score or Wald statistics. The use of random effects models appears to have been constrained to
continuous outcomes, where estimation of the treatment effect is more straightforward. For discrete
responses, in particular ordinal outcomes, except in rare cases (the complementary log-log function
with the log of a gamma or inverse Gaussian distribution for the random effects), the likelihood
function cannot be written in closed form and therefore must be approximated.90 The recommended
approximation is via Gauss-Hermite quadrature, a procedure for performing numerical integration of
the likelihood function using a series expansion evaluated at certain quadrature points. An alternative
method is to take a quasi-likelihood approach. A quasi-likelihood approach starts by linearizing and
approximating the nonlinear response model using a Taylor series expansion before maximising the
likelihood. If the Taylor series expansion is based on the fixed parameters only it is referred to as
a marginal quasi-likelihood (MQL), if it is also based on the random effects it is called penalized
quasi-likelihood (PQL) and depending upon the extent of the Taylor approximation it may be first-
or second-order quasi-likelihood.
Ratio of variances
Rather than generating a specific statement about power or sample size requirement some papers
derived inflation factors directly by specification and comparison of the variance of the treatment
effect estimate under two alternative designs.
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These inflation factors are referred to as design effects or measures of relative efficiency. The difference
between the definitions of these two inflation factors is not always clear. In this thesis I use the
following definitions, taken from the Cambridge Dictionary of Statistics91
The design effect is defined as ‘the ratio of the variance of an estimator under the particular sampling
design used in a study to its variance at equivalent sample size under simple random sampling
without replacement’. Therefore, in the context of this thesis, the design effect is a comparison of
the cluster randomised design with the individually randomised design. The sample size required
for the individually randomised design is multiplied by the design effect to calculate the sample size
required for the cluster randomised case.
The relative efficiency is defined as ‘the ratio of the variances of two possible estimates of a parameter,
or the ratio of the sample sizes required by two statistical procedures to achieve the same power’.
Therefore, the relative efficiency can be a comparison of the cluster randomised and individually
randomised designs but can also be used to compare two alternative clustered designs. In the
comparison of cluster and individually randomised trials the reciprocal of the relative efficiency is
equivalent to the design effect. The reciprocal of relative efficiency provides the multiplication factor
by which the sample size must be inflated. Many of the papers identified in the review resulted in
a sample size calculation involving a design effect. However, in only one paper was this calculated
directly as the variance of the cluster summary statistic assuming variable cluster sizes divided by
the equivalent statistic ignoring clustering.92
In the literature relative efficiency inflation factors have been defined to compare: unequal ver-
sus equal cluster sizes;93–95 cross-sectional versus cohort samples;;96 matched versus unmatched
designs;97 and a cross-over versus parallel group design.98
Defining optimality criteria
In cluster randomised trials there may be several combinations of cluster size and number of clusters
that produce designs with equivalent power. In these situations the optimal sample size at each level
may be constrained by the total budget for the trial. This total cost function is fixed and is made
up of the cost of sampling a cluster and the cost of sampling an individual. The optimal allocation
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of clusters and individuals, subject to cost constraints have been derived for binary and continuous
outcomes.99–109
Sample size by simulation
Five papers were identified that described sample size calculation through the use of simulation.110–114
These authors used simulation due to the lack of available simple sample size formula for their design
or because of the inherent complexity in their proposed design.
The general process for sample size by simulation involves simulating a large number of data sets,
most commonly at the level of the individual, each one to represent a potential dataset of results from
the trial. For each simulated data set the planned analysis is conducted and the empirical power
calculated as the percentage of tests where the null hypothesis is rejected. Changes in the input
parameters, such as number of clusters, can be made until adequate power is achieved. Simulation
has the flexibility to incorporate all the complexities of the trial. However, it can be computationally
intensive to implement.
From a more technical viewpoint the simulation procedure starts with generating an observation for
each cluster alongside a variable to indicate which treatment group the cluster belongs to. Within
each cluster an observation is generated for each individual. The number of individuals per cluster can
be chosen to be fixed, randomly selected for each cluster with defined probability from one of several
user-defined cluster size values, or randomly selected from a user-defined probability distribution. It
is also possible to randomly assign covariates at this stage using user-defined probability distributions.
A model is then defined for generating the outcome variable for the dataset, with a user defined
treatment effect, for example a linear or logistic random effects model for continuous or binary
outcomes respectively. The level of the ICC is controlled through the assumed distribution of the
cluster-level random effects and the individual-level residuals. This procedure is repeated to generate
a large number of datasets.
Bayesian methodology
Four papers took a Bayesian perspective to sample size determination.115–118 Bayesian statistics is a
branch of statistics that expresses uncertainty about unknown parameters in terms of a probability
distribution (known as a posterior distribution). This posterior distribution is calculated using both
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prior knowledge and the observed data. In several of these papers the prior knowledge involved
specification of a distribution for the ICC. The probability distribution for the power of the study
reflecting ICC uncertainty would then be derived. Posterior distributions for unknown parameters
can often be computationally complex and in these situations Markov Chain Monte Carlo (MCMC)
simulation methods using specialist Bayesian software such as WinBUGS are needed to find estimates
from the distribution, for example the average power. Bayesian methods are considered by many to be
more complex to implement than classical methods. The development of statistical methodology for
clinical trials and the corresponding statistical software has largely focused on classical, or frequentist,
approaches. Many of the papers that implemented a Bayesian approach to sample size did assume
that the eventual analysis would take a frequentist approach.
Adaptation of a pre-existing method
There were three papers that adapted or extended a previously derived method. Examples included
extending methods used for rates to time-to-event data, methods for re-estimating the sample size
at an interim look and dealing with ICC uncertainty.119–121
2.3 Discussion
2.3.1 Main findings
This review is the most comprehensive and up-to-date review of sample size calculations for cluster
randomised trials. Additional methodology published between the date of this review and the end
of my research is summarised in Chapter Six of this thesis.
The results of this review show that there is a large body of literature available on sample size
methodology for cluster randomised clinical trials, 85 papers were identified. The literature is dom-
inated by methods which are applicable to binary or continuous outcomes. Methods for alternative
outcomes, particularly ordinal outcomes were lacking. In 2005 a paper by Kim discussed sample
size for correlated ordinal outcomes. Their method assumes that the analysis will be by GEE with
the treatment effect evaluated using a Wald test, and that each cluster is of the same size. As it
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currently stands it is not obvious how this method can be transferred to the cluster randomised trial
situation.
A second method proposed by Campbell and Walters proposes multiplication of the sample size
formula for individually randomised trials for ordinal outcomes by the standard design effect.33 This
method offers great benefits of being simple to implement and familiar to researchers. However
its performance has not been formally evaluated and no recommendations are provided to guide
researchers on an appropriate estimate of the ICC to use.
Of the 85 papers the most popular derivation approach was to derive a sample size formula from first
principles. This approach was used in over half of the papers, 52%. For individual-level analyses the
GEE method of analysis was assumed for discrete outcomes. The use of random effects models was
constrained to continuous outcomes.
2.3.2 Strengths and limitations
This review has some limitations. The search results are biased towards methodology that has
been published in the English language. There is also a bias towards methodology published in
the medical/healthcare literature with the choice of the electronic databases chosen for searching.
However, I felt that this is where the majority of cluster randomised trial methodology is published
and health research is my area of expertise. Potential limitations of the search process include the
fact that the search was not performed by two independent researchers and decisions about initial
inclusion of a paper were made by me alone. This means there is potential that some papers may
have been missed during the process. However, the search results were reviewed by experts in the
field and I am therefore confident that no key methods have been excluded.
There is limited guidance available for the conduct and reporting of reviews of methodology such as
this and different methods from those used in more traditional systematic reviews are required. A
strength of this review is that the search procedure was developed to be as systematic as possible
and the methods used mirrored those of a more traditional review where possible to ensure a com-
prehensive summary of the methodology available. The search terms were validated prior to use and
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data abstraction independently reviewed for a select number of articles. The only previous review
of CRT methodology to implement such robust methods was conducted 15 years ago8
2.3.3 Implications for this research
Sample size methodology for ordinal outcomes were set out in only two of the 85 papers, of these
both have scope for further development.
At the beginning of this research I started, in parallel, two approaches to sample size calculation
for ordinal outcomes. The first was to derive a formula from first principles and the second was to
calculate the required sample size using simulation based methods and explore whether any patterns
in the required sample size emerged.
As the most common approach to the analysis of ordinal outcomes for the non-clustered case is by
proportional odds model it seemed most sensible to assume the analysis for the clustered case would
be the random effects extension to this model. However, it became clear from my review that there
would be great difficulty in using a random effects model as the basis for formula derivation from
first principles due to the complexity involved in estimation and inference, an issue that had been
identified for binary outcomes. The alternative was a GEE approach but this had already been used
by Kim et al and is not a popular analysis approach for ordinal outcomes.65
From an initial exploration of sample size by simulation it appeared that some patterns were emerging
and the simple design effect might offer an appropriate approach to sample size calculation for ordinal
outcomes.
While working on the two approaches above the use of the design effect for sample size calculation
with ordinal outcomes was proposed by Campbell and Walters.33 However, the performance of the
method in different scenarios was unknown and there was no guidance around which estimate of the
ICC should be used.
The focus of my research therefore was diverted in order to evaluate the design effect method and
provide guidance for applied researchers around its use. I made this decision because the design effect
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method: has the advantage of simplicity that would likely outweigh any newly derived formula, that
may be a more complex calculation; is already well established for binary and continuous outcomes
and Donner’s paper proposing this method still remains highly cited, despite its age; is familiar to
researchers; and the calculation is easy to perform.
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Chapter 3
Ordinal outcomes in CRTs
In this thesis I concentrate on providing practical guidance for using the sample size method for
clustered ordinal outcomes which suggests multiplication of the sample size derived by Whitehead2
for individual randomisation by the design effect.
In this chapter I establish whether there is sufficient demand for such guidance i.e. a prevalence
of cluster randomised trials with primary outcomes that are ordinal. Using an existing sample of
300 published cluster randomised trials, I estimate the prevalence of ordinal outcomes, look at the
methodological approaches used in their design and analysis, and describe the design characteristics
of these trials. The characteristics of these trials will be used to inform the design of simulation
studies presented in Chapter Five that will evaluate the design effect approach for sample size
calculation in CRTs with ordinal outcomes.
Some of the work within this chapter was undertaken collaboratively. Aspects that were conducted
collaboratively, and my role in the collaboration, are clearly described within the following sections.
3.1 Background
Ivers et al conducted the largest review to date of 300 cluster randomised trials published between
2000 and 2008 with the aim of describing the quality of methods and reporting.30 I planned to use
the same sample of 300 trials to meet the aims of this chapter. My plan was to utilize some of the
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information the Ivers et al group had already collected on this sample such as whether a sample size
was calculated and whether it was appropriately adjusted for clustering. I would then review all
300 papers myself to extract the additional information I required to meet my objectives. However,
the dataset of the information extracted in the original review of these 300 trials was not publicly
available at the time of my research, as the research team were planning further work using these
trials. The statisticians involved in the original review were Monica Taljaard (MT) and Stephanie
Dixon (SDX) who were based at the Ottawa Hospital Research Institute at Ottawa Hospital and
the Schulich School of Medicine and Dentistry at the University of Western Ontario in Canada
respectively. An agreement was reached between us whereby the information previously extracted
would be shared with me and we would combine our resources to extract further information from
each trial to satisfy the planned objectives of my research and that of the Canadian based research
team.
3.2 Methods
3.2.1 Objectives
The review was designed to meet the objectives of my research and that of the Canadian based team.
As the focus of this thesis is my research I have described my objectives as primary and those of the
Canadian research team as secondary to distinguish the two.
The primary objectives:
• To describe the prevalence of ordinal primary outcomes in cluster randomised trials
and for trials with ordinal outcomes:
• To describe the design features of trials using ordinal primary outcomes
• To describe the prevalence of reporting observed estimates required for future sample size calcu-
lations i.e. the proportions in each ordinal category in each treatment group and a measure of the
observed ICC.
• To describe the methodological approach used in the sample size calculation
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• To describe the quality of sample size reporting in comparison to the recommended elements
provided in the CONSORT 2004 extension for cluster randomised trials.50
The CONSORT 2004 statement requires five elements to be included in the description of the sample
size calculation. (1) the type I error rate, (2) power, (3) estimates of outcomes in each group
or minimum important target effect, (4) the number of clusters or average cluster size and, (5)
the assumed measure of intracluster correlation, design effect or coefficient of variation. In 2012
the CONSORT 2004 statement for cluster randomised trials was updated.51 The 2012 version
additionally recommends that it be specified whether equal or variable cluster sizes has been assumed.
In this sample the trials were published between 2000 and 2008 and therefore not expected to report
according to the 2012 extension.
The secondary objectives:
The secondary objectives of this review are restricted to the subset of trials that reported a sample
size calculation. These objectives look at the reporting and methodological quality of sample size
calculations in cluster randomised trials in more detail than was considered in the original review
by Ivers et al. These objectives were generated by the Canadian based research team and jointly
agreed by both research groups.
• To describe the methodological quality of sample size reporting in cluster randomised trials
• To establish which sample size descriptive elements, as recommended in the CONSORT extension
for cluster randomised trials, are best and worst reported
• To determine whether sample size reporting practices have improved since the introduction of the
CONSORT 2004 extension for cluster randomised trials
• To evaluate the accuracy of the a priori estimates used in the sample size calculation by making
comparisons with their observed values at the end of the trial
The methods and results of these secondary objectives have been published, and are not repeated
within this thesis. I took the lead role in the analysis of this data and preparing and submitting the
work for publication.122
In the following sections I describe the methods used to meet the objectives of this review.
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3.2.2 Data source
This review was conducted using the 300 published reports of cluster randomised trials identified by
Ivers et al.30
For trials with ordinal outcomes each primary author was contacted by email to see if their trial
dataset was available, in order to calculate estimates of the ICC and proportions in each ordinal cat-
egory where missing from the trial report. If the primary author could not be reached an alternative
author was contacted.
3.2.3 Justification of data source
I chose trial reports as the data source for this review as I considered them to provide a more
representative sample of clinical trials than other sources, such as published protocols. However, the
level of detail and general reporting quality may be less than ideal given the strict length restrictions
often imposed by journals at the time these trials were reported.
I did consider published trial protocols as a data source. The biggest advantage of the trial protocol
over the trial report is the level of detail is likely to be greater, as they are not subject to the
same length restrictions. The trial protocol may contain detailed information about decisions made
during the course of design, for example possible justification for dichotomising an ordinal outcome,
treating it as continuous, or choosing an alternative outcome. The protocol may provide insight
into whether these decisions were driven by clinical relevance or the availability and complexity
of statistical methods for ordinal outcomes. However, although the publication of trial protocols
appears to be more common in recent years those trials which publish their protocols are more likely
to be of high quality and not a representative sample of all cluster randomised trials. Their use was
not considered further.
In Chapter one twenty-three reviews of cluster randomised trials were summarised in Table 1.1.
The number of trials included in each review ranged from 15 to 300. With the availability of these
existing reviews, and due to the time limitations imposed upon my research, I chose to utilize an
existing review as my data source rather than conduct a new one. I opted to use the review by Ivers
et al for two reasons.30 Firstly it was the largest review to have been conducted and secondly, unlike
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some of the other reviews it was less restrictive in the databases searched and health areas included
and was more likely to provide a representative sample of published cluster randomised trials across
all areas of health research.
3.2.4 Inclusion and exclusion criteria
The search strategy implemented in the review by Ivers et al produced a sample of CRTs that the
authors describe to be representative of all Medline publications. A publication was included if it
was the main study report and was published in an English language journal between the years 2000
and 2008. Trial protocols, pilot studies, or papers that reported only baseline results or secondary
analyses were excluded.
For my research I initially considered all 300 trials and then refined this to the subset reporting
ordinal outcomes. The collaboration work with the Canadian group was restricted to those trials
that reported a sample size calculation.
3.2.5 Data collection
In the original review by Ivers et al 47% of trials did not identify a primary outcome. In these
cases, for the purpose of data extraction an outcome was designated as primary. Where multiple
outcomes were specified the primary outcome was chosen as that which was reported first in the
abstract or analysis. All data extraction in the original review was related to the primary outcome.
The same approach was taken in my review with the exception being those that reported a sample
size calculation. For these trials data extraction was based upon the outcome used in the sample size
calculation if this was different from the originally defined primary outcome. This was not a frequent
occurrence and was done in order to maximise information gained about sample size calculations.
Where several follow-up time points were given data extraction was based on the final time point,
unless an earlier time-point was identified as primary.
Descriptive information collected in the original review was made available to me by the authors. It
included information on year of publication, impact factor, trial design (parallel trial, factorial, cross-
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over, other), method of randomisation (completely randomised, stratified, pair-matched, other), a
description of the primary outcome and whether a sample size calculation had been reported.
The following sections describe the details of what information was additionally extracted and by
whom.
Information extracted collaboratively (by CR, MT, and SDX)
For papers that reported a sample size calculation the following information was collected collabo-
ratively: (the full data extraction form can be found in appendix iii):
Study design:
• The outcome for which the sample size calculation was performed for
Sample size:
• The method, or citation, of sample size calculation
• Data type of the primary outcome (binary, categorical, ordinal, continuous, count, time-to-event
data, other, unclear)
• Type I, Type II error rate, and whether a one or two-sided test assumed
• The estimator used to describe the correlation within clusters, its value and any justification for
its value
• Additional aspects accounted for in the calculation i.e. attrition, variable cluster sizes
• The value of the expected response in the control and treatment arms with a measure of the effect
size and any justification provided for these values
• Target sample size: Total number of clusters and individuals
Analysis:
• The achieved sample size used in the analysis: Total number of clusters and individuals
• The method of analysis used
• Data type at the level (cluster or individual) corresponding to the analysis (binary, categorical,
ordinal, continuous, count, time-to-event data, other, unclear)
• Data type as used in the analysis (binary, categorical, ordinal, continuous, count, time-to-event
data, other, unclear)
• Observed values of: the measure of correlation; the response in the control and treatment arms;
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and unadjusted effect size
Information extracted independently (by CR)
The following information was extracted independently on all articles that did not report a sample
size calculation:
Study design:
• Data type of the primary outcome (binary, categorical, ordinal, continuous, count, time-to-event
data, other, unclear)
For the subset of trials identified with an ordinal primary outcome the following information was
extracted :
Study design:
• Description of the outcome
• Number of ordinal categories, with category description
• Description of the intervention
• Description of the cluster
• Description of the sub-units within a cluster
If a sample size calculation was present the following information was included in the information
collected collaboratively, else this information was extracted independently:
Analysis:
• The achieved sample size used in the analysis: total number of clusters and sub-units
• The method of analysis used
• Data type as used in the analysis (binary, categorical, ordinal, continuous, count, time-to-event
data, other, unclear)
• Observed values of: the measure of correlation; the response in the control and treatment arms;
and unadjusted effect size
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3.2.6 Data management
Collaborative extraction (by CR, MT, and SDX)
I drafted a data extraction form. This was discussed and finalised with MT, SDX, SE, and AC. The
extracted data was transcribed from the data extraction form and stored in an Access database, to
which the data collection from the originally review was also imported. I designed and tested the
database (screen shots available in appendix iv).
CR, MT, SDX extracted the data in pairs for each article that reported a sample size calculation.
The trials were divided into batches of approximately ten trials. Each batch of trials was assigned
to an extracting pair. MT was responsible for the allocation and rotation of extraction pairs. Each
member of the team had a copy of the database and was responsible for storing the paper and
electronic versions for the trials to which they were assigned. After each set of 10 trials had been
extracted the electronic database from each extracting pair was emailed to me. I imported each
set of data into Stata where I used the cf2 command to compare the two datasets and list the
discrepancies. The list of discrepancies was then sent to the extracting pair and were reviewed and
resolved by consensus within the pair.
After the discussion of any discrepancies in the data extraction one member of each extracting pair
was responsible for updating the database. This was MT for all her batches and CR for the batches
marked with SDX. At the end of the project these two datasets were merged to create the final
dataset on which data checking took place, described in the next section.
Individual abstraction (by CR)
The majority of the information I extracted independently was for those trials that had an ordinal
primary outcome. As the number of trials for which this information was extracted was small an
Excel spreadsheet was deemed adequate for its storage.
3.2.7 Validation and data checking
Collaborative extraction
The final version of the data extraction form was tested on five papers selected by MT, who was
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most familiar with the trials included in the sample, with the aim of testing the form on a variety of
trials. No changes to the form were deemed necessary after piloting the form.
After the collection of all the data a data checking plan was agreed to ensure consistent recording
between both extraction pairs and extractions over time. This data checking included some of the
following aspects:
• Agreeing the categorisation of free text responses such as the method of analysis used
• Ensuring consistency in reporting percentages as decimals rather than whole numbers for example
0.85 versus 85%
• Double checking papers where a large discrepancy was seen between target and actual sample size
• Double checking papers where a large discrepancy was seen between target and actual sample size
parameter estimates
• Checking that absolute and relative differences had been calculated correctly
• Part way through data extraction it was agreed that the target total number of clusters required
should be left blank if not explicitly reported in the sample size calculation. All papers where this
question was not missing were double checked to ensure it had been explicitly reported and not
inferred.
• Logical checks, for example, if the sample size does not account for the ICC then no value should
be given for the ICC
Individual extraction
All information I extracted on trials with ordinal outcomes was performed twice, a month apart,
in order to provide a double check of the extraction. A second data extraction was feasible due to
the small number of trials included. As both extractions were performed by me there was some
limitation to the validation provided. However, it was thought that the information to be extracted
would be a key part of the trial report and should be easily identified. If any ambiguity was present
it was discussed with SE and AC.
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3.3 Results
3.3.1 Description of included trials
The characteristics of the 300 trials have previously been described in detail.30 Selected character-
istics are presented in Table 3.1. Just over half of the trials reported a sample size calculation,
N=166 and of these 61% accounted for clustering. This number is larger than the 164 reported in
the original review because that review focused on whether a sample size calculation was present for
the variable defined as primary. In this review the outcome used in the sample size calculation was
deemed primary.
Despite the willingness of authors no datasets for the eleven trials with ordinal outcomes were
available to calculate observed data summaries. The unavailability was due to data being deleted,
archived, corrupt or the research team disbanded and the data location unknown.
3.3.2 Prevalence of ordinal outcomes and design characteristics
There were 11 (4%) trials identified as having an ordinal primary outcome. The design of these trials
were most often parallel group 10 (91%), two-arm 6 (55%), completely randomised 8 (73%), and
used a cohort sample, meaning the same individuals within a cluster are measured at more than one
time point, 9 (82%) (Table 3.2). In all but one of these cohort trials the baseline measure or post
randomisation measurements have been incorporated into the analysis. Use of the design effect for
clustered ordinal data does not allow for the inclusion of baseline or post randomisation measures.
The inclusion of such measurements would introduce additional components of correlation or require
the ICC to be suitably adjusted. For ordinal outcomes estimates of the ICC are not routinely
published and are likely to be difficult to find, estimates of additional or adjusted correlations due
to incorporation of baseline or repeated measures will be more so. Therefore, for the purpose of this
thesis I focus on sample size methods for an analysis of the final time point only, which should be
conservative for analyses that include baseline or repeated measures.
The majority of the interventions being tested within these trials were counselling or skills train-
ing interventions aimed at changing various aspects of behaviour (9/11 (82%) of trials). The ran-
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Table 3.1: Characteristics of the 300 CRTs included in the published review by Ivers*. Figures are numbers
(percentages) of trials unless stated otherwise
Characteristic N %
Publication year:
2000-4 139 (46)
2005-6 93 (31)
2007-8 68 (23)
Journal impact factor (n=294)
Median (IQR) 2.9 (2.1-5.1)
Range 0.45-50.0
Setting:
Clinical 169 (56)
Non-clinical 131 (44)
No. of clusters randomised (n=285)
Median (IQR) 21.0 (12-52)
Range 2-605
Average cluster size (n=271)
Median (IQR) 33.9 (12.5-88.5)
Range 1.7-122 855
No. of participants per arm (n=290)
Median (IQR) 329 (143-866)
Range 20-614 275
Sample size reported 166 (55)
Accounted for clustering
in sample size 102 (61)
* Ivers et al30
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domised units were either health care practices/providers with outcomes measured for each patient
(5/11(45%)) or schools/classrooms with outcomes measured for each pupil (4/11(36%)). Over half
of these ordinal outcomes had either four or five levels, Table 3.2.
The total number of clusters randomised was small, median 18 with inter-quartile range 9 to 61.
Similarly the number of individuals enrolled per trial arm was small, median 128 with interquartile
range 71 to 150, Table 3.2.
In two of the trials a random effects ordinal regression was performed. The outcome was dichotomised
in four trials, treated as continuous in four trials and categorical in one.
3.3.3 Reported values of ICCs and category proportions
Campbell and Walters’ design effect method for sample size calculation for clustered ordinal outcomes
requires estimates for the expected proportions in each category within each treatment group at the
end of the trial as well as a measure of the ICC. These estimates were not routinely reported, only
two of the eleven trials provided information on the observed proportions in each category at the
end of the trial. These two trials and their estimates are summarised below.
The trial by Steptoe et al assessed the impact of a behavioural counselling programme, implemented
at the level of general practice, in changing the state of change in fat reduction of patients at risk
of coronary heart disease.56 State of change was measured on 5-levels (pre-contemplation, contem-
plation, preparation, action and maintenance). The authors combined the action and maintenance
stages since they felt the distinction between the two may be subject to recall bias. After 4 months
the proportions in these categories in the intervention group were 9.9%, 8.9%, 14.1% and 67.1% and
in the control group 17.7%, 10.9%, 17.7% and 53.6%. These figures translate to log-odds ratios of
-0.67, -0.54 and -0.56. At the 12 month time point the proportions in the intervention group were
14.1%, 5.7%, 11.9%, 68.4% and the control group 16.5%, 7.5%, 16.8% and 59.2%. These figures pro-
vide log-odds ratios of -0.19, -0.25, and -0.40. From observation alone the log-odds are not similar
for each dichotomisation indicating that the assumption of proportionality may not be met. The
assumption of proportional odds, what it means and how it can be formally assessed will be explored
further in the next chapter.
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Table 3.2: Design features for 11 CRTs with ordinal primary outcomes identified from the 300 published
CRTs included in the review by Ivers*. Figures are number (percentage) of trials unless stated
otherwise
Trial Design N (%)
Publication year
2000-2004 5 45%
2005-2008 6 55%
Trial design
Parallel trial 10 91%
Factorial trial 0 0%
Cross-over trial 1 9%
Other 0 0%
Randomisation method
Completely randomised 8 73%
Stratified 1 9%
Pair-matched 0 0%
Other 2 18%
Design at patient level
Cross sectional 2 18%
Cohort 9 82%
Number of arms Two 6 55%
Three 4 36%
Four 1 9%
Sample size reported 1 9%
Number of ordinal levels
3 2 18%
4 4 36%
5 3 27%
6 0 0%
7 1 9%
8 0 0%
9 1 9%
No. of clusters randomised
median (IQR) 18 (9 to 61)
Range 7 to 345
No. of participants enrolled per arm
median (IQR) 128 (71 to 150)
Range 30 to 316
* Ivers et al30
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In the second trial by Howlin expert training and consultancy was provided to teachers of children
with autism. The frequency of communication initiations by children was measured on a 4-level
outcome variable.123 Using figure 2 from the trial publication the proportions in each ordinal category
for the two follow up measurements can be estimated. In the immediate treatment group the
proportions observed in each category are 7.7%, 57.7%, 11.5%, 23.1% and in the no treatment group
these are 17.9%, 46.4%, 32.1%, 3.6%. These translate to log-odds ratios of -0.96, 0.05, and -2.08 .
At the third time point the proportions in the immediate treatment group are 16%, 52%, 20% and
12% and in the control group 14.3%, 39.3%, 39.3% and 7.1%. These translate to log-odds ratios
0.13, 0.61, and -0.58. Each of these log-odds are very different and not always in the same direction,
again indicating that the proportional odds assumption may not be reasonable.
3.3.4 Reporting quality according to CONSORT guidelines
Of the 11 trials with ordinal primary outcomes only one paper by Howlin et al reported a sample
size calculation based on an expected odds ratio.123 The paper by Brody did state that an a priori
power analysis based on effect sizes from a previous study informed the sample size but no details of
the calculation were actually reported and the corresponding author did not respond to my e-mail
inquiries about this study.124 The expected proportions in each ordinal category at the design stage
were not provided in any of the eleven papers.
In the Howlin trial all five of the elements recommended by CONSORT were reported (1) the type I
error rate (2) power (3) estimates of outcomes in each group or minimum important target effect, (4)
the number of clusters or average cluster size and (5) the assumed measures of intracluster correlation,
design effect or coefficient of variation. No allowances were made for attrition or possible cluster size
imbalance.
3.3.5 Assessment of methodological approach to sample size calculation
In the Howlin trial the clustered nature of the data was acknowledged and accounted for in the
sample size calculation. The ICC was used as the measure of correlation, but no justifications for
any of the estimates used in the calculation were provided.
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It was agreed through the collaborative extraction that the Howlin paper assumed a binary outcome
and the sample size compares a difference in proportions adjusted for clustering. However, on further
consideration the exact calculation of the sample size is slightly ambiguous as to whether it has been
calculated on the ordinal outcome, or a dichotomous version. The reference quoted for the method
used would allow for both of these options and the description of the method does not include
enough information to recreate the formula in order to check either approach. The authors were not
contactable by email and the study protocol was not available to check the method used.
3.4 Discussion
3.4.1 Main findings
In a random sample of 300 cluster randomised trials 11 (4%) trials had primary outcomes that
were ordinal. Nine (82%) of these outcomes had between 3 and 5 ordinal categories and most often
measured an aspect of behaviour 9/11 (82%).
The design of these trials were most often parallel group (10, 91%), two-arm (6, 55%), completely
randomised (8, 73%), and used a cohort sample (9, 82%). Both the total number of clusters ran-
domised and the number of enrolled participants per arm tended to be small.
Only one paper reported a sample size calculation which incorporated adjustments for clustering
and followed all the CONSORT recommendations for sample size reporting for cluster randomised
trials.
Few trials reported the observed proportions in each category at the end of the trial that might be
used in future sample size calculations. Where provided these proportions did not appear to fulfil the
assumption of proportional odds, a requirement of Whitehead’s sample size formula for individually
randomised trials to which the design effect is applied.
3.4.2 Strengths and limitations
The sample used in this review is unique due to its size and coverage. With 300 cluster randomised
trials included it is the largest review of CRTs that has been conducted to date, with the next largest
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containing 173.44 The majority of other reviews have contained less than 40 trials. Many previous
reviews have focused on particular areas of health such as stroke, oral health, and primary care
or targeted particularly high ranking journals during the search. The way in which the sample of
300 used in this review was selected makes it the most representative of cluster randomised trials
across the medical research field. However it should be acknowledged that the sample contains trials
published between 2000 and 2008. There is a possibility that the inclusion of more recent publications
may have provided a different estimate of ordinal outcome prevalence. The true estimate of demand
for ordinal sample size methods might also be larger as this review does not identify those trials that
chose an alternative outcome due to a lack of available methods for ordinal outcomes and the added
complexity of the analysis.
3.4.3 Comparison with other work
The objectives of previous reviews of cluster randomised trials have mainly focused on assessing the
quality of methods used and the quality of reporting. This is the first review of cluster randomised
trials to focus on the type of outcome used. Some recent research has been conducted on the analysis
of ordinal outcomes for cluster randomised trials by Ruochu Gao, a PhD student of Allan Donner,
whose thesis is available online.125 In this work Gao provides examples of 11 recent cluster ran-
domised trials using ordinal outcomes. The types of outcomes are consistent with those seen in my
review: behavioural outcomes related to tobacco, drug and condom use and satisfaction outcomes
related to patient and physician. The types of clusters are also similar: schools, medical practices
and physicians. In nine (82%) of these trials the number of ordinal categories is between three and
five, the same figure as seen in my review. Gao does not describe how her sample of trials was se-
lected but it provides consistent findings about the characteristics of trials that use ordinal outcomes.
3.4.4 Implications for this research
Four percent of trials were identified as having an ordinal primary outcome. Although less common
than binary or continuous outcomes ordinal outcomes are not especially rare. In only one of these
eleven trials was a sample size calculation reported. It is clear that researchers still need further
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support and guidance in the design of trials for clustered ordinal outcomes and they need access to
appropriate sample size methodology to do this. The development towards practical guidance for
sample size calculations with ordinal outcomes follows in the proceeding chapters.
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Chapter 4
Analysis of ordinal outcomes
Whitehead’s sample size formula for ordinal outcomes in individually randomised trials assumes
proportional odds and an analysis by Mann-Whitney test, which is equivalent to ordinal regression
when only treatment is included in the model. Ordinal regression methods are more available
in statistical software than their non-parametric counterparts and are a popular approach to the
analysis of ordinal outcomes. The assumed analysis method for Campbell and Walters’ extension of
Whitehead’s method for clustered data is not explicitly stated. The extension of ordinal regression for
clustered data, the random effects ordered logistic regression model, would seem a logical approach
to use.
The aim of this chapter is to describe analysis methods for clustered ordinal data with a focus on
the random effects ordered logistic regression model and its assumptions. As the analysis methods
for clustered data are often extensions of the methods used for non-clustered data the methods
for non-clustered data are described first. Methodological issues surrounding each analysis method
are discussed, providing justification to the decisions made in the design of the simulation studies
to evaluate the design effect approach for sample size calculations for clustered ordinal outcomes,
which follow in the next chapter.
Three proposed ICC estimators for ordinal outcomes are presented in this chapter and their use in
the design effect will be evaluated in the next chapter.
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4.1 Analysis methods for non-clustered data
An ordinal outcome, as defined in chapter one, is a variable which consists of a set of categories that
can be ordered or ranked, for example disease severity (mild, moderate or severe). The absolute
difference between the categories is often unmeasurable or unknown.
Alan Agresti has made a large contribution to the work on the analysis of ordinal outcomes. The
first version of his book on the analysis of ordered categorical data was published in 1984 and a
second edition, published in 2010, included developments for clustered data. Agresti has contributed
to several reviews of methods available to analyse ordinal data with the earliest in 1989 and the
latest in 2005.90,126–128 These articles highlight the substantial methodological development that
has occurred in recent years in the analysis of ordinal outcomes. In the most recent review paper
invited researchers were given the opportunity to discuss the work and give their thoughts on the
future direction of ordinal outcome research, power and sample size calculations for clustered data,
the focus of this thesis, was raised as an area for development. Lall et al have also reviewed ordinal
regression models applied specifically to health-related quality of life outcomes.129
With an ordinal outcome one can either ignore or incorporate the ordinality in the data into the
analysis. Methods which ignore the ordinal nature of the data are described here for completeness,
as they are commonly undertaken, but are not recommended as they will likely give different results
to an analysis that incorporates ordinality.130
4.1.1 Methods which ignore ordinality
If ignoring the ordinal nature of the data the outcome would alternatively be considered to be
nominal, continuous or could be reduced to a binary outcome. Treating the outcome as nominal
means treating the categories as if there is no natural ordering among them. The Pearson’s Chi-
squared test is commonly used to analyse nominal data. However, it has been shown that when used
to analyse an ordinal outcome the Chi-squared test can produce different conclusions to those made
using analyses that take the ordering into account.130
Another simple approach which ignores the ordinality is to combine adjacent categories to reduce the
ordinal outcome to a binary variable, to which standard statistical methods such as the chi-squared
103
4.1. ANALYSIS METHODS FOR NON-CLUSTERED DATA
test or logistic regression can be applied. This produces a valid analysis but dichotomisation of the
outcome results in a loss of information, more power can be gained by retaining the full ordinal
variable. The power of this dichotomisation approach has been examined using data from the
CRASH trial which investigated the efficacy of corticosteroids in traumatic brain injury patients.131
The primary outcome variable in this trial was the 5-point Glasgow Outcome Scale which was
dichotomised as unfavourable (dead, vegetative, severe disability) or favourable (moderate disability,
good recovery). The analysis of the binary outcome was non-significant, yet the analysis of the
ordinal outcome with proportional odds regression was highly significant. The authors attributed
this difference in conclusions to the increased statistical power of the ordinal approach. In previous
simulation studies the authors had also explored the effects of non-proportionality, where a significant
treatment effect was present in only one category cut-off. They reported that surprisingly the results
showed that even when the assumption of proportionality was not met the ordinal analysis assuming
proportional odds had more power than the binary approach (dichotomised at the point of the
significant treatment effect).
According to the authors trials in traumatic brain injury have traditionally been powered on the
dichotomous variable of a favourable versus unfavourable outcome. The increased power from an
ordinal analysis implies that powering on the ordinal outcome could reduce sample sizes. However,
the authors investigating the CRASH data did not advise going down this route because they argue
that trials in critical care medicine are generally under powered due to a systematic overestimate of
the treatment effect size during the design. Instead the increased efficiency of an ordinal analysis
should aid in the detection of smaller treatment effects for the same sample size. However, I would
argue that under powering in the strictest sense refers to a trials inability to recruit and measure
the required number of individuals as indicated by the sample size calculation. The issue here
seems to be that the sample size calculation, in particular the way that the minimum clinically
important difference is chosen, is not adequate. Investigators may be too optimistic about the
expected treatment effect or the treatment effects are chosen to provide a sample size requirement
that is attainable to recruit.
In contrast to the above recommendations on sample size for critical care medicine the recommen-
dation for stroke trials is to conduct the design and analysis using approaches which utilize the
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ordinality of the data, as opposed to a dichotomous approach based on stroke/no stroke, as the re-
duction in sample size can reduce the competition for patients between trials and reduce the cost and
complexity of the trial itself.132 For individually randomised trials Whitehead’s method of sample
size calculation for ordinal outcomes has been shown to produce sample sizes that are on average
28% smaller than those for a binary version of the outcome.57 The impact on power when using
more than two categories is large. However, additional power gains are marginal once the number
of ordinal categories goes beyond five.2
The final approach ignoring the ordinal nature of the data assigns scores to the ordinal categories and
assumes the variable is continuous and analysed using methods such as ANOVA or linear regression.
Most commonly equally spaced scores are used across the ordinal categories, although other scoring
systems may be used. Aside from how to assign scores the biggest problem with this approach
is that the created variable often violates the normality assumption required for many analyses,
more so when the sample size is small. The t-test and ANCOVA however, have been shown to be
robust to the normality assumption (i.e. to produce significance levels close to nominal levels) using
simulation with three-, four- and five-level ordinal data.133,134 To avoid the assumption of normality
non-parametric methods such as the Mann-Whitney-U test can be used.
Walters et al have explored methods for sample size and analysis within the context of quality of
life data. Their results suggest that when the outcome has a limited number of discrete values
(less than 7) and/or the proportion of cases at either of the bounds is high Whiteheads method
of sample size performs well. However, where seven or more populated categories are present and
the proportion of cases at the bounds is low then sample size and analysis methods based on the
simplifying assumption of an assumed continuously distributed variable may be used.135,136
4.1.2 Methods that incorporate ordinality
In this chapter I assume that the ordinal outcome is a discrete measure of an underlying continuous
variable and therefore I focus on the model often most appropriate for this situation, the proportional
odds model (also referred to as ordered logistic regression) which is described by McCullagh.137 Lall
et al have reviewed ordinal regression models applied to health-related quality of life assessments,
and include discussion of the stereotype model that can be useful in situations where the categories
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are not assumed to be a discrete version of an underlying continuous variable. The ordinality of the
response is assessed within the model.129
Model formulation
Let us assume an ordinal response variable with k ordered categories q = 1, 2, . . . , k and Yj be the
categorical response for the j′th individual. Yj takes the value q if the response is in category q.
The probability of an individual j being in category q is pijq and the cumulative probability of being
in category q or below, denoted Pjq is given by
P (Yj ≤ q) = Pjq = pij1 + pij2 + . . .+ pijq
We assume that the ordinal response is a crude measure of some underlying continuous distribution
which is unknown and unmeasurable (referred to as a latent response), Y ∗j . The ordinal variable
is obtained by chopping Y ∗j into categories using a series of cut points αq where q = 1, . . . , k − 1.
Figure 4.1 illustrates an unobserved latent response for a four-level ordinal outcome. A value of
Y ∗ < α1 corresponds to a response in the first category, values between α1 and α2 correspond to
a response in the second category and so on. The cumulative probability of being in category q or
below, denoted Pjq is now given by
P (Y ∗j ≤ αq) = P (Yj ≤ q) = Pjq (q = 1, 2. . . . k − 1)
If we know the distribution of the latent response this cumulative probability can be easily calculated.
The most common choice for the distribution of the latent response is a logistic distribution with
mean µ and variance, pi
2
3 . The cumulative distribution function for the standard logistic distribution
is:
F (x) = P (X ≤ x) = 1
1+e−(x−µ) or equivalently F (x) =
e(x−µ)
1+e(x−µ)
Therefore if we assume the underlying latent response Y ∗j follows a logistic distribution
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F (y∗j ) = P (Y
∗
j ≤ y∗j ) = e
y∗j−µ
1+e
y∗
j
−µ
and so
Pjq = F (αq) =
eαq−µ
1+eαq−µ
Applying the logistic transformation it follows that
logit[P (Yj ≤ q)] = log
(
Pjq
1−Pjq
)
= αq − µ
Assuming that µ is a linear combination of the explanatory variables the proportional odds model,
or more specifically the proportional odds version of the cumulative logit model is given as:
logit[P (Yj ≤ q)] = αq − βxj (4.1)
Where β represents the treatment effect, assumed the same across all q (the proportional odds
assumption).
The existence of a latent response is not required for model interpretation. However, if the latent
response can be assumed then the treatment effect is unaffected by the choice of number of categories
and cut points. Therefore when the model fits well different trials using different scales to measure
the treatment effect should agree in their conclusions.
Alternative link functions
The model can be written more generally as
G−1[P (Yj ≤ q)] = αq − βxj (4.2)
Where G−1 is a link function, the inverse of the continuous cumulative distribution G. In the previous
section a logit link was applied, other link functions may be used such as the probit, log-log and
complementary log-log.
The logit link is the most commonly used followed by the probit link. The probit link assumes the
underlying latent response Y ∗j follows a standard normal distribution and the link function G
−1 is
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Figure 4.1: Graphical representation of how a 4-level ordinal outcome, Y, can be represented by an assumed
underlying continuous latent variable Y ∗ with cut points α
the inverse of the standard normal distribution. The shape of the normal and logistic distributions
is similar so if the model fits well with logit link it should also fit well with a probit link. The
advantage of the logit link is that the treatment effect can be interpreted as an odds ratio. Under
the probit link the treatment effect relates to an underlying normal latent variable for an ordinary
regression model. The log-log and complementary log-log link functions are appropriate when the
distribution of the underlying continuous variable is non symmetric. For small sample sizes it may
be difficult to assess which link function is most appropriate.128 In this thesis I consider only the
two most frequently used links, the logit and probit links.
Assessment of proportional odds
The proportional odds assumption assumes that the treatment effect is the same for all the possible
ways that the k-category response variable might be collapsed to a binary variable.
One approach to checking the assumption of proportional odds is to fit separate treatment effects
across the categories, replacing β by βq and then compare this model to the single effect model
using methods such as a likelihood ratio test. Another approach proposed by Brant138 views the
proportional odds model as describing a set of k-1 separate binary logistic regression models. Pro-
portionality is assessed by examining and comparing the fit of these binary logistic models. A
goodness-of-fit test statistic, which follows a Chi-squared distribution, formally assesses the propor-
tional odds assumption and is implemented in Stata as part of the user-written omodel command.
Peterson and Harrell139 also propose a formal test of proportional odds via a score test.
If the assumption of proportional odds is not met the main approaches to analysis, which still make
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use of the ordinal nature of the data, include using a more general model which involves fitting
a separate effect for each category or a partial proportional odds model as suggested by Peterson
and Harrell.139 The partial proportional odds model allows the treatment effect to be the same for
some values of the categories and different for others. This method reduces the number of required
estimates in comparison to fitting a separate effect for each category. Partial proportional odds
models can be estimated in Stata using the user-written gologit command.
Methods that do not make use of the ordinal nature of the data but are sometimes considered include
assuming a nominal response or dichotomising the outcome and using logistic regression. However,
different conclusions may be made using these methods compared to those for ordinal data.
4.1.3 Significance testing
Under maximum likelihood estimation significance tests for the treatment effect for the proportional
odds model are usually conducted using the likelihood-ratio, Wald or score test statistics.
The likelihood ratio test compares two nested models, the null and alternative i.e. in this case with
and without a treatment effect fitted. The likelihood ratio statistic follows a Chi-squared distribution
and is calculated as twice the difference in the log-likelihoods from each model. The test produces
similar results to the Wald test for large sample sizes but performs better under smaller sample sizes,
where use of the Wald test can lead to inflated Type I error rates.
The Wald statistic approximates the likelihood ratio test and is used to test the hypothesis that
the estimate of the treatment effect, β, is 0. It is the default in most statistical packages and is
calculated as:
w = βse(β)
Under the null distribution this statistic follows a normal distribution, and the square of the statistic
follows a Chi-squared distribution. The Wald test is advantageous over the likelihood ratio test in
that it only requires one model to be fitted, but for small sample sizes the Type I error rate can be
inflated meaning a statistically significant treatment effect may be declared when no such difference
exists.
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The score test (also known as the Lagrange multiplier test) is asymptotically equivalent to the
likelihood ratio test. It follows a Chi-squared distribution and is based on the derivative of the
log-likelihood and its standard error evaluated at the null hypothesis value. Both the Wald and
Likelihood ratio tests are easily implemented in statistical software, but the score test less so.
4.2 Analysis of clustered ordinal outcomes
I now consider the extension of these methods to account for clustering.
4.2.1 Non-parametric methods
Rosner and Grove140 have extended the Wilcoxon rank sum test to individual-level analysis of clus-
tered ordinal data. The authors present the variance of the test statistic for both the clustered and
unclustered case, hence a design effect could be calculated, although not of simple form. The authors
propose that where the number of ordinal categories is large their method is more appropriate than
parametric methods, such as the proportional odds model. However their method requires estimates
of four clustering parameters, values for which may not be readily available. The method does not
allow the inclusion of covariates and is not available as standard in statistical packages. Hence, I do
not consider its use further in this thesis.
4.2.2 Random effects model
In a cluster randomised trial the ordinal response is Yij for individual j in cluster i, i = 1, . . . , C,
j = 1, . . . , n. The cumulative logit model with random effects, assuming proportional odds, is given
as141
logit[P (Yij ≤ q)] = αq − βxij ′+ µi, q = 1, 2, . . . , k − 1 (4.3)
Where µi represents a random effect of the cluster and distributed N(0, σ
2
b ).
As in the non-clustered case this model can be motivated by the assumption of an underlying
continuously distributed latent response Y ∗ij such that
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Y ∗ij = xijβ + µi + ij
and
yij =

1 if y∗ij ≤ α1
2 if α1 < y
∗
ij ≤ α2
...
k if αk−1 < y∗ij
The error terms ij are distributed as logistic with mean zero and variance pi
2/3 and are independent
of µi. Error terms distributed as N(0, 1) correspond to a probit link, see Section 4.1.2
As touched upon in Chapter two, Section 2.2.3 random effects models with discrete outcomes can
be difficult to fit via maximum likelihood and the likelihood function must be approximated by such
methods as Gauss-Hermite quadrature.
4.2.3 Marginal models
In the random effects model (or cluster-specific model) the focus is on modelling a cluster-specific
response and the regression coefficient for treatment represents the average effect of treatment if an
individual stays in the same cluster but moves from the control to the intervention arm. The random
effects model uses maximum likelihood estimation and explicitly models the covariance structure by
introducing cluster-specific random effects into the model.
In a population averaged, or marginal, model the regression coefficient for treatment represents the
effect of treatment if an individual in the population moves from control to intervention arm. The
model does not fully specify the distribution of the population, as in the random effects model,
instead the marginal expectations are modelled and a variance-covariance structure (referred to as
the working or hypothesised correlation) is chosen to describe the correlation between members of a
cluster. The model is not fitted via maximum likelihood; an estimate of the treatment effect can be
found by solution of a generalised estimating equation (GEE).
Generalised Estimating Equation methods for the analysis of ordinal outcomes have been described
by Lipsitz, Kim and Zhao and are summarised here.68
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For each individual we observe the response on a k-level ordinal outcome with categories q =
1, 2, . . . , k. To keep with the terminology of Lipsitz et al a higher category here is used to indi-
cate a better outcome. Let Zij denote the ordinal response of the j’th individual in the i’th cluster,
j = 1, 2, . . . , n and i = 1, 2, . . . C. The size of the cluster is assumed fixed and denoted by n.
We form k indicator variables Yijq, where Yijq = 1 if subject j has response q and Yijq = 0 otherwise.
For each subject we form a k-1 response vector of indicator variables Yij = [Yij1, . . . , Yij(k−1)]′ , and
for each cluster Yi = [Y
′
ij, . . . ,Y
′
in]
′
The marginal probability is denoted by Pr[Zij = q] = E[Yijq] = Pr[Yijq = 1] = piijq and the
corresponding marginal cumulative probabilities by Pr[Zij ≤ q] = Pijq
Lipsitz et al analyse the data using a marginal model based on cumulative logits
logit[Pijq] = Xβ (4.4)
Where X denotes a (k − 1) × k design matrix for the j′th individual of the i′th cluster and β =
[α1, . . . , αk−1, β]′ denotes a k×1 parameter vector. Where the αq corresponds to the q′th cumulative
logit and β denotes the effect of treatment.
In Chapter Two, Section, 2.2.2, I presented a worked example of the sample size methodology
proposed by Kim et al which assumed a GEE model. In Step 10 of their sample size process the
parameter vector β is found by solution of the GEE equation:
βˆ = [
∑
t D
′
tV
−1
t Dt]
−1[
∑
t X
′
tWth(θt)]
Where t is an index representing treatment group, Dt = ∆tXt where ∆t =
∂pi
∂η a matrix of partial
derivatives of the mean of the outcome with respect to the regression parameters, η is the linear
predictor Xβ, Xt is the design matrix and Vt is the working covariance matrix and Wt = ∆tV
−1
t ∆t
and h(θt) is a vector of cumulative logits i.e. ln(cumulative probability/(1-cumulative probability).
The Wald test statistic for the model with only treatment fitted with H0 : β = 0 is
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W = β
2
var(β) ∼ χ21
The variance of the treatment effect can be calculated in two ways. The model-based estimate of
the variance provides valid inferences only if the working covariance matrix is correctly specified.
var(β) =
T∑
t=1
[D′tV
−1
t Dt]
−1 (4.5)
An alternative estimate that is more robust to miss-specification of the working covariance matrix
is calculated by
varr(β) =
T∑
t=1
[D′tV
−1
t Dt]
−1
T∑
t=1
[D′tV
−1
t var(Yt)V
−1
t Dt]
−1
T∑
t=1
[D′tV
−1
t Dt]
−1 (4.6)
4.2.4 Comparison of random effects and marginal models
Of those trials identified in Chapter Three with ordinal outcomes the random effects model was the
most popular choice of analysis.
The GEE, or population averaged (PA) method provides consistent estimation even when the cor-
relation structure is miss-specified and is computationally simple compared to the random effects
(RE) model, where the likelihood function must be approximated. However, because the method
does not specify a full multivariate distribution for the responses the GEE method does not have a
likelihood function. No likelihood function means that the likelihood ratio test and other likelihood
based methods cannot be used to check model fit, compare models or make inferences about the
model parameters. With a GEE model inference about the model parameters must be made via
a Wald test, which can give spurious results, particularly for small samples. The empirical-based
standard errors calculated from a GEE model may be underestimated unless the sample size is very
large.
The two models also differ in the assumptions they make with regard to missing data. Missing
data mechanisms have been described by Little and Rubin and I use their terminology here.142 The
GEE model makes the strongest assumption, that the data are Missing Completely At Random
(MCAR). In simple terms this means that the probability that the observation is missing does not
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depend on the value itself, or any other observed measurement. Maximum likelihood based random
effects methods make a weaker assumption that the data are Missing At Random (MAR), that is
the probability that the observation is missing does not depend upon the value itself but can be
explained by other observed measurements. Violations of these assumptions in either model may
lead to biased results.
The relationship between the treatment effect estimated from a RE model and that estimated from
a PA model have been described by Agresti.130 These relationships are briefly summarised here as
they will be used in the design of the simulation study described in the next chapter.
• The treatment effect from a marginal model will be smaller than that from a random effects model,
the difference increases as the level of within-cluster correlation increases.
•When a probit link is used the treatment effect estimate from the RE model and that from the PA
model can be directly compared, with the RE estimate being
√
(1 +σ2w) times that of the PA effect.
• For the logit link the relationship between the model estimates is only approximate with the RE
estimate being
√
1 + 0.346σ2wtimes that of the PA effect.
•Despite the difference in interpretation and magnitude between the random effects and population
averaged models the significance of the treatment effect is likely to be similar.130
• Using the fact that the standard normal cumulative distribution function (cdf) at a point z is well
approximated by the standard logistic cdf at 1.7z the estimates from models with a logit link are
approximately 1.7 times those from probit models.130
4.2.5 Software
In Stata version 13 the xtologit command fits random-effects models via maximum likelihood using
adaptive Gauss-Hermite quadrature as the default for approximating the likelihood. The accuracy
of this quadrature can be checked using the command quadchk. The xtologit command assumes
that larger values of the ordinal response correspond to better outcomes. The command xtoprobit
is available for ordered probit models. The gllamm command is a user-written command that can
also be used to fit these models and pre-dates the inbuilt functions. Currently there is no option
available in Stata to analyse ordinal outcomes with a GEE model.
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The SAS software can accommodate random effects and GEE models using PROC NLMIXED and
PROC GENMOD respectively.
4.2.6 Assessment of proportional odds
For the individually randomised trial formal methods have been proposed to test the assumption
of proportional odds and for cases when the assumption of proportional odds is not valid non-
proportional or partial proportional odds models have been suggested as alternative analysis methods
and have been incorporated into statistical software, see Section 4.1.2.
For the clustered case there has been less development and limited guidance around how to formally
assess proportional odds. As in the individually randomised case to test the assumption of propor-
tional odds one may consider fitting a separate effect for each category and comparing this to the
proportional odds model via a likelihood ratio test. Hedeker and Mermelstein have extended the ran-
dom effects proportional odds model to allow for non-proportional or partial proportional odds.143
Their approach extends Peterson and Harrell’s approach for partial proportional odds for the fixed
effects model.139 The partial proportional odds method described by Hedeker and Mermelstein has
been implemented in an extension to the MIXOR package available in R for mixed effects ordinal
regression.144
The partial proportional odds model of Hedeker and Mermelstein was developed within the context
of behavioural state of change data, where participants are categorised according to their readiness
to change ranging from pre-contemplation to action. The authors considered the assumption of
proportional odds to be unreasonable for this type of data. Of the 11 CRTs with ordinal outcomes
identified in Chapter Three there were three trials that used such an outcome. Therefore non-
proportional odds may be a significant problem in the design and analysis of ordinal outcome trials
with behavioural outcomes.
4.2.7 Significance testing
As in the individual case the Null hypothesis that there is no effect of treatment can be assessed
via a likelihood ratio, Wald or score test for random effects models or Wald test for GEE. However,
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the approximation of the Wald test statistic to the normal distribution is worse in the clustered case
when the number of clusters is small or the cluster size is variable. This tends to inflate the Type
I error rate, so we are likely to see more than 5% of calculated P-values being less than 0.05 under
the null hypothesis. A suggested solution is to compare the Wald statistic to a t-distribution, but
this may reduce the Type I error to below the nominal value.
4.3 The ICC
Estimators of the ICC have been extensively described for binary and continuous data.145,146 The
most common interpretation of the ICC is that it represents the proportion of variance due to
between-cluster variation, for continuous outcomes this is defined as
ρ =
σ2b
σ2b+σ
2
w
Where σ2b is the between-cluster variance, σ
2
w is the within-cluster variance and the sum of the two
is the total variance.
For binary outcomes the definition is slightly different
ρ =
σ2b
pi(1−pi)
The ICC is dependent on pi, the prevalence in the population. The total variance is calculated as
pi(1−pi). The prevalence, and therefore the within-cluster variance will likely vary between clusters.
Therefore the assumption of constant within-cluster variance does not hold for binary outcomes.
This ICC for binary outcomes is referred to as being on the proportions scale and it is this ICC
which should be used in the design effect when calculating sample size for binary outcomes.147
Like ordinal outcomes the model for binary outcomes can be motivated by the existence of an
underlying continuous variable on the logistic scale and an ICC can also be calculated on this logistic
scale. This estimate will be different from the ICC on the proportions scale and there is no easy
formula to convert one to the other, instead simulation must be used.148 Eldridge, Ukoumunne and
Carlin have compared the two estimates through simulation and provide a useful table that shows
the relationship between the ICC on the proportions scale and that on the logistic scale for different
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levels of overall prevalence. The difference between the two values is greatest when the ICC on the
proportions scale is large or the prevalence is further from 50%.
4.3.1 ICC of the latent response
The underlying latent variable, Y ∗ij is assumed to be continuous and follows the random effects model
Y ∗ij = xijβ + µi + ij
with error terms ij distributed as logistic with mean zero and variance pi
2/3 and are independent
of µi, the random effects for clusters, which are distributed N(0, σ
2
b ).
The intracluster correlation coefficient on this underlying (logistic) scale is defined as
ρ(l) =
σ2b
σ2b + pi
2/3
(4.7)
This ICC is relatively straight forward to calculate and is often automatically provided by statistical
software, such as Stata, after model fitting. However, the fact that this ICC relates to the underlying
variable means it is not clear whether its use in the design effect for ordinal outcomes is appropriate.
For the probit link pi2/3 is replaced by 1 in the denominator.
4.3.2 Analysis of variance ICC
It is possible to assign numerical values to the ordinal categories and calculate an ICC using a one-
way analysis of variance.146
ρ = MSB−MSWMSB+(n−1)MSW
Where MSB and MSW are the mean squares between and within clusters estimated from the analysis
of variance and n is the cluster size.
The estimated ICC will be dependent upon how the numerical scores have been assigned. For
example the simplest approach is to assign equally spaced values such as 1, 2, 3 and 4. Alternatively
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if it was felt that the gap between categories 3 and 4 was twice that of other adjacent categories the
scores could be assigned as 1, 2, 3, and 5. If the categorical variable was formed from the grouping
of scores from a health questionnaire, for example, scores may be defined from using mid-points of
the categories. In this thesis I assume equally spaced scores. Departures from equally spaced scores
are heavily dependent upon the nature of the outcome and the ordinal outcome trials reviewed in
Chapter Three provided no evidence against equally spaced scores. Use of equally spaced scores
should therefore apply more widely than alternative scoring methods.
4.3.3 Kappa-type ICC
For discrete outcomes the ICC can be interpreted as a version of the kappa statistic. For binary
outcomes kappa is a measure of agreement corrected for chance, most often used to measure inter-
rater agreement, which is the agreement among a set of raters recording measurements about a
binary trait on the same individual. It is calculated as the observed proportion of agreement minus
that expected by chance, divided by the maximum agreement over chance:
ρˆk =
pˆiO − pˆiE
1− pˆiE (4.8)
Where piO and piE are the proportions of observed and expected agreement, respectively. A value of
1 for the statistic represents perfect agreement.
Gao has proposed a kappa-type ICC estimator for ordinal data in the cluster randomised trial
context.125 It is similarly constructed as the proportion of observed agreement among pairs of
observations within clusters minus that expected by chance, divided by the maximum agreement
over chance. However, weighting is used to define the distance between ordinal categories. For
equally spaced scores the weight, wjj′ (termed the square error rate) corresponding to the agreement
between two categories q and q′ is:
wqq′ = 1− (q−q
′)2
(k−1)2
wqq′ = 1 if q = q
′
118
4.3. THE ICC
Response
Response 1 2 3 4 Total
1 Yi1(Yi1−1)/2
2 Yi2Yi1 Yi2(Yi2−1)/2
3 Yi3Yi1 Yi3Yi2 Yi3(Yi3−1)/2
4 Yi4Yi1 Yi4Yi2 Yi4Yi3 Yi4(Yi4−1)/2
Total n(n-1)/2
Table 4.1: Intermediate calculations required for estimating the kappa-type ICC for an ordinal outcome:
How to define the number of each possible pairwise response across a 4-level ordinal category
within a cluster
The weighting increases the closer the categories are to each other. For example, for a 4-level ordinal
outcome the two categories furthest apart (1 and 4) are given a weighting of 0. Categories that are
two apart (1 and 3, 2 and 4) are given a weighting of 0.55. Categories that are 1 apart (1 and 2, 2
and 3, 3 and 4) are given a weighting of 0.88 and categories that are the same are given a weighting
of 1.
Table 4.1 provides a visual representation of all possible pairings among two observations from a
cluster for a 4-level ordinal outcome, where Yiq is the number of observations in category q for cluster
i. The table summarises the numbers of each possible pair, with a total of n(n− 1)/2 possible pairs
of observations for a cluster of size n. The details of how the number of each possible pairings is
calculated is as follows:
For each cluster it is straightforward to calculate the number of observations in category q, Yiq. If
we know the number of observations in a given category we can calculate the number of possible
pairs in perfect agreement, i.e. the same category, using standard combination rules Yiq(Yiq − 1)/2.
For two different categories q and q′ we can calculate the total number of possible pairings ([(Yiq +
Yiq′)(Yiq+Yiq′−1)]/2) and then subtract the number of pairings expected to be in perfect agreement
([Yiq(Yiq−1)+Yiq′(Yiq′−1)]/2). This simplifies so that the number of pairs of two different categories
q and q′ i.e. the off-diagonal observations in Table 4.1 is YiqYiq′ .
The estimated proportion of observed agreement for a cluster, pˆiO is a weighted summation of those
observations in perfect agreement (on the diagonal in Table 4.1) and the remaining observations on
the lower diagonal, divided by the total number of possible observation pairs:
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1
2
∑k
q=1 wqqYiq(Yiq−1)+
∑k
q=1
∑k
q′>q wqq′YiqYiq′
1
2n(n−1)
Therefore the average weighted proportion of agreement over all the clusters is:
pˆiO =
1
c
∑c
i=1
1
2
∑k
q=1 wqqYiq(Yiq−1)+
∑k
q=1
∑k
q>q′ wqq′YiqYiq′
1
2n(n−1)
Using similar calculations the averaged expected (E) proportion of pairwise agreement, pˆiE is given
by:
pˆiE =
1
2
∑k
q=1 wqqYiq(Yiq−1)+
∑k
q=1
∑k
q>q′ wqq′YiqYiq′
1
2nc(nc−1)
These calculations can be performed separately for each treatment group and the estimates combined
to provide an overall value.
4.3.4 Other ICC estimators for ordinal data
In 1979 Rothery proposed a nonparametric measure of intracluster correlation. Rothery illustrates
the idea with observations taken on individuals within a family (cluster). Take a pair of randomly
selected families, observations xαi and xαj are from two individuals in one family and observation
xβk from one individual from the other family. The ICC ρc is defined to be the complement of the
probability that the outsider xβk falls between the two observations from the same family, xαi and
xαj .
149 Therefore ρc is largest when the two observations from the same family are close together.
When the data is normally distributed this estimate is a monotone function of the parameter from
a one-way ANOVA.150 A similar measure was proposed by Shirahata.151 As these estimates are not
as familiar to interpret or easy to calculate as the ANOVA and kappa-type estimates they are not
considered further.
4.3.5 Relationship between ICC estimators
Gao evaluated the relative bias of the ANOVA and kappa-type ICC estimators via simulation with
parameters defined as follows:125
• Ordinal outcomes with 3 categories
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• Trials with 10 or 20 clusters per arm
• Mean cluster size 50 and 120
• Coefficient of variation in cluster size 0.8 and 1
• Treatment effect (OR) 1 and 1.2
Gao generated clustered ordinal data from a marginal model using a Dirichlet-multinomial distribu-
tion with corresponding fixed ICCs of 0, 0.005 and 0.01. Relative bias was calculated as (average
observed value minus the true value)/true value. Therefore a positive value indicated an overestimate
and a negative value an underestimate in comparison to the ICC from the data generating model.
ANOVA ICCs were calculated by assigning both equally spaced and midrank scores. Negative ICCs
were truncated at zero.
The simulation results showed that both ICC estimates were closer to the true ICC when either
cluster size or the number of clusters was large. When the cluster size was small the ANOVA
estimate was a much larger overestimate of the true ICC than the kappa-type ICC. Truncating the
ICCs at zero may have elevated the resulting average ICC. However, the percentage of negative values
was similar for the two estimates for fixed cluster size. When cluster size was variable the ANOVA
estimate produced a larger proportion of negative values and was less biased than the kappa-type
estimate for variable cluster size.
Although the work by Gao provides an insight into the relationship between the ANOVA and kappa-
type ICC estimates it does not provide information about how these relate to the ICC on the
continuous latent response assumed to underlie the random effects ordered logistic regression model,
the focus of my research, as Gao used a marginal model to generate and analyse her clustered
ordinal data. Also the situations explored by Gao do not reflect the targeted scenarios for my
research identified in Chapter Three.
4.3.6 Estimates of ICC from real-life data
In the next chapter I will formally explore the relationship between the ICC on the latent variable, the
ANOVA ICC and the kappa-type ICC through a simulation study. In order to inform what range of
ICC values should be considered in the simulation study, and to gain some understanding of potential
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patterns in ICC values for different outcomes/trial settings, I had planned to calculate each ICC
estimate using the data from the 11 trials with ordinal outcomes that I identified in Chapter Three.
However, none of their accompanying datasets were available from the authors. Instead I calculated,
where possible, the ANOVA ICC, latent variable (via a random effects ordinal regression) and kappa-
type ICC for three datasets that were available publicly or through the Pragmatic Clinical Trials
Unit (PCTU). The estimates are presented below for each dataset, separately for each treatment
group and pooled where applicable.
The first dataset is the scenario most relevant to this research, a cluster randomised trial, although the
total number of clusters recruited (N=47) was moderate. I was the trial statistician for this trial and
was involved in the planning and conduct of the analysis.152 The second dataset is an observational
study and so the ICC for the latent variable cannot be calculated as there is no treatment effect to
be modelled but this dataset is large with 720 clusters of size two. The final example is a fairly large
longitudinal clinical trial in arthritis with 289 individuals followed up over three time points. This
example was referenced by both Lipsitz and Kim in their respective methods for the analysis and
sample size calculation of clustered ordinal outcomes by GEE.65,68
The EPOS trial: A pragmatic CRT in community care
In the EPOS study clinicians within community mental health teams across three London boroughs
were randomised to receive the intervention, DIALOG+, or no intervention. DIALOG+ is a com-
puter mediated intervention consisting of a structured assessment of patients concerns, combined
with a solution-focused approach to initiate change. Clinicians (n=47) implemented DIALOG+
with their community patients suffering with psychosis (n=147).
All outcomes were measured at baseline, three months, and six months post randomisation. Social
outcomes, including employment, accommodation, and living situation were assessed using the Ob-
jective Social Outcomes Index (SIX) with a total score ranging from 0 to 6. A higher score indicates
a more positive social outcome. To avoid a small number of observations in some categories and for
the purpose of illustration I combined responses to form a 3-level ordinal outcome with the categories
low, medium and high.
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Response Control Intervention Log odds
N (%) N (%)
Low 32 (43%) 26 (36%) -0.29
Medium 32 (43%) 28 (39%) -0.72
High 10 (14%) 19 (26%)
Table 4.2: Real life example results from the EPOS trial of community mental health: 3-level ordinal
outcome of social functioning at 6 months
At the 6 month time point there were 47 clinicians who each treated between 1 and 6 patients, the
average cluster size was 3.13 (SD 1.24) which implies a coefficient of variation in cluster size of 0.40.
The total number of individuals was 147 and the ordinal response at 6 months can be seen in Table
4.2.
I calculated each of the three ICC estimates. The ANOVA estimate of the ICC, accounting for
variable cluster sizes using the method described by Eldridge and Kerry21 was -0.01 in the treatment
group and 0.009 in the control group. The pooled estimate was -0.0001. The pooled Kappa-type
estimate was -0.25 with estimates of -0.163 in the control group and -0.326 in the treatment group.
I fitted a random effects ordinal regression model to the data with treatment included as a covariate.
From this model the estimated ICC for the underlying latent variable was approximately zero with
both logit link and probit link. All the ICCs for this trial were low but also showed some differences
across treatment groups.
An observational study of Diabetic Retinopathy
The Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) was a population based
epidemiological study based in southern Wisconsin, USA designed to identify the risk factors of
diabetic retinopathy. The dataset from this study is publicly available,
www.stat.ufl.edu/ aa/ordinal/ord.html. It contains 720 individuals with measurements on the sever-
ity of retinopathy taken on both eyes for each individual.153
Categories of the diabetic retinopathy scale were combined to create a 4-level ordinal outcome of
severity formed of the categories none, mild, moderate and proliferative. The responses from each
eye for each individual can be seen in Table 4.3.
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Right eye
Response None Mild Moderate Proliferative Total
Left eye
None 237 37 1 0 275
Mild 31 200 35 4 270
Moderate 0 39 80 9 128
Proliferative 0 1 11 35 47
Total 268 277 127 48 720
* (Source: Williamson et al153)
Table 4.3: Real life example results from an observational study of Diabetic Retinopathy: 4-level ordinal
outcome of severity for each eye*
I calculated the ANOVA estimate of the ICC to be 0.841, and the value for the kappa-type ICC to be
0.837, indicating a strong correlation between the measurements recorded on each eye. As this is an
observational model there is no treatment estimate to be assessed and therefore it was not possible
to fit a random effects model to calculate the ICC on the underlying variable.
A longitudinal design: An Arthritis clinical Trial
This trial was used in Chapter Two to demonstrate the Kim methodology for sample size calculations
with ordinal outcomes.65 Subjects were randomised to receive the drug Auranofin or placebo for the
treatment of arthritis. The primary outcome was self-assessment of arthritis, measured as poor, fair
or good at baseline, 1, 3, and 5 months post randomisation. The dataset for this trial is publicly
available www.stat.ufl.edu/ aa/ordinal/ord.html.
Eighteen observations were missing in total across the follow-up time points. For the purpose of this
example individuals with any missing data have been excluded. There were 289 subjects included
in the analysis, each with three follow up measurements. Table 4.4 shows the responses over time
for each treatment group.
I calculated the pooled ANOVA estimate of the ICC to be 0.517, 0.559 in the placebo group and
0.447 in the treatment group. Values for the pooled kappa-type ICC were 0.518, 0.577 in the placebo
group and 0.446 in the treatment group. I fitted a random effects ordinal regression model to the
data with treatment included as a covariate. The estimated ICC for the underlying latent variable
was 0.60 with logit link and 0.62 with probit link. These ICCs indicate substantial correlations
among the repeat responses.
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Response Baseline 1 month 3 months 5 months
N (%) N (%) N (%) N (%)
Auranofin
Poor 45 (31%) 17 (12%) 28 (19%) 20 (14%)
Fair 66 (46%) 73 (51%) 51 (35%) 51 (35%)
Good 33 (23%) 54 (38%) 65 (45%) 73 (51%)
Total 144 144 144 144
Placebo
Poor 46 (32%) 43 (30%) 40 (28%) 37 (26%)
Fair 67 (46%) 48 (33%) 61 (42%) 50 (34%)
Good 32 (22%) 54 (37%) 44 (30%) 58 (40%)
Total 145 145 145 145
*(Source: Lipsitz et al68)
Table 4.4: Real life example results from a longitudinal arthritis clinical trial: 4-level ordinal outcome of
self-assessed arthritis over time*
4.4 Discussion
4.4.1 Main findings
Analyses that do not account for the ordinality in the data are not recommended as they can be
less powerful and produce different results to those methods that take account of the ordinal nature
of the data. Two popular approaches to the analysis of clustered ordinal outcomes that account
for the ordinal nature of the outcome are the GEE model and the random effects ordered logistic
model. The ordered logistic model, is an extension of the proportional odds model commonly used
to analyse ordinal outcomes in the non-clustered situation. Both GEE and random effect models
allow incorporation of cluster- and individual-level covariates and can be implemented in standard
statistical software. The GEE model makes the stronger assumption that any missing data is MCAR,
while the random effects model assumes MAR.
Three ICC estimators were considered for ordinal data. The simplest is calculated using the standard
ANOVA method, after assigning equally spaced scores to the ordinal categories. The second ICC is
a kappa-type ICC which, for a large number of clusters, is equivalent to the ANOVA estimate. The
third is the ICC on the latent continuous scale assumed to underlie the ordinal outcome.
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4.4.2 Strengths and limitations
The focus of this chapter has been on the two most well established methods for the analysis of clus-
tered ordinal outcomes. The first is the random effects extension to the cumulative logit model with
proportional odds proposed by McCullagh in 1980 and the second is the marginal GEE model pro-
posed by Lipsitz in 1994.68,137 These two classes of model were the focus of Agresti and Natarajan’s
2001 review on methods for modelling clustered ordinal data.90 Their review also identified some
alternative methods such as Bayesian modelling and semi-parametric random effects models as well
as raising some areas for future research such as the handling of missing data. In this thesis I did not
consider these alternative methods as the random effects method was shown, in Chapter Three, to
be the most popular approach used for the analysis of clustered data, can be easily fitted in current
software, and is appropriate given the assumptions behind Campbell and Walters’ proposed use of
the design effect in sample size calculation. The focus on easy to use available analysis methods is
a strength of my research. Given ten years has passed since Agresti and Natarajan’s review there is
scope for it to be updated. This will be beneficial for future work on sample size methods for ordinal
outcomes in circumstances where the assumptions underlying the use of the design effect may not
be appropriate, for example under extensive deviations from the proportional odds assumption, and
when alternative analysis methods are required.
To find papers describing the calculation of potential estimators of the ICC for ordinal outcomes
I performed a broad search in PubMed using the search terms ”‘ordinal”’ and ”‘cluster*”’. I then
targeted alternative data sources that I thought were most likely to report ICC calculations. These
were: the PhD thesis of Ruochu Gao which looked at the statistical analysis of correlated ordinal
outcomes;125 the PhD thesis by Sandra Eldridge that focused on cluster randomised trials with a
chapter on sample size methods and calculating the ICC; and papers identified during the course of
my research describing ICC estimators.145,147 There may be alternative ICC estimators that were
not identified in this review. However, I expect the possibility of this to be small given ICC estimators
were investigated in the two PhD theses I searched, the most recent of which was completed in 2012.
The ICC estimators that I have considered have the advantages of being simple to calculate and all
three are familiar concepts to statisticians.
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4.4.3 Comparison with other work
Estimates of ICCs for continuous and binary outcomes have been extensively summarised.145,146
The methods available for ordinal outcomes have received little attention. Gao has compared the
ANOVA and kappa-type ICCs for trials with a small number of large clusters and an ordinal outcome
with three categories. The data was generated and analysed using a marginal model, hence the link
between these ICCs and that defined on an assumed underlying continuous variable is unknown. In
my research I plan to evaluate the design effect for sample size calculation which assumes a random-
effects ordered logistic regression model with proportional odds. There is still a need to evaluate the
relationship between the ICC on the assumed underlying variable for this model and the ANOVA and
kappa-type estimators. In this chapter I presented a few real-life examples of these ICCs. However,
further datasets are required to identify any clear patterns. There has been no work that I am aware
of that looks at patterns in ICCs for ordinal data. Future work should focus on providing more real
life estimates and exploring patterns in ICCs.
4.4.4 Implications for this research
This chapter has summarised the main approaches to the analysis of clustered ordinal outcomes and
discussed their advantages and disadvantages. In this thesis I focus on analysis using the random
effects ordered logistic regression, with proportional odds assumption. The random effects model is
the assumed method underlying the use of the design effect for sample size calculations for ordinal
outcomes. The estimated treatment effect from the model can be interpreted easily as an odds ratio
and it is implemented in the majority of statistical software packages. The model is an extension
of the most popular method for analysing ordinal data for the non-clustered case and therefore is
likely to be more familiar and acceptable to researchers. In Chapter Three I identified 11 papers
with ordinal outcomes, of those that accounted for ordinality in the analysis they did so by using a
random effects ordered logistic regression model rather than GEE.
The performance of the ANOVA ICC, Kappa-type ICC, and the ICC on the underlying continuous
variable in the design effect for sample size calculation will be explored in the next chapter.
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Simulation studies
Although not as common as binary or continuous outcomes the use of ordinal outcomes in CRTs is
not particularly rare. In Chapter Three, using a sample of 300 published cluster randomised trials
I identified 11/300 (4%) trials with ordinal outcomes. The design of these eleven trials were most
often parallel group (10, 91%), two-arm (6, 55%), completely randomised (8, 73%), and used a cohort
sample (9, 82%). Both the total number of clusters randomised (median 18, IQR 9 to 61) and the
number of enrolled participants per arm (median 128, IQR 71 to 150) tended to be small. Nine
(82%) of these trials had outcomes with between 3 and 5 ordinal categories, the remaining trials had
between 6 and 9 categories.
A simple approach to sample size calculation in cluster randomised trials with ordinal outcomes is to
inflate the sample size formula for individually randomised trials by the standard design effect (de-
scribed in Chapter Two). However, the performance of this method under different design scenarios
has not been studied and no recommendations exist for how the ICC in the design effect should be
calculated.
In this chapter Monte Carlo simulation studies are conducted to explore the relationship between the
three possible ICC estimators for ordinal outcomes defined in the previous chapter, (ANOVA, kappa-
type estimate, and the ICC on the underlying continuous variable) and to assess the performance in
terms of the resulting empirical power when using each of these ICCs in the design effect for sample
size calculation. The simulation scenarios were chosen to reflect, as much as possible, the design
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characteristics of the eleven trials identified with ordinal outcomes. However, I chose to exclude
situations where the number of clusters was particularly small as the analysis method is unlikely
to perform adequately in these situations. The use of a cohort design in 9/11 (82%) of these trials
meant that the analysis of these trials incorporated either a baseline measure or post randomisation
measurements of the outcome into the analysis. The effect of such an analysis is to reduce the
between-cluster variance. For simplicity the methods evaluated within this chapter assume analysis
at the final time point only and are expected to provide conservative estimates for designs which
incorporate baseline or repeated measurements.
The chapter concludes with recommendations for implementation of the design effect approach for
sample size calculation for cluster randomised trials with ordinal outcomes. The practicalities around
using this method are discussed in the final chapter of this thesis.
5.1 Aims and objectives
Monte Carlo simulation studies were conducted to meet the following aims:
1. To explore the relationship between three ICC estimators for ordinal data; the ANOVA ICC,
kappa-type ICC and the ICC on the latent continuous response.
2. To determine which ICC provides empirical power closest to the expected nominal value when
used in the design effect for sample size calculation.
3. To determine the effect that minor deviations from the proportional odds assumption has on
power when using an appropriately (identified in objective 2) calculated design effect for sample size
calculation.
4.To determine whether empirical power is consistent when alternative analysis methods are used
(i.e. random effects ordered logistic or probit regression, assuming proportional odds ) when using
an appropriately (identified in objective 2) calculated design effect for sample size calculation.
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5.2 Simulation procedures
The best known guidance on the design and reporting of simulation studies was published in 2006 by
Burton et al.154 The simulations described within this chapter were designed and reported following
this guidance.
The computational time required to run each simulation restricted the number of scenarios I could
reasonably evaluate.
5.2.1 Level of dependence between simulated data sets
The simulations were fully independent, in that a completely different set of independent datasets
was generated for each scenario considered. This was achieved by using a different random seed for
each scenario. For details on selection of the random seed see section 5.2.4.
5.2.2 Treatment of failures
Any simulated data sets for which the analysis model did not converge were discarded and replace-
ment data sets were generated.
5.2.3 Software
The simulations were performed in Stata version 13. The procedure I used was to write a user-
defined command which generated a dataset of clustered ordinal data, performed an appropriate
analysis, or calculation of ICC, and stored the relevant estimates. I then used the Stata command
simulate to replicate my command a large number of times. The details of each of these procedures
are described in the sections that follow, and the Stata code can be found in appendix v.
The simulations were performed using the Queen Mary University of London High Performance
Computing (HPC) cluster, named Apocrita. The aim of the HPC cluster is to enable tasks to be
completed quickly by splitting them across processors. The HPC is accessed remotely and therefore
has the advantage that jobs may be submitted to it from any location, thus leaving the user’s desktop
free to complete other tasks. The HPC uses a Linux operating system with commands entered via
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the command line, therefore some learning and use of Linux commands was required in running these
simulations. Using the HPC meant my simulations were run in parallel and hence the computational
time was substantially reduced compared to running these directly within Stata from a desktop
computer.
5.2.4 Random number generator and starting seeds
Random number generation within Stata is technically pseudo-random in that numbers are not truly
random, but generated by a specific algorithm. Number generation can therefore be replicated by
specification of a starting value for the algorithm, referred to as the starting seed (a number between
0 and 2,147,483,647 in Stata). In my command I needed to generate variables from a Normal
distribution. To do this I used the random number function rnormal (µ, σ) in Stata which returns
a normal variable with mean µ and standard deviation σ.
For each scenario I used a different starting seed. The associated Stata help guide for use of random
number functions states that it does not matter how the seeds are chosen as long as they do not
exhibit any patterns. I chose seeds of varying length and without the use of any systematic selection
that would exhibit patterns. I checked that all the seeds used were different from each other.
5.3 Methods for generating the datasets
At the time of my research there was no universally recommended method for generating clustered
ordinal data. I explored the 85 papers identified in my review of sample size methods to see how
simulation data was generated for binary outcomes but no one method was consistently used. I
explored the literature to evaluate the best approach to use for generating clustered ordinal data.
The generation of ordinal clustered data has been described in the literature in the multivariate
context i.e. several dependent ordinal outcomes that are correlated with each other. To translate
these methods to the cluster randomised trial context we could think of each dependent outcome as
representing an individual within a cluster.
In 1995 Gange proposed a method for generating clustered ordinal outcomes.155 This method sim-
ulates ordinal data with a specified marginal and pairwise probability structure using an iterative
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algorithm. A disadvantage of the algorithm, as stated by the author is, that as cluster size and
the number of ordinal categories increases the required computing power may limit the feasibility of
the approach. With the advances in computing since 1995 it is not clear whether this issue is still
relevant today. The method was used to evaluate the GEE-based sample size method proposed by
Kim et al.65 However, a cluster size of three was assumed and the number of ordinal categories was
four.
In 2004 Biswas proposed an algorithm for data generation for specific correlation structures, namely
first and second order auto-regressive correlations.156 These correlation structures imply that as the
distance between two observations within the same cluster increases their correlation decreases. This
structure is most relevant to longitudinal designs where a cluster is an individual and measurements
are taken at repeated time points, and hence it may be reasonable to assume that the correlation
will decrease as the lag between time points increases. This correlation structure is a less obvious
choice for cluster randomised trials and so this method has limited applicability to my research.
In 2006 Demirtas proposed a data generation procedure which in the first step generates binary
data, using what the authors describe as well-accepted data generation methods, and in the second
step converts these to ordinal outcomes. The authors state that their method is more general than
the methods suggested by Gange155 and Biswas156 in that there are no restrictions on the marginal
distributions and pairwise correlations and that a large number of ordinal categories does not lead
to excessive computational complexity. In 2014 the package ”‘MultiOrd”’ was developed in R to
implement the methods of Demirtas.157 The software makes the method more straightforward to
implement and ensures that the data are generated as intended by the authors. However, my
experience of using this package with large cluster sizes highlighted that the computational time
required was still lengthy.
The method by Gange appears to be the most popular method, with 80 citations in Google Scholar
at the time of writing. A common disadvantage to all of the above methods is the complexity and
computational time involved as the cluster size increases. Given the number of simulations to be
undertaken and the values of the parameters to be investigated in my research it was not feasible to
use these methods.
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Demirtas described an alternative common approach to ordinal data generation; generate the latent
continuous variable and convert to an ordinal outcome by chopping up the continuous outcome into
categories using appropriate threshold values. However, Demirtas states that this latent variable
approach is generally inappropriate as correlations between the ordinal variables are not of simple
form or interpretation, the same comment was also made earlier by Biswas, without any further
elaboration.156 I contacted Demirtas by email and he explained that what he meant by this comment
was that the correlation of the underlying latent variable will be different to that of the ordinal version
of the outcome and that there is no simple formula to convert one to the other. A similar issue exists
for binary data and simulations have been used to link values of the two correlations on the different
scales.147
Although this latent variable approach is described by Demirtas as being common there is no asso-
ciated source that provides any evidence of this. In fact it is unclear how often any of these data
generation methods have been used. The latent variable approach appears to have been used by
Jung and Kang in their evaluation of a score test for clustered ordered categorical data, although
the published description of their approach lacks sufficient detail to replicate it.158 There is scope
for further research looking at the prevalence and evaluation of these data generation methods for
ordinal outcomes.
I chose to simulate clustered ordinal data using the latent variable approach, evaluating the link
between the ICC calculated on the latent continuous variable and the ICCs calculated on the ordinal
outcome (kappa-type and ANOVA) by simulation. This method: appears to most closely reflect the
proportional odds model whose derivation is motivated by the existence of an underlying continuous
variable; the methodology can be easily described and hence replicated by others; the generation can
be easily implemented in any statistical package; and the computational time required to generate a
dataset is reasonable.
5.3.1 Data generating model
Clustered ordinal data was generated using the latent variable approach. Under this approach we
think of the ordinal response categories as being a crude measure of some underlying continuous
scale. A linear random-intercept model describes this underlying continuous response Y ∗ij
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Y ∗ij = βxij + µi + ij
Where µi represents a random effect of the cluster and are independent N(0, σ
2
b ). The distribution
of the error term, ij , informs the link function used in the random effects model for the ordinal
response. A standard logistic distribution with mean 0 and variance pi2/3 corresponds to a logit
link and a standard normal distribution to the probit link. I used the probit link and fixed the
distribution of the error terms to be Normal with mean 0 and variance 1.
The ordinal variable Yij was determined from a categorisation of the latent response via the following
threshold model
Yij =

1 if Y ∗ij ≤ α1
2 if α1 < Y
∗
ij ≤ α2
...
...
c if αc−1 < Y ∗ij
The thresholds were chosen to reflect the proportions expected in each ordinal category in each
treatment group (See sections 5.4.4 and 5.4.5). The Stata function invnormal was used to find the
inverse of the cumulative standard Normal distribution, and hence the appropriate threshold values.
To utilise this function the variable Y ∗ij first had to be standardised (subtraction of the mean and
division by the standard deviation) to follow a standard Normal distribution.
Using the probit link meant that the distribution of Y ∗ij for the control group followed a known Normal
distribution N(0, 1 + σ2b ) and hence the calculation of appropriate threshold values to achieve the
required proportions in each ordinal category for the ordinal response were much simpler than with
a logit link.
5.4 Scenarios to be investigated
The values of the parameters were chosen to reflect as closely as possible the scenarios identified
from the eleven real life examples of trials with ordinal outcomes described in Chapter Three.
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For all simulations equal allocation to two treatment arms was assumed: 50% of the clusters allocated
to intervention and 50% to the control. The cluster size, number of ordinal categories, ICC on the
underlying scale and treatment effect were controlled and varied across scenarios. A description of
the estimates used are described in the following sections and summarised in Table 5.1
5.4.1 Analysis method
In a cluster randomised trial for an ordered categorical outcome with k levels q = 1, 2, . . . , k the
ordinal response is given by Yij for individual j in cluster i, i = 1, . . . , C, j = 1, . . . , N . Each
simulated dataset was analysed by a random effects ordered regression model, given by
G−1[P (Yij ≤ q)] = αq − βxij ′+ µi, q = 1, 2, . . . , k − 1 (5.1)
Where the µi represent a random effect of the cluster and are distributed N(0, σ
2
b ) and G
−1 is
the probit link. Although use of the probit link provides simpler calculations in the generation of
clustered ordinal data use of the logit link is a more popular choice for real life analysis, as it allows
the model parameters to be interpreted as odds ratios. The normal and logistic distributions are
similar and therefore I expect the simulation results to be similar if either the probit or logit link were
used in the analysis. To confirm an analysis via logit link was also investigated in the simulations.
The proportional odds assumption for ordinal regression with logit link implies that the value of the
treatment effect does not depend on q, the level of the ordinal response, and therefore the treatment
effect of being in category q or better can be represented by a single value β for each value of q.
For the ordered probit model the treatment effect is also assumed the same for each cumulative
probability. However, as the interpretation of the treatment effect does not relate to odds ratios it
is not appropriate to refer to the ordered probit model as a proportional odds model.130
5.4.2 Number of clusters and cluster size
The relationship between ICC estimators was investigated for both small and large cluster sizes
(5 and 50) and a large number of clusters (100). I conducted sensitivity analysis to look at the
relationship of ICC estimators when the number of clusters was small (10).
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Table 5.1: Summary of the scenarios to be investigated in the Monte Carlo simulations, designed to meet
the following aims (i) to explore the relationship between ICC estimators and (ii) to determine
the empirical power when using each ICC estimator in the design effect for sample size calculation
Parameters Values
Exploration of the relationship between ICC estimators (40 scenarios)
Allocation ratio 50:50
Number of ordinal categories 3,4,5
Cluster size (fixed) 5, 50
Total clusters* 10*, 100
ICC on the underlying scale 0.01, 0.08, 0.16, 0.25, 0.53
Treatment effect (log odds) 0
*investigated only for the 4-level outcome
Investigation of empirical power using each ICC in the DE (120 scenarios)
Allocation ratio 50:50
Number of ordinal categories 3,4,5
Cluster size (fixed) 5, 10, 50
ICC on the underlying scale 0.01, 0.08, 0.16, 0.25, 0.53
ICC in DE ANOVA, underlying ICC*
Treatment effect (log odds) 0.493, 0.887
*investigated only for the 4-level outcome
Investigation the effect of non-proportional odds (30 scenarios)
Allocation ratio 50:50
Number of ordinal categories 4
Cluster size (fixed) 5, 10, 50
ICC on the underlying scale 0.01, 0.08, 0.16, 0.25, 0.53
ICC investigated ANOVA
Treatment effect (log odds) 0.35, 0.45
Investigation of empirical power with ANOVA ICC and logit link (30 scenarios)
Allocation ratio 50:50
Number of ordinal categories 4
Cluster size (fixed) 5, 10, 50
ICC on the underlying scale 0.01, 0.08, 0.16, 0.25, 0.53
ICC investigated ANOVA
Treatment effect (log odds) 0.493, 0.887
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For all other simulations cluster sizes were fixed at 5, 10 and 50. The number of clusters for each
scenario was determined by calculating the sample size required under individual randomisation
using Whitehead’s formula and multiplying by the appropriate design effect for the scenario.
5.4.3 Number of ordinal categories
The simulation studies focused on ordinal outcomes with four levels, the most common number of
levels used in the trials I identified in Chapter Three with ordinal outcomes. The sensitivity of the
main results, the assessment of power when using the design effect for sample size calculation, was
explored for outcomes with three and five levels.
5.4.4 Estimated probabilities in each category
The control group proportions for the four-level ordinal outcome were chosen to be the same as those
used in the example by Whitehead. The four ordinal categories were very good, good, moderate and
poor and the corresponding proportions expected in each category were 0.20, 0.50, 0.20, 0.10. These
proportions correspond to threshold values for the underlying latent response of α1 = −0.84, α2 =
0.52, α3 = 1.28.
For the exploration of relationships amongst ICC estimators I also considered an alternative cate-
gorisation of the four-level ordinal outcome of 0.10, 0.30, 0.40 and 0.20 to determine whether the
relationships are affected by the proportions expected in each category.
For the sensitivity analyses the control proportions for the three-level version of the outcome were
0.20, 0.70 and 0.10 with corresponding threshold values for the underlying latent response of α1 =
−0.84, α2 = 1.28. For the five-level outcome the control proportions were 0.20, 0.20, 0.30, 0.20, and
0.10 with corresponding threshold values for the underlying latent response of α1 = −0.84, α2 =
−0.25, α3 = 0.52, α4 = 1.28. Proportions for the three and five-level versions of the outcome were
chosen by expanding or combining categories from the four-level version of the outcome so as to
introduce minimal changes and maintain the same underlying proportions to maintain comparability
amongst the three-, four-, and five-level versions of the outcome.
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The proportional odds assumption implies that the treatment effect can be represented by a single
value β for each value of q. Violation of the proportional odds assumption may occur in a variety of
ways. The treatment effect may be different for each category q, with the effects being in the same
or alternative directions across the categories. Alternatively one or more of the log odds ratios may
be different for one or two categories only. The magnitude of any differences in the treatment effect
across categories will determine whether proportional odds are still a reasonable assumption. In
situations where proportional odds is unreasonable the partial proportional odds model or nominal
regression may be more suitable analysis methods.
In this simulation I examined the empirical power of the design effect approach, followed by an
analysis by random effects ordinal regression with probit link, under a minor deviation from pro-
portional odds. I considered the deviation where one odds ratio was slightly different from the rest
for a four-level outcome. The log odds ratio for the first dichotomisation was 0.35 and 0.493 for the
other categories. These log-odds were chosen to ensure a relatively large number of clusters per arm
in order to provide reliable empirical power estimates.
To assess the effect of non-proportional odds an initial dataset was generated using the methods
described in this section. In order to adjust the observed proportions to reflect non-proportionality
I generated a uniformly distributed random variable for every observation using Stata’s runiform()
command. The dataset was then sorted by treatment group, ordinal category and the random
variable. In the treatment group the first 10% in the first ordinal category were assigned the category
below. Therefore the proportions in the control group remained as 0.20, 0.50, 0.20 and 0.10 and
in the treatment group the proportions became 0.26, 0.53, 0.14 and 0.06, which correspond to the
required log-odds of 0.35 for the first dichotomisation and 0.493 for the others.
5.4.5 Treatment effect
For the simulations that explored the relationships between ICC estimators I assumed there was
no treatment effect i.e. a log-odds of 0. See the discussion section at the end of this chapter for a
discussion of the implications of this assumption.
The simulations were designed around the example provided in Whitehead’s paper on sample size
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methods for ordinal outcomes in the individually randomised design. Whitehead’s example was used
as a starting point in order to be able to compare the results to the clustered case. In Whitehead’s
example a log-odds of 0.887 (OR 2.43) was assumed, which indicates superiority of the new treatment.
I expanded his example to additionally consider log-odds either side of this, 0.493 (OR 1.6), and
1.207 (OR 3.3) in order to explore patterns for small, medium and large effect sizes. However, the
larger odds ratio was later removed from the simulations as the analysis model did not perform well
on the small number of clusters calculated for the sample size with this treatment effect.
The above estimates of log-odds were based on a proportional odds cumulative logit model. I
used an ordered probit model to generate my data as it provided simpler calculations (see section
5.3.1). Therefore in the data generating process the above log-odds needed to be transformed to
the corresponding treatment effect that would be expected from an ordered probit regression on
this data. Using the fact that the standard normal cumulative distribution function (cdf) at a
point z is well approximated by the standard logistic cdf at 1.7z the estimates (log-odds) from
the logit model are approximately 1.7 times those from ordered probit models.130 Therefore, the
corresponding treatment estimates for the probit model used in data generation were 0.29 and 0.52.
As the treatment effect under a random effects model is proportional to the total variance the
treatment effect was multiplied by the value of
√
(1 + σ2w) for that particular scenario to account for
an analysis by random effects ordered probit regression. In the presentation of the results I use the
values of the log odds from the logit model, 0.887 and 0.493 as their interpretation is more familiar
and simpler than the treatment effect under a probit link.
When exploring the empirical power for the minor deviation from proportionality for the four-level
outcome the proportions expected in the control group are 0.20, 0.50, 0.20 and 0.10 and in the
treatment group 0.26, 0.53, 0.14 and 0.06. This corresponds to log-odds ratios of 0.35, 0.493 and
0.493 for the three possible dichotomisations of the outcome. Whitehead’s sample size method
requires all expected proportions to be specified and a single estimate for the treatment effect. I
investigated the resulting power under two different scenarios for estimating the treatment effect (i)
summarise the log-odds using the mean, 0.45 (ii) use the smallest log odds ratio of 0.35.
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5.4.6 Incorporation of clustering
It is only the ICC on the underlying continuous variable that can be fixed during the data generation
process. The ICC for the underlying continuous variable, with probit link is defined as
ρl =
σ2b
σ2b+1
The relationship between this and other ICC estimators is unknown. The values of ICCs likely to
be observed in practice for ordinal outcomes are relatively unknown, although they are probably
not that dissimilar to those seen for binary and continuous outcomes, particularly if an underlying
continuous variable can be assumed.
Several publications describe the general behaviour and patterns in ICCs across different therapeutic
areas, outcomes and clusters.14–18 These patterns have been summarised by Eldridge and Kerry.21
Process outcomes generally have higher ICC values (median 0.063) than clinical or individual level
outcomes (median 0.03); ICCs are higher in secondary care settings (median 0.061) than primary
care (median 0.045); ICCs are larger when the natural cluster size is small; ICCs are lower for binary
outcomes with extreme prevalence; ICCs over 0.35 are unlikely for binary outcomes. The values of
ICC for the underlying continuous variable considered in the simulation (assumed to be the same in
both treatment arms) were chosen to cover a large range of ICC estimates, 0.01, 0.08, 0.16, 0.25, and
0.53. The reason these specific values were chosen was that in the paper by Eldridge these ICCs on
the underlying latent scale were shown to correspond to ICCs for binary outcomes on the proportions
scale of 0.01, 0.05, 0.1, 0.15, 0.3, when overall prevalence is 0.30.147 Using these values with known
relationship to the binary ICC on the proportions scale allowed scope for some validation of my data
generation (see section 5.7).
5.5 Estimates to be stored
Summary statistics
For each simulated dataset the proportion in each ordinal category and treatment group were calcu-
lated and stored.
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Analysis
For each simulated dataset a random effects ordered probit regression model was fitted to the data
and the estimated treatment effect was stored. The hypothesis of no treatment effect was tested via
the Wald statistic which was calculated as the estimated treatment effect divided by its standard
error. The Wald statistic was compared to a Normal distribution and the P-value stored.
Post-estimation
For each simulated dataset the ANOVA estimate of the ICC was calculated by first assigning equally
spaced scores to the ordinal outcome. The Stata inbuilt commands for calculating the ANOVA ICC
truncate the ICC at zero, inflating the average ANOVA ICC estimate. To avoid this I calculated the
ANOVA ICC from first principles using the estimates of the between and within sums of squares (SSb
and SSw) and associated degrees of freedom (DFb, DFw) that are provided by the Stata command
loneway which performs a one-way analysis of variance . The between-group mean squares MSb is
calculated as SSb/DFb and similarly the within-group mean squares, MSw is calculated as SSw/DFw
and n is the cluster size. The ANOVA ICC is then calculated as:
ρa =
MSb−MSw
MSb+(n−1)MSw
The observed ICC on the latent scale was calculated using the between-cluster estimate of the vari-
ance provided directly from the probit model fitted in Stata, input into the following formula
ρl =
σ2b
σ2b+1
I programmed the calculation of the kappa-type ICC using the formula described in Chapter Four,
Section 4.3.
Summary statistics over all simulations
Descriptive statistics for ICC estimates calculated over all simulated datasets within a scenario were
mean (SD), median(IQR), minimum and maximum, and the percentage of negative values.
Empirical Power
For each scenario the empirical power was calculated as the proportion of datasets with a P-value
141
5.6. NUMBER AND SIZE OF SIMULATED DATASETS
of less than 0.05. The sample size was deemed appropriate if the empirical power was close to the
calculated power of 90%. In order to determine how others had defined what would be considered to
be sufficiently close I reviewed 18 papers that evaluated their sample size method through simulation,
from the 85 sample size papers identified in Chapter Two. However, in the majority of papers no
formal definition of what constituted sufficiently close was provided. A few papers calculated an
absolute difference between empirical and nominal power, reporting the maximum difference seen or
those that were at least 2% different. One paper reported the relative bias of power calculated as the
calculated power minus empirical power divided by the empirical power. Biases that were greater
than 10% were highlighted. In my simulations I report empirical power, the standard error and the
absolute difference from the calculated power. I consider the design effect approach appropriate if
simulated power is within 2% of nominal power.
5.6 Number and size of simulated datasets
Due to the large number of scenarios studied the number of simulations for each scenario was limited
to 1000. In comparison to the 18 papers identified with simulation studies from my sample of 85
sample size papers the number of simulations conducted were 1000 (n=7), 2000 (n=2), 4000 (n=1),
5000 (n=3) and 10,000 (n=5). In only one of these papers was the number of simulations (10,000)
justified. However, it is unclear whether this justification was post-hoc. The authors state that the
Monte Carlo standard error for the resulting power calculations is no greater than 0.25%.72 The
standard error is presented for each of my simulation scenarios in the results section.
The size of each dataset was dependent upon the scenario being investigated. The sample size was
first calculated using Whitehead’s formula assuming individual randomisation with 90% power and
a 2-sided 5% significance level. Table 5.2 summarises the sample size required under individual
randomisation for the 3-,4- and 5-level ordinal responses under each of the possible treatment effects
and when the assumption of proportional odds is relaxed. The sample size was multiplied by the
standard design effect, 1+(n−1)ρ for each combination of cluster size and ICC estimate investigated.
Estimates were always rounded up to ensure an equal number of clusters, of required size, per
treatment group.
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Table 5.2: Sample size requirements under individual randomisation for ordinal outcomes with 3,4, or 5 categories for various treatment effects
Outcome levels Control proportions Treatment proportions Treatment effect (log OR) Total sample size required
3-level 0.20, 0.70, 0.10 0.29, 0.65, 0.06 0.493 764
0.38, 0.58, 0.04 0.887 226
4-level 0.20, 0.50, 0.20, 0.10 0.29, 0.50, 0.14, 0.06 0.493 608
0.38, 0.47, 0.11, 0.04 0.887 188
non-proportional odds
0.20, 0.50, 0.20, 0.10 0.26, 0.53, 0.14, 0.06 0.35 1200
0.20, 0.50, 0.20, 0.10 0.26, 0.53, 0.14, 0.06 0.45 738
5-level 0.20, 0.20, 0.30, 0.20, 0.10 0.29, 0.23, 0.27, 0.14, 0.06 0.493 550
0.38, 0.24, 0.23, 0.11, 0.04 0.887 172
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5.7 Validation
Data Generating model
After discussion and agreement of the data generating process with SE and AC several strategies
were employed to validate the process and ensure confidence in the results.
I sent a written summary of the data generating process to Alan Agresti, one of the leaders in the
field of ordinal outcomes. However, he did not have experience of generating clustered data and
as he has now retired from academia he did not have any PhD students or colleagues that I might
confirm the process with.
My simulation code was checked by a colleague, Neil Wright, from the PCTU who has experience of
generating clustered binary data using similar methods to mine. No issues for concern were identified.
From the datasets generated for the four-level ordinal outcome to explore the relationships between
ICC estimators I created a binary outcome which combined the first two categories and the last two
categories, resulting in an overall prevalence of 0.30. From the work conducted by Eldridge et al it
is known that for an overall prevalence of 0.30 ICC values on the underlying scale of 0.01, 0.08, 0.16,
0.25, and 0.53 correspond to ICCs on the proportions scale of 0.01, 0.05, 0.1, 0.15 and 0.3.147 This
result was reassuringly replicated in my dataset.
The analysis method
In order to ensure that my test procedure, the Wald test, performed well under the simulation
scenarios I examined the empirical Type I error rate to determine the minimum number of clusters
required in the analysis to provide an empirical Type I error rate close to the nominal error rate of
5%.
Datasets of clustered ordinal outcomes were generated assuming the null hypothesis of no difference
between treatment groups and analysed with a random effects effects ordered probit regression
model. The effect of treatment was tested using a Wald test comparing the test statistic to a normal
distribution and using a Wald test comparing the test statistic to a t-distribution with degrees of
freedom calculated as the number of clusters minus two. One thousand datasets were generated for
a 4-level ordinal outcome with 5, 10, 15, 20, 25 and 40 clusters per arm, cluster sizes of 5, 10 and 50,
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Figure 5.1: Empirical Type I error rates for the Wald test for the treatment effect from a random effects
ordered probit model, compared to both the Normal and t-distributions (varying number of
clusters of size 5)
and ICCs on the underlying latent variable of 0.01, 0.08, 0.16, 0.25, and 0.53. The empirical Type I
error rate was calculated as the proportion of P-values that were less than 0.05.
The results for clusters of size 5, 10 and 50 are presented in figures 5.1, 5.2 and 5.3. These figures
show that the type I error for the Wald test compared to a t-distribution was always lower than that
compared to the normal distribution. The empirical Type I error rate comes closer to the nominal
value as the number of clusters increases, with 40 clusters per arm showing good results.
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Figure 5.2: Empirical Type I error rates for the Wald test the treatment effect from a random effects
ordered probit model, compared to both the Normal and t-distributions (varying number of
clusters of size 10)
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Figure 5.3: Empirical Type I error rates for the Wald test for the treatment effect from a random effects
ordered probit model, compared to both the Normal and t-distributions (varying number of
clusters of size 50)
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5.8 Results
All scenarios were simulated reliably. The number of analysis models that did not converge was less
than 10 (1%) for all scenarios considered.
5.8.1 Relationship between ICC estimators
For fixed values of the ICC on the latent continuous variable (ρl) 1000 datasets were generated for a
total of 100 clusters of size 5 and 50 for ordinal outcomes with 3,4, and 5 levels. For each dataset the
ANOVA ICC (ρa) and the kappa-type ICC (ρk), were calculated. The ANOVA ICC calculated on
a dichotomised version of the outcome (ρb) was also calculated as validation of the data generating
process, as its relationship with the ICC on the latent scale is known.
The relationship between ICCs for the 3-, 4-, and 5-level outcomes are provided in Tables 5.3, 5.4
and 5.5. The results show the ICC on the latent response to be largest, followed by the ANOVA
and kappa-type ICCs that were almost identical. Both the ANOVA ICC and kappa-type estimates
produced a similar proportion of negative estimates in each scenario. The proportion of negative
estimates decreased as the level of clustering and number of clusters increased. As the number of
ordinal categories increased so too did the estimated ANOVA and Kappa-type ICCs. These observed
patterns were consistent across the 3-, 4- and 5-level outcome variables.
Sensitivity analysis looked at the relationship between ICC estimators for the 4-level outcome when
the number of clusters was small (Table 5.6). Results show that the ICC on the latent response
tended to be largest followed by the ANOVA and kappa-type ICCs, with the ICC on the dichotomised
version of the outcome being the smallest. As the level of clustering increases so too does the differ-
ence between the ANOVA and kappa-type estimates with the ANOVA estimate being consistently
larger. The relationships between ICC estimators for the 4-level outcome with a small and large
number of clusters are displayed in Figures 5.4 and 5.5.
Table 5.7 shows the relationship between ICCs for a four-level ordinal outcome where different
proportions from those used in the main simulations are expected in each category. Comparing
these to the results seen in Table 5.4 shows that for a fixed ICC on the underlying latent variable
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the values of the ANOVA and kappa-type ICC are the same even when the proportions in each
category change if the level of clustering is low. When the level of clustering is larger the values of
the ANOVA and kappa-type ICC are affected by the change in proportions expected in each category.
Table 5.3: Results showing the relationship between the ICC on the underlying continuous latent variable
(ρl) and ICCs calculated on the 3-level ordinal outcome, ANOVA (ρa) and kappa (ρk), when
the number of clusters is large. The dichotomised version of the ordinal outcome assumes an
overall prevalence of 0.2 and its associated ICC is given by (ρb). It was assumed there was no
effect of treatment.
Parameters (1000 simulations) Descriptive statistics
Total Cluster ρl(σ
2
b ) ICC Mean (SD) Median (IQR) min, max % negative
clusters size
100
5
0.01 (0.01)
ρa 0.01 (0.03) 0.01 (-0.02, 0.03) -0.10, 0.13 435 (44%)
ρk 0.01 (0.03) 0.01 (-0.02, 0.03) -0.10, 0.13 435 (44%)
ρb 0.00 (0.03) 0.00 (-0.02, 0.02) -0.08, 0.12 463 (46%)
0.08 (0.09)
ρa 0.06 (0.04) 0.06 (0.03, 0.08) -0.06, 0.16 59 (6%)
ρk 0.06 (0.04) 0.06 (0.03, 0.08) -0.06, 0.16 59 (6%)
ρb 0.04 (0.04) 0.04 (0.01, 0.07) -0.08, 0.19 138 (14%)
0.16 (0.19)
ρa 0.11 (0.04) 0.11 (0.09, 0.14) -0.03, 0.25 3(< 1%)
ρk 0.11 (0.04) 0.11 (0.09, 0.14) -0.03, 0.25 3(< 1%)
ρb 0.08 (0.04) 0.08 (0.05, 0.11) -0.04, 0.21 18 (2%)
0.25 (0.33)
ρa 0.17 (0.05) 0.17 (0.14, 0.21) 0.05, 0.35 0
ρk 0.17 (0.04) 0.17 (0.14, 0.20) 0.05, 0.34 0
ρb 0.13 (0.05) 0.13(0.10, 0.16) -0.00, 0.28 1(< 1%)
0.53 (1.13)
ρa 0.38 (0.05) 0.38 (0.34, 0.42) 0.18, 0.54 0
ρk 0.38 (0.05) 0.38 (0.34, 0.41) 0.17, 0.54 0
ρb 0.32 (0.06) 0.32 (0.27, 0.36) 0.11, 0.52 0
50
0.01 (0.01)
ρa 0.01 (0.00) 0.01 (0.00, 0.01) -0.01, 0.02 31 (3%)
ρk 0.01 (0.00) 0.01 (0.00, 0.01) -0.01, 0.02 31 (3%)
ρb 0.00 (0.00) 0.00 (0.00, 0.01) -0.00, 0.02 88 (9%)
0.08 (0.09)
ρa 0.06 (0.01) 0.06 (0.05, 0.07) 0.03, 0.10 0
ρk 0.06 (0.01) 0.06 (0.05, 0.07) 0.03, 0.09 0
ρb 0.04 (0.01) 0.04 (0.04, 0.05) 0.01, 0.07 0
0.16 (0.19)
ρa 0.11 (0.02) 0.11 (0.10, 0.13) 0.07, 0.17 0
ρk 0.11 (0.02) 0.11 (0.10, 0.12) 0.07, 0.17 0
ρb 0.08 (0.01) 0.08 (0.07, 0.09) 0.05, 0.14 0
0.25 (0.33)
ρa 0.18 (0.02) 0.18 (0.16, 0.19) 0.10, 0.26 0
ρk 0.18 (0.02) 0.17 (0.16, 0.19) 0.10, 0.26 0
ρb 0.13 (0.02) 0.13 (0.12, 0.15) 0.07, 0.20 0
0.53 (1.13)
ρa 0.38 (0.03) 0.38 (0.36, 0.40) 0.27, 0.50 0
ρk 0.38 (0.03) 0.38 (0.36, 0.40) 0.26, 0.49 0
ρb 0.32 (0.04) 0.32 (0.29, 0.34) 0.20, 0.45 0
Notes. The data was generated for a 3-level ordinal outcome with proportions in each category of
0.20, 0.70, and 0.1 for both treatment groups.
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Table 5.4: Results showing the relationship between the ICC on the underlying continuous latent variable
(ρl) and ICCs calculated on the 4-level ordinal outcome, ANOVA (ρa) and kappa (ρk), when
the number of clusters is large. The dichotomised version of the ordinal outcome assumes an
overall prevalence of 0.3 and its associated ICC is given by (ρb). It was assumed there was no
effect of treatment.
Parameters (1000 simulations) Descriptive statistics
Total Cluster ρl(σ
2
b ) ICC Mean (SD) Median (IQR) min, max % negative
clusters size
100
5
0.01 (0.01)
ρa 0.01 (0.03) 0.01 (-0.01, 0.03) -0.10, 0.12 407(41%)
ρk 0.01 (0.03) 0.01 (-0.01, 0.03) -0.10, 0.12 409(41%)
ρb 0.01 (0.03) 0.00 (-0.02, 0.03) -0.10, 0.12 448(45%)
0.08 (0.09)
ρa 0.07 (0.04) 0.07 (0.04, 0.09) -0.05, 0.19 29(3%)
ρk 0.07 (0.04) 0.07 (0.04, 0.09) 0.05, 0.19 29(3%)
ρb 0.05 (0.04) 0.05 (0.02, 0.07) -0.05, 0.18 90(9%)
0.16 (0.19)
ρa 0.14 (0.04) 0.13 (0.11, 0.16) 0.01, 0.30 0(0%)
ρk 0.13 (0.04) 0.13 (0.10, 0.16) 0.01, 0.30 0(0%)
ρb 0.09 (0.04) 0.09 (0.07, 0.12) -0.02, 0.27 9(1%)
0.25 (0.33)
ρa 0.21 (0.05) 0.21 (0.18, 0.24) 0.06, 0.37 0(0%)
ρk 0.21 (0.05) 0.21 (0.18, 0.24) 0.06, 0.36 0(0%)
ρb 0.15 (0.05) 0.15 (0.12, 0.18) -0.03, 0.33 1(< 1%)
0.53 (1.13)
ρa 0.45 (0.05) 0.46 (0.42, 0.49) 0.26, 0.59 0(0%)
ρk 0.45 (0.05) 0.45 (0.41, 0.48) 0.26, 0.59 0(0%)
ρb 0.34 (0.06) 0.34 (0.30, 0.38) 0.15, 0.55 0(0%)
50
0.01 (0.01)
ρa 0.01 (0.00) 0.01 (0.01, 0.01) -0.00, 0.02 16(2%)
ρk 0.01 (0.00) 0.01 (0.01, 0.01) -0.00, 0.02 16(2%)
ρb 0.01 (0.00) 0.01 (0.00, 0.01) -0.01, 0.02 46(5%)
0.08 (0.09)
ρa 0.07 (0.01) 0.07 (0.06, 0.08) 0.04, 0.10 0(0%)
ρk 0.07 (0.01) 0.07 (0.06, 0.08) 0.03, 0.10 0(0%)
ρb 0.05 (0.01) 0.05 (0.04, 0.05) 0.02, 0.07 0(0%)
0.16 (0.19)
ρa 0.14 (0.02) 0.14 (0.12, 0.15) 0.08, 0.20 0(0%)
ρk 0.13 (0.02) 0.13 (0.12, 0.15) 0.08, 0.20 0(0%)
ρb 0.09 (0.01) 0.09 (0.08, 0.10) 0.05, 0.14 0(0%)
0.25 (0.33)
ρa 0.21 (0.03) 0.21 (0.19, 0.23) 0.14, 0.30 0(0%)
ρk 0.21 (0.02) 0.21 (0.19, 0.22) 0.14, 0.30 0(0%)
ρb 0.15 (0.02) 0.15 (0.13, 0.16) 0.09, 0.23 0(0%)
0.53 (1.13)
ρa 0.46 (0.04) 0.46 (0.43, 0.48) 0.33, 0.57 0(0%)
ρk 0.45 (0.04) 0.45 (0.43, 0.47) 0.33, 0.56 0(0%)
ρb 0.34 (0.04) 0.34 (0.32, 0.36) 0.23, 0.44 0(0%)
Notes. The data was generated for a 4-level ordinal outcome with proportions in each category of
0.20, 0.50, 0.20 and 0.1 for both treatment groups.
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Table 5.5: Results showing the relationship between the ICC on the underlying continuous latent variable
(ρl) and ICCs calculated on the 5-level ordinal outcome, ANOVA (ρa) and kappa (ρk), when
the number of clusters is large. The dichotomised version of the ordinal outcome assumes an
overall prevalence of 0.4 and its associated ICC is given by (ρb). It was assumed there was no
effect of treatment.
Parameters (1000 simulations) Descriptive statistics
Total Cluster ρl(σ
2
b ) ICC Mean (SD) Median (IQR) min, max % negative
clusters size
100
5
0.01 (0.01)
ρa 0.01 (0.03) 0.01 (-0.01, 0.03) -0.09, 0.12 392(39%)
ρk 0.01 (0.03) 0.01 (-0.01, 0.03) -0.09, 0.12 392 (39%)
ρb 0.01 (0.03) 0.01 (-0.02, 0.03) -0.10, 0.14 417 (42%)
0.08 (0.09)
ρa 0.07 (0.04) 0.07 (0.05, 0.10) -0.05, 0.22 20 (2%)
ρk 0.07 (0.04) 0.07 (0.05, 0.10) -0.05, 0.22 20 (2%)
ρb 0.05 (0.04) 0.05 (0.03, 0.08) -0.05, 0.21 81 (8%)
0.16 (0.19)
ρa 0.15 (0.04) 0.15 (0.12, 0.18) 0.01, 0.29 0
ρk 0.15 (0.04) 0.15 (0.12, 0.18) 0.01, 0.29 0
ρb 0.10 (0.04) 0.10 (0.07, 0.13) -0.03, 0.28 3(< 1%)
0.25 (0.33)
ρa 0.23 (0.05) 0.23 (0.19, 0.26) 0.09, 0.37 0
ρk 0.22 (0.05) 0.23 (0.19, 0.25) 0.09, 0.37 0
ρb 0.16 (0.04) 0.16 (0.13, 0.19) 0.02, 0.30 0
0.53 (1.13)
ρa 0.49 (0.05) 0.49 (0.45, 0.52) 0.31, 0.62 0
ρk 0.48 (0.05) 0.49 (0.45, 0.52) 0.31, 0.61 0
ρb 0.35 (0.05) 0.36 (0.32, 0.39) 0.20, 0.53 0
50
0.01 (0.01)
ρa 0.01 (0.00) 0.01 (0.01, 0.01) -0.00, 0.02 9 (1%)
ρk 0.01 (0.00) 0.01 (0.01, 0.01) -0.00, 0.02 9(1%)
ρb 0.01 (0.00) 0.01 (0.00, 0.01) -0.00, 0.02 43 (4%)
0.08 (0.09)
ρa 0.08 (0.01) 0.08 (0.07, 0.08) 0.04, 0.12 0
ρk 0.07 (0.01) 0.07 (0.07, 0.08) 0.04, 0.11 0
ρb 0.05 (0.01) 0.05 (0.05, 0.06) 0.02, 0.08 0
0.16 (0.19)
ρa 0.14 (0.02) 0.14 (0.13, 0.16) 0.09, 0.21 0
ρk 0.14 (0.02) 0.14 (0.13, 0.16) 0.08, 0.21 0
ρb 0.10 (0.02) 0.10 (0.09, 0.11) 0.06,0.15 0
0.25 (0.33)
ρa 0.23 (0.03) 0.23 (0.21, 0.24) 0.15, 0.30 0
ρk 0.22 (0.03) 0.22 (0.21, 0.24) 0.15, 0.30 0
ρb 0.16 (0.02) 0.16 (0.14, 0.17) 0.10, 0.21 0
0.53 (1.13)
ρa 0.49 (0.04) 0.49 (0.46, 0.51) 0.39, 0.59 0
ρk 0.48 (0.04) 0.48 (0.46, 0.51) 0.38, 0.59 0
ρb 0.35 (0.03) 0.35 (0.33, 0.38) 0.25, 0.46 0
Notes. The data was generated for a 5-level ordinal outcome with proportions in each category of
0.20, 0.20, 0.30, 0.20 and 0.1 for both treatment groups.
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Table 5.6: Results showing the relationship between the ICC on the underlying continuous latent variable
(ρl) and ICCs calculated on the 4-level ordinal outcome, ANOVA (ρa) and kappa (ρk), when
the number of clusters is small. The dichotomised version of the ordinal outcome assumes an
overall prevalence of 0.3 and its associated ICC is given by (ρb). It was assumed there was no
effect of treatment.
Parameters (1000 simulations) Descriptive statistics
Total Cluster ρl(σ
2
b ) ICC Mean (SD) Median (IQR) min, max % negative
clusters size
10
5
0.01 (0.01)
ρa 0.01 (0.11) 0.01 (-0.06, 0.08) -0.22, 0.45 486(49%)
ρk 0.01 (0.10) 0.00 (-0.06, 0.07) -0.20, 0.43 485(49%)
ρb 0.01 (0.11) -0.00 (-0.08, 0.08) -0.21, 0.44 505(51%)
0.08 (0.09)
ρa 0.06 (0.12) 0.05 (-0.02, 0.14) -0.20, 0.46 320(32%)
ρk 0.06 (0.11) 0.05 (-0.02, 0.13) -0.18, 0.43 321(32%)
ρb 0.04 (0.11) 0.03 (-0.04, 0.11) -0.20, 0.59 381(38%)
0.16 (0.19)
ρa 0.13 (0.14) 0.12 (0.02, 0.22) -0.18, 0.66 189(19%)
ρk 0.12 (0.13) 0.11 (0.02, 0.21) -0.16, 0.63 191(19%)
ρb 0.09 (0.13) 0.09 (-0.01, 0.18) -0.19, 0.56 263(26%)
0.25 (0.33)
ρa 0.20 (0.14) 0.19 (0.09, 0.29) -0.17, 0.64 77(8%)
ρk 0.18 (0.13) 0.18 (0.09, 0.27) -0.15, 0.61 79(8%)
ρb 0.14 (0.14) 0.12 (0.03, 0.23) -0.18, 0.65 153(15%)
0.53 (1.13)
ρa 0.43 (0.16) 0.44 (0.32, 0.55) -0.11, 0.83 6(1%)
ρk 0.40 (0.16) 0.41 (0.30, 0.52) -0.10, 0.81 6(1%)
ρb 0.33 (0.18) 0.33 (0.21, 0.45) -0.14, 0.80 33(3%)
50
0.01 (0.01)
ρa 0.01 (0.01) 0.01 (-0.00, 0.02) -0.02, 0.07 292(29%)
ρk 0.01 (0.01) 0.01 (-0.00, 0.01) -0.01, 0.06 290(29%)
ρb 0.01 (0.01) 0.00 (-0.00, 0.01) -0.02, 0.05 370(37%)
0.08 (0.09)
ρa 0.07 (0.04) 0.07 (0.04, 0.09) -0.01, 0.26 9(1%)
ρk 0.06 (0.03) 0.06 (0.04, 0.08) -0.01, 0.24 9(1%)
ρb 0.05 (0.03) 0.04 (0.02, 0.07) -0.01, 0.22 22(2%)
0.16 (0.19)
ρa 0.13 (0.06) 0.12 (0.09, 0.17) -0.01, 0.44 2(< 1%)
ρk 0.12 (0.06) 0.11 (0.08, 0.15) -0.01, 0.41 2(< 1%)
ρb 0.09 (0.05) 0.08 (0.06, 0.12) -0.01, 0.34 4(< 1%)
0.25 (0.33)
ρa 0.21 (0.08) 0.21 (0.14, 0.26) 0.03, 0.45 0(0%)
ρk 0.19 (0.08) 0.19 (0.13, 0.24) 0.03, 0.42 0(0%)
ρb 0.15 (0.07) 0.14 (0.10, 0.19) 0.01, 0.38 0(0%)
0.53 (1.13)
ρa 0.44 (0.12) 0.44 (0.36, 0.52) 0.07, 0.75 0(0%)
ρk 0.41 (0.12) 0.41 (0.33, 0.49) 0.06, 0.73 0(0%)
ρb 0.33 (0.12) 0.33 (0.24, 0.41) 0.03, 0.66 0(0%)
Notes. The data was generated for a 4-level ordinal outcome with proportions in each category of
0.20, 0.50, 0.20 and 0.1 for both treatment groups.
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Figure 5.4: Relationship between ICC estimators for a 4-level ordinal variable with a total of 10 clusters,
of size 5 or 50. It was assumed there was no effect of treatment.
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Figure 5.5: Relationship between ICC estimators for the 4-level ordinal variable with a total of 100 clusters,
of size 5 or 50. It was assumed there was no effect of treatment.
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Table 5.7: Results showing the relationship between the ICC on the underlying continuous latent variable
(ρl) and ICCs calculated on the 4-level ordinal outcome (different proportions from those used
in main simulations) ANOVA (ρa) and kappa (ρk), when the number of clusters is large. It was
assumed there was no effect of treatment.
Parameters (1000 simulations) Descriptive statistics
Total Cluster ρl(σ
2
b ) ICC Mean (SD) Median (IQR) min, max % negative
clusters size
100
5
0.01 (0.01)
ρa 0.01 (0.03) 0.01 (-0.01, 0.03) -0.09, 0.16 395 (40%)
ρk 0.01 (0.03) 0.01 (-0.01, 0.03) -0.09, 0.16 395 (40%)
0.08 (0.09)
ρa 0.07 (0.04) 0.07 (0.05, 0.10) -0.03, 0.21 22 (2%)
ρk 0.07 (0.04) 0.07 (0.05, 0.10) -0.03, 0.21 21 (2%)
0.16 (0.19)
ρa 0.14 (0.04) 0.14 (0.11, 0.17) 0.00, 0.29 0(0%)
ρk 0.14 (0.04) 0.14 (0.11, 0.17) 0.00, 0.28 0 (0%)
0.25 (0.33)
ρa 0.22 (0.05) 0.22 (0.19, 0.25) 0.08, 0.36 0(0%)
ρk 0.21 (0.04) 0.22 (0.19, 0.24) 0.08, 0.35 0 (0%)
0.53 (1.13)
ρa 0.47 (0.05) 0.47 (0.44, 0.50) 0.30, 0.63 0(0%)
ρk 0.46 (0.05) 0.46 (0.43, 0.49) 0.30, 0.62 0(0%)
50
0.01 (0.01)
ρa 0.01 (0.00) 0.01 (0.01, 0.01) -0.00, 0.02 11 (1%)
ρk 0.01 (0.00) 0.01 (0.01, 0.01) -0.00, 0.02 11 (1%)
0.08 (0.09)
ρa 0.07 (0.01) 0.07 (0.06, 0.08) 0.04, 0.12 0(0%)
ρk 0.07 (0.01) 0.07 (0.06, 0.08) 0.04, 0.11 0(0%)
0.16 (0.19)
ρa 0.14 (0.02) 0.14 (0.13, 0.15) 0.08, 0.20 0(0%)
ρk 0.14 (0.02) 0.14 (0.12, 0.15) 0.08, 0.20 0(0%)
0.25 (0.33)
ρa 0.22 (0.02) 0.22 (0.20, 0.23) 0.14, 0.29 0(0%)
ρk 0.21 (0.02) 0.21 (0.20, 0.23) 0.14, 0.29 0(0%)
0.53 (1.13)
ρa 0.47 (0.03) 0.47 (0.44, 0.49) 0.37, 0.59 0(0%)
ρk 0.46 (0.03) 0.46 (0.44, 0.48) 0.36, 0.59 0(0%)
Notes. The data was generated for a 4-level ordinal outcome with proportions in each category of
0.10, 0.30, 0.40 and 0.20 for both treatment groups.
5.8.2 Power of a trial designed using the design effect with each ICC
estimate
Tables 5.3, 5.4 and 5.5 show the ANOVA ICC and kappa-type ICCs to be asymptotically equivalent
in samples with a large number of clusters. For this reason it was not necessary to assess the empirical
power of both estimates in the design effect. I chose to only consider use of the ANOVA ICC as it
was seen to be slightly larger than the kappa-type ICC in small samples and hence would provide a
slightly larger sample size estimate in these situations.
For fixed values of the ICC on the latent continuous variable (ρl) 1000 datasets were generated for
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clusters of size 5, 10 and 50 under two estimates of treatment effect for the 3, 4, and 5 level ordinal
outcomes. The size of each dataset was calculated by using Whitehead’s formula for individually
randomised trials multiplied by the design effect. The design effect used the estimate of the ANOVA
ICC that corresponds to the ICC on the latent continuous variable used to generate the data for
that scenario, identified in the previous section.
Tables 5.8, 5.9, and 5.10 summarise the empirical power when using the ANOVA ICC estimate
in the design effect. The evaluation of power is only sensible if the Type I error rate for the test
statistic is controlled at 5%. For the Wald test the Type I error is valid when there are at least 40
clusters per arm. For situations with less than 40 clusters the Type I error is inflated and therefore
the expected power will also be inflated. This phenomenon can be seen in the Tables 5.8, 5.9, and
5.10. In chapter three the eleven trials identified with ordinal outcomes often included only a small
number of clusters. The types of clusters in these trials were health care practices or schools which
would suggest that the number of clusters available would not necessarily be restricted. Only one
trial provided a sample size calculation and therefore the small numbers of clusters used in these
trials may not be typical of future, appropriately designed, cluster randomised trials with ordinal
outcomes. For these reasons I did not evaluate the use of small sample corrections in my simulations
and I am discounting those situations where the number of clusters is less than 40. Future work is
required to generalise my results to situations with a small number of clusters.
For the 3-level ordinal outcome all calculated empirical powers are larger than 90% , the additional
power over 90% ranges from 0.9% to 4.20%. The standard error of the simulated power ranges from
0.73 to 0.91.
For the 4-level outcome the empirical powers are all above or very close to the expected 90%, the
additional power over 90% ranges from 0% to 2.8% . The standard error of the simulated power
ranges from 0.82 to 0.95. For the 5-level outcome we see some situations where the number of clusters
is greater than 40 but 90% power is not achieved. However, the difference in power ranges from -1.4%
to 2.7% which is still within the limit of 2% I specified for empirical power to be considered sufficiently
close to nominal power. The sample size using the ANOVA estimate produces an adequately powered
trial.
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Table 5.8: Empirical power when using the ANOVA estimate of the ICC for the 3-level ordinal outcome in
the design effect for sample size calculation. For each combination of cluster size and ICC: 1000
datasets generated with a 90% target level of power
Fixed Design Parameters log odds=0.493 log odds=0.887
C Empirical power C Empirical power
Cluster size ρa(ρl) Design effect (SE, θˆ − θ) (SE, θˆ − θ)
5
0.01 (0.01) 1.04 80 92.7 (0.82, 2.7) 24 92.8 (0.82, 2.8)
0.06 (0.08) 1.24 95 90.2 (0.86, 0.2) 29 92.1 (0.85, 2.1)
0.11 (0.16) 1.44 111 91.7 (0.87, 1.7) 33 92.0 (0.86, 2.0)
0.18 (0.25) 1.72 132 92.4 (0.84, 2.4) 39 91.1 (0.90, 1.1)
0.38 (0.53) 2.52 193 91.8 (0.87, 1.8) 57 90.9 (0.91, 0.9)
10
0.01 (0.01) 1.09 42 92.7 (0.82, 2.7) 13 92.4 (0.84, 2.4)
0.06 (0.08) 1.54 59 94.2 (0.74, 4.2) 18 91.4 (0.89, 1.4)
0.11 (0.16) 1.99 77 91.9 (0.86, 1.9) 23 90.4 (0.93, 0.4)
0.18 (0.25) 2.62 101 92.2 (0.85, 2.2) 30 90.8 (0.91, 0.8)
0.38 (0.53) 4.42 169 91.8 (0.87, 1.8) 50 91.7 (0.87, 1.7)
50
0.01 (0.01) 1.49 12 95.9 (0.63, 5.9) 4 97.4 (0.50, 7.4)
0.06 (0.08) 3.94 31 94.2 (0.74, 4.2) 9 92.6 (0.83, 2.6)
0.11 (0.16) 6.39 49 92.1 (0.85, 2.1) 15 92.5 (0.83, 2.5)
0.18 (0.25) 9.82 76 92.8 (0.82, 2.8) 23 93.2 (0.80, 3.2)
0.38 (0.53) 19.62 150 92.2 (0.85, 2.2) 45 92.3 (0.84, 2.3)
Notes. Assuming a 3-level ordinal outcome with proportions 0.20, 0.70, and 0.1 in the control
group and C clusters per group. Empirical power, θˆ is calculated as the proportion of fitted
probit models with a treatment effect significant at the 5% level. θˆ − θ represents the absolute
difference between empirical and nominal power
The ICC on the underlying latent continuous variable was shown to be larger than the ANOVA
ICC and therefore will produce sample sizes that produce more power than required, as can be seen
in Table 5.11 for a 4-level outcome. All calculated empirical powers were larger than 90%, the
additional power over 90% ranges from 1.6% to 5.3%. The standard error of the simulated power
ranges from 0.67 to 0.88.
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Table 5.9: Empirical power when using the ANOVA estimate of the ICC for the 4-level ordinal outcome in
the design effect for sample size calculation. For each combination of cluster size and ICC: 1000
datasets generated with a 90% target level of power
Fixed Design Parameters log odds=0.493 log odds=0.887
C Empirical power C Empirical power
Cluster size ρa(ρl) Design effect (SE, θˆ − θ) (SE, θˆ − θ)
5
0.01 (0.01) 1.04 64 90.2 (0.94, 0.2) 20 89.5 (0.97, -0.5)
0.07 (0.08) 1.28 78 92.0 (0.86, 2.0) 25 91.2 (0.90, 1.2)
0.14 (0.16) 1.56 95 90.8 (0.91, 0.8) 30 90.0 (0.95, 0.0)
0.21 (0.25) 1.84 112 90.1 (0.94, 0.1) 35 89.5 (0.97, -0.5)
0.46 (0.53) 2.84 173 90.8 (0.91, 0.8) 54 91.3 (0.89, 1.3)
10
0.01 (0.01) 1.09 34 89.9 (0.95, -0.1) 11 91.5 (0.88, 1.5)
0.07 (0.08) 1.63 50 90.0 (0.95, 0.0) 16 92.4 (0.84, 2.4)
0.14 (0.16) 2.26 69 91.5 (0.88, 1.5) 22 93.5 (0.78, 3.5)
0.21 (0.25) 2.89 88 92.1 (0.85, 2.1) 28 91.2 (0.90, 1.2)
0.46 (0.53) 5.14 157 91.5 (0.88, 1.5) 49 91.6 (0.88, 1.6)
50
0.01 (0.01) 1.49 10 95.5 (0.67, 5.5) 3 94.8 (0.70, 4.8)
0.07 (0.08) 4.43 27 90.9 (0.91, 0.9) 9 94.0 (0.75, 4.0)
0.14 (0.16) 7.86 48 90.2 (0.94, 0.2) 15 90.9 (0.91, 0.9)
0.21 (0.25) 11.29 69 91.9 (0.86, 1.9) 22 91.4 (0.89, 1.4)
0.46 (0.53) 23.54 144 92.0 (0.86, 2.0) 45 92.8 (0.82, 2.8)
Notes. Assuming a 4-level ordinal outcome with proportions 0.20, 0.50, 0.20 and 0.1 in the
control group and C clusters per group. Empirical power, θˆ is calculated as the proportion of
fitted probit models with a treatment effect significant at the 5% level. θˆ − θ represents the
absolute difference between empirical and nominal power
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Table 5.10: Empirical power when using the ANOVA estimate of the ICC for the 5-level ordinal outcome
in the design effect for sample size calculation. For each combination of cluster size and ICC:
1000 datasets generated with a 90% target level of power
Fixed Design Parameters log odds=0.493 log odds=0.887
C Empirical power C Empirical power
Cluster size ρa(ρl) Design effect (SE, θˆ − θ) (SE, θˆ − θ)
5
0.01 (0.01) 1.04 58 90.1 (0.94, 0.1) 18 89.2 (0.98, -0.8)
0.08 (0.08) 1.32 73 91.8 (0.87, 1.8) 23 92.1 (0.85, 2.1)
0.14 (0.16) 1.56 86 88.6 (1.00, -1.4) 27 90.1 (0.94, 0.1)
0.23 (0.25) 1.92 106 91.1 (0.90, 1.1) 34 90.4 (0.93, 0.4)
0.49 (0.53) 2.96 163 89.8 (0.96, -0.2) 51 88.8 (0.99, -1.2)
10
0.01 (0.01) 1.09 30 88.6 (1.00, -1.4) 10 91.6 (0.88, 1.6)
0.08 (0.08) 1.72 48 92.3 (0.84, 2.3) 15 91.4 (0.89, 1.4)
0.14 (0.16) 2.26 63 89.6 (0.97, -0.4) 20 91.5 (0.88, 1.5)
0.23 (0.25) 3.07 85 90.7 (0.92, 0.7) 27 91.5 (0.88, 1.5)
0.49 (0.53) 5.41 149 89.9 (0.95, -0.1) 47 91.6 (0.88, 1.6)
50
0.01 (0.01) 1.49 9 93.2 (0.80, 3.2) 3 96.5 (0.58, 6.5)
0.08 (0.08) 4.92 28 93.2 (0.79, 3.2) 9 94.0 (0.75, 4.0)
0.14 (0.16) 7.86 44 88.6 (1.00, -1.4) 14 91.7 (0.87, 1.7)
0.23 (0.25) 12.27 68 91.1 (0.90, 1.1) 22 91.3 (0.89, 1.3)
0.49 (0.53) 25.01 138 92.4 (0.84, 2.4) 44 92.7 (0.82, 2.7)
Notes. Assuming a 5-level ordinal outcome with proportions 0.20, 0.20, 0.30, 0.20 and 0.1 in
the control group and C clusters per group. Empirical power, θˆ is calculated as the proportion
of fitted probit models with a treatment effect significant at the 5% level. θˆ − θ represents the
absolute difference between empirical and nominal power
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Table 5.11: Empirical power when using the ICC estimate for the underlying continuous variable for the
4-level ordinal outcome in the design effect for sample size calculation. For each combination
of cluster size and ICC: 1000 datasets generated with a 90% target level of power
Fixed Design Parameters log odds=0.493 log odds=0.887
C Empirical power C Empirical power
Cluster size ρl Design effect (SE,θˆ − θ) (SE,θˆ − θ)
5
0.01 1.04 64 91.7 (0.87, 1.7) 20 89.4 (0.97, -0.6)
0.08 1.32 81 91.6 (0.88, 1.6) 25 90.3 (0.94, 0.3)
0.16 1.64 100 93.1 (0.80, 3.1) 31 93.2 (0.80, 3.2)
0.25 2.00 122 92.0 (0.86, 2.0) 38 93.8 (0.76, 3.8)
0.53 3.12 190 92.4 (0.84, 2.4) 59 94.1 (0.75, 4.1)
10
0.01 1.09 34 91.4 (0.89, 1.4) 11 91.6 (0.88, 1.6)
0.08 1.72 53 92.6 (0.83, 2.6) 17 92.7 (0.82, 2.7)
0.16 2.44 75 93.8 (0.76, 3.8) 23 94.2 (0.74, 4.2)
0.25 3.25 99 94.3 (0.73, 4.3) 31 93.1 (0.80, 3.1)
0.53 5.77 176 93.5 (0.78, 3.5) 55 93.9 (0.76, 3.9)
50
0.01 1.49 10 96.4 (0.59, 6.4) 3 95.7 (0.64, 5.7)
0.08 4.92 30 94.5 (0.72, 4.5) 10 94.7 (0.71, 4.7)
0.16 8.84 54 95.3 (0.67, 5.3) 17 93.8 (0.76, 3.8)
0.25 13.25 81 93.8 (0.76, 3.8) 25 95.4 (0.66, 5.4)
0.53 26.97 164 94.3 (0.73, 4.3) 51 93.4 (0.79, 3.4)
Notes. Assuming a 4-level ordinal outcome with proportions 0.20, 0.50, 0.20 and 0.1
in the control group and C clusters per group. Empirical power, θˆ is calculated as the
proportion of fitted probit models with a treatment effect significant at the 5% level.
θˆ − θ represents the absolute difference between empirical and nominal power
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5.8.3 Power of a trial designed using the design effect under minor devi-
ations from the proportional odds assumption
For the four-level outcome Table 5.12 shows the effect on power when there is a minor deviation
from the assumption of proportional odds, in this case the treatment effect for the first category
was assumed to be different (smaller) than for the other categories. Power was calculated using
Whitehead’s formula multiplied by the design effect with the treatment effect based on either the
smallest log-odds, 0.35 or the average log-odds of 0.45.
Use of the smallest log-odds in the power calculation resulted in substantially larger sample sizes
than the average log-odds. The smallest log-odds produced overly conservative designs, the additional
power over 90% ranged from 7.5% to 8.9% and the standard error of the power estimates ranged
from 0.33 to 0.49. Use of the average log-odds resulted in trials which were slightly underpowered
with the difference in power from the expected 90% ranging from -2.6% to 0.3%. The standard error
of the power estimate ranges from 0.94 to 1.05.
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Table 5.12: Empirical power when using the ANOVA estimate of the ICC for the ordinal outcome in the
design effect for sample size calculation when there is a minor violation of the proportional
odds assumption. For each combination of cluster size and ICC: 1000 datasets were generated
with a 90% target level of power
Fixed Design Parameters log odds=0.35 log odds=0.45
Empirical power Empirical power
Cluster size ρa(ρl) Design effect C (SE, θˆ − θ) C (SE, θˆ − θ)
5
0.01 (0.01) 1.04 127 97.6 (0.48, 7.6) 77 88.8 (0.99, -1.2)
0.07 (0.08) 1.28 157 98.7 (0.36, 8.7) 95 88.5 (1.00, -1.5)
0.14 (0.16) 1.56 191 98.6 (0.37, 8.6) 116 89.4 (0.97, -0.6)
0.21 (0.25) 1.84 225 98.9 (0.33, 8.9) 136 87.4 (1.05, -2.6)
0.46 (0.53) 2.84 347 98.2 (0.42, 8.2) 210 88.2 (1.02, -1.8)
10
0.01 (0.01) 1.09 67 98.8 (0.34, 8.8) 41 87.8 (1.04, -2.2)
0.07 (0.08) 1.63 100 98.7 (0.36, 8.7) 61 88.8 (0.99, -1.2)
0.14 (0.16) 2.26 138 98.4 (0.40, 8.4) 84 89.8 (0.96, -0.2)
0.21 (0.25) 2.89 177 98.4 (0.40, 8.4) 107 89.5 (0.97, -0.5)
0.46 (0.53) 5.14 314 97.5 (0.49, 7.5) 190 89.4 (0.97, -0.6)
50
0.01 (0.01) 1.49 19 98.8 (0.34, 8.8) 11 91.7 (0.87, 1.7)
0.07 (0.08) 4.43 55 98.2 (0.42, 8.2) 33 90.2 (0.94, 0.2)
0.14 (0.16) 7.86 96 98.4 (0.40, 8.4) 59 89.7 (0.96, -0.3)
0.21 (0.25) 11.29 138 98.2 (0.42, 8.2) 84 90.3 (0.94, 0.3)
0.46 (0.53) 23.54 288 98.7 (0.36, 8.7) 174 87.9 (1.03, -2.1)
Notes. Assuming a 4-level ordinal outcome and C clusters per group. Empirical power, θˆ is
calculated as the proportion of fitted probit models with a treatment effect significant at the 5%
level. θˆ − θ represents the absolute difference between empirical and nominal power
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5.8.4 Power of a trial designed using the design effect under alternative
analysis method
The data generation model assumed a probit regression model for simplicity. However, use of the
logit link is a more popular analysis method. Using the ANOVA estimate of the ICC in the design
effect the simulations for the four-level outcome variable were repeated with analysis via a logit link
rather than probit. The results are summarised in Table 5.13. All empirical powers were above or
very close to the calculated 90%. The difference in empirical to expected power ranged from -1.6%
to 2.4% . The standard error of calculated power ranged from 0.84 to 1.01.
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Table 5.13: Empirical power when using the ANOVA estimate of the ICC for the ordinal outcome in the
design effect for sample size calculation followed by an analysis with a logit model. For each
combination of cluster size and ICC: 1000 datasets generated with a 90% target level of power
Fixed Design Parameters log odds=0.493 log odds=0.887
C Empirical power C Empirical power
Cluster size ρa(ρl) Design effect (SE, θˆ − θ) (SE, θˆ − θ)
5
0.01 (0.01) 1.04 62 88.4 (1.01, -1.6) 20 89.7 (0.96, -0.3)
0.07 (0.08) 1.28 76 90.8 (0.91, 0.8) 25 91.9 (0.86, 1.9)
0.14 (0.16) 1.56 93 90.9 (0.91, 0.9) 30 91.0 (0.91, 1.0)
0.21 (0.25) 1.84 109 90.6 (0.92, 0.6) 35 92.2 (0.85, 2.2)
0.46 (0.53) 2.84 169 90.2 (0.94, 0.2) 54 89.8 (0.96, -0.2)
10
0.01 (0.01) 1.09 33 91.9 (0.86, 1.9) 11 93.9 (0.76, 3.9)
0.07 (0.08) 1.63 49 91.6 (0.88, 1.6) 16 92.1 (0.85, 2.1)
0.14 (0.16) 2.26 67 90.6 (0.92, 0.6) 22 90.9 (0.91, 0.9)
0.21 (0.25) 2.89 86 92.1 (0.85, 2.1) 28 91.2 (0.90, 1.2)
0.46 (0.53) 5.14 153 88.8 (0.99, -1.2) 49 90.6 (0.92, 0.6)
50
0.01 (0.01) 1.49 9 92.8 (0.82, 2.8) 3 92.7 (0.82, 2.7)
0.07 (0.08) 4.43 27 91.5 (0.88, 1.5) 9 92.2 (0.85, 2.2)
0.14 (0.16) 7.86 47 90.8 (0.91, 0.8) 15 92.1 (0.85, 2.1)
0.21 (0.25) 11.29 67 89.8 (0.96, -0.2) 22 92.5 (0.83, 2.5)
0.46 (0.53) 23.54 140 90.7 (0.92, 0.7) 45 92.4 (0.84, 2.4)
Notes. Assuming a 4-level ordinal outcome with proportions 0.20, 0.50, 0.20 and 0.1 in the
control group and C clusters per group. Empirical power, θˆ is calculated as the proportion of
fitted probit models with a treatment effect significant at the 5% level. θˆ − θ represents the
absolute difference between empirical and nominal power
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5.9 Discussion
5.9.1 Main findings
To explore the relationship between ICC estimators
With a small number of clusters results showed that the ICC on the latent response tended to be
largest followed by the ANOVA and kappa-type ICCs. As the level of clustering increased so too
did the difference between the ANOVA and Kappa-type estimates with the ANOVA estimate being
consistently larger. With a large number of clusters results also showed that the ICC on the latent
response was largest, however, the ANOVA and kappa-type ICCs were almost identical. This was
expected as it has been shown that these two estimators are asymptotically equivalent as the number
of clusters increases.125
For each scenario investigated as the number of ordinal categories increased so too did the estimated
ANOVA and kappa-type ICCs. This was expected because as the number of ordinal categories
increases the variable more resembles a continuous variable and therefore we would expect the ICC
to tend towards the ICC calculated on an assumed underlying continuous variable.
By comparing two possible patterns in the expected proportions across categories for a 4-level ordinal
outcome the observed ANOVA ICC was shown to depend upon both the number of categories but
also the proportions observed in each category. The two patterns of proportions explored both had
a fairly even spread in the proportions expected in each category and the difference in observed
ANOVA ICCs for the two categorisations was small. Larger deviations from an even spread of
proportions across categories might have a more substantial impact on the ANOVA ICC.
To determine which ICC results in an adequately powered trial
The use of the ANOVA ICC estimate in the design effect resulted in adequately powered trials. The
empirical power was within 2% for 3-, 4- and 5-level outcomes. The efficiency of Whiteheads method
increases with the number of ordinal categories and is most efficient when the proportions in each
ordinal category are evenly spread. However, once you go beyond five categories further efficiency
165
5.9. DISCUSSION
gains are marginal. In my simulations as the number of categories increased the proportions in each
ordinal category subsequently became more evenly spread. The ANOVA ICC estimate appeared
to be conservative when the spread was less even. Hence, I saw a slight decrease in power as the
number of categories increased but became more evenly spread.
The largest differences between nominal and empirical power were in situations with a small number
of clusters, which was expected due to the inflated Type I error rates for these situations.
Use of the ICC of the underlying latent variable in the design effect resulted in overly conservative
sample sizes, having an additional 1.6% to 5.3% power over the required 90%.
To determine the effect of non-proportional odds on power
I considered the situation where a minor deviation to proportional odds occurred. For the 4-level
ordinal outcome, there are three possible ways to dichotomise the outcome to calculate the log-
odds of being in category q or better. I assumed that two of these were the same and one was
slightly lower, but all indicated a beneficial treatment effect. I deemed this a minor deviation to the
proportional odds assumptions. For this situation a sample size based upon an average estimate of
log-odds was shown to result in a marginally underpowered trial. Power calculations based on the
smallest log-odds were overly conservative.
There are alternative situations which might also be classified as minor deviations from proportional
odds for example the situation where one odds ratio is slightly larger than the other two. Use of the
average log odds in the design effect for these situations was not explored and may not necessarily
result in a marginally underpowered trial.
The use of the design effect sample size approach is not recommended for situations in which major
deviations to proportional odds occur such as all the log odds being very different, or some log-odds
showing inconsistency around the effect of treatment.
To determine whether similar conclusions are made with alternative analysis methods
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Sample size using the ANOVA ICC and analysis via a logit link also resulted in adequately powered
trials, analysis with the probit link was slightly more conservative. Due to the similarity in shape of
the logistic and normal distributions the fit of a model using either of these links should be similar
and therefore this result was expected.
Despite the difference in interpretation and magnitude between a random effects and GEE model
the significance of the treatment effect is likely to be similar.130 Therefore I expect the results of my
simulation to be applicable if a GEE model was used to analyse the data. As Stata cannot be used
to fit GEE models for ordinal outcomes I did not test this within my simulations. Given more time
this could have been done using an alternative software package, such as SAS.
5.9.2 Strengths and limitations
There are several strengths to the research described within this chapter. The simulation study was
planned and reported following the most commonly used guidance for reporting simulation studies
and is therefore described in sufficient detail for this work to be fully reproduced by others. The
scenarios chosen for the simulations are largely reflective of the characteristics of real life cluster
randomised trials that have used ordinal outcomes, except that designs with a small number of
clusters were excluded. Appropriate analysis methods when the number of clusters is small require
some adjustment to account for the inflated Type I error and these methods have not been well
established for ordinal outcomes. To explore different analysis methods for clustered ordinal outcomes
when the number of clusters is small was beyond the scope of this thesis. Some approaches that might
be appropriate are discussed in the final chapter of this thesis alongside some practical guidance with
regard to sample size calculation in general for clustered ordinal outcomes.
I explored the relationship between ICC estimators under the simplifying assumption of no treatment
effect. This assumption implies that the ICC is the same in both treatment arms and thus using
these ICC estimates in sample size calculations would be equivalent to using an ICC estimate based
on control data alone. However, like binary data I identified from the simulation study that the value
of the ANOVA ICC for the ordinal outcome was dependent upon the proportions observed in each
ordinal category. This would suggest that in the presence of a treatment effect the ANOVA ICC
estimates would be different across treatment arms and in these situations it is more appropriate to
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use a pooled ANOVA ICC estimate in the sample size calculation.147 To assess the implication that
my assumption of no treatment effect may have had on my simulation results I re-ran one of the
simulation scenarios from Table 5.4 this time assuming the same log-odds values of 0.493 and 0.887
that were used in the later sample size calculations (4-level outcome, 100 clusters of size 50 with
an underlying latent ICC of 0.53). The results showed that for these treatment effects there was
only a minor difference in the observed ANOVA ICCs across the treatment groups and the pooled
ANOVA ICC estimate was the same as, or very close to, the ANOVA ICC estimate calculated when
assuming no treatment effect. Therefore my initial assumption is unlikely to have affected my results
significantly.
My simulations generated clustered ordinal data using the latent variable approach. However, as
discussed in Section 5.3 this is not the only method that might be used for data generation and it
is unclear as to whether a different method would have any impact upon my findings.
The ANOVA ICC was shown to depend upon both the number of ordinal categories and the propor-
tions observed in each category. In this research I have considered scenarios where there is a fairly
even spread in the proportions expected in each category, this is the situation for which Whitehead
states his method is most efficient. In situations where this is not the case the estimate of the
ANOVA ICC may be less similar to the latent variable ICC and therefore the performance of the
ANOVA ICC in the design effect may be affected.
5.9.3 Comparison with other work
Gao125 investigated analysis strategies for clustered ordinal data, with a focus on adjusted Cochran-
Armitage tests. She considered the use of both the kappa-type ICC and ANOVA ICCs in the test
statistic, and showed that the Cochran-Armitage test had greatest power with the kappa-type ICC
estimate. Gao saw similar results to mine in that the ANOVA and kappa-type ICC estimates were
asymptotically equivalent as the number of clusters increased. Her work used datasets generated
using marginal models and hence the relationship with the ICC on the underlying continuous variable
was not included.
There has been no other work which has considered the power of the design effect method for sample
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size calculations with ordinal outcomes analysed via a random effects model.
5.9.4 Implications
In this research I have identified that using the ANOVA estimate of the ICC, calculated by assigning
equally spaced numerical values to the ordinal outcome, within the design effect for sample size
calculations results in adequately powered trials. However, before implementing this method the
researcher must ask themselves two questions: Is a good estimate of the ICC available? and is the
assumption of proportional odds reasonable? Both of these elements will impact upon the power of
the trial. With only minor deviations to the proportional odds assumptions the use of the design
effect and an analysis which assumes proportional odds may result in only marginal over or under
powering. Major deviations are likely to require alternative analysis methods and sample size would
be best estimated through simulation. The sensitivity of the sample size calculation to the range
of plausible ICCs should be examined. If no reasonable estimates are available researchers might
consider a sample size calculation and analysis based upon the dichotomised version of the outcome,
for which ICC estimates may be more readily available.
With binary outcomes the overall prevalence of the observed endpoint is a single proportion. There-
fore in simulation studies of binary outcomes it is straightforward to examine several proportions to
gain insight into emerging patterns as the prevalence increases for example 10%, 30% and 70%. For
ordinal outcomes the situation is less straightforward. The number of ways that the proportions can
occur across the ordinal categories is numerous and it is not easy to try and systematically explore
all possible combinations or identify patterns. In Whitehead’s work for individually randomised
trials he considered two patterns. The first where there was an even spread across categories and
the second where one category was dominant. He showed that an even spread across categories was
a more efficient design. In this research I have focused on scenarios where there is generally an even
spread of the proportions expected in each ordinal category. For situations in which there is a less
even spread, perhaps one or more categories are dominating, the ordinal outcome looks less like a
continuous outcome and hence the ANOVA estimate of the ICC may be less similar to the ICC on
the latent variable. Therefore using the ANOVA estimate of the ICC in the design effect for these
situations may not perform as well. Simulation studies should be conducted in these situations to
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confirm the sample size required.
This work has provided some guidance for sample size calculation for those designing trials with
ordinal outcomes. However, in order to move forward estimates of the required ANOVA ICC are
needed. I would therefore recommend that authors reporting results with ordinal outcomes report
the ANOVA ICC and also provide the estimates of each log-odds in order that the reader may
evaluate the assumption of proportional odds.
My work will impact those working in fields where ordinal outcomes are prevalent. However, there
are still many other design aspects of cluster randomised trials for which the corresponding sample
size development is still lacking. These areas are identified and discussed in the next chapter. In
the final chapter I bring all my research together to discuss the future of sample size calculations for
CRTs and formulate clear practical guidance for sample size calculations with ordinal outcomes.
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Chapter 6
Remaining methodological gaps in
sample size methods for CRTs
In Chapter Two I reviewed the published literature on sample size calculation for cluster randomised
trials up to the year 2011, I identified 85 papers reporting sample size methods. However, of these
only two were applicable to ordinal outcomes, and the development of one of these methods became
the focus of my research. Therefore, there is much scope for developing some of the methods
reported in the remaining papers or identifying new areas for development where there are currently
no published methods available.
In this chapter I return my attention to my review of sample size methods. I provide an update to
the review which additionally includes methods published between 2011 and 2015. The aim of this
chapter is to describe where methods are lacking or need further development to encourage or enable
routine use for a given design, outcome, or analysis.
6.1 Methods
The methods of the review have been described in detail within Chapter Two. In summary the review
was conducted using electronic online databases, a personal collection of 41 articles on sample size in
CRT’s provided by SE, key text books on cluster randomised trials,6–8,32 and special issue journals
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on cluster randomised trials.61–64 The electronic search was conducted using the online databases
PubMed and Web of Science. The initial search was conducted on the 31st March 2011. Given
the time that has elapsed since conducting the review the online databases were searched again in
August 2015 and the additional methods identified are included within this chapter.
An article or method was included in the review if it provided a method of sample size calculation
for cluster randomised trials, via a formula, simulation or other approach. The first paper to report a
particular methodology was included in the review; subsequent papers describing the same approach
were excluded. The two electronic databases searched, PubMed and Web of Science contained articles
from 1946 and 1970 onwards respectively, no further date restrictions were applied.
6.2 Results
The structure of this results section is summarised in Figure 6.1. This structure was chosen to
mirror that of the published version of my initial review, which summarised sample size methods
available for CRTs for a given design, outcome and analysis.60 In contrast to the published review
the focus of this chapter is to highlight where there are gaps in the methodology.
The results start with the simplest and most common design for a cluster randomised trial; the
two-arm, completely randomised, parallel-group trial with fixed cluster sizes.
The methodology gaps for variations or adaptations to the simple design are discussed next. Vari-
ations to the design include: variability in cluster size or attrition; uncertainty around the ICC;
unequal allocation; and inclusion of baseline measurements or repeated measures.
The third section discusses alternative design choices such as the cross-over, stepped-wedge, matched
and three-level designs. The section concludes with a brief description of emerging topics that were
identified in the 2015 update to the review.
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Standard parallel group design 
 
Continuous; binary; count; ordinal; time-to-event; rate outcomes 
Design variations  
 
ICC uncertainty; variable cluster size; internal pilots; unequal 
allocation; small number of clusters; equivalence and non-inferiority; 
attrition; non-compliance, covariates; repeated measures 
Alternative designs 
 
Matched/stratified; cross-over; stepped-wedge; three-level 
 
Emerging themes 
Evidence-based perspective, cost-effectiveness, mediation, three-
arm designs, factorial trials, dog-leg design 
Figure 6.1: Sample size methodology and gaps in the literature for CRTs: Flow diagram describing the
order in which these are presented within the chapter
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6.2.1 Standard parallel-group, two-arm design
Table 6.1 summarises the methodology available by outcome type and analysis method for the
standard parallel-group, completely randomised design with fixed cluster sizes. I consider each of
the outcome types in turn.
Continuous and binary outcomes
The surge in the development of sample size methods for cluster randomised trials started with meth-
ods for binary and continuous outcomes analysed at the cluster-level, described in the seminal paper
by Cornfield in 197831 and the 1981 paper by Donner, Birkett and Buck.52 Cluster-level summaries
can often be considered continuous regardless of the nature of the variable at the individual level.
Therefore these methods are often applicable to alternative types of individual-level outcomes. With
the development of statistical software, individual-level analyses have now become a more popular
analysis and Shih has demonstrated that the simple design effect described by Donner, Birkett and
Buck for binary and continuous outcomes can be used to calculate the sample size when the planned
analysis is by GEE.83 The reason for this is that for continuous outcomes with equal cluster sizes, as
assumed here, the cluster-level and individual-level analyses (population-averaged or cluster-specific
approaches) are equivalent. However, in many situations the assumption of equal sized clusters is
not realistic.
For continuous outcomes it is most common to assume the variable is normally distributed. Rosner
and Glynn161 have presented the only sample size approach for non-normally distributed outcomes
analysed with a clustered version of the Wilcoxon test, but their method requires a large number
of calculations and associated SAS macros for implementation. There is therefore, scope to develop
simpler or alternative methods for non-normally distributed continuous outcomes.
In a cluster randomised design the sample size calculation requires estimates of both the number of
clusters and the cluster size. In the majority of situations there will be constraints on the values
of either of these parameters. For example if the cluster is a GP practice there will be a finite
number available within a specified geographical location. However, in a minority of situations
the values of these may be unconstrained and several different combinations may lead to equally
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Outcome measure Analysis Reference
Continuous Cluster-level 20,52,104,159,160
Adjusted test 161 [162]
Mixed model 99
GEE 83
Binary Cluster-level 20,31,52,104,159,160 [163]
Mixed model 105
GEE 83
Count GEE 73
Ordinal GEE 65
Mixed model 33
Time-to-event Cluster-level 72,110
Mixed model 119[164]
Marginal model 71,89 [165]
Rate Cluster-level 20
Table 6.1: Results from my systematic review of sample size methods for CRTs: Sample size methods for
the standard two-arm, parallel group, equal allocation, fixed cluster sizes completely randomised
design. Those references identified in the update to the review are enclosed in square brackets.
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powered trials. In these situations the cost of each design becomes important. If the total budget for
sampling and measuring clusters and individuals is fixed the optimal design is one that maximises
the precision of the treatment effect and power. If the required power and precision of the treatment
effect are fixed the optimal design is one which minimises the total costs of measuring clusters and
individuals. The total budget constraint is a combination of the cost per subject and cost per cluster.
This optimization problem has been considered by Connelly,104 Moerbeek105 and Raudenbush.99 A
potential limitation of these methods is the simplicity of the cost functions used, which assume fixed
costs over time and in each treatment group. In 2011 Tokola et al opted for a more general approach
which allows costs in each treatment group to be different, both at the cluster and individual level.162
The majority of methods available for binary and continuous outcomes assume the ICC as a measure
of between-cluster variance. The coefficient of variation in outcome, k, has only been proposed for
cluster-level analysis by Hayes and Bennett.20 For continuous outcomes the majority of sample size
calculations make the assumption that the measure of correlation, be it the ICC or coefficient of
variation in outcome, is the same in each treatment group. However, if the coefficient of variation is
the same in each treatment group the ICC will not be, and vice versa.7 Therefore the use of these
different correlation measures will produce different sample size requirements. The assumption of
a constant ICC is reasonable if the intervention effect is likely to be constant across clusters. The
assumption of a constant k is reasonable if the intervention effect is likely to be proportional to the
cluster mean.21
Similarly for binary outcomes different sample size requirements are calculated depending upon
whether the ICC or coefficient of variation is used in the calculation. For binary outcomes there
is an additional complication that the between-cluster variance also depends upon the value of the
overall outcome proportion. The use of the ICC is recommended for sample size calculations of
binary outcomes, unless the proportion is very small.21
Due to the high dependence on prevalence of the ICC for binary outcomes ICC values from one
study may not be generalizable to seemingly similar studies that have different outcome prevalence.
To address this problem in 2011 Crespi et al proposed a parameter which they call R, that helps
to isolate the part of the ICC that measures dependence among responses within a cluster from the
176
6.2. RESULTS
outcome prevalence ρ = (R−1)pi(1−pi) where ρ is the ICC and pi the outcome proportion.
163 However, this
is not necessarily a new concept as it can be easily shown that R− 1 = k2 where k is the coefficient
of variation used in the sample size methods by Hayes.20
To summarise, for the standard parallel-group trial with binary or continuous outcomes there are few
areas that require future development. Sample size methods for these situations, using a variety of
analysis methods are well established and have also been extended to incorporate budget constraints.
Only one sample size approach considered non-normally distributed continuous outcomes and there
is scope to consider whether this approach might be simplified or alternative methods developed.
Count outcomes
Use of the standard design effect has been shown to be appropriate for count outcomes when analysed
with a GEE model.73 However, the authors did not provide any indication of how this method
might perform for alternative analyses such as the mixed model and so there is scope for some
further research here. The only other sample size approach for count data has been via simulation
for cross-over designs.113
Ordinal outcomes
Methods available for ordinal outcomes and how they might be developed further were described
in detail in Chapter Two and updated in Chapter Five in the light of my research results. These
summaries are not repeated here and no further methods were identified in the update to the review.
Time-to-event outcomes
For the individually randomised trial there are two common formulae used for sample size calculation
for time-to-event outcomes, those by Schoenfeld3 and Freedman.4 Each of these methods has been
adapted for the clustered case for cluster-level analyses, mixed, and marginal models by Gang, Jahn-
Eimermacher, and Xie respectively71,72,119 A further approach assuming an alternative marginal
model was also considered by Manatunga however, it does not result in a simple explicit formula.89
A simulation-based sample size calculation was proposed by Jung which assumed a weighted rank
test with allowance for variable cluster size.166
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Since the publication of my initial review two further sample size methods for time-to-event out-
comes have been proposed by Zhong and Cook in 2014165 and Moerbeek in 2012.164 The method
by Zhong assumes a semi-parametric proportional hazards model fitted under a working indepen-
dence assumption with robust variance estimates. Kendall’s τ is used to describe the association
within clusters and the required number of clusters is calculated for both right-censored and interval-
censored time-to-event outcomes. The method by Moerbeek considers discrete event times based on
a generalised linear mixed model.
The definition of the ICC used within the papers for time-to-event outcomes was not always easy
to determine. There is scope to look at the ICCs for time-to-event data in more detail, perhaps
reviewing the alternative estimators and presenting some real life estimates. The use of time-to-
event outcomes is less common than binary or continuous outcomes. In my published review of 166
CRTs that reported a sample size calculation no papers were identified with time-to-event outcomes,
one was identified to have an ordinal outcome, in thirteen papers the outcome was unclear and in the
remaining papers the outcome was either binary, continuous or a rate.122 Some practical guidance
would be useful to describe the issues common to time-to-event designs and to explain the differences
and appropriateness of the various proposed sample size methods under different circumstances.
Rate outcomes
When it comes to rate outcomes an ICC cannot be defined and therefore the coefficient of variation
in outcome must be used in sample size calculations. In my review there was only one calculation
applicable to rate outcomes for the simple design assuming a cluster-level analysis.20 There is scope
to explore the performance of this method, or develop new methods, for individual-level analysis
methods.
6.2.2 Adaptations to the standard parallel-group design
In this subsection I consider some of the additional aspects related to design or analysis of a parallel-
group trial that one may wish to additionally account for in the sample size calculation. Some of
these aspects may be under the control of the investigators, such as the inclusion of covariates or
repeated measurements in the analysis and others may be less under their control such as variability
178
6.2. RESULTS
Table 6.2: Results from my systematic review of sample size methods for CRTs: Sample size methodology
for design adaptations to the standard two-arm, parallel-group, completely randomised design.
Those references identified in the update to the review are enclosed in square brackets
Adaptation Outcome measure Analysis Reference
Design
ICC uncertainty Continuous Cluster-level 118
Adjusted test 121
Mixed model 116–118 [167 ]
GEE 117,118
Binary Cluster-level 114
Variable cluster size Continuous Cluster-level 92,168,169
Adjusted test 74
Mixed model 95
GEE 86
Binary Cluster-level 92,112,168
Adjusted test 76
Mixed model 93
GEE 75,86
Time-to-event Cluster-level 110
Internal pilot Continuous Mixed model 120 [170,171]
GEE 88
Binary Cluster-level [172]
GEE 88
Unequal allocation Continuous Cluster-level 169
Mixed model 101
Small number of clusters Continuous Cluster-level 173,174 [175]
Binary Cluster-level 173[175]
Equivalence Continuous Adjusted test 33
Binary Adjusted test 78
Non-inferiority Binary Adjusted test 176
Attrition Continuous Adjusted test 85
Mixed model 177
Binary Adjusted test 85
Non-compliance Binary Adjusted test 176,178
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Table 6.3: Results from my systematic review of sample size methods for CRTs: Sample size methodology
for analysis adaptations to the standard two-arm, parallel-group, completely randomised design.
Those references identified in the update to the review are enclosed in square brackets
Adaptation Outcome measure Analysis Reference
Analysis
Inclusion of covariates Continuous Cluster-level 84,179
Mixed model 96,99,102,109,180,181 [182]
GEE 86,181,183
Binary Mixed model 96,107,180
GEE 86,111,181,183,184
Inclusion of repeated measures Continuous Mixed model 177,185–188[189,190]
GEE 87
Binary Marginal model 87 [191]
in cluster size and attrition.
Tables 6.2 and 6.3 summarise the methodology available for adaptations to the standard parallel-
group design categorised by outcome measure and analysis method. What is immediately striking
from these tables is that all the methods described for these variations are applicable only to binary
and continuous outcomes, the exception being when cluster size is variable with a time-to-event
outcome which has been considered by Jung via simulation methods.110 Given that some of these
variations from the standard design are quite common there is a considerable lack of methods avail-
able to those who wish to perform an individual-level analysis using an outcome that is not binary
or continuous.
I now discuss each adaptation in turn.
Uncertainty around the estimate of the ICC
The estimate of the ICC used in the sample size calculation can have a substantial impact upon the
resulting sample size, yet there is often a large amount of uncertainty surrounding the estimate.
Informal methods to address the problem have been to opt for a conservative estimate, but this may
result in unnecessarily large trials. Turner and Spiegelhalter have described more formal methods
for incorporating ICC uncertainty into the sample size calculation. For continuous outcomes these
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methods make distributional assumptions for one or many previously observed ICC values and from
these calculate a distribution for the power.116–118 These methods adopt a Bayesian perspective but
assume that the analysis will follow a classical approach, mixed model or GEE. ICC uncertainty for
binary outcomes has received less attention, Feng considers the effect of two possible ICC estimators
on sample size via simulation with a cluster-level analysis assumed.114
The sample size formulae based around the coefficient of variation in outcome are not always as
simple as the design effect and therefore the effect of miss-specification of the estimate of coefficient
of variation in outcome is not as obvious. There has been no formal work that considers how potential
uncertainty around the estimate of the coefficient of variation in outcome could be incorporated into
the trial design, or whether the methods described for ICC uncertainty could translate to uncertainty
in the coefficient of variation in outcome.
Where the cluster size and number of clusters are not fixed or constrained for the standard parallel
group design methods have been derived to solve the optimality problem of finding the numbers of
individuals and clusters that will 1) maximise power and precision of the treatment effect under a
fixed budget or 2) minimise total costs given a fixed power and precision of the treatment effect. In
addition to the possible oversimplified cost functions used in these methods they also assume that
the number sampled from each cluster is the same and the ICC is known, assumptions which may
not be realistic. To overcome the issue of unknown ICC van Breukelen derives a Maximin design
based on relative efficiency. This provides a design which is robust against miss-specification of the
ICC and cost-effective.167 The Maximin design is found using a series of steps. First the parameter
space for the ICC is defined and then the design space is defined for the number of clusters and
cluster size. For each ICC value in the parameter space the locally optimal design is calculated using
methods by Raudenbush or Moerbeek.99,105 The relative efficiency (RE) of each design in the design
space is compared to the locally optimal design. For each design in the design space its minimum
RE within the ICC parameter space is calculated. The maximin design is that which has the highest
minimum RE among all designs in the design space.
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Variable cluster sizes
The standard design effect commonly applied to binary and continuous outcomes in the standard
parallel-group design makes the assumption that the number of observations from each cluster in
the analysis is the same. This may be a reasonable assumption in some situations such as trials of
ophthalmology where the cluster is a person and measurements are taken on eyes. However, in other
studies where the cluster might be a GP surgery or hospital and we intend to take measurements
on the entire cluster we are likely to experience drop out within clusters. At the design stage it is
good practice to account for or at least consider the impact of variable clusters. A simple approach
is to replace cluster size in the design effect with the mean cluster size but this will result in an
underestimated sample size, more so as the variation in cluster size increases. Alternatively, using
the maximum cluster size may be overly conservative. Replacement of cluster size with the harmonic
mean of the sample size in each cluster provides an appropriate sample size when using the cluster-
level approach with coefficient of variation described by Hayes.7
Of all the adaptations to the simple parallel-group trial variable cluster sizes has received the most
attention. Methods for continuous and binary variables assuming both cluster-level and individual-
level analyses have been derived. These methods can be divided into those that require each cluster
size to be known in advance75,86,92 and those which require only an estimate of the mean and
standard deviation of cluster size to be known.74,76,93,168 A simple design effect has been derived
for the latter approach.168 Although this design effect has been derived for cluster-level analyses
it provides a conservative estimate in the case of individual-level analyses. However, it has been
argued by van Breukelen that the approximation of efficiency loss used in many of these approaches
is inaccurate and he proposes two simple alternatives95,192
The main development required for the case of variable cluster sizes is towards methods for outcomes
that are not continuous or binary.
Internal and external pilot studies
A pilot study is a small study conducted before the main trial which aims to refine the design and
procedures such as recruitment, randomisation, data collection and follow up to be used in the main
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study. The data from an external pilot is not intended to be included with the data from the main
trial, hence an external pilot provides more flexibility to change and refine the design and procedures.
The sample size for a pilot study should not be calculated as we would for the main trial, i.e. on the
expected difference between treatment groups. Instead it should be powered to meet the aims of the
pilot study which are usually based around the feasibility of the main study, for example whether
the required recruitment rate can be met or the required rate of follow up met. For binary outcomes
Ahn et al consider sample size calculations based upon a hypothesised proportion for a single arm
clustered design with varying cluster size. The authors suggest that their method can be used to
calculate sample sizes for pilot or early stage trials.172
If good estimates of the ICC and other required parameters are not available at the design stage it
may be possible to re-estimate the sample size once the trial is running, using an internal pilot, as
described by Lake et al120 and Yin and Shen.88 The data from an internal pilot will be included in the
analysis of the data from the main trial. An internal pilot is most suited to trials that recruit a large
number of clusters over a relatively long time period. The methods developed so far for sample size
re-estimation using an internal pilot assume analysis by a mixed model with a continuous outcome
or by a GEE model with binary or continuous outcomes. Internal pilots are less common in cluster
randomised trials than they are in the individually randomised setting and there is much scope for
further investigation to establish the best practice for their use, for example determining at what
point an interim estimate of the ICC could be considered stable and hence used to re-estimate the
sample size appropriately.
The method by Lake120 focuses on situations in which there are a large number of small clusters. In
2012 van Schie and Moerbeek proposed sample size re-estimation methods for situations where there
is a limited number of clusters but where the clusters are potentially large and one can continue
to recruit participants in a participating cluster after sample size re-estimation in order to reach
the required sample size.170 In 2012 van Breukelen published simpler guidance for sample size
calculations with unknown ICC and variable cluster sizes. His recommendations were to base initial
sample size calculations upon the midpoint of an assumed ICC range and then re-estimate the ICC
from the data once the trial is running. The sample size is then increased only if the ICC is larger
than the midpoint. The authors state that the final analysis can be conducted without the need to
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account for this interim look.171
Further guidance on the design of pilot studies is provided by Eldridge and Kerry.21
Allocation ratio
Equal allocation provides the most efficient design and was often assumed for simplicity in the
majority of methodology identified in the review. However, if the costs per sampling unit are different
in each treatment group an equal allocation ratio may produce a smaller sample size for a fixed budget
than an unequal allocation. Optimal unequal allocation of clusters to treatment arm can reduce the
overall cost of the study and attain higher power than the equal allocation design.101 Besides cost,
unequal allocation may be desired if we wish to gain more information about one of the treatment
arms. In situations where a design effect is applied directly to the sample size calculation under
individual randomisation unequal allocation may be incorporated in the usual way to the formula
for individual randomisation. There is very little published work which focused on the considerations
of unequal allocation.
Small/fixed number of clusters
Many of the formulae in the review were based upon the normal distribution and therefore are
appropriate when a large number of clusters are to be recruited. When the number of clusters is
small these approximations will underestimate the required sample size.
A simple solution to this problem, suggested by Snedecor and Cochran is to add one cluster per
arm when testing at the 5% level,193 implemented in the formulae by Hayes.20 Alternatively the
normal distribution in the formula can be replaced by the t-distribution, or methods based upon the
non-central t-distribution used.169,173
Campbell first described methods that can aid in calculating the number of subjects per cluster
when the number of clusters is fixed194 Hemming et al has discussed this further for both binary
and continuous outcomes. A trial with a limited number of clusters is feasible if the required power
can be obtained by increasing the number of individuals sampled within the cluster. As a simple
check the trial will be feasible if the number of clusters is greater than the product of the number of
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individuals needed under individual randomisation and the ICC. If the design is not feasible either
the power must be reduced or the detectable difference must be increased.175
It is currently recommended that trials with a small number of clusters be avoided. In addition to
the fact that sample size methods may be inappropriate many analysis methods do not perform well
with a small number of clusters and imbalance in the cluster characteristics is also more likely to
occur when the number of clusters is limited.21 These two issues would indicate that, at present,
further development of sample size calculations that perform well with a small number of clusters
may not be useful. Sample size by simulation may be the best approach in these situations.
Equivalence and non-inferiority
Non-inferiority and equivalence designs are less common in the clustered setting. For equivalence
designs with binary or continuous outcomes the standard design effect can be used to multiply the
sample size calculated under individual randomisation.33,78 There are no methods described for
equivalence designs with alternative outcomes.
For non-inferiority designs Lui and Chang have derived an approach where the treatment effect is
based upon the effect among compliers, along similar lines to the Complier Average Causal Effect
(CACE) analyses sometimes seen for individually randomised trials. The calculation of the variance
for this complier treatment effect is complex meaning this method is not straightforward to imple-
ment.176 Given the role that non-compliance can play in the evaluation of non-inferiority it may not
be sensible to try and simplify this method by ignoring non-compliance. For individually randomised
trials it is well established that an intention to treat (ITT) analysis (i.e. include non-compliers) of
a non inferiority trial may lead to a diluted treatment effect and therefore makes it easier to declare
non-inferiority. A per protocol analysis (i.e. exclude non-compliers) of such a design may be biased
as the benefits of randomisation are lost and the power is reduced.
Non-inferiority designs have also been considered under an evidence-based perspective to sample size
estimation and will be described later in this chapter in the section on emerging themes in sample
size methods.195
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Attrition
In cluster randomised trials attrition among members of a cluster is a common problem. If the
proportion that are lost to follow up is θ then the required sample size can be calculated by dividing
CRT sample size formulas by (1− θ). Alternatively, assuming equal drop out per cluster, n can be
replaced by θn in the design effect. However, these methods overestimate and underestimate sample
size respectively.
For continuous and binary outcomes, analysed at the individual level using either the individual-level
t-test or chi-squared test suitably adjusted for clustering,6 a simple design effect has been proposed
by Taljaard to calculate the sample size.85 In addition to the ICC this design effect requires an
estimate of the probability that an outcome is observed and an intracluster correlation coefficient
for the binary missingness indicator, defined as 0 if the outcome is missing and 1 otherwise.
When there is no attrition the individual-level t-test adjusted for clustering is identical to both
the standard two-sample t-test based on cluster means and the test of the regression coefficient
in a mixed-effects regression model with no other covariates. The drawback of this sample size
method is that the analysis does not allow for inclusion of covariates and estimates of the ICC
for the missing data mechanism are not routinely published, making the choice of an appropriate
figure more difficult. Further work could be done to look at the performance of this method under
alternative, and more commonly used, analysis methods and to summarise patterns in the ICC
for the missing data mechanism from real life trials. Although Roy has considered an alternative
approach for mixed models and drop-out for longitudinal clustered designs his method is iterative
and therefore fairly complex.177
In 2014 Corrigan et al considered the impact of cluster composition changes, namely clusters merging
post-randomisation, on the design and analysis of CRTs. The issue is related to variability in cluster
size and loss-to-follow up of clusters; cluster sizes change when clusters merge and we in effect have
drop out of an entire cluster. In their simulation studies merging clusters had a detrimental effect on
study power. However, the merging of clusters in the same treatment group resulted in only a small
loss in power because the ICC decreased with the merge. The authors recommendations are that
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allowance for cluster merges in the sample size calculation should depend on the perceived likelihood
of merges given the costs involved in recruitment of additional clusters.196
Non-compliance
In a truly pragmatic trial the effect of the intervention is usually assessed in the presence of non-
compliance using an ITT analysis and during the trial compliance may not be measured or actively
sought. Therefore accounting for non-compliance at the design stage may not be necessary. An ex-
ception to this is the non-inferiority design where ignoring non-compliance may mean non-inferiority
is declared more easily.
In trials where you wish to estimate the effect of treatment for those who comply a per-protocol
analysis is often conducted. However by excluding participants such an analysis suffers from a
reduction in power and the benefits of randomisation are lost. Complier Average Causal Effect
models have been suggested as a method to estimate the treatment effect under compliance without
the disadvantages of a per protocol analysis. For individually randomised designs CACE analyses are
still not routinely used and hence it may be too early to expect routine use of appropriate analysis
methods for non-compliance in the clustered case. However they have been considered for both
non-inferiority and superiority clustered designs.176,178
Inclusion of baseline measurements
The inclusion of covariates, which are correlated with the outcome, into the analysis will likely reduce
the between-cluster variation, and a reduced ICC leads to a reduction in the required sample size.
Inclusion of the baseline value of the outcome has the biggest effect on reducing the ICC. The inclusion
of a baseline measurement of the primary outcome introduces additional sources of correlation. In
a repeated cross-sectional sample different individuals are measured at each time point. This leads
to two sources of correlation: the correlation of outcomes from individuals within a cluster at the
same time point (our familiar ICC) and the correlation between baseline and follow-up outcomes
for individuals within a cluster (cluster autocorrelation). In a cohort sample the same individuals
are measured at baseline and follow up and therefore an additional correlation is encountered across
time points on the same individual conditional on the cluster (subject autocorrelation). The cohort
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sample is more efficient. However, cohort designs can suffer from larger loss-to-follow up than the
cross-sectional design and therefore their sample size must be inflated to account for this. The relative
efficiency of the cohort design to the cross sectional design has been quantified by Feldman.96
For continuous outcomes and a cluster-level analysis of covariance a simple design effect is derived by
Teerenstra for the sample size calculation that allows either a cohort sample, cross-sectional sample
or a mixture of the two.84,179 Cohort and cross-sectional designs for binary and continuous outcomes
have also been considered by Preisser et al183,184 their sample size method is based upon cluster-level
summary statistics but uses an estimating equations approach to estimate the ICCs.
Like so many other methods the practical use of these methods is dependent upon finding good
estimates of the additional correlation parameters and further work is required to do this.
Inclusion of other covariates
To account for the inclusion of baseline covariates Neuhaus and Segal180 have suggested that in
general multiplying the ICC by the ICC for the individual-level covariate results in an estimate of
the adjusted ICC . This adjusted ICC can then be used in the standard design effect.
When considering the inclusion of covariates other than the baseline measurement of the outcome
much of the work has focused around the cost-benefit of their inclusion. The inclusion of the covariate
being most cost efficient when the cost of measurement is small and the correlation between the
covariate and outcome is large. Raudenbush derived the optimal sample sizes at each level to
minimise the standard error of the treatment effect for a continuous outcome under a fixed budget
for both individual and cluster-level covariates.99 His work has been extended for the three-level
design by Konstantopoulus.182 Moerbeek has been very active in this area defining optimal sample
sizes at each level to minimise the variance of the treatment effect under a given cost constraint for
continuous outcomes108,109 and binary outcomes with a binary covariate.107
Given there is little guidance about how to choose covariates in a cluster randomised trial and
correlation estimates may be difficult to find a conservative approach would be to ignore the covariates
in the sample size calculation.
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Inclusion of repeated measurements
In a longitudinal cluster randomised design there is a three-level structure with outcomes measured
at specific time points within subjects, within clusters. The final analysis model now contains
fixed effects for time and the treatment-by-time interaction. The identified sample size methods
for these trials were considerably more complex than the methods seen for other scenarios, and the
calculations more substantial. The added complexity came from: allowing for different hypothesised
paths of the intervention effect over time by Koepsell;185 incorporation of differential drop-out by
Roy;177 the introduction of random coefficients to the model by Murray;187marginal models by Liu87
and Reboussin,191 testing of the treatment-by-time interaction by Heo186 and testing the treatment
effect at the final time point with incorporation of information from the entire study period by
Heo.188
Since the initial review Heo has continued to develop new methods in this area. In 2013 Heo looked
at including a subject-specific random slope and in 2014 adapted a previously derived method to
allow for anticipated attrition.186,189
This area of sample size methodology would benefit from a detailed evaluation and comparison of
each of these methods in order to provide some explicit guidance about when each approach might
be suitable and the information that is required to implement each method.
6.2.3 Alternative designs
Sample size methodology for alternative designs is summarised in Table 6.4. Like the adaptations
presented in the previous section this methodology has largely focused on continuous and binary
outcomes.
Stratification and matching
Generally speaking cluster randomised trials recruit a smaller number of units than an individually
randomised trial. This means there is potential for baseline imbalances in cluster characteristics
across the treatment groups. Matching or stratification is used is help balance the treatment groups
for characteristics that are thought to affect the outcome. In a matched-pair design similar clusters,
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Table 6.4: Results from my systematic review of sample size methods for CRTs: Sample size methodology
for alternative designs to the standard two-arm, parallel-group, completely randomised design.
Those references identified in the update to the review are enclosed in square brackets.
Trial design Outcome measure Analysis Reference
Matched/stratified Continuous Cluster-level 20,160,197
Mixed model 198
Bayesian 115
Binary Cluster-level 20,97,160,197,199
Mixed model 198
Adjusted test 200
Rate Cluster-level 20,201
Cross-over Continuous Cluster-level 77,113,174
Mixed model 98
Binary Cluster-level 113[202]
Count Cluster-level 113
Stepped-wedge Continuous Mixed model 82,203 [204,205 ]
Binary Mixed model [205 ]
Time-to-event Equivalent to Cox proportional hazards [206]
Three-level continuous Mixed model 79,81,103,106[182,207]
GEE 80
Binary GEE 80
190
6.2. RESULTS
similarities being defined on aspects such as size or geographical location, are matched. One cluster
is allocated to control and the other to the treatment group. The reduction of the between-cluster
variance induced by matching can provide efficiency in sample size. It should be noted that any
potential gain in efficiency may be lost if clusters drop out, which renders the matched pair unusable
in the analysis. However, for trials that recruit a small number of relatively large clusters ignoring
matching in the analysis of a matched design has been shown to be valid and efficient and can avoid
the problem of lost clusters from a matched analysis.208
Analysis of a matched-pair design is conducted at the cluster level and sample size calculations
have been proposed for continuous, binary and rate outcomes using either the coefficient of vari-
ation in outcome within matched pairs,20 direct measures of the between and within-cluster vari-
ances160,198,199,201 or the correlation in the outcome between matched pairs.97 To account for the
small number of clusters randomised two, rather than one, cluster should be added per group to
account for the use of the normal approximation in sample size formulae. This is incorporated into
the formula by Hayes.20
Stratification is related to the matched-pair design in that there are several clusters within a stratum,
rather than two. A simple sample size method has been developed for binary outcomes200 and a less
common Bayesian approach developed for continuous outcomes.115
As the impact of stratification is difficult to ascertain in advance, recommendations are to ignore
it in the sample size calculation for a more conservative estimate.21 Therefore, at present, there is
probably less need for further development of these methods.
Cross-over designs
Cross-over designs are useful when the availability of clusters is limited as these designs require a
smaller number of clusters than a standard parallel-group trial. When different subjects from each
cluster are included in separate periods of the trial the design has a cross-sectional sample. Alter-
natively each subject could be included in both periods within the cluster, a cohort sample. With
the cohort design the treatment effect is calculated within subjects, within clusters so both between-
cluster and between-subject variations are eliminated making this this most efficient of the cluster
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randomised cross-over designs. The relative efficiency of the cross-over design with either cohort or
cross-sectional sample over the parallel group cluster randomised design have been quantified for
continuous outcomes with an assumed analysis by mixed model.98
For the cohort sample a simple design effect has been proposed by Giraudeau for continuous outcomes
analysed at the cluster level.77 In 2015 this methodology was extended to accommodate imbalances
in cluster sizes with a focus on binary outcomes.202
Methods for continuous, binary and count outcomes for the cross-over design have also been explored
via simulation.113
Future extensions for the cross-over design could be to include allowance for covariates.
Stepped-wedge design
In the stepped-wedge design all clusters receive the control intervention at baseline. At points in
the trial one or more clusters will cross-over to receive the treatment intervention, with all clusters
receiving the treatment intervention by the end of the trial. This design is similar to the cross-over
design except that cross-over is in one direction and staggered over time. The point at which a
cluster crosses over is randomly determined at the beginning of the trial. See Figure 6.2.
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Figure 6.2: Graphical representation of the cluster randomised stepped-wedge design
A stepped wedge design might be used when the implementation of the intervention can only be
performed sequentially across clusters or when it is believed the intervention will do more good than
harm and so it is thought to be unethical to deny clusters from receiving the intervention during the
trial.
These designs are increasing in popularity but guidance regarding best practice around their design
and analysis is limited. The first published guidance by Hussey in 2005203 has since been extended
to develop a design effect for the stepped wedge design with continuous outcomes analysed by mixed
model by Woertman et al.82 The appropriate use of this design effect has been further clarified by
Hemming and Girling.209 These calculations have now been implemented in the statistical software
Stata.210
For time-to-event outcomes Moulton et al propose an adaptation of Hayes formula for rates to
account for the stepped-wedge design.206
Power calculations for stepped-wedge designs have assumed a cross-sectional design with equally
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spaced steps, an equal number of clusters randomised at each step and data collected at every step.
Methods to account for some variations to these assumptions have been proposed by Hemming,
Lilford and Girling in 2014.204 The variations dealt with include multiple layers of clustering or
incomplete data i.e. at some steps for some clusters data are not collected or do not contribute to
the analysis. At present only a simulation-based approach has been proposed which can address
some of the more complex variations in design, including a cohort design.205 However, calculations
based on a cross-sectional design are likely to be conservative for the cohort design.
Methodological developments in the design, conduct and analysis of stepped wedge designs appear to
be occurring at a rapid pace and so there is a lot of scope for development of sample size methodology
in parallel.
Three-level cluster randomised trial
Three-level cluster randomised trials commonly occur in educational research where pupils (level 1)
are sampled within classrooms (level 2) and randomisation occurs at the school level (level 3). The
total variance now includes the variance between schools, the variance between classrooms within
schools and the variance of students within classrooms and schools (see Figure 6.3). Aggregating
the data at the classroom or school levels reduces this design to the standard parallel group trial
where sample size methodology is widely available.
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Figure 6.3: Graphical representation of the cluster randomised three-level design
The three-level design lends itself to an individual-level analysis by mixed model or GEE and simple
design effects have been proposed for these methods for binary or continuous outcomes by Teeren-
stra79,80 and Heo.81 For the three-level design two ICCs are required, in this example one for
students within schools and the second for students within classrooms. The calculation of the opti-
mal sample sizes at each level under a cost constraint has also been considered by Moerbeek106 and
Konstantopoulos.103,182
Most methods discussed so far for three-level designs have assumed that randomisation will take
place at the highest level e.g. school. If randomisation were to occur at the second-level these
designs can be thought of as multi-center cluster randomised trials. Cunningham and Johnson have
proposed a simple design effect for randomisation at the lower levels.207 The same is not true for
longitudinal CRTs where outcomes are measured at specific time points within subjects, within
clusters. If randomisation were to occur at the second-level the design would be equivalent to a
longitudinal multi-center trial.
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The most obvious development of the design effect for three-level trials would be to incorporate
variable cluster sizes and other adaptations to the standard design as described in Table 6.2.
6.2.4 Emerging themes
The majority of methods identified in the review derived a sample size calculation to reach a pre-
specified level of power for a superiority analysis of the primary outcome. Exceptions to this were
those methods based on a non-inferiority design or those which optimised the cluster size and number
of clusters to provide the maximum precision under a fixed budget constraint. In the update to the
review four additional motivations to sample size calculations emerged and are briefly described here.
The evidence-based perspective: Rotondi and Donner took an evidence-based approach to sample
size determination. The appropriate sample size is derived based upon its potential impact on the
literature i.e. the trial should be large enough to establish whether there is a treatment effect on its
own but to also provide a definitive answer when used in subsequent meta-analysis.195
Powering for tests of mediation: Mediation analysis is undertaken in order to explain the process
by which the intervention affects response. Using simulation methods Hox et al derive the lowest
number of clusters required to accurately test and estimate mediation in cluster randomised trials
both when maximum likelihood and Bayesian methods are used in estimation.211
Powering for cost-effectiveness: In 2014 Manju et al considered optimal sample sizes at the individual
and cluster levels under a cost constraint where the outcome is the cost-effectiveness of treatments
on a continuous scale.212 Their approach uses a maximin design and therefore is robust to miss-
specification of the parameters such as the ICC.
Powering for a pre-specified confidence interval width : The final approach taken by Pornprasert-
manit and Schneider is described as the accuracy in parameter estimation (AIPE) approach.213
This method helps researchers to find the smallest sample size that will ensure that the confidence
interval around the treatment effect will be sufficiently narrow to be informative. Their methods are
also extended to include a covariate and deal with unequal cluster sizes.
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The remaining emerging themes centred on aspects of the design: three-arm trials; factorial trials;
and the dog-leg design.
Three-arm trial: For a three-arm cluster randomised trial the simplest approach to sample size esti-
mation would be to assume that three independent comparisons between the groups are to be made
and the maximum sample size is then used for each treatment group.33 Methods of calculation based
upon an overall test of treatment effect have recently been proposed.214
Factorial trial: Two methods for factorial designs have been proposed since the original review.
The first by Dziak in 2012 for continuous outcomes can accommodate a pre-test measure of the
outcome.215 The second approach in 2015, also for continuous outcomes, by Lemme et al calculates
the optimal numbers at each unit in order to minimise the variance of the treatment effect estimator
under a total budget constraint and heterogeneous variances across treatment groups. The authors
conclude that the 2x2 factorial design is quite robust against heterogeneity of variance and any loss
in efficiency can be compensated by the addition of one of two clusters per treatment group.
The dog-leg design: The stepped-wedge design is a form of cross forward design where all clusters
cross-over to the intervention arm at some point during the trial. These designs often require a
large number of individuals, as repeated cross sectional samples are taken from each cluster. An
incomplete cross forward design can reduce the number of individuals required as it leaves gaps in
the assessment schedule in some of the arms. The dog-leg design has been proposed as the simplest
incomplete cross forward design by Hooper and Bourke which can potentially reduce the number of
individuals required and aid researchers to meet ethical and financial requirements for limiting the
number of research participants. The name dog-leg comes from the pictorial representation made by
the assessment schedule.216
6.3 Discussion
In the original review of sample size methods 85 papers were identified published over the 33 years
spanning 1978 and 2011. When this review was updated in August 2015 an additional 28 papers
were identified published over the 4 years between 2012 and 2015 (see appendix vi for details). This
shows the methodology is still increasing.
197
6.3. DISCUSSION
Papers which made reference to a particular trial as the motivation behind the proposed sample size
method were in the minority. Therefore, this rapid increase in methodology may not necessarily
reflect a trend towards more varied and/or complex designs but instead may indicate that methods
are being developed which are yet to have practical applications.
The focus of my thesis has been on sample size and analysis methods for ordinal outcomes. In this
chapter I have taken a side step from this and presented a very broad overview of all the methodology
available. I now describe some of the gaps in the methodology that I consider most striking or that I
can see would be of interest to the applied statistician. Statisticians with a more detailed knowledge
of specific areas for example time-to-event data or longitudinal designs may identify more specific
issues that I have not raised here.
For the standard parallel group trial methods are available across a range of outcome measures:
continuous, binary, count, ordinal, time-to-event and rates. In this thesis I have further developed
the design effect method for ordinal outcomes to provide guidance around its use. However, for
variations to this design and alternative design choices the methodology almost solely centres on
binary and continuous outcomes.
In the vast majority of methods homogeneity of the between-cluster correlation across treatment
groups is assumed and has rarely been challenged. It would be interesting to look further into this
to see how reasonable this assumption is in different situations.
Cluster randomised trials with longitudinal designs produced some of the most complex sample
size methods. This complexity makes it difficult to identify how they should be implemented and
understand the differences between them and the situations to which they can be applied. Further
work to consider a comparison of these methods and provide simple advice on their use is needed.
For outcomes which are not binary or continuous and designs other than the standard parallel-group
trial many of the sample size methods require estimates of additional parameters. For example
for time-to-event outcomes an ICC must be defined and estimated, when cluster size is variable a
coefficient of variation in cluster size is required, or when attrition is expected an estimate for the
probability that the outcome is missing and an ICC of the missing data mechanism are needed.
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These parameters are not yet well established or routinely reported. Finding appropriate estimates
to use is therefore one of the biggest barriers to the practical application of these methods. There
is scope for much work to be done in this area. Summaries of these parameters from real life data
across a range of health areas are needed. More awareness amongst researchers and journal reviewers
about the need to report these estimates for the design of future trials would also be helpful.
This is the first comprehensive review of sample size methodology for cluster randomised trials. The
full details, including formulae for the methods identified in this review have been described in the
associated publication.60 Given that sample size methods appear to still be expanding. I plan to
publish future updates to this review. A strength of the results presented here are that the areas
where there is the biggest need for sample size development are immediately highlighted. A thorough
critique and comparison of the methods within each section was beyond the scope of this thesis but
may reveal some further areas that warrant development.
In this chapter I have highlighted several avenues for future exploration in sample size calculations
for cluster randomised trials. One of the most useful aspects of my research on ordinal outcomes was
my review of published clustered randomised trials (Chapter Three). This provided great insight into
whether there was a need to develop methods for ordinal outcomes and the characteristics of these
trials then guided the development of the sample size method, tailoring it to the needs of researchers
to make it more practical. Before embarking on the development of any of the methodological gaps
highlighted in this chapter I would strongly advise researchers to conduct similar reviews of CRTs to
inform their research so that we see more pragmatic methodology, which is actually needed, being
developed. My research into ordinal outcomes also raised several questions about situations which
are not uncommon such as the appropriate analysis method if the number of clusters is small, what
reasonable estimates of the ICC may be and what to do if non-proportional odds are suspected.
These issues will be discussed further in the final chapter but I think they highlight the fact that
there are still many questions of a very practical nature worth exploring before we move on to develop
more complex methods to deal with design variations.
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Chapter 7
Discussion and conclusions
The focus of this thesis was to provide a unique contribution towards the review and development
of sample size methods for cluster randomised trials, with particular emphasis on ordinal outcomes.
The specific objectives are provided in Figure 7.1
Prior to my research none of the objectives of this thesis had been fully addressed in the literature.
Several reviews of sample size methodology for CRTs had been published but many of these were
not designed to provide a comprehensive overview of all the methods available and the most recent
of these was published in 2007. At the time of starting my research there was no proposed simple
method for sample size calculations for ordinal outcomes. During the course of the research use of
the design effect was proposed but there was little guidance around best practice for its use, including
which estimate of the ICC should be used and under which circumstances the method should be
used.
Although not in the context of sample size some research had proposed the same ICC estimators as
used in this thesis for ordinal outcomes and explored the relationship between them. However, this
work assumed a marginal model for both data generation and analysis and hence these results were
not directly comparable to the mixed effects context used in my research.
The focus of many of the published reviews of CRTs was the reporting or methodology quality of
the included trials. Mine was the first, which I am aware of, to explore the prevalence of ordinal
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1. Provide a comprehensive summary of sample size methods available for CRTs (Chapter
Two)
2. Identify the distinct processes that have been used to derive sample size methods for
CRTs (Chapter Two)
3. Develop sample size methodology with a particular focus on ordinal outcomes, achieved
via the following steps:
→ Identify the prevalence of sample size methods for ordinal outcomes (Chapter Two)
→ Determine the prevalence and design characteristics of CRTs with ordinal primary
outcomes (Chapter Three)
→ Summarise proposed estimators of the ICC for ordinal outcomes (Chapter Four)
→ Explore the relationship between ICC estimators via simulation (Chapter Five)
→ Determine which ICC provides empirical power closest to the nominal value when used
in the design effect for sample size calculation (Chapter Five)
→ Explore the effect on power under variations of the assumptions underlying use of the
design effect (Chapter Five)
4. Provide a comprehensive summary of the remaining gaps in sample size methodology for
CRTs (Chapter Six)
Figure 7.1: Research objectives of the thesis
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outcomes in cluster designs and summarise the design features common to these trials.
In this chapter I summarise the new knowledge around sample size calculation for cluster randomised
trials generated as a direct result of my research and describe its significance, strengths, and weak-
nesses. The main results of my research are translated into explicit practical guidance for those
wishing to conduct sample size calculations using ordinal outcomes. The chapter concludes with
a description of future research opportunities generated from this work, those specific to ordinal
outcomes and those of a broader nature.
7.1 Main findings
In this section I describe the main findings in relation to the thesis objectives described in Figure
7.1
7.1.1 Sample size methods available for CRTs
My systematic review of sample size methods for cluster randomised trials identified a large body
of literature, 85 papers. In the 2015 update to the review a further 28 papers were identified, which
shows that sample size methodology is still rapidly developing. The literature is dominated by
methods applicable to continuous or binary outcomes. Under the standard, parallel group design
some methods have been developed for alternative outcomes such as rates, time-to-event and ordinal
outcomes but methods available for these types of outcomes under variations or adaptations to the
standard design are considerably lacking.
The intracluster correlation coefficient is more frequently used as a measure of between-cluster corre-
lation than the coefficient of variation in outcome. This is most likely due to the wide availability of
ICC estimates and literature on the patterns in ICCs for different outcomes and cluster types. More
recently an alternative measure of correlation, R, has been proposed specifically for binary outcomes
that is not dependent upon the overall prevalence in the way the ICC is.163
As the complexity in the design increases the sample size methods often require estimates of further
parameters over and above the ICC and cluster size, for example additional measures of correlation
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are needed for the pre- post- design. The opportunity to use any of the sample size methods
identified depends upon the availability and quality of estimates for the required parameters. Many
of the sample size methods papers requested that authors report the required estimates with the
results of their trial. However, for this to happen more awareness by researchers of these sample
size methods and how to calculate the required parameters is needed. It is not clear how this
should be done. Recommendations in the CONSORT guidelines might at first seem the obvious
place to raise awareness. However, the aim of the CONSORT statement extension for CRTs is to
provide a minimum set of reporting requirements, these sample size parameters are additional to the
minimum requirements and often trial specific. To recommend reporting via CONSORT would be
inappropriate.
In 2015 a summary of methodology for sample size calculations in cluster randomised trials was
published by Gao et al.217 In comparison to my review this review focuses on a smaller range of
design situations but additionally includes worked examples of sample size calculations for each type
of outcome.
7.1.2 Approaches to sample size derivation
In the majority of papers the sample size method was derived from first principles (n=44, 52%).
Using this approach the treatment effect, with its corresponding variance, is defined alongside a
definition of the analysis method and an appropriate test statistic, from which a statement about
power or sample size can be generated. Other approaches to derivation included: calculating a ratio
of the variances of alternative treatment effect estimates; defining the optimal allocation of clusters
and cluster size, subject to optimality criteria such as a cost constraint; sample size by simulation;
Bayesian methods; or the adaptation of a pre-existing sample size method.
7.1.3 Sample size methods for ordinal outcomes
In my systematic review of sample size methods two methods were identified relevant to ordinal
outcomes.33,65 The method by Campbell and Walters proposed multiplication of the sample size
assuming individual randomisation by the design effect and was the focus of my research. My aim
was to determine which ICC estimator should be used and explore how this method performed
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under design characteristics common to ordinal outcome trials. These design characteristics were
identified from my review of 300 cluster randomised trials, of which 11 (4%) were found to have
ordinal primary outcomes. Nine (82%) of these outcomes had between 3 and 5 ordinal categories
and these outcomes most often measured an aspect of behaviour 9/11 (82%). The design of these
trials were most often parallel group 10 (91%), two-arm 6 (55%), completely randomised 8 (73%),
and used a cohort sample 9 (82%). Both the total number of clusters randomised and the number
of enrolled participants per arm tended to be small.
Three estimators for the ICC in the design effect were considered. The ICC of an underlying latent
continuous variable, the ANOVA ICC calculated by assigning numerical equally spaced values to the
ordinal categories and a weighted kappa-type ICC measuring chance-corrected agreement.
The results showed that when the number of clusters was large the ICC on the latent response was
largest, the ANOVA and kappa-type ICCs were smaller and almost identical. These observed patterns
were consistent across the 3-, 4- and 5-level outcome variables. For each scenario investigated as the
number of ordinal categories increased the estimated ANOVA and Kappa-type ICCs became closer
to the ICC on the latent response.
The use of the ANOVA ICC estimate in the design effect resulted in adequately powered trials, the
empirical power was never more than 2% below nominal power. Sample size was more conservative
when the proportions in each ordinal category were less evenly spread (see section 5.9.1). Power
was only marginally decreased under a minor deviation from the proportional odds assumption.
7.1.4 The future of sample size methods
In chapter Six I presented a summary of the 85 sample size methods for CRTs that were identified
in my original review and an additional 28 methods identified in an update to the review conducted
in 2015.
For variations to the standard parallel group design such as variability in cluster size, attrition, and
inclusion of baseline covariates or repeated measures there is much scope for further development
for outcomes which are not binary or continuous.
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The practical use of sample size methods rely on the ability to find suitable estimates of the required
parameters. Rather than developing new methods of sample size calculation provision of some real
life estimates required by these existing methods would go a long way to allowing researchers to
implement these methods.
In some papers a particular trial example provided the motivation behind the development of a
sample size method and hence a practical application was clear. Where no motivating example was
given it was difficult to see how or why these methods would be used, particularly when the method
or assumed analysis was computationally complex. Methodologists involved in the development of
these methods and statisticians involved in their implementation may wish to consider whether there
is a future in developing complex formulae that may be inaccessible to many researchers. Perhaps
sample size by simulation may be a better approach to cope with increasing complexity in design,
explore ranges of parameter estimates and most importantly reflect analysis methods for which
software is available.
7.2 Strengths
Limited guidance has been published around the methodological aspects of conducting and reporting
reviews of methodology. My review of sample size methods was implemented using robust methods
that aimed to mirror the approaches used in more conventional systematic reviews. These approaches
included developing and agreeing a protocol and validation of electronic search terms, data collection
and review coverage. This has provided a reliable comprehensive review of sample size methods that
future researchers can use to further develop sample size methods.
In this thesis I chose to extend the design effect approach to sample size calculation for ordinal
outcomes. The design effect is a familiar and simple approach to sample size calculation and the
underlying assumption of analysis via a proportional odds model is the most commonly used method
of analysing ordinal data. Contribution to enabling widespread use of the design effect approach will
likely have a larger impact in improving trial design than developing a new, but potentially more
complicated method.
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One of the greatest strengths of my work is its strong generalisability to real-life ordinal outcome
trials. The design of the simulation studies were informed by the characteristics of trials that have
used ordinal outcomes, identified from a review of 300 cluster randomised trials representative of all
areas of health research. This means the results and recommendations for sample size calculation
can immediately be applied to similar trials with a reasonable number of clusters. As there was
no data available to inform the estimates of ICC investigated in the simulations a wide range of
estimates were used to cover the majority of situations.
7.3 Limitations
Since I conducted the review of sample size methods for CRTs there has been 28 new methods
published. These new methods were described in Chapter Six. However, with such an increase in
sample size methodology over the last five years my review of sample size methods, published in
2015, will quickly be out of date and an update to the published paper will be required.
The prevalence of trials with ordinal primary outcomes was identified from a review of 300 clus-
ter randomised trial results published between 2000 and 2008. Eleven trials with ordinal primary
outcomes were identified. It would have been interesting to gain an understanding of whether inves-
tigators were actively avoiding using ordinal outcomes due to the lack of sample size methodology
available or whether alternative outcomes or methods of analysis were just clinically more relevant.
Some qualitative work interviewing or surveying investigators may have provided some insight here.
The characteristics of the eleven trials with ordinal primary outcomes informed the parameters
under which I evaluated the design effect methodology. A more up-to-date review, or one which
was more focused on areas commonly implementing ordinal outcomes, such as trials in stroke, may
have provided more data on which to base the simulation studies. However, this would have been a
substantial amount of work which was beyond the time frame of this research and the results would
have been less generalizable to all areas of health research.
Despite investigator willingness it was not possible to gain access to the data for any of the 11 trials
with ordinal outcomes. This lack of available data or summaries of ICCs for ordinal outcomes meant
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that a very broad range of possible ICCs were used in the simulation studies and they may not all
be applicable to real life trials.
No single method for generating clustered ordinal outcomes has been recommended. I investigated
several methods and considered alternative statistical software. This process took considerable time
and meant that there was less time for investigating a wider range of scenarios, such as variable
cluster sizes and methods for dealing with a small number of clusters, in the simulation study. It is
not known whether an alternative data generation method would affect the results.
7.4 Comparison to other work
In this research I extended the design effect approach for sample size calculations for ordinal outcomes
to include recommendations on how to calculate an appropriate estimate of the ICC. The calculations
involved in this approach are simple and easy to implement and the assumed analysis is a straight
forward extension of the proportional odds regression model commonly used for ordinal outcomes in
independent data. Kim et al have proposed a sample size method for correlated ordinal outcomes
in the longitudinal setting. Their approach assumes a GEE analysis and involves substantially more
calculations than the design effect approach, as the cluster size increases the calculation burden also
increases. Further work is needed to evaluate this method in the CRT context65
In 2012 Ruochu Gao published her thesis on the statistical analysis of correlated ordinal data in
cluster randomised trials. Her work was restricted to 3-level ordinal outcomes and community
intervention trials, where a small number of large clusters are expected.125 Although her work did
not propose methods for sample size determination she did consider the validity and power of different
analysis methods, the focus being on the non-parametric adjusted Cochran-Armitage test and small
sample adjustments to the Wald test from a GEE model with clustered ordinal data generated using
a marginal model.
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7.5 Implications
In this section I translate the results of my research into a series of recommendations for the design
of cluster randomised trials with ordinal outcomes. These recommendations are summarised at the
end in Figure 7.2.
7.5.1 Choosing the number of categories
When the investigator is in control of the number of categories to use in the ordinal outcome the
method by Whitehead has shown that sample size can be most dramatically reduced when increasing
the number of categories beyond two, but there is little to be gained in increasing the number of
categories beyond five.2 Depending upon the sample size an increased number of categories may also
lead to some categories containing very few observations which may impact the analysis. Whitehead’s
method is most efficient when the proportions are equally spread across all outcome categories and
least efficient when one category is dominant. These results are equally applicable to the clustered
design.
7.5.2 Estimating the ICC
For an ordinal outcome the design effect can be calculated using the ANOVA estimate of the ICC,
assuming equally spaced numerical scores assigned to the ordinal categories. The value of the ANOVA
ICC depends upon the number of categories and the proportions expected within each category. If
a weighted kappa-type estimate is used similar levels of power to the ANOVA will be achieved when
the number of clusters is large or the level of clustering is small. In the remaining situations the
kappa-type estimate is smaller than the ANOVA and hence will lead to reduced statistical power
if used in the design effect. Use of the ICC on the latent scale will always lead to a conservative
estimate of sample size compared to the ANOVA or kappa-type ICC, but less so as the number of
ordinal categories increases. The latent variable ICC is provided in the output from random effects
models fitted in Stata and hence estimates may be more available for this ICC than the ANOVA
and kappa-type ICC. Other approaches to assigning scores to the ordinal outcome should be used
with caution, the performance of the ANOVA ICC estimate in the design effect for these situations
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is not known.
If no estimates of the ICC are available researchers may consider getting an estimate by utilising
estimates or patterns seen for continuous or binary versions of similar outcomes and exploring the
sensitivity of the sample size estimate to a range of values. However, a conservative estimate may
result in an unnecessarily large trial. There have been no methods that have looked at formally
incorporating ICC uncertainty for ordinal outcomes into sample size calculations. Methods developed
for continuous outcomes may provide a starting point for some development in this area.116–118
Researchers could consider re-estimating the ICC value and sample size part way through the trial,
in an internal pilot. However, these methods are only really appropriate when a large number of
clusters are to be recruited over a long period of time.
7.5.3 Dealing with a small numbers of clusters
When the analysis is performed at the cluster level the addition of one cluster per arm has been
suggested to account for a small number of clusters. When an individual-level analysis is planned
it is sensible to also add one cluster per arm which will go some way to reduce the impact of any
clusters dropping out. However, when the number of clusters is small the Wald test of the treatment
effect from an individual-level analysis by random effects regression does not perform well. In
these situations the Type I error is inflated and therefore the possibility of finding a statistically
significant treatment effect when no such effect exists is increased. In Chapter Five I looked at
whether comparison to the t-distribution, rather than the Normal distribution, may improve the
type I error rate of the Wald test for small number of clusters. However, in many situations this
reduced the Type I error below 5%. I removed this issue from my simulations by only considering
scenarios with at least 40 clusters per arm where the Type I error rate was maintained at 5%.
Another approach to correct for the inflated Type I error rate with a small number of clusters
is to use an approximated Wald F test to test the treatment effect in a random effects model.
With this test there are several possibilities for estimating the denominator degrees of freedom
(DDF). Overestimation will lead to an increased Type I error rate and underestimation will lead
to a conservative test and loss of power. Numerous methods have been proposed to approximate
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the DDF, two of the most well-known are the Kenward-Roger and Satterthwaite methods.218,219
The Kenward and Roger method generates a more conservative test than the Satterthwaite method.
These corrections tend to perform best under a balanced design, alternative methods may be required
when cluster sizes vary and have been evaluated for binary and continuous outcomes.220,221 These
correction methods are now part of the Stata 14 update to the mixed command. I am not aware of
any work evaluating these methods for ordinal outcomes or considering the sample size implications
of their use. I would recommend using simulation methods to explore the sample size requirements
for ordinal outcomes employing these analysis corrections.
Although GEE models are not the focus of the thesis I consider their small sample adjustments
briefly here. The Wald test can be similarly applied in the GEE case i.e. the treatment effect di-
vided by its standard deviation and the result compared to a Normal distribution. There are two
possible estimates of the variance from the GEE model: the model based variance or the sandwich
(robust) estimator. The sandwich estimator is considered robust to miss-specification of the corre-
lation structure but is biased downwards when the number of clusters is small. Some bias-corrected
sandwich estimators have been proposed when there are a small number of clusters, such as those
by Kauermann and Carroll, Fay and Graubard, Mancl and DeRouen and Morel and Bokossa.222–225
These approaches have been evaluated via simulation for cluster randomised trials with binary out-
comes.226 The Kauermann and Carroll method works well with moderate variation in cluster size.
The authors also proposed a sample size formula for the minimum number of clusters required when
using the Kauermann and Carroll correction.
In her research on analysis methods for ordinal outcomes Gao explored the power and Type I error
via simulation of the adjusted Cochran-Armitage test and the GEE model with correction and
modification strategies applied to the Wald test and score test. Her recommendations were to use
the bias-corrected sandwich variance estimator of Mancl and DeRouen.125
Brennan Kahan and colleagues from the Pragmatic Clinical Trials Unit (PCTU) at Queen Mary
University of London have been doing some research into how big the issue of increased Type I error
is among cluster randomised trials. Of 100 randomly selected cluster randomised trials 65% were
identified as being at risk from increased Type I error. The majority of these performed an analysis
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at the individual level without an appropriate small-sample correction (work not yet published).
7.5.4 Choosing the analysis method
Due to the similarity between the logistic and normal distributions the design effect approach for
ordinal outcomes can be used when the analysis is via a proportional odds cumulative logit model
or ordered probit regression model. The choice between a random-effects model and marginal model
should not be crucial to inferential conclusions if the variance components are similar in the two
groups.130 Therefore I would expect the design effect to be applicable to a GEE analysis. This was
not tested in my simulations as it is currently not possible to fit a GEE model to ordinal outcomes in
Stata. It should also be remembered that the GEE analysis is only valid under the strong assumption
of Missing Completely At Random (MCAR). When choosing the analysis method one should also
consider the number of clusters to be randomised. If the number of clusters is small small-sample
correction methods will need to be applied and for ordinal outcomes there is no consensus over which
to use, as described in the previous section.
7.5.5 Dealing with non-proportional odds
In order to use Whitehead’s method of sample size calculation the proportions expected in each
ordinal category must be known. From these we can calculate the log odds ratios for dichotomisation
at each ordinal category and make an assessment of whether the assumption of proportional odds
are reasonable.
With the minor deviation from the proportional odds assumption explored in this research use of
the design effect to calculate sample size (with treatment effect estimated as the average log-odds)
followed by a random effects ordinal regression analysis with probit link resulted in a marginally
underpowered trial. Given the difficulty in systematically exploring all possible deviations from
proportionality here I would recommend that sample size requirements be confirmed via simulation
where non-proportional odds are present. Future reporting of trial results should contain the pro-
portions observed in each category across treatment groups and the associated log-odds ratios so
that these estimates may be used in future sample size calculations and the appropriateness of the
proportional odds assumption observed.
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When larger deviations from proportional odds occur the assumptions of the design effect approach
are not met and a simulation approach to sample size is required. However, the alternative analysis
methods required for non-proportional odds, and the software to implement them, have received
little attention for the clustered case. There are three alternative analyses to consider when the
proportional odds assumption is violated i) dichotomise the outcome and carry out a random effects
logistic regression ii) assume the outcome is nominal and conduct a multinomial regression or iii) fit
a model that allows for non-proportional or partial proportional odds. The first of these approaches
is appealing as sample size methods and analysis are well established, but the required sample size
is likely to be substantially larger than if the ordered nature of the data had been accounted for.
The second approach appeals due to the fact that multinomial random effects regression methods
are available in statistical software, but it is not clear whether this method would result in different
conclusions compared to a method that takes the ordinal nature of the data into account, as is the
case for unclustered data. The final approach is appealing as it maintains the ordinal nature of the
data while allowing for non-proportional odds or partial proportional odds and the effects of each
category can be seen within the same model. The partial proportional odds method described by
Hedeker and Mermelstein143 has been implemented in an extension to the MIXOR package available
in R for mixed effects ordinal regression.144
Some simulation methods for sample size are likely to be required when non-proportional odds is
expected. This requires some further research to recommend methods and associated software for
generating clustered ordinal data with non-proportional odds.
7.5.6 Incorporating baseline measurements
Many of the trials with ordinal primary outcomes identified used a cohort design with an analysis that
incorporated baseline measurements. The incorporation of baseline measurements would require an
estimate of an appropriately adjusted ICC value to use in the design effect. As ICCs are not routinely
available and there is likely to be considerable uncertainty around any ICC estimate I suggest that,
at present, baseline measurements are ignored for the purpose of sample size calculations using the
design effect for a conservative estimate.
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7.5.7 Dealing with cluster size variability
As with design effects used in other settings if there is a large amount of variability in cluster size , i.e.
a coefficient of variation greater than 0.23 use of the mean cluster size in the design effect will likely
underestimate the required sample size. A design effect which incorporates cluster size variability
has been proposed for binary and continuous outcomes but its use for ordinal outcomes has not
yet been evaluated.168 If variability in cluster size is expected I would suggest that a simulation
approach to sample size should be taken. If a small number of clusters are to be randomised then
small-sample adjustments to the analysis behave differently under variable cluster sizes and should
also be explored in the simulations.
7.6 Future work
In this section I describe the future work which has been generated from the work conducted in this
thesis.
7.6.1 Guidance on parameter estimation
A common thread throughout this thesis is that the proposed sample size formulae are only useful
if we have good estimates to use with them, finding reasonable estimates is the biggest practical
barrier to their use. The design effect for ordinal outcomes is no exception. Future work is needed
to explore patterns in ICCs for different types of outcomes and clusters to mirror the literature that
is available for binary and continuous outcomes.
When reporting the results of the trial it is imperative to the design of future trials that researchers
report the ICC value for the ordinal outcome alongside an explicit description of the method of
calculation and the proportions observed in each ordinal category for each treatment group.
7.6.2 Research impact
In Chapter Three I identified eleven trials that had an ordinal primary outcome. In only two of
these trials the analysis was performed on the ordinal version of the outcome, in others it was either
213
7.6. FUTURE WORK
1. Sample size method
Use Whitehead’s formula for individually randomised trials multiplied by the design effect,
1 + (n− 1)ρ
2. Number of categories
Whitehead’s method is most efficient when the proportions are equally spread across all
outcome categories. There is little gain in using more than 5 categories.
3. Estimating the ICC
ICC should be calculated using an ANOVA estimate, assuming equally spaced numerical
scores assigned to the ordinal categories
→ When the number of clusters is large a weighted kappa-type ICC estimate may alterna-
tively be used
→ Use of the ICC on the latent scale will lead to a conservative estimate of sample size, but
less so as the number of categories increases
→ Recommend at present that incorporation of baseline measurements are ignored for a
conservative sample size calculation
4. Clusters
Cluster size is assumed fixed
→ If cluster size variability, measured by the coefficient of variation, is greater than 0.23 I
recommend sample size by simulation instead of the design effect approach
5. Analysis
Assumed analysis is a random-effects ordered regression model assuming proportional odds
and missing data is missing at random. Performs well when the number of clusters is large,
around 40 per group
→ With minor deviations to proportional odds the design effect approach may still be
appropriate
→ With larger deviations to proportional odds alternative analyses are required and sample
size should be calculated by appropriate simulation
→ If the number of clusters is small there is a risk of an inflated Type I error. Small sample
correction methods are required and sample size via simulation is recommended
Figure 7.2: Recommendations and considerations for sample size calculation for cluster randomised trials
with ordinal outcomes
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dichotomised or treated as continuous. It is unclear whether ordinal outcomes are less frequently
used because the sample size and analysis methods are not as well understood as those for binary
and continuous outcomes or that treating the outcome as binary or continuous rather than ordinal
is actually more clinically relevant. The answer to this question was not addressed in this research.
However, if the reason is due to the former then I expect to see an increase in ordinal outcome trials
after the dissemination of the guidance contained within this chapter. Measuring the impact of my
research in this way is something I wish to consider in the future.
7.6.3 Comparison of sample size methods
With such a large number of sample size methods identified for cluster randomised trials in my review
it was often difficult to identify the specific methodological differences between similar methods and
the potential impact these may have on the resulting sample size. It was not easy to determine how
much was gained in sample size efficiency by using a complex approach over a simpler method, and
under which circumstances the gain is maximised. In particular, methods for time-to-event outcomes
or longitudinal designs were very complex. More work is needed to evaluate the performance of
competing approaches under various conditions to aid researchers in sample size decision making.
The need for this work was also recognised by Campbell.55
7.6.4 Reporting guidelines for methodology papers
In conducting this research I read many methodological papers describing proposed sample size
calculations for cluster randomised designs. Despite there being 113 papers describing sample size
methods only a handful of these are highly cited. The reason why some methods are not being used
could be down to the fact that no practical application has yet arisen, or the new methodology may
be considered to provide minimal benefit in light of the added complexity, or no reasonable estimates
can be found for the required parameters. I hypothesise that the way in which many methodologies
are currently reported has a large influence on their accessibility to a wide audience. I found the
reporting quality to be highly variable among the papers and the key assumptions and parameter
definitions underpinning each method were often difficult to locate or comprehend. An improvement
in the reporting quality may lead to increased identification and uptake of new methods.
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7.6. FUTURE WORK
Within health research improvements in research reporting are being driven by the creation of
reporting guidelines such as CONSORT.49 Currently there are no guidelines that I am aware of
for the reporting of methodology papers in health research. In future research I intend to examine
more formally the quality of reporting of statistical methodology using the sample from this research
and identify the need for a reporting guideline to be developed. I wish to highlight potential items
for inclusion on any subsequent reporting checklist and provide examples of good reporting practices.
7.6.5 Extending sample size methods for ordinal outcomes
The development of statistical methodology in general commonly starts with continuous or binary
outcomes, as these are the most frequently used and simplest type of data. Extensions for alternative
outcomes and then clustered data follow later, if at all. This is certainly true for ordinal outcomes
with both sample size and analysis methods limited for clustered data. The use of the design effect
in the context of cluster randomised trials with ordinal outcomes assumes: proportional odds; a
reasonable number of clusters; fixed cluster size; and an ANOVA ICC assuming equally spaced
numerical values are assigned to each ordinal category. It is reasonable to say that more often than
not one of these assumptions may not be satisfied. In the future it would be useful to look at
the behaviour of the design effect under different violations of these assumptions and be able to
extend or develop new methods of sample size for these circumstances. In order to do this further
work is required to provide guidance around such aspects as: the analysis method to use under
non-proportional odds with or without variable clusters; which small-sample correction should be
applied in the analysis when the number of clusters is small; and which method should be used for
generating clustered ordinal data under which circumstances.
In addition to undertaking some of the above future research I intend to publish my work from this
thesis on ICC selection when using the design effect for sample size calculation with clustered ordinal
outcomes.
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7.7. CONCLUSIONS
7.7 Conclusions
A large amount of literature has been dedicated to sample size calculations for cluster randomised
trials. The early work concentrated on the standard parallel group trial with fixed cluster sizes and
binary or continuous outcomes. In recent years the literature has expanded to include alternative
designs and allowance for variations from the standard design such as variable cluster sizes. However,
binary and continuous outcomes still remain the assumption for the vast majority of sample size
methods. Trials with alternative types of outcomes, such as ordinal, are conducted and guidance is
needed in how to calculate their sample size.
In this thesis I focused on ordinal outcomes for which the proposed sample size approach is to
calculate the sample size under individual randomisation and multiply by the standard design effect,
which is a function of the cluster size and intracluster correlation coefficient.
At the start of this research the biggest practical barriers to implementation of this approach were
that there were no recommendations as to how the ICC should be calculated or under which circum-
stances the method performed adequately.
In this thesis I evaluated the empirical power of using three alternative ICC estimators in the design
effect under scenarios common to ordinal outcome trials. I demonstrated that the ANOVA ICC, by
assigning numerical equally spaced values to the ordinal categories, performs sufficiently.
In conclusion, I have provided practical guidance for the strategy to be adopted by researchers
calculating sample sizes for cluster randomised trials with ordinal outcomes which was not previously
available.
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1.1 Background
1.1.1 An introduction to cluster randomised trials
Well designed and conducted Randomised Controlled Trials (RCT’s) are seen as the gold standard
in research design for the evaluation of new interventions for improving participant outcomes. In
this research design we compare the outcomes of those participants who recieve the new intervention
with a control group who receive either standard treatment or a placebo. In order to be able to
reliably conclude the effect of the treatment the characteristics of these two groups of individuals
should be similar so that the only systematic difference between them is the treatment received.
This is acheieved by randomly allocating each individual to one of the treatment arms under study,
this helps to avoid potential selection bias where participants with certain characteristics, such as
severe disease, may end up more likley in one of the treatment arms [7].
There are some circumstances when it becomes necessary to randomise groups of individuals together,
as a unit, rather than individually [4]. This process is known as cluster or group randomisation. The
cluster may be large, such as a hospital or General Practice surgery, or may be smaller like a family.
When we conduct a cluster randomised trial we may sample an entire cluster such as all participants
registered at a General Practice, or take a subsample for inclusion into the trial. Throughout this
report, when we refer to cluster size, we are specifically refering to the sample of the cluster that is
to be included in the analysis, which may or may not be the entire cluster.
1.1.2 Sample size calculations in cluster randomised trials
In designing a randomised controlled trial we must determine the number of participants we need
to recruit in order to be able to make meaningful and precise conclusions about our treatment ef-
fect. This is done through the use of sample size or power calculations. Power calculations require
knowledge or decisions about the primary outcome measure, how the data will be analysed, the
Type I error to be tolerated , the amount of statistical power required, and an estimate of the ex-
pected treatment difference [7]. Randomisation by cluster presents additional complexity in both
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the design and analysis, compared to individually randomised trials and the sample size calculation
requires estimates of two more parameters, the cluster size and the intracluster correlation coefficient.
The response of individuals within a cluster are likely to be more similar than the responses of those
from different clusters i.e. the data within a cluster is correlated and the data between clusters is
assumed to be independent. The magnitude of this clustering is quantified by a parameter known
as the intracluster correlation coefficient (ICC), usually deoted by ρ. When ρ = 0 we have, in effect,
statistical independence between members of a cluster. When ρ = 1 the opposite is true and we have
total dependence among members of a cluster. An estimate of the ICC is required for the sample
size calculation. For a researcher this presents difficulties as historically ICCs have not always been
explicitly published with the reults of CRT’s. Where ICC’s are provided they are often acompanied
by wide confidence intervals, indicating a lack of precision. Further difficulties arise as to whether
an adjusted or unadjusted ICC has been reported, what if any the adjustments are, and whether
these adjustments are relevent to the reader.
The expected value of the ICC will vary with the choice of outcome measure and the type of unit
under study. The outcomes from small units such as a family are likely to be more correlated than
outcomes from larger units. It is important to note that each unit has an underlying ICC for a
particular outcome. If you increase the number you sample from each unit you will increase the
precision with which you can estimate the ICC but will not impact upon its underlying value.
The effect of clustering is that the information gained is less than an individually randomised trial
of the same size, making it a less efficient design [2]. It was proposed by Donner, Birkett and Buck
[3] that a sample size calculated assuming individual randomisation can be inflated by a Variance
Inflation Factor (VIF), or Design Effect (DE)to provide the sample size required under cluster ran-
domisation to reach the required level of statistical power. This design effect is given by
DE = 1 + (m− 1)ρ (1.1)
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where m is the number of individuals per cluster and ρ is the intracluster correlation coefficient.
1.1.3 Motivation for this review
Donner and Klar [4] describe several methodological reviews of cluster randomised trials. The con-
sensus of these reviews were that between-cluster variation was accounted for in the design of only
around 19% of the CRTs studied and was accounted for at the analysis stage by only 57%.
The authors speculate that the reason why many CRT designs do not include formal sample size
calculations may be due to
1. Inaccesability of formulas
2. Difficulties with estimation of the intracluster correlation, required for the calculation
3. CRTs enrolling large numbers of participants may give the misleading impression of extensive
statistical power
With the recent extension of the CONSORT statement to provide guidelines for the reporting of
cluster randomised trials [1] researchers are becoming more aware of cluster randomised trials and
the need to account for the clustering at both the design and analysis stages. The CONSORT ex-
tension also reccomends that researchers report the ICC for their outcomes. This development will
go some way towards enabling researchers to find appropriate ICC estimates for their sample size
calculations, and ensuring that the appropriate sample size methodology is implemented.
However we still need to tackle the issue of inaccesability of formulae. The widely used methodology
for sample size calculation in cluster randomised trials is to calculate the sample size under the
assumption of an individually randomised trial, with equivalent design features, and multiply this by
the design effect, equation 1.1. This standard methodology is described for trials where the analysis
may be a comparison of means, proportions, or incidence rates and the design may be completely
randomised, matched pair or stratified [4].
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This methodology assumes that the size of each cluster is the same, a condition which does not tend
to hold true for the majority of trial designs.
1.2 Objectives of the review
• To produce a thorough review of the exisiting state of knowledge of sample size calculations
for cluster randomised trials
• To identify gaps in the knowledge, particularly for ordinal, count and time-to-event data.
1.3 Search methodology
1.3.1 Inclusion/exclusion criteria
When searching for papers on sample size calculations in cluster randomised trials, from an exami-
nation of the literature, we are likely to encounter the following main types of paper:
1. Those which derive some or all methodological aspects of sample size formulae. This may be
done using either a Bayesian of frequentist approach.
2. Those which provide suggested adaptations and extensions to previously derived formulae.
3. Papers evaluating or comparing current methodology.
4. Papers which focus on the calculation/use of the intracluster correlation or coefficient of vari-
ation.
5. Papers with a broader focus that discuss design features in general for cluster randomised
trials.
6. Overviews or summaries of the current methodology in a particular area.
7. Papers with a general discussion on the effects of clustering upon sample size and power.
8. Papers describing application tools for implentation of the methodology.
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9. Protocols or design papers for specific cluster randomised trials, describing the sample size
calculation, as applied in the trial design.
10. Reports of results from cluster randomised trials.
To fulfil the objectives of this review we aim to collate articles of type 1-6, papers reporting spe-
cific trials are likely to be numerous and an examination of current practices is beyond the scope
of this review. The above list is not exhaustive, however it does show that the types of paper can
vary greatly making it necessary to take a broad approach to defining inclusion and exclusion criteria.
we have defined inclusion and exclusion criteria based on the following categories:
Data Type: Articles will be eligible for the review if the methods described can be applied to clus-
tered or correlated data, where the correlation of data is present in at least one of the comparison
groups, and hence could be applied to cluster randomised trials.
Content: We shall exclude papers reporting design or results of specific randomised trials, or those
which provide a very general discussion on the effects of clustering or correlated data.
Methodology: Articles will be eligible for the review if they discuss any aspect relating to the method-
ology of sample size or power. This includes those papers which may discuss or simulate only com-
ponents of the sample size.
Methodology may be described under a frequentist or Bayesian approach, both shall be included in
this review.
Language: Papers included in the review will be restricted to those written in English. To conduct
this search in other languages would not be feasible within our resources due to time and cost in-
volved in translation of manuscripts.
All articles retrived during the serach will be examined for eligibility using these criteria, as sum-
marised in table 1.1. The inclusion/exclusion criteria has been piloted on 20 search results in order
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Inclusion Exclusion
Data Clustered data Non-clustered
Content Methodological piece
or simulation study.
Bayesian or frequentist
approach.
Non-methodological. Descrip-
tion of a specific trial.
Methodology Aspect of sample size No sample size
Language English Non-English
Table 1.1: Inclusion/exclusion critera
to identify any need for revision.
1.3.2 Review sources
This review will be conducted using electronic searches, personal collections of articles on sample
size in CRT’s, key text books on cluster randomised trials, and discussions with experts in the field
of cluster randomised trials.
The electronic databases used in the search will be PubMed and Web of Science.
PubMed database:
The MEDLINE database is the largest component of the PubMed database. The subject scope of
searches conducted in the MEDLINE database is biomedicine and health articles dating from 1946
onwards. Articles in the MEDLINE database are indexed using Medical Subject Heading (MeSH)
terms. MeSH terms are used by indexers to provide a consistent way to index articles which may
use different terminology to describe the same concepts.
In addition to the MEDLINE database PubMed also contains additional references such as those
which are yet to be indexed with MeSH and citations that preceed the date that a journal was
selected for MEDLINE indexing.
The search terms for the electronic databases was guided by the personal collection of articles from
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Professor Sandra Eldridge. I examined the list of 41 papers available in the personal collection of
articles, appendix A.1. Thirty five of these were available via PubMed, and so, had associated MeSH
terms. One hundred and ninety nine MeSH terms were associated with these 35 papers. The most
frequent being “randomized controlled trials as Topic” (n=28), “cluster analysis” (n=20), “research
design” (n=16), and “sample size”(n=20).
Due to the wide variety of terminology we can expect to see in our target papers the use of MeSH
terms would be ideal. However it is clear that the use of MeSH terms alone would not be sufficient
to provide us with a comprehensive review of the literature. Therefore we will suppliment our search
with further search terms based on freetext.
The definition of the MeSH term “Cluster analysis” does not include reference to cluster randomised
trials 1. Instead it describes cluster analysis which is an unrelated method of analysis. However from
an examination of the search results retrieved with only this term it is clear that cluster randomised
trials have been indexed with this term. Therefore a search using the term “cluster analysis” alone
will retrieve some results irrelevant to this review. There is no alternative MeSH term for cluster
randomised trials.
Similarly a search on “randomized controlled trials as topic” will retrieve clinical trial reports, there
may also be instances where papers describe sample size calculations for clustered data which may
not be in the context of clinical trials, but could be applied to them. With these in mind I shall not
restrict the search using the MeSH term for randomised controlled trials or research design.
The MeSH terms I have therefore chosen to search on is the combination of “cluster analysis” and
“sample size”.
The freetext search will be conducted on the article title only. This is to improve the efficency of
1MeSH description of cluster analysis is “A set of statistical methods used to group variables or observations into
strongly inter-related subgroups. In epidemiology it may be used to analyse a closely grouped series of events or cases
of disease or other health related phenonomen with well-defined distribution patterns in relation to time or place or
both”
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our search by avoiding extraction of articles reporting results from clinical trials which are likely to
be identified when using a broader search strategy on title and abstract.
It is expected that the term “sample size” will be the term most frequently used in the title of
relevent articles. However the term “Design effect” is common in cluster randomised trials. The
term “power” is commonly used in discussion of sample size, however as this has a wide number of
meanings, we will retrict its search to those trials which additionaly mention clustering in some form.
The list below is a summary of the search terms for the PubMed database.
Search terms:
1. cluster analysis[MeSH] AND sample size[MeSH]
2. “sample size” [Title]
3. “design effect”[Title] OR “design effects”[Title] OR “variance inflation factor”[Title]
4. (design*[Title] OR plan*[Title] OR siz*[Title]) AND cluster*[Title] 2
5. power [title] AND cluster*[Title]
6. “intraclass correlation*”[Title] OR “interclass correlation*”[Title] OR “intracluster correla-
tion*”[Title] OR “coefficient of variation”[Title] OR “between cluster”[Title]
7. coefficient[Title] AND variation[Title]
8. (design[Title] OR matching[Title]) AND community[Title]
9. power[Title] AND correlated[Title]
10. number[Title] AND clusters[Title]
11. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10
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Monthly email notifications based on these search items will be set up within the database for the
duration of the project in order to keep informed of new developments.
Within PubMed the word “of” is a stopword and is ignored when searching for a phrase. Therefore
rather than search on the phrase “coefficient of variation” I have chosen to search on the seperate
components, as described in 7 above. Similarly with the phrase “number of clusters”.
Web of Science:
The Web of Science database contains seven citation databases. We will conduct this search using
the “Science citation index expanded database” only. This database contains articles accross 150
scientific disciplines from the year 1970.
The Web of Science does not index articles with MeSH so this search will not be performed. We
will conduct the search based upon a search of the artice titles using the free text search items as
described for the PubMed search.
Web of Science treats the word “of” as a placeholder when contained in the search for a phrase.
Therefore a search with the phrase “coefficient of variation” will retrieve all results where the two
terms are seperated by one word, such as “coefficient and variation” and “coefficient of variation”.
We shall use this search rather than the search on the two seperate components which was required
when searching Pubmed. The word “between” is similarly treated as a placeholder in Web of Science.
This means that a search on ”“between cluster” will retrieve any article with the word cluster in
the title. This retrieves a vast number of articles, with many irrelevant articles relating to disease
clusters and laborartory data. Therefore the search term “between cluster” will be excluded from
the Web of Science search.
The searches within Web of Science will additionally be refined by limiting the search to articles
2The “*” is used as a wildcard to search on all words that are formed from the truncated word entered. For example
siz* will find all words formed from siz such as “size” and “sizing”.
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only, thereby excluding conference proceedings and letters etc.
Monthly notifications based on these search items will be set up within the database for the duration
of the project in order to keep informed of new developments.
Text books:
There are currently four books on cluster randomised trials, from Donner and Klar [4], Murray [6],
Ukoumunne [8], and Hayes [5]. These will be reviewed, after the electronic search and data extrac-
tion is complete, for any methodology not already present in the review.
Expert opinion:
The following experts in the field will be approached to provide opinion on the final list of included
papers to determine their thoughts upon its coverage. This list of experts may evolve as we conduct
the review and identify other individuals making significant contributions to the field.
Obi Ukoumunne
Mike Campbell
Steven Tereenstra
G.J.P. van Breukelen
Allan Donner
1.3.3 Search strategy
The search strategy is summarised in figure 1.1.
The search terms will be implemented in the electronic databases.The title of each paper will be
examined for inclusion into the review following the inclusion/exclusion criteria described in table
1.1. If eligibility is unclear from the title, the abstract and then full text will be examined until
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eligibility is clear. Any papers where eligibility is still unclear after examination of the full text will
be discussed with Professor Sandra Eldridge and Dr Andrew Copas.
The full text will be extracted for all papers eligible for inclusion in the review.The references pro-
vided in each article will be examined for eligibility into the review following the process described
above.
We will conduct a search in both PubMed and Web of Science on the authors of each paper included
in the review and examine the results against the inclusion and exclusion criteria for potential in-
clusion into the review.
Any new eligible articles will be added to the review and the process of reference and author search-
ing will continue until it is demmed that we have reached sufficient saturation of new methodology
or concepts.
1.3.4 Validation of search methodology
We have attempted to validate the appropriateness of the proposed search strategy in two ways.
First the titles of the papers included in the personal collection were compared to our search terms
to see if the papers would have been identified from the proposed electronic search. In the majority
of cases it was found that the papers would have been identified. For those which were not identified
we examined the citations for these papers, in all cases these articles were cited by a paper that
would have been included in our review based upon the search terms. As we are searching references
of all included papers these papers would have been identified.
For our second validation technique we wanted to compare our search strategy with a “gold standard”
search. We conducted a search of the Statistics in Medicine journal as a “gold standard” search as
it was considered most likely to contain articles on methodology of sample size calculations. Using
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Figure 1.1: Flow diagram of literature search process
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PubMed all articles published in Statistics and Medicine from 1982 to March 2011 were retrieved.
Each article title was examined; any titles with reference to clustered data or cluster randomised
trials were exported. This search produced just less than 200 results. These results were then further
examined, on title alone, to reduce the list to those which would be eligible into the review or would
warrant further examination. These results were then compared to our proposed search terms to see
if they would have been identified. This highlighted the fact that there were a number of articles
about the intracluster correlation coefficient which were currently not included in our search terms.
This was added to the search terms for the review along with its alternative descriptions.
Many of the early articles made reference to community intervention trials rather than cluster ran-
domized trials, for which they are now more commonly known. The term community was added
to the search terms in combination with design or matching to pick up these articles. “Number of
clusters” was also a common phrase used to describe sample size and so was added to the search terms.
1.4 Data management
A database will be created in Microsoft Access 2010 to store and organise the details of all of the
references located as part of the systematic review.
The database contains a data entry form to allow the user to enter additional information, navigate
through the database and categorise the papers for inclusion into the review or for further follow
up or discussion. The variable names, description and entry values can be found in appendix B.1
alongside a screen print of the data entry form.
Naming conventions when exporting the results from the two electronic databases, PubMed and
Web of Science need to be standardised to ensure compatibility with each other and the Access
database. To do this the located references will first be extracted to Excel, where variable names
can be changed to those used in the Access database. The Excel files can then be directly imported
in a batch to the Access database, where each imported result will be given a unique numeric ID
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auto generated in the database.
Within web of science the following variables for each paper can be extracted in separate fields in
a format suitable for importing into Excel: title, authors, journal, publication year, volume, issue,
start page, end page, publication year, and abstract.
PubMed does not provide an easy method with which to export the search results in a format com-
patible with Excel. However they can be imported to Excel using a tool called FLink (Frequency-
weighted Links) provided by the National Center for Biotechnology information.
This tool exports the following variables for each paper into separate columns: PubMed ID; Authors,
Year of publication; month of publication; title; and a summary of all this information in one column.
Duplicates, based upon year and title of publication within the Access database will be located and
removed using the “find duplicates” query in Access. Preference for inclusion will be given to the
more detailed Web of Science entries.
For each record the user will navigate through the database, categorising the papers for inclusion or
exclusion into the review. The reason for exclusion at each stage will be recorded by the user from a
list of options which have been proposed based upon a test sample of 20 search results. Where the
list does not provide an adequate description the user may add a reason using free text.
The information missing from PubMed produced results, in particular the abstract, will only be
added to the database if the paper is eligible for the review or where abstract information is required
to aid determination of eligibility.
Once all original papers have been categorised the full text will be located for all eligible papers.
These will be stored in both hardcopy and electronic format, this may involve scanning of papers
currently not available in electronic format. paper copies will be stored in alphabetical order based
upon the surname of the first author.
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Further searches on the reference lists of each paper will be conducted by hand. As these refer-
ence lists are not always available electronically only those deemed eligible will be entered into the
database.
Further searches on the first author surname with first initial, will be conducted in both PubMed
and Web of Science and these results will be entered into the database following the methodology of
the original search.
This process will continue for new papers found until either no more additional papers are located
or it is deemed that further searching will not significantly improve the methodological coverage of
the review.
The process of data extraction to the Access database and data entry has been tested prior to the
start of the review.
1.5 Data extraction
A data extraction template will be devloped and piloted on 5 papers eligible for inclusion into the
review. The test papers were selected in order to test the extraction template on different types and
styles of article. This highlighted the need for some variation in the extraction template for different
styles of articles. All extraction templates can be found in Appendix C.
The data extraction will be mainly qualitative. The completed data extraction form will be stored
both electronically and in hard copy format with each article and will be linked to the datbase entry
through the inclusion of the database generated identification number.
The data extraction process will be validated by a double data extraction for 10 randomly selected
articles. Five will be extracted by Professor Eldridge and five by Dr Copas. A discussion will take
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place to agree any differences in interpretation.
During the data extraction process any articles with ambiguity will be discussed with SA and AC.
1.6 Synthesis of results
The results of the search strategy will be summarised in a flow diagram as in figure 1.2.
The results of the search will be provided in a narrative form. The discussion will be similarly
structured to the systematic review of organisation-based interventions in health care conducted by
OC Ukoumunne [8]. Each trial design will be discussed in turn (with equal and unequal allocation
ratio handled in turn), and within each design the methodological aspects for different outcome types
will be summarised. Proposed summary tables of the information are provided in appendix E.
• completly randomised design
– Continuous data
Analysis methods, measures of correlation, measures of cluster size
– Binary data
Analysis methods, measures of correlation, measures of cluster size
– Ordinal data
Analysis methods, measures of correlation, measures of cluster size
– Time-to-event data
Analysis methods, measures of correlation, measures of cluster size
– Count data
Analysis methods, measures of correlation, measures of cluster size
• matched-pairs design . . .
• stratfied design . . .
• Other designs (e.g. crossover, factorial) . . .
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Figure 1.2: Flow diagram of literature search results
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Database field Data type Description Field values
id Text Unique numeric identifier for paper
authors Text List of authors
year Number Year of publication
title Text Title of paper
journal Text Name of journal
volume Number Volume
issue Number Issue
bp Number Beginning page
ep Number End page
abstract Text Abstract
exc title Text Exclusion from review based on title Yes/No
exc tit reason Text Reason for exclusion based on title irrelevent subject/methodological area,
not clustered data, not related to sam-
ple size, analysis method, too general,
other
exc tit reason other Text Reason for exclusion based on title, other
exc abs Text Exclusion from review based on abstract Yes/No
exc abs reason Text Reason for exclusion based on abstract irrelevent subject/methodological area,
not clustered data, not related to sam-
ple size, analysis method, too general,
other
exc abs reason other Text Reason for exclusion based on abstract, other
exc ft Text Exclusion from review based on full text Yes/No
exc ft reason Text Reason for exclusion based on full text irrelevent subject/methodological area,
not clustered data, not related to sam-
ple size, analysis method, too general,
other
exc ft reason other Text Reason for exclusion based on full text, other
source Text Search source of paper electronic database, reference search,
author search, book, other
source other Text other source
review Text meets inclusion into the review
comment Text Comments field
Table 1.2: Data base description
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Figure 1.3: Screen print of database
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1.1 Paper details:
database ID:
Paper type: Derivation or adaptation to formulae
First Author Surname:
Year of Publication:
Journal name:
Full title:
1.2 Trial design components:
Id number for trial design:
Outcome type:
Number of groups:
Trial design:
Matching:
Allocation ratio:
Cluster size:
1.3 Formulae described:
1. Id number for trial design: 1
(a) Reference number of the relevent formula in paper or link to previously ex-
tracted formula by database id: id number for method:
(b) Re-produce formula below:
(c) List any relevent references provided for this formula:
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2. Id for trial design: 2
(a) Reference number of the relevent formula in paper or link to previously ex-
tracted formula by database id: id number for method:
(b) Re-produce formula below:
(c) Define components of formula:
(d) List any relevent references provided for this formula:
1.4 Correlation measure:
1. Id for trial design: 1
(a) Name of the term used to estimate correlation:
(b) Reference number of the relevent formula in paper:
(c) Re-produce formula below or name the method used:
(d) Define components of formula:
(e) List any relevent references provided for this formula:
2. Id for trial design: 2
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(a) Name of the term used to estimate correlation:
(b) Reference number of the relevent formula in paper:
(c) Re-produce formula below or name the method used:
(d) Define components of formula:
(e) List any relevent references provided for this formula:
1.5 Analysis method:
1. Id for trial design: 1
(a) Hypothesis to be tested:
(b) Name of the method assumed for analysis:
(c) List any relevent references provided for this method:
2. Id for trial design: 2
(a) Hypothesis to be tested:
(b) Name of the method assumed for analysis:
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(c) List any relevent references provided for this method:
1.6 Assumptions:
1. Id for trial design: 1
(a) State assumptions of the sample size methodology:
2. Id for trial design: 2
(a) State assumptions of the sample size methodology:
1.7 Strengths/weaknesses:
Describe any simulation study of the formulae provided:
Is an example of formula use provided:
1. Id for trial design: 1
(a) Provide the strengths as stated by the author: none provided
(b) Provide the weaknesses as stated by the author: none provided
2. Id for trial design: 2
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(a) Provide the strengths as stated by the author: none provided
(b) Provide the weaknesses as stated by the author: none provided
1.8 Extensions:
1. Id for extension: 1
(a) Id for trial design:
(b) Describe the extension provided:
(c) Reference number of its relevent formula in paper:
(d) Re-produce formula below:
(e) Define components of formula:
(f) List any relevent references provided for this extension:
(g) Provide the strengths of the extension as stated by the author:
(h) Provide the weaknesses of the extension as stated by the author:
2. Id for extension: 2
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(a) Id for trial design:
(b) Describe the extension provided:
(c) Reference number of its relevent formula in paper:
(d) Re-produce formula below:
(e) Define components of formula:
(f) List any relevent references provided for this extension:
(g) Provide the strengths of the extension as stated by the author:
(h) Provide the weaknesses of the extension as stated by the author:
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1.1 Paper details:
Database ID:
Type of paper: Assessment of current methodology
First Author Surname:
Year of Publication:
Journal name:
Full title:
1.2 Methods to be assessed:
1. Id number for method:
(a) Reference number of the relevent formula in paper:
(b) Re-produce or describe formula below:
(c) State assumptions of the methodology:
(d) Define components of formula:
(e) List any relevent references provided for this formula:
2. Id number for method:
(a) Reference number of the relevent formula in paper:
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(b) Re-produce or describe formula below:
(c) State assumptions of the methodology:
(d) Define components of formula:
(e) List any relevent references provided for this formula:
1.3 Simulated data:
1. Id for simulation:
(a) Objective of the simulation:
(b) Model used to simulate the data:
(c) simulation method: Monte Carlo simulations
(d) Range of variables used in the simulations:
(e) Procedure:
(f) Results:
2. Id for simulation:
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(a) Objective of the simulation:
(b) Model used to simulate the data:
(c) simulation method:
(d) Range of variables adjusted in the simulations:
(e) Procedure:
(f) Results:
1.4 Conclusions and Recommendations:
1. Provide the recommendations as stated by the author:
1.5 Strengths/weaknesses:
1. Provide the strengths as stated by the author:
2. Provide the weaknesses as stated by the author:
1.6 Extensions:
1. Id for extension:
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(a) Describe the extension provided:
(b) Reference number of its relevent formula in paper:
(c) Re-produce formula below:
(d) Define components of formula:
(e) List any relevent references provided for this extension:
(f) Provide the strengths of the extension as stated by the author:
(g) Provide the weaknesses of the extension as stated by the author:
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Appendix E: Proposed tables
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Data Type: Analysis Methods: Corresponding
database ID:
Continuous
Binary
Ordinal
Time-to-event
Count
Table 1.3: Completely randomised design, equal allocation: Description of analysis methods
assumed in sample size calculations
Data Type: Measure of correlation: Corresponding
database ID:
Continuous
Binary
Ordinal
Time-to-event
Count
Table 1.4: Completely randomised design, equal allocation: Description of measures of cor-
relation used in sample size calculations
Data Type: Measure of cluster size: Corresponding
database ID:
Continuous
Binary
Ordinal
Time-to-event
Count
Table 1.5: Completely randomised design, equal allocation: Description of measures of cluster
size used in sample size calculations
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Reporting of sample size calculations in cluster randomised trials. 
Data Abstraction form 
   
Note: Items previously abstracted will be automatically uploaded to the abstraction 
Access database.   
 
1. Study ID (this is the Medline UID number – also the pdf file name)  
2. Reviewer name  
3. Publication year  
4. Journal name  
 
Study Design 
 
Note: For items colored in black the data have been collected previously and will not be 
re-abstracted, although in some cases described below data may need to be updated.  
These items will be automatically uploaded to the abstraction Access database.  They are 
included here to ensure consistency in abstraction of other data, for example when 
talking about the primary outcome, and also included for completeness of information 
regarding sample size reporting. 
 
5. Were primary outcome measure(s) identified by authors? (Authors clearly distinguished 
between main (or primary) and secondary outcomes measures?) (Note: Not acceptable if authors 
merely stated primary objectives without operationalizing in terms of specific variables.) 
1 Yes (specify number)  
2 No 
 
6. For quality control purposes, state the single primary outcome identified during the 
initial review.  NOTE: when multiple outcomes are specified by authors, the main 
outcome will be the first outcome stated in the abstract or the analysis. 
 
 
 
7. If a sample size calculation is not presented for the outcome described in Q6, state the 
single outcome that the sample size calculation has been performed for and data 
abstraction will be based on.  (Note: if more than one outcome possible, choose the first outcome 
described.) 
 
 
  Same as 
above 
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8. Trial design at cluster-level: 
1 Parallel trial (clusters independently randomized to different treatments with or 
without pre-test) 
2 Factorial trial (specify factors and levels) (e.g., 2x2)  
3 Cross-over trial 
4 Other (specify) (e.g., latin squares, split-plot, stepped wedge)  
 
9. Method of random allocation: 
1 Completely randomized design (unrestricted randomization) 
2 Stratified design  
3 Pair-matched design 
4 Other (specify) (e.g., minimization algorithm)  
 
10. Trial design at patient-level (primary outcome): 
1 Nested cross-sectional design (each patient measured only once or different 
patients measured each time point) 
2 Nested cohort design (same patients measured at different time points or in 
continuous surveillance) (NOTE: Patient-level attrition is possible in a cohort design but 
NOT in a cross-sectional design) 
3 Primary outcome evaluated on both cross-sectional and cohort 
components 
 
11. Number of study arms (we need to know if there were multiple intervention or control arms so 
that patient numbers can be divided up appropriately when assessing imbalances): 
a) Intervention arms  
b) Control arms  
 
 
Sample size 
 
Note: The data collected in this section should be based upon the sample size outcome as 
defined in Q7.  Where this is different from Q6 please update previously abstracted data 
i.e. Q12 for this section. 
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12. Sample size / power calculations presented? 
1 Not presented or presented for substudy or outcome regarded as 
secondary only 
2 Patient-level accounting for ICC (“Sample size was based on a 
significant effect size of 0.5, incorporated an ICC of 0.05 and was based on 
enrollment of 4 patients per physician”; “Based on a mean (SD) number of 
admission days per resident enrolled, within cluster variance of 2 days and 
between-cluster variance of 3 days and 10 residents per nursing home”. 
Usually will involve stating at least the average cluster size and the ICC/ 
design effect/ overdispersion factor/within-and between-cluster variance or 
stated that accounting for clustering without reporting value of ICC.) 
3 Cluster-level (Should be clear that cluster-level summary data are used for 
calculation e.g., “sample size was based on the hospital as the unit of 
analysis…assuming a rate of episiotomy of 42% at baseline, with a standard 
deviation of 15%, we need 18 hospitals to identify a decrease in episiotomy 
rate.” Use of standard deviation in the case of proportions indicates that binary 
data was summarized at cluster-level and treated as continuous data for the 
purpose of sample size calculation.) 
4 Patient-level without accounting for ICC (usually difficult to tell 
whether at patient- or cluster-level unless specifically stated) 
5 Unclear whether at patient- or cluster-level or whether accounted 
for clustering (e.g., “sample size was calculated to give a power of 80% of 
detecting a difference of 1 SD at 5% significance in mean diagnosis 
concordance score”; “sample size of 500 participants would result in 80% 
power to detect a difference of 10 points between groups”) 
6 Other (specify) (e.g., based on intermediate level of clustering)  
 
 
Note:Questions 13-29 are not applicable for papers which do not report a sample size 
calculation. Not applicable will be automatically generated in the database for all the 
relevant papers, based upon the answer to question 12. Those where question 12 is 
updated will be updated manually 
 
13.  Describe the method or citation of sample size calculation that has been used (for 
example: Hsieh, Donner and Klar, Hayes and Bennett, standard two-sample t-test adjusted for 
clustering): 
 
 
 
14. What type of data has been assumed for the sample size calculation? (Note: this question 
aims to address any occasions where ordinal or count data may have analyzed as a dichotomous or 
continuous variable for simplicity.) 
1 Binary (two categories) 
2 Categorical  
(more than two categories, but no natural ordering to the categories) 
 
3 Ordinal (more than two ordered categories) 
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4 Continuous (normal or non-normal)  
5 Count data  
6 Time to event data  
7 Unclear  
8 Other  
9 Not applicable  
 
 
15. What is the type I error rate that has been assumed for the sample size calculation? 
1 5% 
2 1%  
3 Unclear or not stated  
4 Other  
5 Not applicable  
 
 
16. What is the power (1 minus the Type II error rate) that has been assumed for the 
sample size calculation? (Note: record "at least 80%" as 80%). 
1 80% 
2 90%  
3 Unclear or not stated  
4 Other  
5 Not applicable  
 
 
17. Does the sample size calculation assume a one or two-sided test? 
1 1-sided 
2 2-sided  
3 Unclear or not stated  
4 Other  
5 Not applicable  
 
 
18. How is correlation within clusters described in the sample size calculation? 
1 Intracluster correlation 
2 Coefficient of variation  
3 Unclear or not stated  
4 Other (for example between and within cluster variance)  
5 Not applicable (i.e. sample size does not account for clustering 
or sample size calculation is at cluster level) 
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19. State the value of the assumed correlation 
 
 
  Not provided/Not Applicable 
 
20. Does the sample size account for attrition (either of clusters or individuals)? NOTE: 
if not stated then assume “no”. 
1 Yes 
2 No  
3 Unclear   
4 Other  
5 Not applicable  
 
 
21. Does the sample size account for cluster size imbalance? NOTE: if not stated (even if 
the calculation was at cluster level) then assume “no”. 
 
1 Yes 
2 No  
3 Unclear   
4 Other  
5 Not applicable  
 
 
22. Justification for the ICC or other correlation measure assumed in the sample size 
calculation: 
1 No justification  
2 Results from a previous trial   
3 A preliminary/pilot study  
4 Observational data  
5 Results from a systematic review  
6 Baseline data  
7 Other (please explain)  
8 Not Applicable  
 
23. Justification for the control group effect (e.g., proportion, mean or standard deviation) 
assumed in the sample size calculation: 
1 No justification  
2 Results from a previous trial   
3 A preliminary/pilot study  
4 Observational data  
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5 Results from a systematic review  
6 Baseline data  
7 Other (please explain)  
8 Not applicable  
 
24. Justification for the treatment group effect (e.g., proportion, mean or standard 
deviation) assumed in the sample size calculation: Where multiple treatment groups, quote 
the values for the treatment group which produced/drove the sample size requirement.   
1 No justification  
2 Analogy to another trial or treatment  
3 Clinical relevance  
4 Observational data  
5 Results from a systematic review  
6 Other (please explain)  
7 Not applicable  
 
 
25. State the target total number of clusters required for the analysis. (Note: this is before 
adjustments for attrition.) 
 
 
  Not provided/unclear 
 
26. State the target total number of individuals. (Note: this may need to be calculated: e.g., 
number of clusters multiplied by average cluster size.) 
 
 
  Not provided 
/unclear 
  NA (e.g., sample 
size calculation is 
at cluster level) 
 
27. Assumed effect in the control arm: (Note: for dichotomous and time-to-event outcomes, 
provide the rate of events; for continuous outcomes, provide the mean and standard deviation.)  
 
Proportion 
 
 
  Not provided/unclear 
 
Mean         Standard deviation 
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28. Assumed effect in the treatment arm: (Note: for dichotomous and time-to-event outcomes, 
provide the rate of events; for continuous outcomes, provide the mean and standard deviation. Where 
multiple treatment groups, quote the values for the treatment group which produced/drove the sample 
size requirement.  With papers that do not provide a SD for the treatment arm, we will assume a 
common standard deviation)  
 
Proportion 
 
 
  Not 
provided/unclear 
 
Mean         Standard deviation (if SD not stated, enter the same value as for the 
control arm) 
 
 
   
 
Note: Q29 is only to be completed if Q27 and Q28 are incomplete and only a 
standardized effect size has been provided. 
 
29. State the standardized effect size if provided (e.g.,  the difference in means divided by 
the standard deviation, Relative Risk, or Odds Ratio): 
 
Effect size 
 
 
  Not provided/Not 
applicable 
 
Specify the type of effect (e.g., difference in means, Relative Risk, Odds Ratio) 
 
 
 
 
 
Analysis 
 
Note: The data collected in this section should be based upon the sample size outcome as 
defined in Q7.  Where this is different from Q6 please update previously extracted data 
i.e. Q32 and Q40 for this section. 
 
30. State the total number of clusters used in the analysis of the sample size outcome. 
(Note: try to limit the use of the “unclear” option.) 
 
 
  Not 
provided/unclear 
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31. State the total number of individuals used in the analysis of the sample size outcome. 
(Note: try to limit the use of the “unclear” option.) 
 
 
  Not 
provided/unclear 
 
 
32. Analysis for sample size outcome: (NOTE: primary and sample size outcome will be the same 
if 6 and 7 are the same) 
1 At patient-level accounting for ICC (e.g., using mixed-effects 
logistic regression, GEE taking account of clustering by physician, Chi-
square statistic adjusted for clustering, random effect for physician, 
hierarchical modeling, multi-level modeling, alternating logistic 
regression) 
2 At cluster-level (clearly stated that analysis at cluster-level, e.g., 
“analyses performed using patient-level variables aggregated at the 
provider-level”, analysis was based on hospital rates, t-test weighted by 
inverse variance etc.) 
3 At patient-level not accounting for ICC (more difficult to 
distinguish, e.g., multivariable regression analysis of patient-level data 
with no mention of clustering, or standard 2-sample test on patient-
level data without mention clustering or stated that since ICCs were 
low, clustering was ignored in presentation of results)  
4 Unclear whether at patient-level or cluster-level or whether 
accounted for clustering  
5 Other (specify) (e.g., based on intermediate level of clustering, both 
individual-level and cluster-level analyses used for primary outcome 
analysis) 
 
 
33. Describe the analysis method or citation (e.g. adjusted two-sample test, permutation 
test, GEE, hierarchical model): 
 
 
 
 
34. What type of data is the raw sample size outcome at the level (cluster or individual) 
corresponding to the analysis? (Note: this is a description of the data as it was measured, 
regardless of how it may have been treated at sample size or analysis stages.)  
1 Binary (two categories) 
2 Categorical 
 (more than two categories, but no natural ordering to the categories) 
3 Ordinal (more than two and  <7 ordered categories) 
4 Continuous, normal or non-normal  
5 Count data  
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6 Time to event data  
7 Unclear  
8 Other (specify)  
 
 
35. How has the data for the sample size outcome been used for the analysis? 
1 Binary (two categories) 
2 Categorical  
(more than two categories, but no natural ordering to the categories) 
3 Ordinal (more than two ordered categories) 
4 Continuous, normal or non-normal  
5 Count data  
6 Time to event data  
7 Unclear  
8 Other (specify)  
 
36. State the value of the observed intracluster correlation for the sample size outcome 
(or tick if not provided) 
 
 
  Not 
provided 
 
 
37. Observed effect in the control arm: (Note: for dichotomous and time-to-event outcomes, 
provide the rate of events; for continuous outcomes, provide the mean and standard deviation. Where 
multiple time-points are given use the time-point corresponding to the sample size calculation; if not 
provided use the final time-point.) 
Proportion 
 
 
  Not 
provided 
 
Mean             Standard deviation 
 
 
   
 
 
38. Observed effect in the treatment arm: (Note: for dichotomous and time-to-event outcomes, 
provide the rate of events; for continuous outcomes, provide the mean and standard deviation. Where 
multiple treatment groups, please quote the values for the treatment group which produced the sample 
size requirement, or the treatment group producing the largest difference).  
 
Proportion 
   Not provided 
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Mean        Standard deviation 
 
 
   
 
 
 
 
 
 
 
Note: Q39 is only to be completed if Q37 and Q38 are incomplete and only a 
standardized effect size has been provided. 
 
39. State the unadjusted effect size if provided (e.g.,  the standardized difference in 
means, Relative Risk, or Odds Ratio): 
Effect size 
 
 
  Not provided/Not 
applicable 
 
Specify the type of effect (e.g., standardized difference in means, Relative Risk, 
Odds Ratio) 
 
 
 
 
40. Is the sample size outcome reported as statistically significant?  
1 Yes 
2 No 
 
41. Do authors reference a separate publication which may provide further details on 
items required in this data abstraction form?  (Note: If yes, please refer to the separate 
publication to complete this abstraction form.) 
1 
Yes 
2 
No 
 
 
Comments: 
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log using "de_simulations.log",replace 
*program drop s_cluster_ologit 
program define s_cluster_ologit,rclass 
syntax, CLUSTERSPERGRP(integer) SIGMAV(real) CSIZE(integer)   
drop _all 
clear 
 
set obs `=2*`clusterspergrp'' 
gen group=mod(_n,2) 
 
gen b2=-0.52*sqrt(1+`sigmav') 
 
 
*cluster level errors are normally distributed N(0,sigma^2 v) 
gen ybar=rnormal(b2*group,sqrt(`sigmav')) 
 
gen clusterid=_n 
expand `csize' 
gen outcome=rnormal(ybar,1) 
gen outcome_normal=(outcome)/(sqrt(1+`sigmav')) 
 
gen ordinal=1 if outcome_normal<=-.84162123 
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replace ordinal=2 if outcome_normal<=.52440051 & ordinal==. 
replace ordinal=3 if outcome_normal<=1.2815516 & ordinal==. 
replace ordinal=4 if outcome_normal>1.2815516 & ordinal==. 
 
tab ordinal group,col matcell(freqs) 
 
return scalar cat1_group0=(freqs[1,1]/(`clusterspergrp'*`csize'))*100 
return scalar cat2_group0=(freqs[2,1]/(`clusterspergrp'*`csize'))*100 
return scalar cat3_group0=(freqs[3,1]/(`clusterspergrp'*`csize'))*100 
return scalar cat4_group0=(freqs[4,1]/(`clusterspergrp'*`csize'))*100 
 
return scalar cat1_group1=(freqs[1,2]/(`clusterspergrp'*`csize'))*100 
return scalar cat2_group1=(freqs[2,2]/(`clusterspergrp'*`csize'))*100 
return scalar cat3_group1=(freqs[3,2]/(`clusterspergrp'*`csize'))*100 
return scalar cat4_group1=(freqs[4,2]/(`clusterspergrp'*`csize'))*100 
 
 
xtset clusterid 
capture noisily { 
     xtoprobit ordinal group 
      return scalar p=2*normal(-abs(_b[group]/_se[group])) 
    return scalar p_t=2*t(2*`clusterspergrp'-2,-abs(_b[group]/_se[group])) 
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   matrix b=e(b) 
  return scalar coef=round(b[1,1],0.001) 
  return scalar cor_icc_ord=e(sigma_u)^2/(e(sigma_u)^2+(1)) 
    
**Alternative ICC estimates 
 
*anova-assuming scale assigned to ordinal outcome with equal distance 
loneway ordinal clusterid 
oneway ordinal clusterid 
*calculate the ICC myself as Stata automatically truncates at 0 
return scalar icc_ordinal_anova=((r(mss)/r(df_m))-
(r(rss)/r(df_r)))/((r(mss)/r(df_m))+(`csize'-1)*(r(rss)/r(df_r))) 
 
} 
 
end 
 
clear 
 
simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
, saving(pow1) reps(1001) seed(421892): s_cluster_ologit,clusterspergrp(20) 
sigmav(0.01) csize(5)  
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simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
,saving(pow2) reps(1001) seed(136787): s_cluster_ologit,clusterspergrp(25) 
sigmav(0.09) csize(5)  
simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
,saving(pow3) reps(1000) seed(0034525): s_cluster_ologit,clusterspergrp(30) 
sigmav(0.19) csize(5)  
simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
, saving(pow4) reps(1000) seed(422101): s_cluster_ologit,clusterspergrp(35) 
sigmav(0.33) csize(5)  
simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
, saving(pow5) reps(1000) seed(5359235): s_cluster_ologit,clusterspergrp(54) 
sigmav(1.13) csize(5)  
 
simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
, saving(pow6) reps(1002) seed(32124): s_cluster_ologit,clusterspergrp(11) sigmav(0.01) 
csize(10)  
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simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
,saving(pow7) reps(1000) seed(689987): s_cluster_ologit,clusterspergrp(16) 
sigmav(0.09) csize(10)  
simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
,saving(pow8) reps(1000) seed(123434): s_cluster_ologit,clusterspergrp(22) 
sigmav(0.19) csize(10)  
simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
, saving(pow9) reps(1000) seed(494329): s_cluster_ologit,clusterspergrp(28) 
sigmav(0.33) csize(10)  
simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
, saving(pow10) reps(1000) seed(56024): s_cluster_ologit,clusterspergrp(49) 
sigmav(1.13) csize(10)  
 
simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
, saving(pow11) reps(1003) seed(7458): s_cluster_ologit,clusterspergrp(3) sigmav(0.01) 
csize(50)  
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simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
,saving(pow12) reps(1000) seed(96456): s_cluster_ologit,clusterspergrp(9) sigmav(0.09) 
csize(50)  
simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
,saving(pow13) reps(1000) seed(79002): s_cluster_ologit,clusterspergrp(15) 
sigmav(0.19) csize(50)  
simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
, saving(pow14) reps(1000) seed(57477): s_cluster_ologit,clusterspergrp(22) 
sigmav(0.33) csize(50)  
simulate  anova_ordinalicc=r(icc_ordinal_anova) pvalue=r(p)  pvaluet=r(p_t)  trt=r(coef)  
icc_ordmodel=r(cor_icc_ord) cat1_group0=r(cat1_group0) cat2_group0=r(cat2_group0) 
cat3_group0=r(cat3_group0) cat4_group0=r(cat4_group0) cat1_group1=r(cat1_group1) 
cat2_group1=r(cat2_group1) cat3_group1=r(cat3_group1) cat4_group1=r(cat4_group1) 
, saving(pow15) reps(1000) seed(222234): s_cluster_ologit,clusterspergrp(45) 
sigmav(1.13) csize(50)  
 
 
log close 
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POSTER PRESENTATION Open Access
Inadequate reporting of sample size calculations
in cluster randomised trials: a review
Clare Rutterford1*, Monica Taljaard2, Stephanie Dixon3, Andrew Copas4, Sandra Eldridge1
From 2nd Clinical Trials Methodology Conference: Methodology Matters
Edinburgh, UK. 18-19 November 2013
Objectives
To assess the adequacy of reporting sample size calcula-
tions in published cluster randomised trials (CRTs) and to
evaluate the accuracy and justifications behind the a priori
estimates used.
Methods
A review was conducted of 166 CRTs reporting sample
size calculations published between 2000 and 2008. Each
trial was reviewed independently by two statisticians. The
adequacy of the reporting of key elements in the
CONSORT recommendations for CRTs was evaluated.
Comparisons were made between the authors’ a priori
assumptions and values then observed in the trial.
Results
Of 166 trials, only 56 (34%) reported all key elements of
sample size calculations in line with CONSORT recom-
mendations. Elements specific to CRTs were the worst
reported: the number of clusters or average cluster size
was specified in only 94 (57%) and a measure of intraclus-
ter correlation coefficient (ICC) in only 86 (52%). Only 20
papers (12%) reported a priori and observed ICC values.
In the majority of these reports, the a priori estimate for
the ICC was conservative compared to the observed value.
Few authors provided justifications for their choice of a
priori estimates. Not unexpectedly, trials which reported
no statistically significant difference were more likely to
observe effect sizes smaller than the assumed clinically
important difference.
Conclusions
Even with the CONSORT extension to CRTs, the
reporting of sample size calculations in CRTs remains
below that necessary for transparent reporting. Further
awareness is needed to encourage the reporting of
observed ICCs in order to evaluate the choice of a priori
estimates and interpret the trial results.
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INTRODUCTION 
 
 Transparent reporting of the sample size 
calculation is important to show that a trial 
is designed to adequately address the 
research question 
 
 Without transparent reporting the results 
from trials that may be well conducted 
risk having little impact 
 
 The CONSORT statement extension for 
cluster randomised trials (CRTs)1,2 
describes five required elements for the 
transparent reporting of sample size 
calculations.  These include whether/how 
the sample size calculation accounted for 
within cluster correlation. Failure to account 
for clustering in the calculation risks an 
increased Type II error rate 
 
 Using a large sample of published cluster 
randomised trials we review the adequacy 
of sample size reporting in cluster 
randomised trials 
 
Figure 2: Trials with non-significant results have 
larger target difference a-priori 
CONCLUSIONS 
 
 Sample size elements specific to CRTs 
were the worst reported.  There was no real 
improvement seen in the years post 
CONSORT (2005-08) 
 
 55% of trials reported a sample size 
calculation. Of these, only 55%  clearly 
accounted for clustering 
 
 Additional adjustments for attrition and 
variable cluster sizes were made in only 38 
(23%) and 1(1%) of trials.  Failure to 
consider these may lead to an 
underestimate of the sample size required 
 
 The observed treatment difference was 
often smaller than the a-priori target 
difference.  This could be because 
interventions are very often ineffective or 
because in some cases investigators 
choose inappropriately large target 
differences.  Similar discrepancies have 
been seen in individually randomised trials4 
RESULTS 
 
RECOMMENDATIONS 
 
 Journals and peer reviewers should 
implement stricter requirements for authors 
to follow the CONSORT statement and its 
extensions 
 
 More consideration should  be given to the 
choice of the target difference in the 
sample size calculation  
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METHODS 
 
Data source: A previously published3 review 
of 300 published reports of CRTs in primary 
care and public health from 2000-2008  
 
Data abstraction for each trial included:  
 The estimates reported within the sample 
size calculation for target difference, power, 
type I error, number of clusters, and within 
cluster correlation 
 The sample size methodology used  
 The observed values of the estimates at 
the end of the trial 
 
Data validation: Data abstraction was 
conducted independently in pairs (by CR, MT 
and SD) and discrepancies were resolved by 
consensus 
 
Data Analysis:  
 Proportions reporting each CONSORT 
required sample size element 
 Summary of sample size methodology used 
 Discrepancies between a-priori estimates 
and observed data summarised 
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Figure 1: CONSORT required elements specific 
to cluster randomisation are worst reported 
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All results (N=133) Significant (N=71) Non significant (N=62)
Sample size method 
 
N 
166 
% 
55 
Patient level accounting for correlation  91   55 
Cluster level 9  5 
Patient level without accounting for 
correlation 
48  29 
Unclear /Other 18  11 
Accounted for attrition 38  23 
Accounted for variable cluster sizes 1  1 
Table 1: Sample size methodology practices for 
55% of trials that reported a calculation  
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ORAL PRESENTATION Open Access
A review of methodology for sample size
calculations in cluster randomised trials
Clare Rutterford1*, Sandra Eldridge1, Andrew Copas2
From Clinical Trials Methodology Conference 2011
Bristol, UK. 4-5 October 2011
Objectives
To produce a thorough review of the existing state of
knowledge on sample size calculations for cluster rando-
mised trials (CRT’s) and to identify gaps in the
knowledge.
Methods
A systematic review is being conducted of sample size
methodology for cluster randomised trials. The sources
for the search include electronic databases PubMed and
Web of Science, key text books on cluster randomised
trials and discussions with experts in the field.
The search strategy involves a compliment of Medical
Subject Headings and free text terms to aid a compre-
hensive search. The references of papers eligible for the
review will also be searched and a search on the first
author conducted. This process will continue until no
more additional papers are located.
This work forms the beginning of a PhD research
project.
Results
Of 8697 citations obtained from PubMed and Web of
Science, the majority have currently been assessed for
eligibility into the review and 57 papers so far identified
for inclusion.
The majority of papers discuss sample size for contin-
uous or binary outcomes, with four papers discussing
time to event outcomes. In terms of the analysis method
used, most assume a random effects analysis (cluster
specific approach) or a cluster level analysis, with fewer
papers assuming a generalized estimating Equation
(population averaged approach) methodology.
An emerging theme, discussed in six papers, is sample
size methodology for 3-level cluster randomised trials,
where we may randomise clinics (level 3) and each clinic
will treat multiple subjects (level 2 units) who in turn
are measured on repeated occasions (level 1 units).
Eight papers consider sample size calculations for
trials with varying cluster sizes. These papers account
for the loss in power due to varying cluster sizes
through an examination of the relative efficiency of
unequal versus equal cluster sizes or by proposing an
appropriate design effect to account for this loss for
both continuous and binary outcomes.
Sample size for alternative trial designs such as cross-
over trials, stepped wedge designs, testing for non-infer-
iority, stratified, and matched designs were identified.
Papers covering adjustments to sample size for dealing
with non-compliance or attrition, accounting for the use
of cluster or person level covariates and dealing with
imprecision in the estimate of the intracluster correla-
tion coefficient (ICC) were identified.
Conclusion
We will provide the results of the search and prelimin-
ary insight into potential gaps in the knowledge.
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1):A23.
1Centre for Primary Care and Public Health, Queen Mary University of
London, London, E1 2AB, UK
Full list of author information is available at the end of the article
Rutterford et al. Trials 2011, 12(Suppl 1):A23
http://www.trialsjournal.com/content/12/S1/A23 TRIALS
© 2011 Rutterford et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
325
APPENDIX viii: Oral presentations
                              
   
 
CLINICAL EPIDEMIOLOGY SEMINAR/ROUNDS 
PRESENTATION 
 
 
 
Ms. Clare Rutterford 
                         Statistician 
                 Centre for Primary Care and Public Health 
                  Blizard Institute 
                London, UK 
 
 
Title:  An Introduction to Cluster 
Randomised Trials (CRTs) and a Review of 
Sample Size Reporting Practices 
 
 
Clare’s Bio:  Since completing a BSc in Mathematics and Applied Statistics (Reading 
University, 2003) and an MSc in Statistics with Applications in Medicine (Southampton 
University, 2004), Clare has worked as a clinical trials statistician across a variety of health 
areas; HIV, mental health, domestic violence, and neurological conditions.  She is also a module 
organiser on the distance learning MSc in Clinical Trials run by the London School of Hygiene 
and Tropical Medicine (LSHTM). 
Clare is based within the Pragmatic Clinical Trials Unit (PCTU) at Queen Mary University of London. In 
2011, under the supervision of Professor Sandra Eldridge and Dr Andrew Copas (MRC London Hub 
for Trials Methodology Research) Clare started working towards completion of a PhD. The aim of her 
PhD is to comprehensively review the existing state of knowledge of sample size calculation for cluster 
randomised trials and to focus on developing appropriate, and if possible easily accessible, sample 
size formulae for ordinal, count or time to event outcomes in cluster randomised trials. 
 
 
 
Date:  Friday, June 21, 2013 
Time:  12:00pm – 1:00pm 
    Locations: 
 General Campus – Centre for Practice Changing Research (CPCR)  Seminar 
Room L1111 
(Speaking from General Campus) 
 Civic Campus – Loeb Conference Room #3 
 
 
Next Rounds: June 21, 2013 
Videoconference to all locations 
Pizza lunch available at the Civic and General Campus 
Attached:  CEP Rounds Schedule for 2013 and Poster 
Please note you are receiving this notice as you are included on the OHRI CEP ALL distribution list and also by request. 
Sponsored by:  University of Ottawa, Department of Epidemiology, The Ottawa Hospital Research Institute and CHEO Research Institute 
The Clinical Epidemiology Seminar/Round is a self-approved group learning activity (Section 1) as defined by the Maintenance of 
Certification program of the Royal College of Physicians and Surgeons of Canada 
 
 
326
Sample size calculation for cluster randomised trials with ordinal 
outcomes 
Clare Rutterford
1
, Andrew Copas
2
, Sandra Eldridge
1 
1
 Centre for Primary Care and Public Health, Blizard Institute, Barts and The London School of Medicine and Dentistry, 
Yvonne Carter Building, 58 Turner Street, London, E1 2AB. 
2 Hub for Trials Methodology Research, MRC Clinical Trials Unit at University College London, United Kingdom  
Contact details: 
Clare: Telephone: 020 7882 2518, c.m.rutterford@qmul.ac.uk 
Sandra:  Telephone: 020 7882 2519, s.eldridge@qmul.ac.uk 
Andrew: anc@ctu.mrc.ac.uk 
Conference stream: Medical/biometrics/clinical trials 
 
Presenter biography 
After completing a BSc in Mathematics and Applied Statistics (Reading University, 2003) and 
an MSc in Statistics with Applications in Medicine (Southampton University, 2004), Clare spent 
two years as a statistician at the Medical Research Council Clinical Trials Unit, London, working 
on a large phase III HIV prevention trial, part of the Microbicides Development Programme. In 
2007 Clare joined the Clinical Trials Unit at the Institute of Psychiatry, London, where she was 
the trial statistician for several randomised controlled trials in the areas of dementia, forensic 
mental health, Attention Deficit Hyperactivity Disorder, and neurological conditions. 
She joined the Centre for Primary Care and Public Health in March 2009. Since October 2009 
Clare has also been a module organiser on the distance learning MSc in Clinical Trials run by 
the London School of Hygiene and Tropical Medicine. 
In 2011, under the supervision of Professor Sandra Eldridge (Centre for Primary Care and 
Public Health) and Dr Andrew Copas (MRC London Hub for Trials Methodology Research) Clare 
started working towards completion of a PhD. The aim of her PhD is to comprehensively 
review the existing state of knowledge of sample size calculation for cluster randomised trials 
and to focus on developing appropriate, and if possible easily accessible, sample size formulae 
for ordinal, count or time to event outcomes in cluster randomised trials. 
Intended audience 
This talk is intended for statisticians who are involved in trials or have an interest in sample size 
calculations and/or the use of ordinal outcomes.  
APPENDIX viii: Oral presentations
327
Abstract (max 250 words) 
Background 
A common approach to sample size calculation for cluster randomised trials is to calculate 
the sample size assuming individual randomisation and multiply this by the design effect. 
Calculation of the design effect requires knowledge of the cluster size and intracluster 
correlation coefficient (ICC), a measure of the extent of clustering. It is not yet clear how well 
the design effect method works for ordinal outcomes. 
Objectives 
To evaluate the performance of the design effect approach in sample size calculation for 
cluster randomised trials with ordinal outcomes and to provide recommendations for the 
calculation of the ICC. 
Methods 
The performance of the design effect method was evaluated across a range of scenarios, 
chosen to reflect the characteristics of trials using ordinal outcomes. 
For each scenario sample size was calculated using the design effect approach with three 
alternative estimators for the ICC: an ANOVA based estimate, a Kappa type estimate and 
the ICC on the assumed underlying continuous outcome.  A thousand datasets of 
appropriate size were generated and each analysed via a random-effects model. Empirical 
power was calculated as the proportion of datasets with significant result. 
The simulation studies were extended to explore performance under alternative analysis 
methods and variable cluster sizes. 
Conclusions 
The use of the design effect works well with ordinal data, except in the case of a small 
number of clusters.  Power calculations using the ANOVA estimate of the ICC performed 
adequately, and that ICC is simple to calculate. 
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Clare Rutterforda,*, Monica Taljaardb,c, Stephanie Dixond, Andrew Copase, Sandra Eldridgea
aCentre for Primary Care and Public Health, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London,
Yvonne Carter Building, 58 Turner Street, London E1 2AB, UK
bClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa Hospital, Civic Campus, 1053 Carling Avenue, Civic Box 693,
Ottawa, Ontario K1Y 4E9, Canada
cDepartment of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
dDepartment of Epidemiology and Biostatistics, Schulich School of Medicine and Density, University of Western Ontario, 1151 Richmond St, London,
Ontario N6A 3K7, Canada
eHub for Trials Methodology Research, MRC Clinical Trials Unit at University College London, Aviation House, 125 Kingsway, London, WC2B 6NH, UK
Accepted 17 October 2014; Published online 15 December 2014
Abstract
Objectives: To assess the quality of reporting and accuracy of a priori estimates used in sample size calculations for cluster randomized
trials (CRTs).
Study Design and Setting: We reviewed 300 CRTs published between 2000 and 2008. The prevalence of reporting sample size ele-
ments from the 2004 CONSORT recommendations was evaluated and a priori estimates compared with those observed in the trial.
Results: Of the 300 trials, 166 (55%) reported a sample size calculation. Only 36 of 166 (22%) reported all recommended descriptive
elements. Elements specific to CRTs were the worst reported: a measure of within-cluster correlation was specified in only 58 of 166 (35%).
Only 18 of 166 articles (11%) reported both a priori and observed within-cluster correlation values. Except in two cases, observed within-
cluster correlation values were either close to or less than a priori values.
Conclusion: Even with the CONSORT extension for cluster randomization, the reporting of sample size elements specific to these trials
remains below that necessary for transparent reporting. Journal editors and peer reviewers should implement stricter requirements for au-
thors to follow CONSORT recommendations. Authors should report observed and a priori within-cluster correlation values to enable com-
parisons between these over a wider range of trials.  2015 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Keywords: CONSORT statement; Reporting; Cluster randomized trial; Sample size; Intracluster correlation coefficient; Statistical methods
1. Introduction
In a cluster randomized trial (CRT), groups or ‘‘clusters,’’
rather than the constituent individuals themselves, are
randomly allocated to interventions [1,2]. A cluster could
be, for example a medical practice, hospital, or community.
Cluster randomization may be deemed necessary when
randomization at individual level is impractical, for example,
when the intervention is necessarily administered at the clus-
ter level. There can also be scientific reasons to adopt cluster
randomization, for example to avoid contamination between
treatment groups or for reasons of administrative conve-
nience or cost. In aCRT, the responses from different individ-
uals within the same cluster are usually more similar than
those from different clusters. The degree of this correlation
is commonly quantified by the intracluster correlation coeffi-
cient (ICC) but can also be quantified using the coefficient of
variation of the outcome, often referred to as k [3]. Sample
size calculations for CRTsmust take correlation into account
to avoid potentially underestimating the required sample
size. Donner et al. [4] proposed that a sample size calculated
assuming individual randomization can be inflated by a
design effect (DE) to reach the required level of statistical
power under cluster randomization. This DE is.
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tion, analysis, or interpretation of data; writing of the manuscript; or in the
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What is new?
 This is the first article to evaluate sample size re-
porting prevalence for each of the CONSORT
2004 recommended sample size descriptive ele-
ments for cluster randomized trials (CRTs).
 There is much room for improvement in sample
size reporting. Sample size elements specific to
CRTs were the worst reported.
 Comparisons between a small sample of a priori
estimates and observed values of the within-
cluster correlation show the a priori estimates to
be reasonably accurate.
 There seems to be a discrepancy between endorse-
ment of CONSORT by journals and implementa-
tion by authors.
 We recommend journals to consider making adher-
ence to CONSORT guidelines and extension state-
ments a condition of publication.
DE51þ ðn 1Þr
where n is the number of individuals per cluster and r the
ICC. For example, using this formula, a trial with 35 indi-
viduals per cluster and an anticipated ICC of 0.01 would
require 34% more participants than the equivalent individ-
ually randomized design. When cluster sizes are unequal, n
is usually replaced by the average cluster size, although this
risks potentially underestimating the required sample size
[5]. Since 2001, various methods for accounting for vari-
able cluster size have been published [5e10].
Reporting how the sample size calculation was per-
formed is important from both a scientific and ethical
perspective to show that the trial was designed to
adequately address the research question without wasting
resources or exposing too many participants to potentially
harmful interventions. The CONSORT statement recom-
mends the reporting of 25 items related to the design,
conduct, and analysis of randomized controlled trials. The
statement was first published in 1996 [11] and revised in
2001 [12] and 2010 [13]. This latest revision is referred
to as CONSORT 2010. The CONSORT statement was
developed with the dual aims of standardizing reporting
and facilitating transparency. The transparent reporting of
sample size methods and assumptions provides some reas-
surance to the reader of the quality with which the trial has
been conducted. Ideally, adequate reporting ensures that a
reader can appraise the methodology; identify whether an
appropriate and a priori calculation was performed for the
study design; and assess whether the assumptions made
in the sample size calculation were reasonable.
The item that relates to describing the sample size calcu-
lation in CONSORT 2010 recommends the following
descriptive elements to be reported (1) the estimated out-
comes in each group (which implies the minimum important
treatment effect), (2) the level of significance [or thea (type I)
error level], (3) the statistical power [or the b (type II) error
level], and (4) for continuous outcomes, the assumed stan-
dard deviation of the measurements. The CONSORT state-
ment was extended in 2004 [14] for the reporting of CRTs,
and this was revised in 2012 [15] to be in line with CON-
SORT 2010. This extension includes adaptations to items
relevant to the reporting of CRTs. The item that relates
to describing the sample size calculation additionally recom-
mends the reporting of two further descriptive elements (5)
the number of clusters or the cluster size and (6) the ICC or
coefficient of variation (k), along with a measure of its uncer-
tainty. The 2012 revision additionally recommends specifica-
tion of whether equal or unequal cluster sizes are assumed.
Adherence to all the reporting items provided in the
2004 CONSORT extension for CRTs has been reviewed
in 23 trials in oral health [16], 300 randomly sampled trials
[17], 106 trials in children [18], and 73 trials in residential
facilities [19]. The presence of a sample size calculation in
a trial report is considered an initial indication of reporting
quality in the area of sample size. Across these reviews, the
proportion presenting a calculation was 21 of 23 (91%),
164 of 300 (55%), 87 of 106 (82%), and 43 of 73 (59%),
respectively. The third review also reports that 63 of 87
(72%) of trials reported all 2004 CONSORT recommended
sample size descriptive elements. Unlike our review, none
of these reviews identify which of the six sample size
descriptive elements are reported and which are not.
To ensure methodological quality, a sample size calcula-
tion should be appropriate to the trial design. For a CRT,
this implies a sample size calculation accounting for clus-
tering, either by correctly accounting for the clustered na-
ture of the data using a suitable estimate of within-cluster
correlation or calculating the sample size from cluster-
level measures. A cluster-level sample size provides the
number of clusters required and may be undertaken when
information on cluster size is unavailable at the design
stage and/or the primary outcome itself takes some account
of cluster size [20]. Many reviews of the methodological
conduct of CRTs show that this methodological aspect is
suboptimal: for example, in two reviews mentioned above,
100 of 164 (61%) and 15 of 21 (71%) trials that reported a
sample size calculation also accounted for the clustered na-
ture of the design [16,17].
In addition to using an appropriate methodology, it is
vital that a sample size calculation is realistic and that, in
principle, the required numbers can be recruited. Ideally,
sample size calculations should use a within-cluster corre-
lation based on the best available data and specify a mini-
mum treatment effect that is both clinically important and
is likely to be achievable based on evidence from previous
trials of similar interventions. However, it is recognized
717C. Rutterford et al. / Journal of Clinical Epidemiology 68 (2015) 716e723
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that this is not always achievable as appropriate estimates
may not be available or circumstances outside the investi-
gators’ control may make the same size unobtainable. A
comparison between the estimates used in the sample size
calculations and those observed at the end of the trial in a
sample of individually randomized trials concluded that
sample size calculations are often based on inaccurate as-
sumptions [21]. We are unaware of any previous studies
considering similar discrepancies for CRTs.
The review by Ivers et al. [17] found that the prevalence
of reporting sample size calculations was low and that cal-
culations were not always appropriate for the clustered na-
ture of the trial. In this review, we use the same sample of
trials to look in more detail at sample size calculations in
these trials, assessing adherence to reporting descriptive
sample size elements in the 2004 CONSORT extension.
In particular, we aim to identify which elements are under-
reported, whether reporting has improved since the intro-
duction of the 2004 CONSORT extension, and the
accuracy of the a priori estimates used in the sample size
calculation by making comparisons with their observed
values at the end of the trial.
2. Materials and methods
2.1. Search strategy
We used a previously published review of 300 reports of
CRTs randomly sampled from MEDLINE. The search
strategy and characteristics of the included studies have
been described in detail elsewhere [17]. Briefly, a publica-
tion was included if it was published in an English language
journal between the years 2000 and 2008, and it was the
main report of a CRT; trial protocols, pilot studies, second-
ary analyses of CRTs, and trials with households or families
as clusters, with multistage designs, or presenting only
baseline findings were excluded.
2.2. Data abstraction
We reviewed the sample to identify those that reported
prospective sample size calculations. Data abstraction was
conducted only on these trials. All abstraction relates to
the outcome used in the sample size calculation. This was
the primary outcome in all but 30 trials.
Descriptive information for each journal included year
of publication, impact factor, and whether the journal
endorsed the CONSORT statement (taken from the CON-
SORT Web site [22]). As timing and strength of endorse-
ment are difficult to define, this variable was provided as
a rough indicator of journal quality only and no formal
comparisons of its impact were made. Descriptive informa-
tion for each trial included trial design, method of random-
ization, health area, data type of the sample size outcome,
and whether a statistically significant result was seen for
the sample size outcome (as reported by authors).
For the primary objective of reporting quality, abstracted
information for each trial included the values of the 2004
CONSORT required sample size elements and additionally
whether adjustments had beenmade for variable cluster sizes
or attrition. For the secondary objective of methodological
quality and accuracy, abstracted information included
whether the sample size accounted for clustering, including
anymethodology cited, any justifications provided for the es-
timates of the within-cluster variation and estimates of out-
comes in the control and treatment groups, and the
corresponding observed values of treatment effect and
within-cluster correlation at the end of the trial. No assess-
ment was made of whether the correct formulae had been
referenced or implemented given the particular trial design
or whether the sample size calculation could be reproduced.
The research team developed and piloted a data abstrac-
tion instrument and corresponding Access database for
electronic data storage. Three experienced statisticians
(C.R., M.T., and S.D.) abstracted the data for all the articles
in rotating pairs. After each set of 10 trials had been
abstracted, discrepancies were reviewed within the pair
and resolved by discussion.
2.3. Data analysis
2.3.1. Description of sample
Characteristics of the journals and trials for articles con-
taining sample size calculations are summarized using fre-
quencies and percentages or medians and interquartile
ranges.
2.3.2. Reporting according to CONSORT guidelines
For each trial, we describe the 2004 CONSORT required
elements that were provided for the sample size calculation,
with a maximum of six elements. The required elements
were (1) the type I error rate, (2) power, (3) estimates of
outcomes in each group or minimum important target ef-
fect, (4) the standard deviation for continuous outcomes,
(5) the number of clusters or average cluster size, and (6)
the assumed measure of intracluster correlation, design ef-
fect, or coefficient of variation. Trials that do not have a
continuous sample size outcome would not be expected
to provide a standard deviation, and similarly, trials for
which a cluster-level analysis has been assumed in the sam-
ple size calculation are not required to provide a value of
within-cluster correlation. For each trial, we calculate the
maximum number of possible 2004 CONSORT elements
that could have been reported (given the type of outcome)
and the proportion that were reported. For completeness,
we summarize the number of articles that make adjustments
for attrition and variable cluster sizes, although we expect
the latter to be low given that most publications on the sub-
ject were written after the sample sizes would have been
decided for most of our trials, and the specific 2012 CON-
SORT recommendation for reporting this was introduced
after our sample was collected.
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Adherence to the 2004 CONSORT elements is compared
for those articles published before (2000e2004) and after
(2005e2008) its publication.
2.3.3. Assessment of methodological approach
The sample size methodology and justifications for the
values of a priori estimates are summarized using fre-
quencies and percentages. A scatter plot of a priori esti-
mates and observed values of within-cluster correlations
is presented.
Where possible, discrepancies are calculated between
the minimum important target effect and the observed
effect as (observed effect/minimum important target effect).
The calculation is performed on the scale the authors used
to report the effect, that is, absolute or relative differences,
odds ratio, or hazard ratio. When the observed effect is
smaller than the a priori minimum important target effect,
this value is !1 regardless of measurement scale.
3. Results
Of the 300 articles, 166 trials (55%) reported a priori
sample size calculations and are thus summarized. (This
number differs from the 164 reported in the original review,
which focused on sample size calculation for a particular
variable identified by reviewers as primary.) The vast ma-
jority [155 of 166 (93%)] were parallel group trials, imple-
menting simple or stratified randomization [125 of 166
(75%)], and used binary or continuous primary outcomes
[136 of 166 (82%)] (Table 1).
The median impact factor of included journals was fairly
low (3.6, interquartile range: 2.3e12.1); however, 99 of 166
(60%) of these were journals whose guidance recommends
use of CONSORT. Nearly half (46%) were published in the
years preceding the first publication of the CONSORT
extension for CRTs.
3.1. Reporting according to CONSORT guidelines
Of the CONSORT required elements for sample size
calculation, the most commonly reported were outcome
levels in each group or minimum important target effect
(160 of 166, 96%), power (155 of 166, 93%), and type I er-
ror rate (133 of 166, 80%), Table 2. The elements specific
to CRTs were reported less frequently: number of clusters
or cluster size [94 of 166 (57%)] and a measure of
within-cluster correlation [58 of 166 (35%)].
No articles reported corresponding measures of uncer-
tainty alongside the correlation estimates, although some
[18 of 102 (18%)] assessed sample size sensitivity based
on a range of within-cluster correlation values (Table 3).
The assumed standard deviation was reported in only 18
(32%) of the 56 articles with a continuous outcome. Only
38 (23%) of 166 trials reported explicitly accounting for
attrition, and only one article accounted for variable cluster
sizes (Table 2).
Only 36 of 166 articles (22%) reported all the 2004
CONSORT required elements. There was some improve-
ment in reporting over time with 23 of 89 trials (26%) re-
porting all the CONSORT required elements after the
introduction of the extension, compared with only 13 of
77 (8%) before the 2004 CONSORT extension (Table 2).
In particular, improvements were observed with respect to
the standard deviation for continuous outcomes and the re-
ported value of the within-cluster correlation. Categoriza-
tion of journals as above or below the median impact
factor indicated that articles in higher impact journals
tended to report more CONSORT elements: in lower
impact journals, 13 of 83 (16%) reported all required ele-
ments compared with 23 of 83 (28%) in higher impact
journals.
3.2. Assessment of methodological approach
Of the 166 articles reporting a sample size calculation,
102 of 166 (61%) clearly accounted for the within-cluster
Table 1. Journal and trial characteristics of 166 cluster randomized
trials reporting sample size calculations
Characteristic N (%)
Journal: year of publication
2000e2004 77 (46)
2005e2008 89 (54)
Journal: impact factor, median (IQR) 3.6 (2.3e12.1)
Journal: endorsement of CONSORT 99 (60)
Trial: design
Parallel group 155 (93)
Factorial 5 (3)
Crossover 4 (2)
Stepped wedge 1 (1)
Balanced incomplete block design 1 (1)
Cross sectionala 56 (34)
Cohorta 110 (66)
Trial: method of random allocation:
Completely randomized 61 (37)
Stratified 64 (39)
Within matched sets 31 (19)
Minimization 9 (5)
Other 1 (1)
Trial: health area
Primary or hospital care 116 (70)
Public health 50 (30)
Trial: type of primary outcome
Dichotomous 80 (48)
Continuous 56 (34)
Rate 16 (10)
Ordinal 1 (1)
Categorical 0 (0)
Count 0 (0)
Time to event 0 (0)
Unclear 13 (8)
Abbreviation: IQR, interquartile range.
a In a cohort design, repeated measurements are taken on the
same individuals at each time point, and in a cross-sectional design,
repeated measurements take place on different individuals.
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correlation in the sample size calculation (Table 3). Where
clustering was accounted for, almost three-quarters speci-
fied the ICC as a measure of the correlation [66 of 102
(65%)], others quoted a DE [11 of 102 (11%)] or coefficient
of variation [9 of 102 (9%)]. Only 52 of 166 (31%) cited a
methodology for the calculation.
No justification was provided for the estimate of the
postulated outcome in the control group in 113 of 166 trials
(68%), for the estimated treatment outcome or minimum
important target effect in 127 of 166 (77%), and for the cor-
relation estimate in 52 of 102 (51%). Where justified, the
estimated outcome for the control group was most often
estimated from previous trials, the minimum important
target effect justified by clinical relevance, and the
within-cluster correlation chosen from a plausible range.
Only 18 trials reported a measure of the within-cluster
correlation both a priori and at the end of the trial. With
the exception of two trials, the a priori estimate was close
or slightly larger than the observed estimate. The largest
differences were seen in the smaller trials (Fig. 1).
Comparison of the minimum important target effect and
observed effect was possible for 136 trials (82%). Thirty
trials were excluded from this comparison: 13 due to lack
of reporting a treatment effect, either a priori or observed,
and 17 where it was not possible to abstract comparable
measures of treatment effect at both time points. In most
trials [93 of 136 (68%)], the observed treatment effect
was less than the a priori value used in the sample size
calculation. The median relative reduction was 74% (inter-
quartile range: 25e111%).
4. Discussion
Reporting guidelines such as the CONSORT statement
were developed to aid standardized and transparent report-
ing and to provide the reader with enough information to
critically appraise the design, conduct, and analysis of the
research. It is important to be able to identify whether an
appropriate sample size calculation was performed and
whether the assumptions can be considered reasonable.
Table 2. Reporting of recommended 2004 CONSORT sample size descriptive elements in 166 cluster randomized trials by year of publication
Sample size element
Yr of publication
All yr, N [ 166 (%) 2000e2004, N [ 77 (%) 2005e2008, N [ 89 (%)
(1) Type I error rate (%)
2.5 1 (1)
5 131 (79)
20 1 (1)
Stated 133 (80) 62 (81) 71 (80)
Unclear or not stated 33 (20) 15 (19) 18 (20)
(2) Power (%)
80 115 (69)
85 5 (3)
90 34 (20)
95 1 (1)
Stated 155 (93) 70 (91) 85 (96)
Unclear or not stated 11 (7) 7 (9) 4 (4)
(3) Treatment effect
Outcomes in each treatment group 98 (59)
Minimum important target effect size only 62 (37)
Provided 160 (96) 72 (94) 88 (99)
Not provided 6 (4) 5 (6) 1 (1)
(4) Standard deviationa 18/56 (32) 8/29 (28) 10/27 (37)
(5) Number of clusters or average cluster size 94 (57) 44 (57) 50 (56)
(6) Reported value of ICC, design effect, or coefficient
of variationb
58/93 (62) 26/45 (58) 32/48 (67)
Accounted for attrition 38 (23) 15 (19) 23 (26)
Accounted for variable cluster sizes 1 (1) 1 (1) 0 (0)
Percentage of CONSORT elements reportedc
0 1 (0.6) 1 (1) 0 (0)
1e20 5 (3) 4 (5) 1 (1)
21e40 13 (8) 5 (6) 8 (9)
41e60 54 (33) 21 (27) 33 (37)
61e80 46 (28) 26 (34) 20 (22)
81e99 11 (7) 7 (4) 4 (4)
100 36 (22) 13 (8) 23 (26)
Abbreviation: ICC, intracluster correlation coefficient.
a Standard deviation reported among the 56 trials with a continuous primary outcome.
b Excludes nine trials where the sample size was calculated at the cluster level and hence a measure of correlation is not expected.
c Denominators are 4, 5, or 6 depending on whether values of the standard deviation and correlation are expected given each trial design.
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Among our included trials, adherence to the sample size
recommendations of the 2004 CONSORT extension was
poor, with elements specific to cluster randomized designs
being the worst reportedda phenomenon seen in many re-
views assessing the wider aspects of the 2004 CONSORT
extension recommendations, for example [15]. Twenty-
two percent of trials were compliant with all the 2004
CONSORT extension sample size element recommenda-
tions. This is comparable to results seen for individually
randomized trials: In a review of 215 individually random-
ized trials published in 2005 and 2006 in six high-impact
medical journals, 34% of trials included enough informa-
tion for full replication of the sample size [21]. However,
we are encouraged to see in our review some improvements
over time in the number of trials reporting all the required
CONSORT sample size elements with increases occurring
in the reporting of the within-cluster correlation. This is
particularly important given the large influence that this
parameter has on the required sample size.
Our sample contained only trials published until 2008.
This allowed us to assess the immediate impact of the
CONSORT extension statement in the 4 years after its pub-
lication. This review provides an important baseline with
which to compare the impact of future CONSORT state-
ments. We plan to repeat this review, including more recent
articles, to assess the immediate effects of the 2012 revision
once there has been sufficient time for it to take full effect
and a large number of trials published. A secondary aim of
a future review will be to look at the medium- to long-term
impact of the 2004 CONSORT extension.
We acknowledge the limitation that the current review
does not allow us to assess the medium- to long-term
impact of the 2004 CONSORT extension. However, this
sample is unique in both its size and its coverage of all
medical areas and journals; hence, it provides us with an
important insight into the immediate uptake of the CON-
SORT extension among the medical researcher field in
general. Most of the other reviews of CRTs have contained
less than 40 trials, with the largest containing 173
[16,19,23e33]. This sample of 300 is the largest to date,
with the largest sample of identified sample size calcula-
tions. Previous reviews have also focused on particular
areas of health such as stroke, oral health, or primary care
or targeted particular high ranking journals during the
search. Our sample was designed to be representative of
CRTs across the health research field.
Additional adjustments for attrition and variable cluster
sizes were made in only 38 (23%) and 1 (1%) of trials,
respectively. We expected the latter figure to be low as rele-
vant publications describing how to do this are relatively
recent and the recommendation to report information on
cluster size variability has only recently been included in
CONSORT. Failure to take into account these additional
considerations may lead to an underestimate of the sample
size required, the effect of variable cluster size only being
negligible when the coefficient of variation in cluster size
is small (less than 0.23) [5]. Simple DE approaches to deal
with variable cluster sizes are available [5e8].
Sixty percent of the articles included in our review were
in journals whose recommendations mention CONSORT.
Although we recognize that it is not known at what time
each journal first endorsed CONSORT or whether the
extension statements are similarly endorsed, there does
seem to be a discrepancy between endorsement and use
of CONSORT. The way in which medical journals
Table 3. Sample size approach and justification for values of a priori
estimates for 166 cluster randomized trials
Sample size method N [ 166 (%)
(1) Sample size accounted for clustering 102/166 (61)
Intracluster correlation 66/102 (65)
Design effect 11/102 (11)
Coefficient of variation 9/102 (9)
Unclear or not stated 7/102 (7)
Cluster-level calculation 9/102 (9)
Did not account for clustering 48/166 (29)
Unclear 16/166 (10)
(2) Methodology cited 52/166 (31)
(3) Justification of a priori estimates
(3a) The control group expected outcomes, N 5 166
No justification 113/166 (68)
Results from published data 39/166 (23)
A preliminary/pilot study 6/166 (4)
Conservative estimate 8/166 (5)
(3b) The treatment group expected outcome N 5 166
No justification 127/166 (77)
Results from published data 16/166 (10)
A preliminary/pilot study 3/166 (2)
Clinical relevance (no data referenced) 20/166 (12)
(3c) The within-cluster correlation estimate N 5 102
No justification 52/102 (51)
Results from published data 17/102 (17)
A preliminary/pilot study 6/102 (6)
Plausible range 18/102 (18)
NA due to cluster-level calculation 9/102 (9)
Abbreviation: NA, not applicable.
Fig. 1. A comparison of a priori and observed estimates of the within-
cluster correlation.
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incorporate CONSORT recommendations into their edito-
rial process has been surveyed [34]. That survey found that
38% (62 of 165) and 3% (5 of 165) of journals recommend
that authors comply with CONSORT and the cluster exten-
sion, respectively, within their instructions to authors, but
only 37% (23 of 62) and 60% (3 of 5) make it a require-
ment. These figures are higher when surveying journal ed-
itors directly, with 69% (31 of 45) recommending that
authors comply with the extension for CRTs. However,
we recognize that endorsement of CONSORT by journals
may not be the sole driver behind improving reporting qual-
ity. A recent review of reporting quality in CRTs concluded
that quality of reporting and conduct was influenced more
by the presence of a statistician (or quantitative researcher)
among the authorship than a journal’s endorsement of
CONSORT [19].
From the original sample of 300 trials, only 166 (55%)
presented an a priori sample size calculation. Where a sam-
ple size calculation was reported, clustering was accounted
for in 102 of 166 (61%) of these trials. This figure is quite
poor given the standard trial design adopted by many of the
included studies, for which there are simple sample size
methodologies available. A limitation of our study is that
we did not assess whether each trial was appropriately pow-
ered. We did not reproduce sample size calculations or
assess the assumptions made about cluster size, as a mea-
sure of observed cluster size variability was not collected
and recommendations for reporting this have only been
made recently.
In our sample, only a small number of trials reported
both the a priori and observed correlation estimates. This
was similarly seen in a review of CRTs in cancer screening
where only 7 of 50 (14%) reported both a priori estimated
and observed ICCs, and there was no evidence that its re-
porting improved after the CONSORT statement extension
[35]. Given its influence, it is important for authors to pro-
vide the observed valuednot only to aid the design of
future trials, but also to allow one to assess the accuracy
of the a priori estimates and hence the sample size. Albeit
on a small and possibly unrepresentative sample, compari-
sons between a priori estimates and observed values of the
within-cluster correlation showed that authors tended to as-
sume conservative estimates. Part of the explanation for this
may be that values of ICCs used in sample size calculations
are usually not adjusted for covariates, whereas observed
ICCs may be adjusted for covariates (and hence smaller).
Furthermore, our results are consistent with part of any
discrepancy between observed and assumed ICCs being
due to sampling error; the discrepancy was generally larger
in small trials. Whether our findings remain in a larger,
more representative, sample remains to be seen. The a pri-
ori estimate of the within-cluster correlation may be taken
from a previous trial or alternatively, if using the ICC, there
are published summaries available for ICCs of specific out-
comes [36e39]. In our sample, few authors provided an
explanation for their assumed estimate.
The observed treatment effect was often smaller than the
minimum important target effect used in the sample size
calculation. This could be because interventions are often
ineffective or because in some cases investigators power tri-
als using minimum important target effects that could never
be achieved with the type of intervention under evaluation.
Careful consideration is required in determining the mini-
mally important effect in trials of complex interventions,
both in individually randomized and CRTs [1].
The results from our review show that there is much
room for improvement in the conduct and reporting of sam-
ple size calculations in CRTs. We recommend that journals
consider making adherence to CONSORT guidelines a con-
dition of publication to aid improvement in the quality of
reporting and methodological conduct of CRTs.
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Abstract
Background: The use of cluster randomized trials (CRTs) is increasing, along with the
variety in their design and analysis. The simplest approach for their sample size calcula-
tion is to calculate the sample size assuming individual randomization and inflate this by
a design effect to account for randomization by cluster. The assumptions of a simple
design effect may not always be met; alternative or more complicated approaches are
required.
Methods: We summarise a wide range of sample size methods available for cluster
randomized trials. For those familiar with sample size calculations for individually
randomized trials but with less experience in the clustered case, this manuscript provides
formulae for a wide range of scenarios with associated explanation and recommenda-
tions. For those with more experience, comprehensive summaries are provided that
allow quick identification of methods for a given design, outcome and analysis method.
Results: We present first those methods applicable to the simplest two-arm, parallel
group, completely randomized design followed by methods that incorporate deviations
from this design such as: variability in cluster sizes; attrition; non-compliance; or the
inclusion of baseline covariates or repeated measures. The paper concludes with meth-
ods for alternative designs.
Conclusions: There is a large amount of methodology available for sample size calcula-
tions in CRTs. This paper gives the most comprehensive description of published meth-
odology for sample size calculation and provides an important resource for those design-
ing these trials.
Key words: Sample size, cluster randomization, design effect
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Introduction
Cluster randomized trials
In a cluster randomized trial, groups or clusters, rather
than individuals, are randomly allocated to intervention
groups. This approach may be deemed necessary; if ran-
domization at individual level is impractical, to avoid con-
tamination between treatment groups, i.e. individuals in
the control arm being exposed to the intervention; or for
administrative or cost advantages. The rationale for
cluster randomized trials has been described in detail
elsewhere.1–10
The responses from individuals within a cluster are
likely to be more similar than those from different clusters.
This is because individuals within a cluster may share
similar characteristics or be exposed to the same external
factors associated with membership to a particular cluster.
This lack of independence introduces complexity to the
design and analysis. The degree of similarity, or clustering,
is commonly quantified by the intracluster correlation
coefficient (ICC) denoted in this article as q.
Obtaining a good sample size estimate is particularly
important in cluster randomized trials due to the large cost
that can be associated with recruiting an additional cluster
as compared with recruiting an additional subject in an
individually randomized trial. Equally important are the
ethical implications of over- or under-recruitment where
the addition or loss of one cluster may equate to a large
number of individuals potentially being exposed to the risk
of treatment, or lost.
A simple approach to sample size calculation
A consequence of clustering is that the information gained
is less than that in an individually randomized trial of the
same size, making randomization by cluster less efficient.
This inefficiency was identified in the seminal paper by
Cornfield that sparked the development of methodology
for the design and analysis of cluster randomized trials.11
It has been proposed by Donner, Birkett and Buck that a
sample size calculated assuming individual randomization
can be inflated by a Design Effect (DE) to reach the
required level of statistical power under cluster randomiza-
tion:12
DE ¼ 1 þ ðn 1Þq (1)
where n is the number of individuals per cluster and q the
ICC.
Therefore for a comparison of means, in a two-arm trial
with equal allocation the required the number of individu-
als per group, m, is calculated as:
m ¼ ðZ1a=2 þ Z1bÞ
2 2r2
D2

1 þ ðn 1Þq

(2)
where Zx is the x’th percentage point of the standard nor-
mal distribution, D the clinically important difference in
treatment means and r2 the variance in the outcome.
Analyses may be conducted at either the cluster or indi-
vidual level (see Eldridge and Kerry for a full discussion of
analysis methods1)
In cluster-level analyses, a cluster-level summary is cal-
culated for each cluster, effectively reducing the data to
one observation per cluster. The observations can then be
treated as independent, and standard statistical analysis
methods applied. The main advantages of cluster-level
analyses are their simplicity and applicability to different
types of outcomes. Disadvantages of this approach are that
individual-level covariates cannot be included and the
number of observations per group may be small. However,
the two-sample t-test has been shown to be quite robust to
deviations from normality and a small number of clusters
per treatment group.13
Methods that use individual-level data but adjust for
clustering can be used for analysis, such as the adjusted
chi-square method for binary data, the adjusted two-
sample t-test2 or the non-parametric clustered Wilcoxon
test for continuous data.14 In this article, these are referred
to as adjusted tests. The main drawback to these methods
is that they do not allow for the inclusion of covariates.
Commonly individual-level analyses are conducted
using a regression model that accounts for the clustered
nature of the data and may include either cluster or
Key Messages
• There is a large body of literature on sample size calculations for cluster randomized trials.
• There are relatively simple and accessible methods to allow for design complexities such as variable cluster sizes;
time-to-event outcomes; incorporation of baseline values and cross-over, stepped-wedge and matched designs.
• This is the most comprehensive resource to date for sample size methods for cluster randomized trials.
• There is scope for further methodological development.
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individual level covariates. Mixed effects regression models
are a cluster-specific method (henceforth referred to as
mixed models) and Generalised Estimating Equations
(GEE), a type of population-averaged or marginal method.
Both approaches require a sufficient number of clusters for
optimal performance; when the number of clusters is small,
the mixed model is less biased than the GEE. The differ-
ence between these two approaches lies in the interpreta-
tion of the estimated treatment effect.1
In general, sample size requirements depend upon the
proposed analysis method. In this paper we describe each
sample size method alongside the analysis method for
which it was designed. However, alternative analysis
approaches may also be suitable. For example, with con-
tinuous outcomes a cluster-level analysis is equivalent to
an individual-level analysis if all the clusters are the same
size. When cluster size is variable, the assumptions under-
lying the cluster-level t-test are not met and a weighted
t-test must be used to achieve adequate power and preci-
sion. Individual-level analyses naturally incorporate this
weighting and so are more efficient than cluster-level anal-
yses weighted by cluster size.4 For continuous outcomes
and equal-sized clusters, the cluster-specific and popula-
tion-averaged methods for individual-level analyses are
mathematically equivalent.
For binary outcomes, due to the transformation of the
data onto the logistic scale, the treatment effects calculated
under the cluster-specific and population-averaged meth-
ods are different. For binary outcomes, Austin et al.15 com-
pared the performance of three cluster-level methods: the
t-test, the Wilcoxon rank-sum test and the permutation
test, and three individual-level methods: the adjusted chi-
square test, the mixed effects model and the GEE model.
In the scenarios investigated, which included variable clus-
ter sizes, the difference in power between these methods
was negligible.
Measuring variability between clusters
A key parameter common to all sample size calculations for
cluster randomized trials is the extent of similarity between
units within a cluster. The measure used in the majority of
sample size methodology is the ICC, usually denoted by the
Greek letter q. The ICC can be interpreted as the proportion
of variance due to between-cluster variation. When q ¼ 0
there is statistical independence between members of a clus-
ter, whereas when q ¼ 1, all observations within a cluster
are identical. A review of estimators for calculating the ICC
for continuous and dichotomous outcomes can be found in
the papers by Donner16 and Ridout,17 respectively.
Properties of the ICC have been widely investigated and
patterns in ICCs18–22 and sources of ICC estimates5,23–26 are
available in the literature and have been summarized by
Eldridge and Kerry.1 An alternative measure to the ICC is
the coefficient of variation in the outcome, denoted by k.
This is calculated as the between-cluster standard deviation
divided by the parameter of interest, i.e. the proportion, rate
or mean, within each cluster.27 This measure is particularly
useful when the primary outcome variable is a rate, as an
ICC cannot be calculated.27
When choosing an estimate of the ICC, in addition to
the method of calculation, it is also important to identify
whether the estimate has been adjusted for covariates. This
can impact on its value and hence on the calculated sample
size. Inclusion of the baseline value of an outcome as a
covariate is arguably the strongest factor to reduce the
ICC. However, this level of detail is not always explicitly
reported alongside the ICC estimate.
Comparison of ICC and coefficient of variation
Sample size calculations often make the assumption that
the measure of correlation, be it the ICC or k, is the same
in each treatment group. However, if the coefficient of var-
iation is the same in each treatment group the ICC will not
be, and vice versa.4 Therefore the use of these different
measures will produce different sample size requirements.
The assumption of a constant ICC is reasonable if the
intervention effect is likely to be constant across clusters.
The assumption of a constant k is reasonable if the inter-
vention effect is likely to be proportional to the cluster
mean.1
Similarly for binary outcomes, different sample
size requirements are calculated depending upon whether
the ICC or coefficient of variation is used in the calcula-
tion. For binary outcomes there is an additional compli-
cation that the between-cluster variance also depends
upon the value of the overall outcome proportion. The
use of the ICC is recommended for sample size calcula-
tions of binary outcomes, unless the proportion is very
small.1
Trial design features that impact on sample size
The most common and simplest design choice for a cluster
randomized trial is the completely randomized, two-arm
parallel-group design with fixed cluster sizes. In this paper,
the methods appropriate for this design are discussed first.
Variations to this design may be somewhat outside the
investigator’s control, such as variability in cluster size or
attrition, or more within the investigator’s control, such as
choice of outcome measure or analysis method. With these
variations, the assumptions of constant cluster size, binary
International Journal of Epidemiology, 2015, Vol. 0, No. 0 3
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or continuous outcomes, and ICC underpinning the use of
the simple design effect,(1) may not be met; appropriate
approaches are presented. The paper concludes with the
presentation of methods for alternative design choices such
as the cross-over, stepped-wedge, matched and three-level
designs.
Sample size methodology covering some of these aspects
has been summarized1–5,27 and Campbell et al. have dis-
cussed some of the complexities including: methods for
survival data; allowing for imprecision in the estimate of
the ICC; allowing for varying cluster sizes; sample size re-
estimation; empirical investigations of design effect values;
and adjusting for covariates.28 However, currently there is
no single resource for researchers designing cluster
randomized trials that provides a comprehensive descrip-
tion of existing published sample size methodology. Our
work is based on an assessment of the literature. A descrip-
tion of how the papers were identified and included can be
found in our online appendix (available as Supplementary
data at IJE online). This article aims to provide both a
summary of methods and practical guidance around the
use of different methods.
Results: sample size methods
Where possible, sample size formulae have been re-
expressed to use consistent terminology for ease in compa-
rability. Due to limited space within this manuscript, if
implementing some of the more complex methods or those
whose components require detailed description, readers
are advised to refer to original papers for further informa-
tion and to ensure correct implementation and understand-
ing of the methodology.
Sample size methods are now presented, starting with
the standard parallel-group trial, followed by variations to
this design and concluding with alternative designs.
Standard parallel-group, two-arm design
Continuous and binary outcomes
Table 1 summarizes the methodology available for the
standard parallel-group trial with equal sized clusters.
The standard design effect or equivalent has been
developed for continuous and binary outcomes, analysed
at the cluster-level, or at individual level using a GEE
model.
For continuous outcomes, the number of individuals
per arm, m, is calculated as12,29
m ¼ ðZ1a=2 þ Z1bÞ
2 2r2
D2
½1 þ ðn 1Þq (3)
where Zx is the x’th percentage point of the standard nor-
mal distribution, D represents the clinically important dif-
ference in treatment means, r2 the total variance in the
outcome, n the cluster size and q the ICC.
Alternatively, the number of clusters per arm, c, for a
cluster-level analysis can be estimated using direct esti-
mates of the between- and within-cluster variances, r2b and
r2w.
30–32
c ¼ ðZ1a=2 þ Z1bÞ
2 2ðr2b þ r
2
w
n Þ
D2
(4)
Rosner and Glynn33 present sample size methods for non-
normally distributed continuous outcomes analysed with
Table 1. Sample size methods for the standard two-arm, parallel group, equal allocation, fixed cluster sizes
completely randomized design
Standard trial design Outcome measure Analysis Reference
Two-arm, parallel-group,
completely randomized design
Continuous Cluster-level 12,27,30–32
Adjusted test 33
Mixed model 76
GEE 29
Binary Cluster-level 11,12,27,30–32
Mixed model 78
GEE 29
Count GEE 34
Ordinal GEE 35
Mixed model 36
Time-to-event Cluster-level 39, 103
Mixed model 40
Marginal model 43
Marginal model 42
Rate Cluster-level 27
4 International Journal of Epidemiology, 2015, Vol. 0, No. 0
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an adjusted test, the clustered Wilcoxon test. This method
requires a large number of calculations but can be imple-
mented using SAS macros provided by the authors.
For binary outcomes, the number of individuals
per arm, assuming a cluster-level analysis, is calculated
as12
m ¼ ðZ1a=2 þ Z1bÞ
2 ½P1ð1  P1Þ þ P2ð1  P2Þ
D2
½1 þ ðn 1Þq
(5)
where P1 is the probability of an event in the control
group, and P2 the probability of an event in the treatment
group, and D represents the clinically important difference
in treatment proportions, P1  P2. The design effect can
also be used to inflate the variance for the treatment effect
described by a log odds ratio and assuming a GEE
analysis.29
Alternatively, the number of clusters per group, assum-
ing a cluster-level analysis can be calculated as30,31
c ¼ ðZ1a=2 þ Z1bÞ
2 ½2r2b þ P1ð1P1ÞþP2ð1P2Þn 
D2
(6)
Simple methods are available for continuous and binary
outcomes that use the coefficient of variation in outcome
as a measure of correlation and assume a cluster-level
analysis.27 For continuous outcomes where l1 and l2
are the means in the control and intervention group,
respectively, and r1 and r2 the associated within-cluster
standard deviations, the number of clusters per group is
shown as
c ¼ 1 þ
ðZ1a=2 þ Z1bÞ2 ðr
2
1
þr2
2
Þ
n þ k2ðl21 þ l22Þ
h i
ðl1  l2Þ2
(7)
Similarly for binary outcomes where P1 and P2 are the pro-
portions in the control and intervention group, respec-
tively,
c ¼ 1 þ
ðZ1a=2 þ Z1bÞ2 P1ð1P1Þn þ P2ð1P2Þn þ k2ðP21 þ P22Þ
h i
ðP1  P2Þ2
(8)
One cluster per group has been added to account for the
use of the normal approximation in the sample size
calculation.
Count outcomes
For count outcomes, multiplication of the sample size cal-
culation for ordinary Poisson regression by the standard
design effect can be used to calculate the number of
individuals per group, m, assuming fixed cluster size, and
an analysis by GEE34
m ¼
½Za=2
ﬃﬃﬃ
2
p þ Zb
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
½1 þ e~b
q
2
eb0 ~b2
½1 þ ðn 1Þq (9)
where b0 represents the event rate in the control group and
~b is the treatment effect.
Ordinal outcomes
A method for correlated ordinal outcomes assuming a GEE
analysis has been proposed.35 This method has been
described in the context of longitudinal data where the
number of repeated measurements (or cluster size) is small
and the number of clusters large. Its performance for
smaller numbers of larger clusters is unknown and its
implementation is best done via computer. More recently,
Campbell and Walters36 suggest multiplication of
Whitehead’s sample size calculation for ordinal outcomes
in individually randomized trials by the design effect37
m ¼ 6½z1a=2 þ z1b
2=ðlog ORÞ2h
1 
XI
i¼1
pi3
i ½1 þ ðn 1Þq (10)
pi is the mean proportion expected in ordinal category i
calculated as pi ¼ ðp1i þ p2iÞ=2 where p1i and p2i are the
proportions in category i for the control and intervention
groups. The treatment effect is given by the log odds ratio
and a mixed model analysis is assumed.
Time-to-event outcomes
Methods have been suggested for time-to-event outcomes
that adapt the formulae for individual randomization pro-
vided by Schoenfeld.38
The required number of individuals per group given by
Schoenfeld’s formula for individually randomized trials
assuming equal allocation is
m0 ¼
2ðZ1a=2 þ Z1bÞ2
log2eh ð1  PðCÞÞ
(11)
where PðCÞ is the probability of being censored and h
denotes the hazard ratio.
The standard design effect can be used to inflate the for-
mula of Schoenfeld assuming the cluster-level weighted
log-rank test.39
Jahn-Eimermacher et al.40 present a simple formula
for time-to-event outcomes adjusting Schoenfeld’s formula
and using the coefficient of variation in outcome as a meas-
ure of clustering and assuming a mixed model analysis
using a shared frailty model, a popular method for the
International Journal of Epidemiology, 2015, Vol. 0, No. 0 5
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analysis of clustered time-to-event data. The number of
clusters per group is given by
C  m0 þ ðZa=2 þ ZbÞ2k2 1 þ h
2
ð1  hÞ2 (12)
where m0 is the required number of clusters per group
assuming uncorrelated data according to Schoenfeld (11)
and k is the coefficient of variation in outcome.
Alternatively, Freedman’s formula41 for the number of
events required under individual randomization can be
multiplied by the design effect42
E ¼ ðZ1a=2 þ Z1bÞ2 ð1 þ hÞ
2
ð1  hÞ2 ½1 þ ðn 1Þq (13)
where n is the average cluster size, and analysis by mar-
ginal model is assumed.
Manatunga43 considers time-to-event outcomes also
assuming a marginal model, although the method does not
provide a simple explicit formula.
Rate outcomes
The number of clusters per group, c, for rate outcomes in
an unmatched design with cluster-level analysis is27
c ¼ 1 þ
ðZ1a=2 þ Z1bÞ2 r1þr2y þ k2ðr21 þ r22Þ
h i
ðr1  r2Þ2
(14)
where y is the number of person-years in each cluster
(assumed equal), k the coefficient of variation in the out-
come and r1 and r2 the rates in the control and intervention
group, respectively.
Variations to the standard parallel-group design
Table 2 provides a summary of all sample size methodol-
ogy for variations to the standard parallel group trial. The
key methods in each area are presented and discussed here.
Uncertainty around the estimate of the ICC
There is often large uncertainty around the estimate of the
ICC, leading to wide confidence intervals. As the value of
the ICC has a large impact upon the required sample size,
it is sensible to consider the impact of its uncertainty.
An informal method to address this problem has been to
use a conservative estimate of the ICC in the sample size
calculation; this provides a quick gauge of the impact of
the ICC but could lead to unnecessarily large trials. Several
authors have proposed formal methods of incorporating
ICC uncertainty into the sample size calculation by making
distributional assumptions for one or many previously
observed ICC values and then calculating the correspond-
ing distribution for the power.44–47 Several of these meth-
ods adopt a Bayesian perspective but assume the analysis
will follow a frequentist approach. Incorporating uncer-
tainty about the ICC into the sample size calculation pro-
duces larger sample sizes than using a single estimate.
There may be situations where there are no good
estimates of the ICC available for sample size calculations.
This occurred in a trial of mental illness because the out-
come measure was a newly adaptive questionnaire with
unknown properties.48 In these situations, several
approaches might be considered: an educated estimate could
be gained from assessment of published ICCs and known
patterns in their behaviour for different outcome types and
clusters; graphical methods that compare competing designs
without requiring knowledge of the ICC49; or an internal
pilot could be considered (see later section).
Variable cluster sizes
The use of the standard design effect assumes that the num-
ber of observations from each cluster to be included in the
analysis is the same. In some situations such as ophthalmol-
ogy studies where the cluster is a person and measurements
are taken on eyes, this may be a reasonable assumption.
However, in trials of primary care where the cluster may be
a general practice or drop out may occur within clusters, it
is more likely that clusters of variable size will be present in
the analysis, and it is good practice to consider the potential
impact of this at the design stage. If cluster sizes are variable,
the use of the mean cluster size in the simple design effect
will underestimate the required sample size, more so as the
variation in cluster sizes increases. Use of the maximum
cluster size as an alternative may be overly conservative.
Methods to account for variable cluster size are recom-
mended when cluster size variability is large, i.e. the coeffi-
cient of variation of cluster size, defined as the ratio of the
standard deviation of cluster size Sn to mean cluster size n, is
greater than 0.23.50
The available methods to account for variable cluster
size can be divided into two groups: I, those that require
the size of each cluster to be known and II, those that
require the mean and standard deviation of the distribution
of cluster size.
Methods that require the size of each cluster to be known:
Here the design effect is given by
DE ¼ ncXc
i¼1
ni
1þðni1Þq
(15)
where c represents the number of clusters per group, ni the
size of cluster i and n mean cluster size.
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This DE is appropriate for a cluster-level analysis with
minimum variance weighting for continuous or binary out-
comes.51 It is also applicable for an analysis by GEE with
exchangeable correlation structure, robust variance estima-
tors and binary outcomes.52 By exchangeable correlation
we mean that every subject within a cluster is equally cor-
related to every other subject and this pair-wise correlation
is denoted q. This is a common and reasonable assumption
to make for cluster randomized trials. An alternative
approach is to assume that the within-cluster correlation
can be specified by an identity matrix, also known as the
working independence model. This correlation offers
advantages, in that for model fitting it is simple and can
aid model convergence. If the working independence
model was assumed but the true correlation was exchange-
able, then the following design effect can account for this
misspecification52
DE ¼
nc
Xc
i¼1
ni

1 þ ðni  1Þq

 Xc
i¼1
ni
!2 (16)
In the case of equal cluster sizes, this method reduces to the
standard design effect and the use of the working inde-
pendence model results in no loss in efficiency. These GEE
methods may be less appropriate for small samples, as the
robust variance estimator does not perform well in this sit-
uation. Pan52 recommends that potential misspecification
of the correlation structure be explored at the design stage;
please refer to the paper for further examples of alternative
combinations of working and true correlation structures.
A sample size method that can accommodate variable
cluster sizes and allow adjustments for covariates analysed
with a GEE model has been proposed by Liu.53 However,
except in some special cases (equal cluster sizes and only
treatment fitted in the model), there is no closed form
available and the method must be implemented numeri-
cally. For an exchangeable correlation structure with fixed
cluster size, the methods of Liu and Pan can be compared;
Pan’s method has been shown to produce marginally larger
sample sizes.52 The difference comes from the use of the
score test by Liu compared with the Wald test in the deri-
vation by Pan.
Methods that require only the mean and standard
deviation of the distribution of cluster size:
It is not common to have knowledge about each cluster
size at the design stage. Estimates of the distribution (mean
and standard deviation) of cluster size are likely to be more
available. However, it should be noted that, in some cases,
the mean and SD of the sampling distribution may be dif-
ferent from those of the population distribution of all clus-
ters. The design effect is now
DE ¼ 1 þ fðCV2 þ 1Þn  1gq (17)
CV is the coefficient of variation of cluster size.
This design effect can be used with an appropriately
weighted cluster-level analysis for binary or continuous
outcomes.50,54,55As individual-level analyses are more
Table 2. Sample size methodology for adaptations to the
standard two-arm, parallel-group, completely randomized
design
Adaptation Outcome
measure
Analysis Reference
Design
ICC uncertainty Continuous Cluster-level 45
Adjusted test 49
Mixed model 44–46
GEE 45,46
Binary Cluster-level 47
Variable cluster
sizes
Continuous Cluster-level 50,51,61
Adjusted test 55
Mixed model 56
GEE 53
Binary Cluster-level 50,51,105
Adjusted test 54
Mixed model 57
GEE 52,53
Time-to-event Cluster-level 103
Internal pilot Continuous Mixed-model 58
GEE 59
Binary GEE 59
Unequal allocation
ratio
Continuous Cluster-level 61
Mixed model 60
Small number of
clusters
Continuous Cluster-level 13,107
Binary Cluster-level 13
Equivalence Continuous Adjusted test 36
Binary Adjusted test 63
Non-inferiority Binary Adjusted test 64
Conduct
Attrition Continuous Adjusted test 65
Mixed model 66
Binary Adjusted test 65
Non-compliance Binary Adjusted test 64, 67
Analysis
Inclusion of
covariates
Continuous Cluster-level 70,71
Mixed model 69,74–76,79,81,108
GEE 53,73,108
Binary Mixed model 69,74,80
GEE 53,72,73,104 108
Inclusion of
repeated
measures
Continuous Mixed model 66,82–84,86
GEE 85
Binary GEE 85
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efficient, it provides an overestimate of sample size
required for most individual level analyses.
Van Breukelen56 and Candel57 propose the total num-
ber of clusters, as computed assuming equal cluster size
and mixed model analysis, multiplied by the following
design effect to account for variability in cluster size. It
potentially has wide applicability as the authors suggest its
use for correction of sample sizes calculated using any cur-
rent formulae where equal-sized clusters are assumed.
DE  1
1  CV2 n
nþ1qq
h
1  n
nþ1qq
i (18)
The above DE is calculated via Taylor approximation but
is considered to provide a good approximation for all rea-
sonable distributions of cluster size. Heterogeneous varian-
ces across treatment groups can also be accommodated.57
Internal pilots
For trials that recruit a relatively large number of clusters
over a fairly long period of time, it may be appropriate to
re-estimate the sample size during the trial once informa-
tion has been gained on the ICC and other nuisance param-
eters.58,59 These methods assume a mixed model analysis
for continuous outcomes and GEE for binary or continu-
ous outcomes. The use of these internal pilots is less com-
mon in clustered trials and further investigation is required
to determine best practice for their use, for example it is
not known at which stage an interim estimate of the ICC
can be considered stable and used to adequately re-esti-
mate the sample size.
Allocation ratio
Design efficiency is maximized with equal allocation to
treatment groups, and this has been assumed in the major-
ity of the methodology presented here. However, there is
an argument that unequal allocation may occasionally be
desirable, particularly in cases where the costs associated
with the intervention are high. Liu studies the optimal allo-
cation of units to treatment group when the cost per cluster
varies across the treatment groups, assuming a mixed
model analysis.60 The optimal cluster allocation ratio
depends upon the cost ratio between the treatment and
control.
Small number of clusters
The majority of the methods assume that a relatively large
number of clusters is to be recruited, making the approxi-
mation to the normal distribution in the formulae appro-
priate. When the number of clusters is small, calculations
based upon these approximations will likely underestimate
the required sample size. In this case the normal
distribution can be replaced by the t-distribution or meth-
ods based on the non-central t used. Donner13 presents a
power calculation based upon the non-central t-distribu-
tion with a simple non-centrality parameter for cluster-
level analyses. Extensions to this non-centrality parameter
can additionally allow for unbalanced designs.61 As the
percentage points of the non-central t-distribution are not
routinely available in statistical texts, these methods are
best implemented with a statistical package using the code
provided by the authors.
Alternatively, Snedecor and Cochran62 suggest adding
one cluster per arm when testing at the 5% level and the
number of clusters is small, which is incorporated into the
formulae described by Hayes (equations 7, 8 and 14)27 or
could be added to the other formulae presented.
In general however, trials with a small number of clus-
ters should be avoided. As well as the difficulties in sample
size estimation, many analysis methods do not perform as
well with a small number of clusters and imbalance in clus-
ter characteristics across treatment groups is more likely to
occur.1
Equivalence and non-inferiority
Non-inferiority and equivalence designs are less commonly
used in cluster randomized trials. The methods presented
here assume an analysis using an adjusted test. For equiva-
lence designs, the standard design effect can be applied to
the sample size calculated under individual randomization
for binary outcomes63
m ¼ 2Pð1  PÞðZ1a þ Z1bÞ
2
d2
½1 þ ðn 1Þq (19)
where P is the true event proportion in both groups and d
represents the equivalence limit for the upper limit of the
confidence interval of the difference in intervention pro-
portion, and for continuous outcomes36
m ¼ 2ðZ1a þ Z1bÞ
2
ðd=rÞ2 ½1 þ ðn 1Þq (20)
Here we have specified one-sided tests. To be conservative,
two-sided tests could be used.
The calculation for the number of clusters per treatment
group, c, in a non-inferiority trial with binary outcome,
is64
c ¼ ðza þ zbÞ
2Varðlog ðORÞÞ
ðlogðdÞ  logðORÞÞ2 (21)
where the relative treatment effect is measured by the odds
ratio (OR) of a positive response among compliers and d
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represents the non-inferiority margin of the OR. This
method additionally incorporates non-compliance and,
due to this, the variance of this odds ratio is complex to
calculate (see original paper).
Attrition
In a cluster randomized trial, individuals within a cluster
may withdraw from the trial or an entire cluster may with-
draw or not recruit any participants. Drop-out of entire
clusters is relatively uncommon but could be incorporated
into the sample size calculation by the addition of 1 or 2
extra clusters per treatment group.
Attrition among members of a cluster is a more com-
mon problem, particularly for cohort samples.
Conventional approaches to account for such attrition
are to divide the sample size by the anticipated follow-up
rate or use the anticipated average cluster size in the
calculation. However, these methods overestimate and
underestimate, respectively, when cluster follow-up rates
are highly variable or the cluster size or ICC is large.
A design effect has been proposed for binary or continu-
ous outcomes assuming adjusted tests, i.e. the individual-
level t-test or chi-square test suitably adjusted for cluster-
ing65
DE ¼ ½1 þ ðnp 1Þqþ ð1  pÞ½1 þ ðn 1Þsq=p (22)
p represents the probability of the outcome being
observed. A binary missingness indicator variable is 0 if
the outcome is missing and 1 otherwise. s is the intracluster
correlation coefficient for the missingness data mechanism,
i.e. at its minimum s ¼  1n1 implies that all clusters
have identical follow up rates and s ¼ 1 implies all the
missingness indicators are the same within a cluster
(entire clusters are completely observed or completely
missing). Currently estimates for s are not routinely
published with the results of trials and the authors
recommend a sensitivity analysis using a range of plausible
values.
Roy has also considered attrition for the longitudinal
clustered design, assuming analysis with a mixed effects
regression model.66 The calculation uses an iterative
method and allows for a differential drop-out across treat-
ment groups and over time.
Non-compliance
Sample size requirements increase as the level of non-
compliance increases. Methods which allow for non-
compliance, where analysis is by an adjusted test, have
been proposed for both non-inferiority and superiority
designs.64,67 However, the allowance for non-compliance
makes the variance of the treatment effect more complex
to calculate. These methods may be less applicable in prag-
matic cluster randomized trials where the effect of the
intervention is usually assessed in the presence of non-
compliance. In a truly pragmatic trial, compliance may not
be measured or actively encouraged.68
Inclusion of baseline measurements
Sample size calculations can be adapted to allow covariates
in the analysis, as this may increase power by explaining
variability and reducing the between-cluster variation,
which is particularly important when the number of avail-
able clusters is limited or the cost of recruiting each addi-
tional cluster is high. Covariates may be collected at the
level of the individual or the cluster and they may be demo-
graphic variables, such as age, or baseline measures of the
primary outcome. Neuhaus and Segal69 suggest, in general,
that multiplication of the ICC by the ICC of any individ-
ual-level covariate provides an estimate of an adjusted ICC
that can be used in the standard design effect, assuming a
mixed model analysis.
Pre-post design
Inclusion of the baseline measurement of the primary
outcome into the analysis is referred to as a pre-post
design.
The nature of the correlation in a pre-post design will
depend upon the population being sampled, for which
there are two types: cross-sectional or cohort sample. With
a cross-sectional sample, different individuals are measured
at each time point. Here there are two sources of correla-
tion to be accounted for: the correlation of outcomes from
individuals within a cluster at the same time point (which
can be thought of as the familiar ICC, q) and the correla-
tion between baseline and follow-up outcomes for individ-
uals within a cluster (referred to as the cluster auto
correlation, qc). With a cohort sample, the same individu-
als are measured at baseline and follow-up and the addi-
tional correlation across time points on the same
individual conditional on the cluster is referred to as the
subject autocorrelation, qs.
Assuming a cluster-level ANCOVA, a relatively
straightforward design effect can be used for the pre-post
design.70,71 The design effect can accommodate either the
cross-sectional sample (qs ¼ 0), cohort sample or a mixture
of the two70
DE ¼ ½1 þ ðn 1Þq

 
1 
 nq
1 þ ðn 1Þq qc þ
1  q
1 þ ðn 1Þq qs
2! (23)
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When the analysis is performed on change from baseline
scores the design effect is
DE ¼ ½1 þ ðn 1Þq
2
 
1 
 nq
1 þ ðn 1Þqqc þ
1  q
1 þ ðn 1Þqqs
!
(24)
Preisser72,73 focuses on binary outcomes with a GEE
analysis. The number of clusters for the cross-sectional
pre-post design is given as
c ¼
Z1a2 þ Z1b
 2
ðr21 þ r22Þ
nððp11  p10Þ  ðp21  p20ÞÞ2
(25)
where
r2h ¼ ½ph1ð1  ph1Þ þ ph0ð1  ph0Þ½1  ðn 1Þq
2nqc
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ph1ð1  ph1Þ þ ph0ð1  ph0Þ
p
and pht is the probability of the outcome for an individual
at time t (0¼ pre-test, 1¼ post-test) from treatment group
h (1¼ control, 2¼ intervention).
In terms of sample size, a cohort sample is more efficient,
although it suffers from several drawbacks. To gain notice-
able precision, the correlation across time points on the same
individual must be fairly substantial. Cohort designs can also
suffer from loss to follow-up and therefore require oversam-
pling at baseline and attentive follow-up of individuals.
The sample size efficiency of the cohort design relative
to the repeated cross-sectional design with 1 measurement
on each individual at each time point, assuming a mixed
model, has been quantified as74,75
RE ¼ nð1  qcÞr
2
b þ ð1  qsÞr2w
nð1  qcÞr2b þ r2w
(26)
Inclusion of other covariates
Although the inclusion of covariates can reduce the sample
size requirements, there are costs associated with taking addi-
tional measurements. In a trial without covariates, suppose
the total budget for the trial is summarized via the cost func-
tion T ¼ nCc1 þ Cc2, where C is the total number of clus-
ters, n the cluster size, c1 the costs per individual and c2 the
costs per cluster. The number of clusters, C, and the number
of individuals, n, which minimize the variance of the treat-
ment estimator, given the budget constraint are given as76–78
C ¼ Tðrw=rbÞ ﬃﬃﬃﬃﬃﬃﬃﬃﬃc1c2p þ c2 ; n ¼
rw
rb
ﬃﬃﬃﬃ
c2
c1
r
(27)
A similar approach can be used with the inclusion of cova-
riates.76,79,80 Alternatively, power-based calculations are
provided by Moerbeek, assuming a mixed model.81 The
total number of clusters is calculated as
N  4
r2wð1 
n
n 1q
2
WÞ þ nr2b ð1  q2B þ
1
n 1 q
2
WÞ
n
ðz1a=2 þ z1b
D
Þ2
(28)
where q2W and q
2
B are the within-cluster and between-clus-
ter residual correlations between the outcome and the
covariate. qW ¼ 0 for a cluster level covariate.
The additional cost to measure a covariate at the indi-
vidual level is c1 and the additional cost of measuring a
covariate at the cluster level is c2. Therefore the total cost
function for individual level covariates becomes
T ¼ nCðc1 þ c1Þ þ Cc2
and for cluster level covariates
T ¼ nCc1 þ Cðc2 þ c2Þ
The costs associated with and without the covariate can be
estimated and compared. The inclusion of covariates is
more cost effective when the cost of measurement is small
and the correlation between covariates and outcome is
large. The formula presented by Moerbeek assumes the
covariates are uncorrelated with the treatment condition.
When the number of clusters is small, this can be achieved
via matching on this covariate, particularly recommended
for covariates that vary at the cluster level.79
Inclusion of repeated measurements
Multiple time points introduce additional components of
correlation, as the observations for each cluster will be cor-
related over time. In a longitudinal cluster randomized trial
we have a three-level structure with outcomes measured at
specific time points within subjects, within clusters.
A three-level mixed effects regression model therefore con-
tains additional fixed effect terms for time and the treat-
ment by time interaction. The sample size methods for
these designs are more complex than others and the
required estimates may be difficult to find. The hypothesis
of interest in these trials is the effect of the intervention
over time. Assuming a mixed model, the calculation by
Koepsell et al.82 is based on the non-central-t distribution,
with the treatment effect adjusted by a design constant
allowing for different hypothesized paths of the interven-
tion effect over time. A formula based upon the Wald test
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of the interaction term for the number of clusters per arm
has been proposed83
n3 ¼
2r2ðz1a=2 þ z1bÞ2ð1  q1Þ
n2n1D
2
Xn1
k¼1
ðTk  TÞ2=n1
(29)
where nx is the number of units at level x ðx ¼ 1;2;or 3Þ,
T represents the equally spaced time variable and q1is the
correlation among level-one units (see later section on
three-level trials for definition).
Roy’s iterative method similarly proposes a test of the
treatment by time interaction from a mixed effect model
but additionally allows incorporation for a differential
drop-out across treatment groups and over time.66 Murray
proposed that a mixed model with random coefficients is a
more appropriate analysis for explicitly modelling more
than two time points in the analysis.84 The additional ran-
dom effects make this method more complex than others
and, although the authors have provided parameter esti-
mates to aid planning for some outcomes, investigators
will likely need to spend time and money sourcing suitable
estimates. Sample size formulae for assessing change over
time assuming an analysis by GEE have been derived by
Liu.85 However, except under certain correlation struc-
tures, the calculations involved in this method are
substantial.
If the effect of treatment is expected to diverge over
time, sample size can be calculated for testing the treat-
ment effect at the final time point with incorporation of
information from the entire study period assuming a com-
pound symmetry structure and mixed model. This produ-
ces smaller sample sizes than an assessment at the final
time point only, but the assumptions underpinning this
method may limit its widespread application.86
Alternative designs
The above methods are described for the parallel group
trial and small variations to this standard design. We now
consider methodology for alternative design choices.
Table 3 summarizes the available sample size methodology
for alternative designs.
Stratification and matching
Cluster randomized trials in general recruit a smaller num-
ber of units than an individually randomized trial. This can
potentially lead to baseline imbalances in cluster characteris-
tics across treatment groups. Matching or stratification can
be used to improve similarity in clusters across treatment
groups. In a matched-pair design, similar clusters are paired,
or matched. One cluster from the pair is allocated to the
intervention and the other to the control and a cluster-level
analysis conducted. Similarity may be defined on cluster-
level characteristics that are thought to affect the outcome,
such as size or geographical location. Matching reduces the
variance between clusters (within strata or within matched
pair) and hence can provide efficiency in sample size. The
efficiency gains depend upon the effectiveness of the match-
ing. The sample size for an unmatched cluster randomized
trial must be inflated by the following DE in order to have
the same precision as the matched study87
DE ¼ 1=ð1 qxÞ (30)
Its calculation requires knowledge of the correlation in the
outcome between matched pairs, qx. This correlation can
be estimated from previous studies or from the correspond-
ing correlation for a surrogate variable observed prior to
randomization, if any exist, otherwise a range of plausible
values can be considered.
In planning a matched trial, it is worth noting that any
potential gain in efficiency can be lost if clusters drop out
of the study, rendering the matched pair unuseable in the
analysis. However, ignoring matching and including all
clusters in an unmatched analysis of a matched design has
been shown to be valid and efficient in trials that recruit a
small number of relatively large clusters.88
The required number of cluster pairs, m0, is calculated
using the following formula assuming analysis at the clus-
ter level
m0 ¼ r
2ðta=2;m01 þ tb;m01Þ2
d2
(31)
Table 3. Sample size methodology for alternative designs
Trial design Outcome measure Analysis Reference
Matched/stratified Continuous Cluster-level 27,32,109
Mixed model 89
Bayesian 92
Binary Cluster-level 27,32,41,87,109
Mixed model 89
Adjusted test 91
Rate Cluster-level 27,90
Cross-over Continuous Cluster-level 93,106,107
Mixed model 94
Binary Cluster-level 106
Count Cluster-level 106
Stepped-wedge Continuous Mixed model 95,96
Three-level Continuous Mixed model 77,98,100,101
GEE 99
Binary GEE 99
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This is the familiar formula for the paired t-test, where d is
the expected difference within pairs, r2 the variance of this
difference and tx;m01 percentage points of the t distribution
with m01 degrees of freedom.
For continuous outcomes the variance is calculated as
2 r2b þ
r2w
n
 
(32)
where r2b is the between-cluster variance within a
matched pair and r2w the within-cluster component of
variability.32,89
For binary outcomes the variance is calculated as
P1ð1  P1Þ þ P2ð1  P2Þ
n
þ 2r2b (33)
where P1 the expected proportion in the control arm and
P2 the expected proportion in the intervention arm.
41
The methods by Hayes which use the coefficient of var-
iation in outcome for unmatched trials (equations 7, 8 and
14) can be used for matched trials with two modifica-
tions.27 Two, rather than one, cluster should be added to
account for the use of the normal approximation and k
should be replaced with km, the coefficient of variation
between clusters within the matched pair. The Hayes
method for rates can be shown to be equivalent to an ear-
lier approach by Shipley.90
Stratification is similar to matching, in that we poten-
tially now have several clusters within each stratum, rather
than two as we have in a pair-matched study. This has
been addressed for binary outcomes with a straightforward
calculation.91 For continuous outcomes, Kikuchi and
Gittins92 follow the less common Bayesian approach to
design and analysis. However, as the impact of stratifica-
tion is difficult to ascertain in advance, recommendations
are to ignore it in the sample size calculation, for a more
conservative estimate.1
Cross-over designs
Cross-over designs require a smaller number of clusters
than a parallel-group trial and are therefore useful when
the availability of clusters is limited. A simple design effect
for cluster-level analysis has been presented for the cross-
over design in which entire clusters switch treatments dur-
ing the course of the trial93
DE ¼ 1 þ 1
2
n1  1
 
q2
 
 1
2
n1g (34)
where n1 is the number of participants recruited within
each cluster across both time periods; q2 is the correlation
between subjects in the same cluster at the same time point
and g is the inter-period correlation. In this design, differ-
ent subjects from each cluster are included in separate peri-
ods of the trial (a cross-sectional sample). The treatment
effect is calculated within clusters and therefore between-
cluster variance is removed and the design is more efficient
than the parallel-group.
Alternatively, each subject could be included in both
periods within a cluster (a cohort sample). Here a mixed
model is assumed. The treatment effect is calculated within
subjects, within clusters, so both between-cluster and
between-subject variations are eliminated, making this the
most efficient cross-over design with cluster level random-
ization. The relative efficiency (RE) of the cross-over
design with cross-sectional sample over the parallel-group
cluster randomized design has been quantified by
Rietbergen94
RE ¼ 1 þ
1
2n1  1
 
q2
  12n1g
1 þ ðn1  1Þq2
(35)
and similarly for the cohort sample
RE ¼ 1
2
1  q1  q2
1 þ ðn1  1Þq2
(36)
where q1 is the intrasubject correlation.
Although cross-over designs can improve efficiency, the
nature of the intervention or condition under study may
make them inappropriate, as occurs in individually
randomized trials.
Stepped-wedge design
The stepped-wedge design is similar to the cross-over
design, except that the cross-over of treatments is all in
one direction and staggered over time. All clusters receive
the control intervention at baseline. At various points
during the trial (referred to as steps), one or more clusters
will cross over to receive the treatment intervention,
with all clusters receiving treatment by the end of the
trial. The point at which a cluster, or group of clusters,
will cross over is randomly determined at the beginning of
the trial.
The main criteria for use of a stepped-wedge design is
when the implementation of the intervention can only be
performed sequentially across clusters, perhaps due to
resource constraints, and when the intervention is believed
to do more good than harm and so it would be considered
unethical for some clusters to not receive the intervention
at some point during the trial. Although these designs are
increasing in popularity, there is little published research
describing best practice in their design and analysis.
Hussey in 200595 provides the first guidance on sample
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size, which has been further developed by Woertman and
assumes analysis by mixed model.96
This recently developed sample-size approach for the
stepped-wedge design with continuous outcomes supposes
that, between each step, one or more cross-sectional sam-
pling waves of the clusters occur and outcome measure-
ments are taken. The total number of individuals required
under individual randomization is multiplied by a DE to
give the number of individuals to be sampled across all
clusters at each sampling wave
Nsw ¼
ðZ1a=2 þ Z1bÞ2 4r2
D2
 1 þ qðktnþ bn 1Þ
1 þ q
 1
2
ktnþ bn 1
 3ð1  qÞ
2t

k 1
k

2
64
3
75
(37)
where k is the number of steps, b the number of pre-
randomization sampling waves, t the number of sampling
waves between each step, n the number sampled from each
cluster at each sampling wave and q is the ICC. Nsw is the
total number of individuals required at each time point,
the required number of clusters is calculated as Nsw=n, the
number of clusters switching treatment at each step is cal-
culated by dividing the number of clusters by k and the
total number of individuals required across the entire trial
is Nsw multiplied by (bþkt).
Three-level cluster randomized trials
Additional levels of clustering may occur due to the choice
of cluster. For example, three-level cluster randomized tri-
als are fairly common in educational research where pupils
(level 1 units) are sampled within classrooms (level 2 units)
and randomization takes place at the level of the school
(level 3 units). The total variance is now made up of the
variance between schools, r23; the variance between class-
rooms within schools, r22; and the variance associated with
students within classrooms and schools, r21 . We can define
two ICCs,97 for students within schools
q2 ¼ r23=ðr23 þ r22 þ r21Þ (38)
and for students within classrooms
q1 ¼ r23 þ r22=ðr23 þ r22 þ r21Þ (39)
In a three-level trial, the required sample size is calculated as
n3n2n1 ¼ DEm (40)
where m is the number of individuals required in each
group in an individual randomized controlled trial
(RCT) and nx is the number of units at level
x ðx ¼ 1;2; or 3Þ.
The Design effect for three levels of clustering is
DE ¼ 1 þ n1ðn2  1Þq2 þ ðn1  1Þq1 (41)
This DE can be used for continuous outcomes with equal
cluster size analysed with either a mixed effects model or
GEE assuming exchangeable correlation, as these methods
are equivalent under equal cluster size.98–100 The design
effect in the original paper by Teerenstra100 has been
re-expressed for the purpose of this paper to use the
Pearson correlations (38 and 39), as these are more famil-
iar quantities and published estimates are more likely than
the variance components described in the original paper.
Following Raudenbush,76 optimization of the sample
sizes at each level can be performed based upon cost
constraints.101,102
Discussion
Sample size calculations for individually randomized trials
must be inflated in order to be used for cluster randomized
trials, to account for the inefficiency introduced by the cor-
relation of outcomes between members of a cluster. A sim-
ple design effect described by Donner, Birkett and Buck12
can be used for parallel-group trials when the cluster size is
assumed constant and the outcome is continuous, binary,
count or time-to-event.
Design effects have been derived for more complex
designs including: variable cluster sizes; individual level
attrition; cross-over trials; stepped-wedge designs; inclu-
sion of baseline measurements; analysis by GEE; and three
levels of clustering. These design effects are relatively
straight forward to calculate. However, the opportunity to
use them may depend upon the availability and quality of
estimates of the parameters required for the calculation.
When incorporating variable cluster size, the choice of
methods depends upon whether every cluster size is known
in advance, or just information on cluster size distribution.
In the case of incorporating stratification, the only method
available requires knowledge about the proportion of indi-
viduals in the stratum as well as the success probabilities in
each, information which is unlikely to be available at the
beginning of the trial. These other parameters, required to
assist others planning future trials, are not currently
reported as part of a trial’s findings, but we hope will
become routinely published in time.
The intracluster correlation coefficient featured more
frequently as a measure of within-cluster correlation than
the coefficient of variation, in our assessment of the sample
size literature. This may be due to the wide availability of
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published reviews of ICC estimates5,23–26 and patterns in
ICCs.18–22
The majority of papers specify binary or continuous
outcomes; few deal with other types of outcome. Simple
approaches for alternative outcomes data potentially war-
rant future development.
Sample size by simulation is an alternative to using an
analytical formula. Although the procedure may be com-
putationally intensive, in some cases it may be preferable
to complex numerical procedures and was used in four
papers identified in the literature.103–106 Many of the
methods proposed recommend validation of the sample
size calculated with a formula through simulation, particu-
larly for time-to-event outcomes or where the number of
clusters is small. However, the type I error is often inflated
when the number of clusters is small, the cluster size is var-
iable and for particular analyses such as the frailty model,
and this should be taken into consideration during the
planning and interpretation of simulations.
We have provided a comprehensive description of sam-
ple size methodology for cluster randomized trials, pre-
sented in a simple way to aid researchers designing future
studies.
With the increasing availability of more advanced meth-
ods to incorporate the full complexity that can arise in the
design of a cluster randomized trial, the researcher may
feel overwhelmed by the volume of methods presented.
However it should be noted that in some situations a sim-
ple formula may perform reasonably well in comparison
with a more complex methodology. For example, when the
coefficient of variation in cluster size is less than 0.23, it is
not deemed necessary to adjust the sample size and the
standard design effect obtained assuming fixed cluster sizes
would suffice.50
For continuous outcomes with equal cluster sizes, the
cluster-level and individual-level analyses are equivalent.
Therefore a sample size calculation assuming either of
these with the same measure of correlation should produce
equivalent results. When cluster size is variable, an individ-
ual-level analysis is more efficient than a cluster-level anal-
ysis weighted by cluster size; therefore a sample size
calculation based upon cluster-level analyses will be some-
what conservative if an individual analysis is then
conducted.
For binary outcomes, if the intervention is designed to
reduce the outcome proportion use of the coefficient of
variation27 will produce marginally smaller sample sizes
than using the ICC.12 When the intervention aims to
increase the outcome proportion, the sample sizes using
the coefficient of variation will be larger. When several
methods may be used, the choice between them is also a
question of practicality. The distribution of the outcome
and whether required estimates are available should be
considered. Further work is required to formally compare
the resulting sample sizes calculated under competing
methods, when alternative analyses are conducted, and to
evaluate the situations in which the simple methods can
provide reasonable results over the more complex. This
was beyond the scope of this paper.
A limitation of this paper is that a full critique and
comparison of the sample size methods were difficult due
to the lack of consistency in reporting across the papers.
No guidelines exist at present to judge the quality of
methodological papers and guide authors in clear and
transparent reporting. We hypothesize that the way in
which these methods are reported can also be a barrier to
their uptake. We hope that their presentation in this
article will improve uptake and research in the perform-
ance of these methods. We are planning further work
looking at developing guidelines for the reporting of
methodology papers.
There is often a large amount of uncertainty associated
with the estimate of the ICC, and the appropriateness of
any of the methods described here will depend upon the
level of uncertainty. In the case of a large amount of uncer-
tainty, we recommend that at a minimum the sample size
sensitivity to a range of ICC values be explored. We recom-
mend that, at the design stage, an appropriate simple for-
mula be used in the first instance to provide the researcher
with a benchmark figure upon which the impact of incor-
porating further complexities can be assessed.
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